NZ617944B2 - Methods and compositions for modulating gene expression using components that self assemble in cells and produce rnai activity - Google Patents
Methods and compositions for modulating gene expression using components that self assemble in cells and produce rnai activity Download PDFInfo
- Publication number
- NZ617944B2 NZ617944B2 NZ617944A NZ61794412A NZ617944B2 NZ 617944 B2 NZ617944 B2 NZ 617944B2 NZ 617944 A NZ617944 A NZ 617944A NZ 61794412 A NZ61794412 A NZ 61794412A NZ 617944 B2 NZ617944 B2 NZ 617944B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- strand
- strands
- target
- antisense
- duplex
- Prior art date
Links
- 230000000694 effects Effects 0.000 title claims abstract description 143
- 230000014509 gene expression Effects 0.000 title claims abstract description 80
- 230000000051 modifying Effects 0.000 title claims abstract description 23
- 230000002987 rna-interference Effects 0.000 title description 112
- 239000000203 mixture Substances 0.000 title description 42
- 230000000692 anti-sense Effects 0.000 claims abstract description 495
- 229920000272 Oligonucleotide Polymers 0.000 claims abstract description 118
- 230000000295 complement Effects 0.000 claims abstract description 106
- 230000027455 binding Effects 0.000 claims abstract description 48
- 238000000338 in vitro Methods 0.000 claims abstract description 28
- 229920002477 rna polymer Polymers 0.000 claims abstract description 5
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims abstract description 4
- 239000000074 antisense oligonucleotide Substances 0.000 claims abstract description 4
- 239000002777 nucleoside Substances 0.000 claims description 467
- 125000003835 nucleoside group Chemical group 0.000 claims description 281
- 229920000972 Sense strand Polymers 0.000 claims description 264
- 238000006011 modification reaction Methods 0.000 claims description 250
- 230000004048 modification Effects 0.000 claims description 248
- 229920001239 microRNA Polymers 0.000 claims description 201
- 239000002679 microRNA Substances 0.000 claims description 191
- 108020004999 Messenger RNA Proteins 0.000 claims description 108
- 229920002106 messenger RNA Polymers 0.000 claims description 108
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 claims description 100
- 206010049460 Abasia Diseases 0.000 claims description 80
- 108020004388 MicroRNAs Proteins 0.000 claims description 44
- 241001367079 Una Species 0.000 claims description 27
- 229920000401 Three prime untranslated region Polymers 0.000 claims description 21
- GEGPMWUYMRCINJ-DELVFIHMSA-N (3R,4S)-4-hydroxy-3-[(2,2,2-trifluoroacetyl)amino]-2-[(1R,2S)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid Chemical compound OC[C@H](O)[C@@H](O)C1OC(C(O)=O)=C[C@H](O)[C@H]1NC(=O)C(F)(F)F GEGPMWUYMRCINJ-DELVFIHMSA-N 0.000 claims description 14
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 242
- 150000001875 compounds Chemical class 0.000 description 204
- 150000003833 nucleoside derivatives Chemical class 0.000 description 186
- 230000025458 RNA interference Effects 0.000 description 153
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 141
- 210000004027 cells Anatomy 0.000 description 121
- 101700027746 AGO2 Proteins 0.000 description 101
- 102100010884 AGO2 Human genes 0.000 description 101
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 88
- 241000282414 Homo sapiens Species 0.000 description 79
- 230000001743 silencing Effects 0.000 description 77
- 102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 70
- 108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 70
- 102100019730 TP53 Human genes 0.000 description 67
- 101710026335 TP53 Proteins 0.000 description 67
- 101700080605 NUC1 Proteins 0.000 description 59
- 101700006494 nucA Proteins 0.000 description 59
- 108020004707 nucleic acids Proteins 0.000 description 55
- 230000001939 inductive effect Effects 0.000 description 54
- 150000007523 nucleic acids Chemical class 0.000 description 54
- 150000004713 phosphodiesters Chemical class 0.000 description 54
- 210000001519 tissues Anatomy 0.000 description 54
- 238000003776 cleavage reaction Methods 0.000 description 52
- 230000003197 catalytic Effects 0.000 description 50
- 230000002401 inhibitory effect Effects 0.000 description 48
- 108010078762 Protein Precursors Proteins 0.000 description 46
- 102000014961 Protein Precursors Human genes 0.000 description 46
- 230000035492 administration Effects 0.000 description 46
- 239000000969 carrier Substances 0.000 description 46
- 230000024881 catalytic activity Effects 0.000 description 44
- 239000000178 monomer Substances 0.000 description 44
- HVAUUPRFYPCOCA-AREMUKBSSA-O PAF Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP(O)(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-O 0.000 description 39
- 201000011510 cancer Diseases 0.000 description 39
- 239000003814 drug Substances 0.000 description 39
- 241000699666 Mus <mouse, genus> Species 0.000 description 35
- 102100008799 PTEN Human genes 0.000 description 35
- 230000000875 corresponding Effects 0.000 description 35
- 230000001419 dependent Effects 0.000 description 35
- 101700009419 PTEN Proteins 0.000 description 34
- 101700079540 FAS Proteins 0.000 description 33
- 230000003278 mimic Effects 0.000 description 30
- 150000002500 ions Chemical class 0.000 description 29
- 230000004224 protection Effects 0.000 description 29
- 210000004185 Liver Anatomy 0.000 description 27
- 239000003795 chemical substances by application Substances 0.000 description 27
- 229940079593 drugs Drugs 0.000 description 27
- 239000003981 vehicle Substances 0.000 description 27
- 230000001965 increased Effects 0.000 description 26
- 239000000126 substance Substances 0.000 description 26
- 101700068417 fol1 Proteins 0.000 description 25
- 230000002829 reduced Effects 0.000 description 23
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 22
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 22
- 238000011068 load Methods 0.000 description 22
- -1 nucleoside cation Chemical class 0.000 description 22
- 230000001225 therapeutic Effects 0.000 description 22
- 230000006907 apoptotic process Effects 0.000 description 21
- 230000015572 biosynthetic process Effects 0.000 description 21
- 239000003380 propellant Substances 0.000 description 21
- 210000000130 stem cell Anatomy 0.000 description 21
- 206010059512 Apoptosis Diseases 0.000 description 20
- 239000003112 inhibitor Substances 0.000 description 19
- 230000001603 reducing Effects 0.000 description 19
- 101700065507 APOB Proteins 0.000 description 18
- 230000001629 suppression Effects 0.000 description 18
- 108010027006 Apolipoproteins B Proteins 0.000 description 17
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 17
- 101700050499 PTPN1 Proteins 0.000 description 16
- 102100017813 PTPN1 Human genes 0.000 description 16
- 210000002381 Plasma Anatomy 0.000 description 16
- 239000005549 deoxyribonucleoside Substances 0.000 description 16
- 201000010099 disease Diseases 0.000 description 16
- 238000000034 method Methods 0.000 description 16
- 239000000651 prodrug Substances 0.000 description 16
- 229940002612 prodrugs Drugs 0.000 description 16
- 239000002253 acid Substances 0.000 description 15
- 239000000443 aerosol Substances 0.000 description 15
- 238000004519 manufacturing process Methods 0.000 description 15
- 210000002216 Heart Anatomy 0.000 description 14
- 238000006722 reduction reaction Methods 0.000 description 14
- 102000018616 Apolipoproteins B Human genes 0.000 description 13
- 210000003734 Kidney Anatomy 0.000 description 13
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 238000005755 formation reaction Methods 0.000 description 13
- 238000009472 formulation Methods 0.000 description 13
- 239000002342 ribonucleoside Substances 0.000 description 13
- 206010007554 Cardiac failure Diseases 0.000 description 12
- 102000004190 Enzymes Human genes 0.000 description 12
- 108090000790 Enzymes Proteins 0.000 description 12
- 206010019280 Heart failure Diseases 0.000 description 12
- 150000001768 cations Chemical class 0.000 description 12
- 230000037361 pathway Effects 0.000 description 12
- 230000002633 protecting Effects 0.000 description 12
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 11
- ASJSAQIRZKANQN-UHFFFAOYSA-N 3,4,5-trihydroxypentanal Chemical compound OCC(O)C(O)CC=O ASJSAQIRZKANQN-UHFFFAOYSA-N 0.000 description 11
- 229940107161 Cholesterol Drugs 0.000 description 11
- 206010012601 Diabetes mellitus Diseases 0.000 description 11
- 229940035893 Uracil Drugs 0.000 description 11
- 201000004681 psoriasis Diseases 0.000 description 11
- 210000004072 Lung Anatomy 0.000 description 10
- 210000003491 Skin Anatomy 0.000 description 10
- 238000004364 calculation method Methods 0.000 description 10
- 230000001413 cellular Effects 0.000 description 10
- 238000011161 development Methods 0.000 description 10
- 230000018109 developmental process Effects 0.000 description 10
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 9
- 108020004461 Double-Stranded RNA Proteins 0.000 description 9
- 210000004940 Nucleus Anatomy 0.000 description 9
- 230000004913 activation Effects 0.000 description 9
- 229910052799 carbon Inorganic materials 0.000 description 9
- 230000015556 catabolic process Effects 0.000 description 9
- 201000010046 dilated cardiomyopathy Diseases 0.000 description 9
- 238000001802 infusion Methods 0.000 description 9
- 108091007164 let-7 family Proteins 0.000 description 9
- 230000011664 signaling Effects 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- 206010003210 Arteriosclerosis Diseases 0.000 description 8
- 241000764238 Isis Species 0.000 description 8
- 102000007330 LDL Lipoproteins Human genes 0.000 description 8
- 108010007622 LDL Lipoproteins Proteins 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- 201000001320 atherosclerosis Diseases 0.000 description 8
- 230000030833 cell death Effects 0.000 description 8
- 235000012000 cholesterol Nutrition 0.000 description 8
- 230000003247 decreasing Effects 0.000 description 8
- 230000004059 degradation Effects 0.000 description 8
- 238000006731 degradation reaction Methods 0.000 description 8
- 239000000539 dimer Substances 0.000 description 8
- 238000005417 image-selected in vivo spectroscopy Methods 0.000 description 8
- 230000001575 pathological Effects 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 230000002194 synthesizing Effects 0.000 description 8
- 231100000419 toxicity Toxicity 0.000 description 8
- 230000001988 toxicity Effects 0.000 description 8
- 206010009802 Coagulopathy Diseases 0.000 description 7
- ASJSAQIRZKANQN-CRCLSJGQSA-N Deoxyribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 7
- 101700008821 EXO Proteins 0.000 description 7
- 101700083023 EXRN Proteins 0.000 description 7
- 102100016439 FAS Human genes 0.000 description 7
- UYTPUPDQBNUYGX-UHFFFAOYSA-N Guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 7
- 102100012475 LDLR Human genes 0.000 description 7
- 208000010125 Myocardial Infarction Diseases 0.000 description 7
- 206010063837 Reperfusion injury Diseases 0.000 description 7
- 230000035602 clotting Effects 0.000 description 7
- 230000015271 coagulation Effects 0.000 description 7
- 230000029087 digestion Effects 0.000 description 7
- 230000003405 preventing Effects 0.000 description 7
- 230000001185 psoriatic Effects 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 206010008958 Chronic lymphocytic leukaemia Diseases 0.000 description 6
- 210000000805 Cytoplasm Anatomy 0.000 description 6
- 102000004533 Endonucleases Human genes 0.000 description 6
- 108010042407 Endonucleases Proteins 0.000 description 6
- 108010001831 LDL receptors Proteins 0.000 description 6
- 208000000429 Leukemia, Lymphocytic, Chronic, B-Cell Diseases 0.000 description 6
- 210000004413 Myocytes, Cardiac Anatomy 0.000 description 6
- 241000288906 Primates Species 0.000 description 6
- 150000007513 acids Chemical class 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- 230000000747 cardiac effect Effects 0.000 description 6
- 230000004087 circulation Effects 0.000 description 6
- 230000024203 complement activation Effects 0.000 description 6
- 230000002222 downregulating Effects 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 230000014759 maintenance of location Effects 0.000 description 6
- 230000036470 plasma concentration Effects 0.000 description 6
- 230000008929 regeneration Effects 0.000 description 6
- 238000011069 regeneration method Methods 0.000 description 6
- 230000000087 stabilizing Effects 0.000 description 6
- MSSXOMSJDRHRMC-UHFFFAOYSA-N 2,6-Diaminopurine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 description 5
- GJTBSTBJLVYKAU-XVFCMESISA-N 2-thiouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=S)NC(=O)C=C1 GJTBSTBJLVYKAU-XVFCMESISA-N 0.000 description 5
- ZLAQATDNGLKIEV-UHFFFAOYSA-N 5-methyl-2-sulfanylidene-1H-pyrimidin-4-one Chemical compound CC1=CNC(=S)NC1=O ZLAQATDNGLKIEV-UHFFFAOYSA-N 0.000 description 5
- 102100001085 APOB Human genes 0.000 description 5
- 101710038084 ARG1 Proteins 0.000 description 5
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Natural products NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 5
- 229960000643 Adenine Drugs 0.000 description 5
- 210000001367 Arteries Anatomy 0.000 description 5
- 206010016654 Fibrosis Diseases 0.000 description 5
- 208000009576 Hypercholesterolemia Diseases 0.000 description 5
- 229920002459 Intron Polymers 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- ZEMGGZBWXRYJHK-UHFFFAOYSA-N Thiouracil Chemical compound O=C1C=CNC(=S)N1 ZEMGGZBWXRYJHK-UHFFFAOYSA-N 0.000 description 5
- 229940035295 Ting Drugs 0.000 description 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 5
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 description 5
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 5
- 210000002317 cardiac myocyte Anatomy 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- 238000009509 drug development Methods 0.000 description 5
- 230000002708 enhancing Effects 0.000 description 5
- 230000002255 enzymatic Effects 0.000 description 5
- 230000004761 fibrosis Effects 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 230000001404 mediated Effects 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 230000004614 tumor growth Effects 0.000 description 5
- 210000000481 Breast Anatomy 0.000 description 4
- 208000005623 Carcinogenesis Diseases 0.000 description 4
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 4
- 108009000280 Complement Activation Proteins 0.000 description 4
- 102000002494 Endoribonucleases Human genes 0.000 description 4
- 108010093099 Endoribonucleases Proteins 0.000 description 4
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 4
- 206010061255 Ischaemia Diseases 0.000 description 4
- 108050005300 MDM4 Proteins 0.000 description 4
- 206010027476 Metastasis Diseases 0.000 description 4
- 229920001850 Nucleic acid sequence Polymers 0.000 description 4
- 210000002307 Prostate Anatomy 0.000 description 4
- 102000001309 Proto-Oncogene Proteins c-mdm2 Human genes 0.000 description 4
- 241001459538 Ute Species 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000001093 anti-cancer Effects 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 230000004700 cellular uptake Effects 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 230000000368 destabilizing Effects 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 239000011737 fluorine Substances 0.000 description 4
- 229910052731 fluorine Inorganic materials 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000002452 interceptive Effects 0.000 description 4
- 230000003834 intracellular Effects 0.000 description 4
- 230000000670 limiting Effects 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 230000003211 malignant Effects 0.000 description 4
- JUHDUIDUEUEQND-UHFFFAOYSA-N methylium Chemical compound [CH3+] JUHDUIDUEUEQND-UHFFFAOYSA-N 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 238000005457 optimization Methods 0.000 description 4
- 210000002856 peripheral neuron Anatomy 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 230000001737 promoting Effects 0.000 description 4
- 230000000717 retained Effects 0.000 description 4
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- OVONXEQGWXGFJD-UHFFFAOYSA-N 4-sulfanylidene-1H-pyrimidin-2-one Chemical compound SC=1C=CNC(=O)N=1 OVONXEQGWXGFJD-UHFFFAOYSA-N 0.000 description 3
- 210000003050 Axons Anatomy 0.000 description 3
- 101710032374 BCL2L1 Proteins 0.000 description 3
- 102100015655 BCL2L1 Human genes 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 3
- 210000001072 Colon Anatomy 0.000 description 3
- 102100017555 DFFB Human genes 0.000 description 3
- 101700036757 ERN1 Proteins 0.000 description 3
- 102100016655 ERN1 Human genes 0.000 description 3
- 101700014948 ERN2 Proteins 0.000 description 3
- 101710003775 ERVK-10 Proteins 0.000 description 3
- 101710037030 ERVK-11 Proteins 0.000 description 3
- 101710009283 ERVK-18 Proteins 0.000 description 3
- 101710009286 ERVK-19 Proteins 0.000 description 3
- 102000033147 ERVK-25 Human genes 0.000 description 3
- 101710035700 ERVK-25 Proteins 0.000 description 3
- 101710038044 ERVK-6 Proteins 0.000 description 3
- 101710014468 ERVK-7 Proteins 0.000 description 3
- 101710014482 ERVK-8 Proteins 0.000 description 3
- 210000002615 Epidermis Anatomy 0.000 description 3
- 102100003082 FASLG Human genes 0.000 description 3
- 108010039471 Fas Ligand Protein Proteins 0.000 description 3
- 101710043924 HERVK_113 Proteins 0.000 description 3
- 230000036499 Half live Effects 0.000 description 3
- 206010020880 Hypertrophy Diseases 0.000 description 3
- 101700085586 IRE1A Proteins 0.000 description 3
- 101700019719 IRE1B Proteins 0.000 description 3
- 206010022114 Injury Diseases 0.000 description 3
- 238000008214 LDL Cholesterol Methods 0.000 description 3
- 210000004698 Lymphocytes Anatomy 0.000 description 3
- 208000003067 Myocardial Ischemia Diseases 0.000 description 3
- 206010052639 Nerve injury Diseases 0.000 description 3
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 description 3
- 108009000071 Non-small cell lung cancer Proteins 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 102000016187 PAZ domain Human genes 0.000 description 3
- 108050004670 PAZ domain Proteins 0.000 description 3
- 102000003993 Phosphatidylinositol 3-Kinases Human genes 0.000 description 3
- 108090000430 Phosphatidylinositol 3-Kinases Proteins 0.000 description 3
- 230000037289 Plasma half life Effects 0.000 description 3
- 230000037240 Plasma half-life Effects 0.000 description 3
- 101710006375 RNASEH1 Proteins 0.000 description 3
- 101700078434 RT67 Proteins 0.000 description 3
- 229920001891 Small hairpin RNA Polymers 0.000 description 3
- 206010042953 Systemic sclerosis Diseases 0.000 description 3
- 102100011579 USP7 Human genes 0.000 description 3
- 101700067451 USP7 Proteins 0.000 description 3
- DRTQHJPVMGBUCF-UCVXFZOQSA-N Uridine Natural products O[C@H]1[C@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UCVXFZOQSA-N 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 230000001058 adult Effects 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 229940037003 alum Drugs 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 230000000903 blocking Effects 0.000 description 3
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 3
- 229910052796 boron Inorganic materials 0.000 description 3
- 238000007385 chemical modification Methods 0.000 description 3
- 230000001447 compensatory Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 230000030279 gene silencing Effects 0.000 description 3
- 150000008282 halocarbons Chemical class 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 230000001976 improved Effects 0.000 description 3
- 230000002757 inflammatory Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 230000015788 innate immune response Effects 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 101700052395 ire-1 Proteins 0.000 description 3
- 239000002105 nanoparticle Substances 0.000 description 3
- 230000001537 neural Effects 0.000 description 3
- 210000002569 neurons Anatomy 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 230000002611 ovarian Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 238000003825 pressing Methods 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 3
- 201000000582 retinoblastoma Diseases 0.000 description 3
- 101700086982 rnh Proteins 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 239000004055 small Interfering RNA Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 201000009594 systemic scleroderma Diseases 0.000 description 3
- 230000001052 transient Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- DCTOHCCUXLBQMS-UHFFFAOYSA-N 1-undecene Chemical compound CCCCCCCCCC=C DCTOHCCUXLBQMS-UHFFFAOYSA-N 0.000 description 2
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Chemical compound C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 2
- JRYMOPZHXMVHTA-DAGMQNCNSA-N 2-amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-pyrrolo[2,3-d]pyrimidin-4-one Chemical compound C1=CC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O JRYMOPZHXMVHTA-DAGMQNCNSA-N 0.000 description 2
- XUYJLQHKOGNDPB-UHFFFAOYSA-M 2-phosphonoacetate Chemical compound OP(O)(=O)CC([O-])=O XUYJLQHKOGNDPB-UHFFFAOYSA-M 0.000 description 2
- 108020005345 3' Untranslated Regions Proteins 0.000 description 2
- 101700006234 AKT1 Proteins 0.000 description 2
- 102100001249 ALB Human genes 0.000 description 2
- 101710027066 ALB Proteins 0.000 description 2
- 206010000880 Acute myeloid leukaemia Diseases 0.000 description 2
- NMYKBZSMOUFOJV-FJSWQEPZSA-N Aprinocarsen Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)CO)[C@@H](OP(O)(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)OP(O)(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)C1 NMYKBZSMOUFOJV-FJSWQEPZSA-N 0.000 description 2
- 229950004932 Aprinocarsen Drugs 0.000 description 2
- 206010003246 Arthritis Diseases 0.000 description 2
- 210000004556 Brain Anatomy 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 229950000741 CENERSEN Drugs 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- 208000008787 Cardiovascular Disease Diseases 0.000 description 2
- 102000019679 Cell-Penetrating Peptides Human genes 0.000 description 2
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 description 2
- UTNSIDJKCKLZLN-UHFFFAOYSA-N Cenersen sodium Chemical compound O1C(N2C(N=C(N)C=C2)=O)C(OC)C(O)C1COP(O)(=S)OC(C(C(O1)N2C(N=C(N)C=C2)=O)OC)C1COP(O)(=S)OC(C(C(O1)N2C3=NC=NC(N)=C3N=C2)OC)C1COP(O)(=S)OC1CC(N2C(N=C(N)C=C2)=O)OC1COP(O)(=S)OC1CC(N2C3=C(C(NC(N)=N3)=O)N=C2)OC1COP(O)(=S)OC1CC(N2C(NC(=O)C(C)=C2)=O)OC1COP(O)(=S)OC1CC(N2C(NC(=O)C(C)=C2)=O)OC1COP(O)(=S)OC1CC(N2C(N=C(N)C=C2)=O)OC1COP(O)(=S)OC1CC(N2C(NC(=O)C(C)=C2)=O)OC1COP(O)(=S)OC(C(O1)COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)CO)CC1N1C=CC(N)=NC1=O UTNSIDJKCKLZLN-UHFFFAOYSA-N 0.000 description 2
- 210000003169 Central Nervous System Anatomy 0.000 description 2
- 230000037250 Clearance Effects 0.000 description 2
- 240000002347 Colocasia esculenta Species 0.000 description 2
- 235000006481 Colocasia esculenta Nutrition 0.000 description 2
- 108020004394 Complementary RNA Proteins 0.000 description 2
- JCAIWDXKLCEQEO-LXOWHHAPSA-N Copalyl diphosphate Natural products [P@@](=O)(OP(=O)(O)O)(OC/C=C(\CC[C@H]1C(=C)CC[C@H]2C(C)(C)CCC[C@@]12C)/C)O JCAIWDXKLCEQEO-LXOWHHAPSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 229940104302 Cytosine Drugs 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N Cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N DEOXYTHYMIDINE Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 230000036947 Dissociation constant Effects 0.000 description 2
- 101700057458 Drice Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 206010058108 Dyslipidaemia Diseases 0.000 description 2
- 206010014561 Emphysema Diseases 0.000 description 2
- 210000001163 Endosomes Anatomy 0.000 description 2
- NBVXSUQYWXRMNV-UHFFFAOYSA-N Fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 2
- 206010017758 Gastric cancer Diseases 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 210000003128 Head Anatomy 0.000 description 2
- 208000006454 Hepatitis Diseases 0.000 description 2
- 210000003494 Hepatocytes Anatomy 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 229940088597 Hormone Drugs 0.000 description 2
- 206010062060 Hyperlipidaemia Diseases 0.000 description 2
- OMEUGRCNAZNQLN-UHFFFAOYSA-N ISIS 5132 Chemical compound O=C1NC(=O)C(C)=CN1C1OC(COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(S)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)CO)C(O)C1 OMEUGRCNAZNQLN-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000003746 Insulin Receptor Human genes 0.000 description 2
- 108010001127 Insulin Receptor Proteins 0.000 description 2
- 206010022489 Insulin resistance Diseases 0.000 description 2
- 102000003812 Interleukin-15 Human genes 0.000 description 2
- 108090000172 Interleukin-15 Proteins 0.000 description 2
- 102100019516 JAK2 Human genes 0.000 description 2
- 210000001630 Jejunum Anatomy 0.000 description 2
- 210000000822 Killer Cells, Natural Anatomy 0.000 description 2
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N Leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 2
- 102000016267 Leptin Human genes 0.000 description 2
- 108010092277 Leptin Proteins 0.000 description 2
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 108060001084 Luciferase family Proteins 0.000 description 2
- 101710028361 MARVELD2 Proteins 0.000 description 2
- 102100013322 MTOR Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 244000278455 Morus laevigata Species 0.000 description 2
- 235000013382 Morus laevigata Nutrition 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 210000003739 Neck Anatomy 0.000 description 2
- 206010053643 Neurodegenerative disease Diseases 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N Oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 108060005900 PDCD4 Proteins 0.000 description 2
- 208000008443 Pancreatic Carcinoma Diseases 0.000 description 2
- 206010061536 Parkinson's disease Diseases 0.000 description 2
- 230000036823 Plasma Levels Effects 0.000 description 2
- 108020004412 RNA 3' Polyadenylation Signals Proteins 0.000 description 2
- 230000004570 RNA-binding Effects 0.000 description 2
- 210000003705 Ribosomes Anatomy 0.000 description 2
- 210000002966 Serum Anatomy 0.000 description 2
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N Thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 229940045145 Uridine Drugs 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 229940050528 albumin Drugs 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 108090001123 antibodies Proteins 0.000 description 2
- 102000004965 antibodies Human genes 0.000 description 2
- 230000003143 atherosclerotic Effects 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 125000005841 biaryl group Chemical group 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 230000002490 cerebral Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 108091006028 chimera Proteins 0.000 description 2
- 230000001684 chronic Effects 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 230000035512 clearance Effects 0.000 description 2
- 230000002860 competitive Effects 0.000 description 2
- 239000003184 complementary RNA Substances 0.000 description 2
- 230000001472 cytotoxic Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000002354 daily Effects 0.000 description 2
- 230000000254 damaging Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000002716 delivery method Methods 0.000 description 2
- DMJZZSLVPSMWCS-UHFFFAOYSA-N diborane Chemical compound B1[H]B[H]1 DMJZZSLVPSMWCS-UHFFFAOYSA-N 0.000 description 2
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical class [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 201000009846 fatty liver disease Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000000302 ischemic Effects 0.000 description 2
- 230000002045 lasting Effects 0.000 description 2
- 229940039781 leptin Drugs 0.000 description 2
- 230000003902 lesions Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 108010045030 monoclonal antibodies Proteins 0.000 description 2
- 102000005614 monoclonal antibodies Human genes 0.000 description 2
- 230000002107 myocardial Effects 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- GQPLMRYTRLFLPF-UHFFFAOYSA-N nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 230000000865 phosphorylative Effects 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 101710039033 pkbA Proteins 0.000 description 2
- 230000001124 posttranscriptional Effects 0.000 description 2
- 230000032361 posttranscriptional gene silencing Effects 0.000 description 2
- 230000002335 preservative Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000001294 propane Substances 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 230000001172 regenerating Effects 0.000 description 2
- 230000001105 regulatory Effects 0.000 description 2
- 230000000268 renotropic Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 2
- 231100000486 side effect Toxicity 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 210000001082 somatic cell Anatomy 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 230000002588 toxic Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 231100000027 toxicology Toxicity 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000002103 transcriptional Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- PISWNSOQFZRVJK-XLPZGREQSA-N 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-2-sulfanylidenepyrimidin-4-one Chemical compound S=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 PISWNSOQFZRVJK-XLPZGREQSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- KYSHJYRTCHNGDK-UHFFFAOYSA-N 1H-indole;2H-oxazaphosphinine Chemical compound N1OC=CC=P1.C1=CC=C2NC=CC2=C1 KYSHJYRTCHNGDK-UHFFFAOYSA-N 0.000 description 1
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- 108010000834 2-5A-dependent ribonuclease Proteins 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N 289-95-2 Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 229920001383 5S-rRNA precursor Polymers 0.000 description 1
- BSZLBGCNMDEPRE-UHFFFAOYSA-N 7H-purin-6-amine;4-sulfanylidene-1H-pyrimidin-2-one Chemical compound O=C1NC=CC(=S)N1.NC1=NC=NC2=C1NC=N2 BSZLBGCNMDEPRE-UHFFFAOYSA-N 0.000 description 1
- 101700086422 ARAF Proteins 0.000 description 1
- 102100011069 ARAF Human genes 0.000 description 1
- 206010000565 Acquired immunodeficiency syndrome Diseases 0.000 description 1
- 208000007788 Acute Liver Failure Diseases 0.000 description 1
- 206010000804 Acute hepatic failure Diseases 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 208000002353 Alcoholic Hepatitis Diseases 0.000 description 1
- 206010001897 Alzheimer's disease Diseases 0.000 description 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N Amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
- 208000007502 Anemia Diseases 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 229920002395 Aptamer Polymers 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 208000006673 Asthma Diseases 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 206010003816 Autoimmune disease Diseases 0.000 description 1
- 108009000409 Autophagy Proteins 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N BRL-49594 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 101700027621 CCAC Proteins 0.000 description 1
- 102100019144 CD46 Human genes 0.000 description 1
- 101710027020 CD46 Proteins 0.000 description 1
- 101700010918 CPP1 Proteins 0.000 description 1
- 101700024612 CTRL Proteins 0.000 description 1
- 102100008563 CTRL Human genes 0.000 description 1
- 210000001736 Capillaries Anatomy 0.000 description 1
- 206010007558 Cardiac failure chronic Diseases 0.000 description 1
- IVUMCTKHWDRRMH-UHFFFAOYSA-N Carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 108010031896 Cell Cycle Proteins Proteins 0.000 description 1
- 102000005483 Cell Cycle Proteins Human genes 0.000 description 1
- 210000000170 Cell Membrane Anatomy 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 206010008479 Chest pain Diseases 0.000 description 1
- 206010067969 Cholestatic liver injury Diseases 0.000 description 1
- 208000003053 Chromosome 5q Deletion Syndrome Diseases 0.000 description 1
- 210000000349 Chromosomes Anatomy 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 206010009192 Circulatory collapse Diseases 0.000 description 1
- 229920001405 Coding region Polymers 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010010099 Combined immunodeficiency Diseases 0.000 description 1
- 229920002676 Complementary DNA Polymers 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 210000004351 Coronary Vessels Anatomy 0.000 description 1
- 206010011401 Crohn's disease Diseases 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-XVFCMESISA-N Cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-XVFCMESISA-N 0.000 description 1
- 102100017556 DFFA Human genes 0.000 description 1
- 101700075195 DFFA Proteins 0.000 description 1
- 108009000097 DNA Replication Proteins 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 108010003605 DO-7 monoclonal antibody Proteins 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010012305 Demyelination Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 108030007123 EC 3.4.21.61 Proteins 0.000 description 1
- 210000001671 Embryonic Stem Cells Anatomy 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000854350 Enicospilus group Species 0.000 description 1
- 108010002700 Exoribonucleases Proteins 0.000 description 1
- 102000004678 Exoribonucleases Human genes 0.000 description 1
- 210000001808 Exosomes Anatomy 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 206010018987 Haemorrhage Diseases 0.000 description 1
- 208000004559 Hearing Loss Diseases 0.000 description 1
- 206010011879 Hearing loss Diseases 0.000 description 1
- 210000003958 Hematopoietic Stem Cells Anatomy 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
- 201000001971 Huntington's disease Diseases 0.000 description 1
- 206010020648 Hyperkeratosis Diseases 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 description 1
- 208000000069 Hyperpigmentation Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000016878 Hypoxia-Inducible Factor 1 Human genes 0.000 description 1
- 108010028501 Hypoxia-Inducible Factor 1 Proteins 0.000 description 1
- 102100004115 ICAM1 Human genes 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010021703 Indifference Diseases 0.000 description 1
- 210000004263 Induced Pluripotent Stem Cells Anatomy 0.000 description 1
- 206010021972 Inflammatory bowel disease Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108009000068 Insulin Signaling Proteins 0.000 description 1
- 206010022491 Insulin resistant diabetes Diseases 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 229940096397 Interleukin-8 Drugs 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- XKTZWUACRZHVAN-VADRZIEHSA-N Interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
- 206010065973 Iron overload Diseases 0.000 description 1
- NNPPMTNAJDCUHE-UHFFFAOYSA-N Isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 1
- AEFLONBTGZFSGQ-UHFFFAOYSA-N Isoglutamine Chemical compound NC(=O)C(N)CCC(O)=O AEFLONBTGZFSGQ-UHFFFAOYSA-N 0.000 description 1
- QWTDNUCVQCZILF-UHFFFAOYSA-N Isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 1
- 101700016050 JAK2 Proteins 0.000 description 1
- 108010019437 Janus Kinase 2 Proteins 0.000 description 1
- 101710034566 K02C4.3 Proteins 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N Ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 208000001083 Kidney Disease Diseases 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N L-serine Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 108060004326 LDLR Proteins 0.000 description 1
- 229920001320 Leader sequence (mRNA) Polymers 0.000 description 1
- 229940067606 Lecithin Drugs 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 208000009856 Lung Disease Diseases 0.000 description 1
- 210000003712 Lysosomes Anatomy 0.000 description 1
- 101710017999 MYLIP Proteins 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 230000035888 Maximum plasma concentration Effects 0.000 description 1
- 241001608711 Melo Species 0.000 description 1
- 230000036740 Metabolism Effects 0.000 description 1
- 229920000348 MiR-155 Polymers 0.000 description 1
- 229920001772 MiR-203 Polymers 0.000 description 1
- 206010028154 Multi-organ failure Diseases 0.000 description 1
- 210000002027 Muscle, Skeletal Anatomy 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N N,N-Diethylethanamine Substances CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
- YVXABFKQJVTPTI-RWEMILLDSA-N NCCNC(=O)C[C@@]1(C[C@H](O)[C@@H](CO)O1)N1C(=O)NC(=O)C=C1 Chemical compound NCCNC(=O)C[C@@]1(C[C@H](O)[C@@H](CO)O1)N1C(=O)NC(=O)C=C1 YVXABFKQJVTPTI-RWEMILLDSA-N 0.000 description 1
- 101710045238 NRPS3 Proteins 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N Naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- CRSOQBOWXPBRES-UHFFFAOYSA-N Neopentane Chemical compound CC(C)(C)C CRSOQBOWXPBRES-UHFFFAOYSA-N 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 208000001738 Nervous System Trauma Diseases 0.000 description 1
- 206010029331 Neuropathy peripheral Diseases 0.000 description 1
- 101700053328 OTC Proteins 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- GBDRQVXIOITESO-UHFFFAOYSA-N P.CB Chemical compound P.CB GBDRQVXIOITESO-UHFFFAOYSA-N 0.000 description 1
- 101710041402 PABG_02447 Proteins 0.000 description 1
- 102100014579 PARP1 Human genes 0.000 description 1
- 102100005352 PCSK9 Human genes 0.000 description 1
- 102100019761 PDCD4 Human genes 0.000 description 1
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 1
- 210000000578 Peripheral Nerves Anatomy 0.000 description 1
- 206010034636 Peripheral vascular disease Diseases 0.000 description 1
- 210000000680 Phagosomes Anatomy 0.000 description 1
- RQQIRMLGKSPXSE-UQPICLANSA-N Phosphatidylinositol-3,4,5-trisphosphate Chemical compound CC(=O)OC(OC(C)=O)COP(O)(=O)O[C@@H]1[C@H](O)[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H]1O RQQIRMLGKSPXSE-UQPICLANSA-N 0.000 description 1
- 108091000081 Phosphotransferases Proteins 0.000 description 1
- 230000036660 Plasma protein binding Effects 0.000 description 1
- 108010064218 Poly (ADP-Ribose) Polymerase-1 Proteins 0.000 description 1
- 229920000795 Polyadenylation Polymers 0.000 description 1
- 241000590419 Polygonia interrogationis Species 0.000 description 1
- 208000003619 Porokeratosis Diseases 0.000 description 1
- TVQZAMVBTVNYLA-UHFFFAOYSA-N Pranoprofen Chemical compound C1=CC=C2CC3=CC(C(C(O)=O)C)=CC=C3OC2=N1 TVQZAMVBTVNYLA-UHFFFAOYSA-N 0.000 description 1
- 108010022249 Proprotein Convertase 9 Proteins 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 102000001253 Protein Kinases Human genes 0.000 description 1
- 102000002727 Protein Tyrosine Phosphatases Human genes 0.000 description 1
- 108020000494 Protein Tyrosine Phosphatases Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 208000005069 Pulmonary Fibrosis Diseases 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- BBEAQIROQSPTKN-UHFFFAOYSA-N Pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 1
- 102100005147 RNASEL Human genes 0.000 description 1
- 206010038436 Renal failure acute Diseases 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 241000242739 Renilla Species 0.000 description 1
- 102000004167 Ribonuclease P Human genes 0.000 description 1
- 108090000621 Ribonuclease P Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000004389 Ribonucleoproteins Human genes 0.000 description 1
- 108010081734 Ribonucleoproteins Proteins 0.000 description 1
- 102100003617 SCNN1A Human genes 0.000 description 1
- 108060000361 SCNN1A Proteins 0.000 description 1
- 101700071021 SETD2 Proteins 0.000 description 1
- 102100000940 SETD2 Human genes 0.000 description 1
- 101710041568 SPCC1223.14 Proteins 0.000 description 1
- 101700002422 STAT3 Proteins 0.000 description 1
- 102100019667 STAT3 Human genes 0.000 description 1
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 1
- 210000004116 Schwann Cells Anatomy 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 210000002265 Sensory Receptor Cells Anatomy 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 208000005682 Shwachman syndrome Diseases 0.000 description 1
- 201000004283 Shwachman-Diamond syndrome Diseases 0.000 description 1
- 108020004459 Small Interfering RNA Proteins 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- 229960000391 Sorbitan trioleate Drugs 0.000 description 1
- 208000008513 Spinal Cord Injury Diseases 0.000 description 1
- 208000007718 Stable Angina Diseases 0.000 description 1
- 210000002784 Stomach Anatomy 0.000 description 1
- MDKGKXOCJGEUJW-UHFFFAOYSA-N Suprofen Chemical compound C1=CC(C(C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 MDKGKXOCJGEUJW-UHFFFAOYSA-N 0.000 description 1
- 229960004492 Suprofen Drugs 0.000 description 1
- 101700004103 TEP1 Proteins 0.000 description 1
- 102000004591 Telomerase Human genes 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 210000001550 Testis Anatomy 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 229940113082 Thymine Drugs 0.000 description 1
- GUHPRPJDBZHYCJ-UHFFFAOYSA-N Tiaprofenic acid Chemical compound S1C(C(C(O)=O)C)=CC=C1C(=O)C1=CC=CC=C1 GUHPRPJDBZHYCJ-UHFFFAOYSA-N 0.000 description 1
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 description 1
- 101710010090 USP46 Proteins 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102400000757 Ubiquitin Human genes 0.000 description 1
- 210000003932 Urinary Bladder Anatomy 0.000 description 1
- 210000003462 Veins Anatomy 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 102100002663 XPO5 Human genes 0.000 description 1
- 101700031704 XPO5 Proteins 0.000 description 1
- 101700078629 YWP1 Proteins 0.000 description 1
- SJEHRUIZCVJWGX-UHFFFAOYSA-N [1-(hydroxymethyl)-2H-pyridin-3-yl]methanol Chemical compound OCN1CC(CO)=CC=C1 SJEHRUIZCVJWGX-UHFFFAOYSA-N 0.000 description 1
- XMUZQOKACOLCSS-UHFFFAOYSA-N [2-(hydroxymethyl)phenyl]methanol Chemical compound OCC1=CC=CC=C1CO XMUZQOKACOLCSS-UHFFFAOYSA-N 0.000 description 1
- PRXRUNOAOLTIEF-XDTJCZEISA-N [2-[(2R,3S,4R)-4-hydroxy-3-[(Z)-octadec-9-enoyl]oxyoxolan-2-yl]-2-[(Z)-octadec-9-enoyl]oxyethyl] (Z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@@H](O)[C@@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-XDTJCZEISA-N 0.000 description 1
- YWMLORGQOFONNT-UHFFFAOYSA-N [3-(hydroxymethyl)phenyl]methanol Chemical compound OCC1=CC=CC(CO)=C1 YWMLORGQOFONNT-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating Effects 0.000 description 1
- 231100000836 acute liver failure Toxicity 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000002730 additional Effects 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 231100000494 adverse effect Toxicity 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 201000004384 alopecia Diseases 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000002424 anti-apoptotic Effects 0.000 description 1
- 230000000111 anti-oxidant Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 description 1
- 229940045698 antineoplastic Taxanes Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000001640 apoptogenic Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000002215 arabinonucleoside Substances 0.000 description 1
- 101700017456 asd-1 Proteins 0.000 description 1
- 125000004429 atoms Chemical group 0.000 description 1
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 description 1
- 230000006877 autophagy Effects 0.000 description 1
- 238000007068 beta-elimination reaction Methods 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- 229910000090 borane Inorganic materials 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 201000006474 brain ischemia Diseases 0.000 description 1
- 238000009937 brining Methods 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- 201000005488 capillary leak syndrome Diseases 0.000 description 1
- 125000004432 carbon atoms Chemical group C* 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 229960003184 carprofen Drugs 0.000 description 1
- 108010042238 caspase-activated deoxyribonuclease Proteins 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 201000001084 cerebrovascular disease Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
- KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 description 1
- 230000031154 cholesterol homeostasis Effects 0.000 description 1
- 230000002759 chromosomal Effects 0.000 description 1
- 201000002403 combined T cell and B cell immunodeficiency Diseases 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 201000008739 coronary artery disease Diseases 0.000 description 1
- 230000002596 correlated Effects 0.000 description 1
- 210000003618 cortical neuron Anatomy 0.000 description 1
- 230000001808 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000010192 crystallographic characterization Methods 0.000 description 1
- 230000001186 cumulative Effects 0.000 description 1
- 201000003883 cystic fibrosis Diseases 0.000 description 1
- 230000001086 cytosolic Effects 0.000 description 1
- 230000000593 degrading Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 230000001809 detectable Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000001627 detrimental Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940000406 drug candidates Drugs 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 101700057606 elaD Proteins 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 108091005938 enhanced green fluorescent protein Proteins 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000006872 enzymatic polymerization reaction Methods 0.000 description 1
- 230000001586 eradicative Effects 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000001747 exhibiting Effects 0.000 description 1
- 201000001386 familial hypercholesterolemia Diseases 0.000 description 1
- 102000018823 fas Receptor Human genes 0.000 description 1
- 108010052621 fas Receptor Proteins 0.000 description 1
- 230000002349 favourable Effects 0.000 description 1
- 230000001605 fetal Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000004992 fission Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000002068 genetic Effects 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth media Substances 0.000 description 1
- 230000003394 haemopoietic Effects 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium(0) Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 230000028974 hepatocyte apoptotic process Effects 0.000 description 1
- 230000003082 hepatotoxic Effects 0.000 description 1
- 231100000334 hepatotoxic Toxicity 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 239000001257 hydrogen Chemical group 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 description 1
- 230000002209 hydrophobic Effects 0.000 description 1
- 230000003810 hyperpigmentation Effects 0.000 description 1
- 231100001006 hyperpigmentation Toxicity 0.000 description 1
- 230000001969 hypertrophic Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000003308 immunostimulating Effects 0.000 description 1
- 230000001506 immunosuppresive Effects 0.000 description 1
- 230000000415 inactivating Effects 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000000977 initiatory Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 239000001282 iso-butane Substances 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 200000000010 kidney injury Diseases 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 230000004301 light adaptation Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000004044 liver cirrhosis Diseases 0.000 description 1
- 201000009673 liver disease Diseases 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000007762 localization of cell Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000000527 lymphocytic Effects 0.000 description 1
- 230000002132 lysosomal Effects 0.000 description 1
- 230000001868 lysosomic Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 210000004962 mammalian cells Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 media Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000003340 mental Effects 0.000 description 1
- 230000035786 metabolism Effects 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-L methylphosphonate(2-) Chemical compound CP([O-])([O-])=O YACKEPLHDIMKIO-UHFFFAOYSA-L 0.000 description 1
- 108091007170 miR-29 Proteins 0.000 description 1
- 108091007171 miR-29b Proteins 0.000 description 1
- 229920005625 miR-34b Polymers 0.000 description 1
- 230000000394 mitotic Effects 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 229960000060 monoclonal antibodies Drugs 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 1
- 229940113083 morpholine Drugs 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000000663 muscle cells Anatomy 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 210000003867 nerve cell Anatomy 0.000 description 1
- 230000014511 neuron projection development Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000001272 nitrous oxide Substances 0.000 description 1
- 230000003000 nontoxic Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 229960000435 oblimersen Drugs 0.000 description 1
- MIMNFCVQODTQDP-NDLVEFNKSA-N oblimersen Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(S)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)CO)[C@@H](O)C1 MIMNFCVQODTQDP-NDLVEFNKSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000000056 organs Anatomy 0.000 description 1
- IIWVFLOQEJCOIX-UHFFFAOYSA-N oxathiaphospholane Chemical compound C1CPSO1 IIWVFLOQEJCOIX-UHFFFAOYSA-N 0.000 description 1
- UQZZQHGRZPTZME-UHFFFAOYSA-N oxazaphospholidine Chemical compound C1CPNO1 UQZZQHGRZPTZME-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 125000004430 oxygen atoms Chemical group O* 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N p-acetaminophenol Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial Effects 0.000 description 1
- 230000001717 pathogenic Effects 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008249 pharmaceutical aerosol Substances 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920000023 polynucleotide Polymers 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000003389 potentiating Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960003101 pranoprofen Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001581 pretranslational Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002035 prolonged Effects 0.000 description 1
- 230000026938 proteasomal ubiquitin-dependent protein catabolic process Effects 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000001681 protective Effects 0.000 description 1
- 230000002685 pulmonary Effects 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N rac-1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000000241 respiratory Effects 0.000 description 1
- 230000000284 resting Effects 0.000 description 1
- 230000002441 reversible Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 101700035834 sdeA Proteins 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000001235 sensitizing Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000002924 silencing RNA Substances 0.000 description 1
- 238000007390 skin biopsy Methods 0.000 description 1
- 230000000391 smoking Effects 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- FIWQZURFGYXCEO-UHFFFAOYSA-M sodium;decanoate Chemical compound [Na+].CCCCCCCCCC([O-])=O FIWQZURFGYXCEO-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 238000004793 spatially offset Raman spectroscopy Methods 0.000 description 1
- 108010068698 spleen exonuclease Proteins 0.000 description 1
- 230000002269 spontaneous Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 101700082652 sseL Proteins 0.000 description 1
- 230000003068 static Effects 0.000 description 1
- 230000004936 stimulating Effects 0.000 description 1
- 235000021092 sugar substitutes Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000000153 supplemental Effects 0.000 description 1
- 230000003319 supportive Effects 0.000 description 1
- 230000004083 survival Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 201000010874 syndrome Diseases 0.000 description 1
- 229960001312 tiaprofenic acid Drugs 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000000699 topical Effects 0.000 description 1
- 230000002110 toxicologic Effects 0.000 description 1
- 102000003995 transcription factors Human genes 0.000 description 1
- 108090000464 transcription factors Proteins 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 230000001131 transforming Effects 0.000 description 1
- 230000001960 triggered Effects 0.000 description 1
- UORVGPXVDQYIDP-UHFFFAOYSA-N trihydridoboron Substances B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 230000003442 weekly Effects 0.000 description 1
- 200000000019 wound Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
- C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
- C12N2320/52—Methods for regulating/modulating their activity modulating the physical stability, e.g. GC-content
Abstract
Disclosed is an in vitro screening method for selecting an antisense strand binding site on a ribonucleic acid target of interest, said method comprising; (i) identifying a site on said target that is available for antisense strand binding using an antisense oligonucleotide; (ii) obtaining a set of a first and a second oligonucleotide with sequences capable of forming a duplex or a set of a first and a second oligonucleotide that are not complementary to each other but which are capable of forming a duplex with a third strand where in at least one strand is complementary to the site identified as available for binding in (i); (iii) modifying said oligonucleotide strands to increase their stability and activity; (iv) contacting a cell expressing said target with said first oligonucleotide strand or said two non-complementary strands and providing a suitable amount of time for said strand(s) to enter said cell; (v) contacting said cell with said second or said second and third oligonucleotide strands not complementary to each other but complementary to a strand in (iv) and; (vi) determining the expression of the target sequence as compared to the expression of the target sequence without step (iii). of a first and a second oligonucleotide with sequences capable of forming a duplex or a set of a first and a second oligonucleotide that are not complementary to each other but which are capable of forming a duplex with a third strand where in at least one strand is complementary to the site identified as available for binding in (i); (iii) modifying said oligonucleotide strands to increase their stability and activity; (iv) contacting a cell expressing said target with said first oligonucleotide strand or said two non-complementary strands and providing a suitable amount of time for said strand(s) to enter said cell; (v) contacting said cell with said second or said second and third oligonucleotide strands not complementary to each other but complementary to a strand in (iv) and; (vi) determining the expression of the target sequence as compared to the expression of the target sequence without step (iii).
Description
METHODS AND COMPOSITIONS FOR MODULATING GENE EXPRESSION
USING COMPONENTS THAT SELF ASSEMBLE IN CELLS AND PRODUCE RNAi
ACTIVITY
This application claims priority to US Provisional Application Nos:61/477,283,
61/477,291 each filed April 20, 2011 and 61/477,875 filed April 21, 2011 respectively, the
sure of all of the ing applications being incorporated herein by nce as
though set forth in full.
FIELD OF THE INVENTION
This invention relates to the fields of medicine, drug development and modulation of
gene expression. More specifically, the invention provides compositions and methods of use
thereof that facilitate the modulation of gene expression using novel oligonucleotide based
drugs that produce an inhibitory RNA (RNAi) ism of .
BACKGROUND OF THE INVENTION
Numerous publications and patent nts, including both published applications
and issued patents, are cited throughout the specification in order to be the state of the
art to which this invention pertains. Each of these citations is incorporated herein by
reference as though set forth in full.
RNA interference (RNAi) refers to molecules and isms whereby n
double stranded RNA (dsRNA) structures (RNAi rs) cause sequence specific gene
inhibition. Two main categories of RNAi have been distinguished: small inhibitory RNA
(siRNA) and microRNA (miRNA). In the case of naturally occurring siRNA the original
source of the dsRNA is exogenous to the cell or it is derived from transposable elements
within the cell. Cells may then process the dsRNA to produce siRNA that can specifically
suppress the activity of the source of the dsRNA. The exogenous sources include certain
viruses where the siRNA generated provides a defense mechanism against such rs.
In contrast, naturally occurring miRNA is produced from precursor molecules that are
generated from independent genes or from very short intron sequences found in some protein
encoding genes. Unlike siRNA molecules, miRNA molecules broadly inhibit le
different genes rather than being narrowly focused on a particular gene. Thus, naturally
ing siRNA characteristically performs more narrowly d inhibitory actions than
does miRNA.
These differences are reflected, in part, in the "targeting codes" that are associated
with these two classes of RNAi. The targeting code can be briefly defined as the subset of the
antisense strand sequence that is primarily or fully responsible for recognizing the target
sequence by complementary base pairing. (Ambros et al., RNA, e a more ed
description of how naturally ing siRNA and miRNA can be experimentally
guished and annotated 9: 277-279, 2003.)
The general mechanisms that underlie the implementation of siRNA and miRNA-
dependent activity are substantially overlapping, but the particulars of how siRNA and
miRNA function to suppress gene expression are substantially different. At the heart of the
general isms able to both of these types of RNAi is the RNA-induced silencing
complex (RISC). The double stranded siRNA or miRNA is loaded into RISC. Next the
sense strand is discarded and the antisense strand is used to direct RISC to its target(s).
In the case of siRNA typically and for a subset of , the RISC complex
includes an enzyme called argonaute-2 (AGO-2) that cleaves a specific mRNA target. Other
enzymes recognize the bifurcated mRNA as abnormal and further degrade it. mRNA
cleavage by AGO-2 requires a high degree of sequence complementarity between the guide
strand and its target particularly with t to the nucleosides adjacent to the AGO-2
cleavage side that are located a positions 10 and 11 counting from the 5'-end of the guide
strand along with several of the nucleosides on either side of positions 10 and 11. The
nucleoside sequence found at this location (central region) is the targeting code in this
context. Typically a perfect complementarity between the targeting code nucleosides and the
corresponding target sides is required for AGO-2 based cleavage. Additional
nucleosides out side of this targeting code can also affect the efficiency of the target
recognition and functional inhibition by RISC but some mismatches can be tolerated in these
flanking areas.
Genome wide identification of miRNA targets and computational predictions estimate
that each mammalian miRNA on average inhibits the expression of ds of different
mRNAs. Thus, miRNA can be involved in coordinating patterns of gene expression. The
ability of particular miRNAs to produce a particular cellular phenotype, however, can be
based on the modulation of the expression of as few genes as one. Most mammalian genes
appear to be post-transcriptionally regulated by miRNAs. Abnormalities in the expression of
particular miRNAs have pathogenic roles in a wide range of medical disorders.
The targeting code most ly used by miRNA resides in a so called "seed
sequence" that is made up of nucleosides 2-8(or 2-7) counting in from the 5'-end of the guide
or antisense strand. This sequence is the major determinant of target recognition and is
sufficient to trigger translational silencing. Target sequences are found in the 3’-untranslated
region (3’UTR) of the mRNA targets. Infrequently, mentarity between nucleosides
down-stream of the seed sequence and the target contribute to target recognition particularly
when the seed ce has a weak match with the target. These are called 3'-supplementary
or 3'-compensatory sites.
r category of miRNA es a target code involving "centered sites" that
consist of 11 or 12 consecutive nucleosides that begin at on 4 or 5 downstream from the
'-end of the guide or antisense strand. To date no 3'-supplementary or 3'-compensatory sites
have been uncovered that support target recognition by the targeting code.
MiRNA, other than the few with a siRNA-like tory mechanism, can suppress
the translation of specific sets of mRNA by interfering with the translation machinery without
affecting mRNA levels and/or by causing the mRNA to be degraded by promoting the
ions necessary to te the naturally occurring 3' mRNA decay pathway.
In addition to the common targeting of the 3'UTR of mRNA, some miRNAs have
been found to target the 5'-UTR or to the coding region of some mRNAs. In some of these
cases the miRNA/RISC complex inhibits the translation of the target mRNA and in others
translation is promoted. Further, there are instances of certain miRNAs forming complexes
with ribonucleoproteins and thus interfering with their RNA binding functions in a RISC-
independent manner. Finally, there are also documented instances in which miRNAs can
affect transcription of particular genes by binding to DNA.
Over the last dozen years, RNAi related mechanisms involving siRNA and miRNA
have been substantially elucidated and found to occur widely in both plants and animals
including in all human cell types. In turn, these advances have been applied to the design and
use of RNAi based drugs for use as therapeutic candidates and as a tool for various research
and drug pment purposes. Tuschl’s group first reported the administration of synthetic
siRNA to cells more than 10 years ago (Elbashir et al., Nature 411: 8, 2001).
Conventional siRNA therapeutics has very recently reached the stage where significant RNAi
activity can be achieved in the livers of primates as well as man. The best of these results to
date are based on the use of second-generation lipid nanoparticles (LNPs) that envelop the
siRNA and e its ry to hepatic cells. These data come from interim s from a
phase I trial of a siRNA directed to PCSK9.
MiRNA is comparatively a fundamentally more complex area of RNAi than siRNA
and consequently attempts to acquire miRNA-based drug candidates for therapeutic as well
as use as a tool for various research and drug development purposes have lagged behind
siRNA. Potential miRNA eutics include miRNA inhibitors and miRNA . Most
advanced is the use of antisense oligonucleotides (oligos) with a steric hindrance mechanism
to inhibit the function of certain miRNAs. One example is a mixed LNA/DNA nucleoside
phosphorothioate oligo that inhibits miR-122 and which has completed phase II testing with
promising results. Mir-122 is highly expressed by liver and is required for HCV tion
and increases the level of total cholesterol in plasma.
Least advanced is the delivery of miRNA mimics to tissues in vivo for therapeutic or
research or drug development purposes. In part this is because the field is still in the early
stages of elucidating the functions and identities of therapeutically relevant miRNAs. A
relatively small number of miRNAs, however, have a substantial body of literature support
for having key roles in certain medical conditions. A number of these miRNAs function as
ncogenes for particular types of cancer where they are pathologically under expressed.
Importantly replacement of the deficient miRNA often has a substantial anti-cancer activity,
for example, miR-34 and let-7 family s.
It is well recognized in the art that the single most important barrier to the
development of siRNA and miRNA mimics as drugs is the very poor uptake of these
compounds by tissues in the body (Aliabadi et al., Biomaterials 33: 2546, 2012; Kanasty et
al., Mol Ther published online ahead of print Jan 17, 2012). It is widely held that for general
use complex carriers are needed that will envelop the siRNA or miRNA mimic and promote
their delivery in to tissues in a bioavailable . To date the success of this approach is
essentially limited to the delivery of such compounds to liver.
In st, steric hindrance antisense oligos being used to inhibit miRNAs are being
successfully delivered tissues without the need for a r. Further, clinically important
endpoints are being achieved. Such , however, e high doses and perhaps most
importantly very high affinity for their target miRNA (Elmen et al., Nature 452: 896, 2008;
Lanford et al., Science 327: 198, 2010). Thus, miRNAs with relatively high G/C content
should be most susceptible to this form of inhibition. It may not be le to effectively
target the majority or miRNAs using this approach and ng antisense oligo chemistries
because of the high affinity ement.
The miRNA sequences and nomenclature used herein are taken from the miRBase
(www.mirbase.org) which has been described in Griffiths-Jones et al., Nucleic Acids
Research 34: D140-D144, 2006. In brief, s that immediately follow the designation
miR-, for example, miR-29, designate particular . This designation is applied to the
corresponding miRNAs across various species. Letters, for example in miR-34a and miR-
34b, distinguish particular miRNAs differing in only one or two positions in the mature
miRNA (antisense strand). Numbers following a second dash, for example in miR1 and
miR2, distinguish distinct loci that give rise to identical mature miRNAs. These
miRNAs can have different sense strands. Multiple miRNAs family members that differ in
only one or two side positions from some other member(s) for the family in the mature
miRNA and which also come from distinct hairpin loci have both letters and additional
s following the s, for example, miR-29b-1 and b-2 with the other family
members being miR-29a and miR-29c. Finally, in some instances two different mature
miRNA sequences are excised from the same hairpin precursor where one comes from the 5'
arm and the other from the 3' arm. These are designated -5p and -3p respectively, for
example, miR5p and miR3p.
SUMMARY OF THE ION
In accordance with the t invention, methods and compositions that provide
RNAi activity in tissues in vivo are disclosed. The compositions of the present invention can
be delivered to subjects as single strand oligos in a e or physiological buffer, with out
the requirement for a carrier or prodrug design while ultimately being capable of suppressing
the intended target(s) in a wide variety of tissue types. Surprisingly, the present inventor has
designed individual oligo strands with features that allow them survive administration,
become bioavailable in a wide variety of tissues where they combine with a partner strand(s)
to form duplexes that result in the efficient loading of the intended antisense oligo into RISC
and produce robust intended silencing activity with minimized rget effects.
The types of compositions of the present invention fall into three basic groups to
include those that: (1) inhibit the expression of dual genes or small numbers of genes by
an AGO-2 based cleavage mechanism; (2) t the expression of particular miRNAs; and
(3)provide miRNA-like functions through partially mimicking the actions of particular
endogenous miRNAs of generating miRNA-like nds with novel seed ces. All
three of these types of nds are broadly defined as sequential RNAi (seqRNAi).They
are individually distinguished by the terms seqsiRNA, R and seqMiR respectively.
Single stranded compounds with these three types of activity, NA, ss-IMiR and ss-MiR
respectively, are also provided.
Exemplary seqsiRNA, R, seqMiR and ss-MiRcompounds are based on the
agents shown in Figures 8, 10, 12, 14, 16, 20-23 and 26-67; Figures 68-81;Figures2, 9, 11,
13, 15, 17, 86-97; and Figures 2, 18 and 19 respectively. An exemplary method entails
contacting a cell expressing the gene target, miRNA target or with a miRNA deficit with an
effective amount of an appropriate seqRNAi nd, the seqRNAi being effective to
inhibit expression of the target or to augment miRNA activity. SeqRNAi can include,
without tion, a single stranded or double stranded oligoribonucleotide or chimeric oligo
with the properties ed for herein.
In a particularly preferred embodiment, a two-step stration method is disclosed.
An exemplary method entails administration of a first oligo strand to a subject, waiting for a
suitable time period, followed by administration of a second oligo strand to said subject, said
first strand and said second strand forming an intracellular duplex in cells in vivo that is
effective to achieve one of the following: (1) catalyze degradation of target gene mRNA or
small number of mRNAs or inhibit translation of said mRNA(s); (2) catalyze degradation of a
particular miRNA or small number of miRNAs; or (3) provide for miRNA activity.The oligo
strands can be administered in a vehicle without a carrier or prodrug design, but a carrier may
be used for special purposes such as the targeting of a particular tissue type to the exclusion
of others.
In one aspect there is provided an in vitro screening method for selecting an
antisense strand binding site on a ribonucleic acid target of interest, said method
comprising;
(i) identifying a site on said target that is ble for antisense strand binding
using an antisense oligonucleotide;
(ii) obtaining a set of a first and a second oligonucleotide with sequences e
of forming a duplex or a set of a first and a second oligonucleotide that are not
complementary to each other but which are capable of forming a duplex with a third
strand where in at least one strand is complementary to the site identified as available
for binding in (i);
(iii) modifying said oligonucleotide strands to increase their stability and activity;
(iv) contacting a cell expressing said target with said first oligonucleotide
strand or said two non-complementary strands and providing a suitable amount of
time for said strand(s) to enter said cell;
(v) contacting said cell with said second or said second and third
oligonucleotide strands not complementary to each other but complementary to a
strand in (iv) and;
(vi) ining the expression of the target sequence as compared to the
sion of the target sequence without step (iii).
It is to be noted that, throughout the description and claims of this specification, the
word 'comprise' and variations of the word, such as 'comprising' and 'comprises', is not
intended to exclude other variants or additional components, integers or steps. Modifications
and improvements to the invention will be readily apparent to those skilled in the art. Such
modifications and improvements are ed to be within the scope of this invention.
Any reference to or sion of any document, act or item of knowledge in this
specification is ed solely for the purpose of providing a context for the present
invention. It is not ted or represented that any of these matters or any combination
thereof formed at the priority date part of the common l knowledge, or was known to
be relevant to an attempt to solve any problem with which this specification is concerned.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1: phosphate Linkage.
Figure 2: Boranophosphate Monomer with Native Ribose.
DETAILED DESCRIPTION OF THE INVENTION
A. Overview of Prior Art
It is currently assumed in the art that the broad application of siRNA-based
compounds and miRNA mimics as drugs will require the development of carriers that do not
currently exist and that likely will involve different designs for different cell types. The
existing carriers have primarily shown limited but meaningful success in obtaining siRNA
activity at significant levels in the liver including in ts. It is generally believed that the
carriers that will be needed to establish conventional siRNA and miRNA mimics as drug
platforms will be of a complex structure and will envelop siRNA or miRNA duplexes. A
possible tissue exception to the carrier requirement could be the proximal tubule cells of the
kidney.
Carriers are ed to be needed for multiple reasons based on what happens when
naked siRNA is ed into subjects including: (1) poor uptake by cells; (2) ction by
nucleases; and (3) rapid clearance of intact duplexes from the body. Further, the carriers
being developed for general drug use have a variety of associated problems including, but not
limited to, toxicity, difficulties in ation, short shelf half-life and large size
(siRNA/carrier or miRNA/carrier xes are >100nm in size while capillary pores are
estimated to range from 5-60nm). In addition, the published studies involving many carriers
have common deficiencies making it difficult to draw firm conclusions; for example, it is
uncommon to see proper dose response curves ularly ones that include comparing the
test siRNA/carrier against an siRNA-control/carrier.
Hence, there is a pressing need for new ches that will result in broad RNAidependent
activity in tissues in vivo. The basic concept behind the present invention is that
properly ed complementary sense and nse strand drugs can be sequentially
administered without a carrier or prodrug to a t and will combine to form duplexes
capable of producing RNAi ty in a wide range of cell types. Thus, in a preferred
embodiment the compounds of the invention can be administered in the absence of a carrier
(which facilitates cellular uptake) but are rather delivered in a vehicle, or physiological buffer
such as saline Thus, this invention provides the means to generate sense and antisense strands
with sufficient intrinsic nuclease stability such that they can be individually administered in
vivo in a sequential manner and induce the production of RNAi activity in numerous tissues.
This general approach has been termed seqRNAi.
In the field of miRNA mimics, there is also a pressing need for the rationale design of
compounds which avoid suppressing ble mRNA types while ting the expression
mRNA types where there is a cial or medical interest in doing so. This is an intrinsic
m when the goal is to closely mimic particular endogenous miRNAs. Using miRNA-
like compounds that are limited their range of mRNA target types (e.g., selected to better
match ular commercial goals) can ameliorate this problem. The seqMiRs of the present
invention can be designed to do this in particular through the use of novel seed sequences and
by manipulating the affinity of the seed sequence for its mRNA targets.
Xu et al., (Biochem Biophys Res Comm 316: 680, 2004) studied the effects of the
sequential administration of single strands by transfection of sense and nse strands
making up a chemically unmodified conventional siRNA duplex on cells grown in culture.
They demonstrated the ability of such an approach to cause RNAi based silencing in cells
under these conditions. The authors made the observation that single stranded siRNA (sssiRNA
) “has a remarkably lower efficacy of reconstituting RISC than duplex siRNA.” This
led them to test the following : “cellular persistence (meaning short persistence) might
not be the main reason of ss-siRNA having lower efficacy than duplex siRNA.” Instead the
duplex structure itself might promote RISC loading. They tested this idea by sequentially
administering the complementary s of a conventional siRNA directed to Renilla
luciferase or of one targeting human CD46 into a cell line expressing the target gene. These
investigators did not disclose the sequential administration of individual strands in vivo nor
the concept of using sequential strand administration to improve uptake compared to the
administration of a .
primarily involves the use of short and/or non-canonical siRNA
triggers and data is provided to show that ones shorter than the standard 21-mers have
substantial activity. The filing also asserts that the two strands that make up conventional
siRNA can be sequentially administered to cells and as a result the RNAi-based ing
effect of the parent siRNA duplex will be replicated in cells. The rationale that the text
provides for doing this is the following: “Because the interferon pathway is triggered by cells
exposed to double-stranded nucleic acids previous RNAi/gene silencing approaches using
such agents could not rule out the concomitant activation of this pathway.” Accordingly, the
inventors claim to provide compositions and methods for ting gene silencing both in
vitro and in vivo in the absence of an eron response.” The idea that sequential
administration of the strands could remedy the in vivo siRNA uptake problem was not
considered, nor were specific compounds for use in this embodiment of the invention.
The sequential administration of complementary sense and antisense strands to
achieve RNAi-dependent activity t a specific mRNA target in cells is clearly
guishable from the practice of sequentially or co-administering conventional siRNA
es to cells in vitro or in vivo. As for drugs generally, there are multiple rationales for
administering more than one conventional siRNA duplex to an animal or individual in either
a sequential or in a aneous manner. These s include, for example, the desire to
produce a more profound suppression of a given target at a given time, to extend the effect on
a given target over time, to achieve a particular commercial purpose by inhibiting multiple
targets in a sequential manner or simultaneously or to reduce the selection pressure for the
production of mutations in the target gene that nullify the intended effect.
US 156529 ses the sequential administration of established types of
RNAi. In this application, “The term "co-administration" refers to administering to a subject
two or more agents, and in particular two or more iRNA agents. The agents can be contained
in a single pharmaceutical composition and be administered at the same time, or the agents
can be contained in separate formulation and administered serially to a subject. So long as the
two agents can be detected in the subject at the same time, the two agents are said to be co-
administered.” Thus, the ors have provided for the sequential administration of “iRNA
agents” (abbreviation for "interfering RNA agent") a term that is not established in the art but
clearly means an agent that induces ependent silencing activity. Indeed, the inventors
defined iRNA agents as follows: “An iRNA agent as used herein, is an RNA agent, which
can down-regulate the expression of a target gene, e.g. ENaC gene SCNN1A…. an iRNA
agent may act by one or more of a number of isms, including post-transcriptional
cleavage of a target mRNA sometimes referred to in the art as RNAi, or pre-transcriptional or
pre-translational mechanisms.” Thus, the term iRNA agent must be an entity that can gulate
the expression of a target gene and such agents may be co-administered in a
sequential manner over time if the agents being so co-administered are present in the subject
at the same time.
In connection with attempts to generate based or miRNA mimic drug
development platforms, investigators are focused on developing complex carriers that
envelop the duplex to deliver conventional siRNA or miRNA mimics to subjects. The
ed nature of these compounds provides a degree of nuclease stability that in turn
affects the ion of specific al modifications to the strands, if any, in order to
promote the various desirable drug attributes of the compound. The duplex structure also has
an important bearing on the intracellular distribution of the compound with respect to
parameters such as relative distribution between the cytoplasm and nucleus and general
stickiness of proteins on a charge/charge basis. Further, the carrier itself introduces additional
nuclease resistance and has a major influence on determining the details of the route followed
by the duplex in becoming bioavailable in cells in vivo. Thus, the ches that have been
developed to promote the desirable drug attributes of conventional siRNA or miRNA mimics
have been arrived at in the context of the these drugs being administered as a duplex by
means of a complex carrier.
The problem of what chemical modifications to use and where to place them in
strands is necessarily substantially greater for seqRNAi than for the strands that comprise
conventional siRNA or miRNA mimics. Basic to the greater difficulty for seqRNAi are the
following facts: (1) seqRNAi strands have a substantially greater need for nuclease ance
than the strands that make up conventional siRNA es. As a result they are necessarily
more heavily modified compared to conventional siRNA or miRNA ; and (2)
essentially all the types of chemical modifications that are applicable for achieving single
strand nuclease resistance are known to be capable of substantially inhibiting or eliminating
the intended RNAi-dependent silencing activity. A number of these are compatible with
conventional siRNA activity but they must be used sparingly and with suitable positioning in
the strand. This has been possible because of the duplex structure and the nuclease tion
provided by carriers. The lack of these factors in the use of i, therefore, presents a
novel challenge.
The t invention provides the means to achieve this by providing sufficient
intrinsic se resistance for each of the strands to e long enough to become
bioavailable duplexes in cells in vivo while not unduly adversely affecting the silencing
activity against the intended target. This es providing the means for the efficient
removal of the sense strand form the seqRNAi-based duplex by RISC. le i-
based duplex architectures are also enabled by the disclosure in the present application. The
algorithms provided herein surprisingly allow these objectives to be achieved without undo
experimentation and provide for the rationale design of compounds having seqRNAi activity
against any mRNA or miRNA target as well as compounds with miRNA-like properties. The
miRNA mimics of the present invention fall into two broad categories: (1) those that are
based on the seed sequences of nous miRNA compounds; and (2) those that are based
on novel seed sequences. So the term “miRNA mimics” in this context is used for compounds
that e miRNA-like activity rather than necessarily suggesting an attempt to exactly
mimic the activity of any given endogenous miRNA. The miRNA mimics of the present
invention are designed to serve as drugs that provide a wide range of miRNA activities that
can be tailored to meet a variety of useful cial or medical needs.
The seqRNAi designs of the present invention are configured for single strand in vivo
administration in a vehicle without a carrier or prodrug design. This results in RNAi activity
in many cell types. While this is frequently desirable, it is also ant to have the ability
to direct the seqRNAi strands to some cell or tissue types to the exclusion of others by using
carriers with cell targeting characteristics. SeqRNAi strands are much better suited for use
with carriers than is conventional siRNA or conventional miRNA mimics because of their
r size and intrinsic nuclease resistance. Hence, the carrier can be simply conjugated to
the seqRNAi strand and it can be relatively small and uncomplicated since it does not need to
envelop the strand. Such relatively simple carriers capable of targeting oligos to particular
tissues are well known in the art.
Select antisense seqRNAi strands can also be used as ss-siRNA or ss-miRNA. Certain
modifications can promote this activity. Typically the activity will be less than that which
can be achieved with the sequential administration of the complementary sense strand(s), but
for some commercial applications the simplicity of a single administration out weighs the
sed potency the sense strand can provide. This would e situations where a very
rapid ssive effect is desired.
It follows that the greater level of chemical modification that is required for seqRNAi
strands compared to the strands in conventional siRNA and conventional miRNA must be
more highly orchestrated such that potentially competing ives are ized. The
present invention surprisingly provides the means to broadly achieve substantial RNAidependent
activity against s of choice in multiple cell/tissue types in subjects without
undo mentation. The RNAi-dependent activity generated by seqRNAi sets or ss-RNAi
based on i antisense designs can occur in either a siRNA-like or miRNA-like format.
B. Definitions
The following definitions and terms are provided to facilitate an understanding of the
invention.
“2’-fluoro”refers to a nucleoside cation where the fluorine has the same
stereochemical ation as the hydroxyl in ribose. In instances where the fluorine has the
te orientation, the associated nucleoside will be referred to as FANA or 2’-deoxy-
2’fluoro-arabinonucleic acid.
pplementary or 3'-compensatory sites” refers to sites in some miRNA antisense
s down-stream of the seed sequence that are complementary to the target ce and
contribute to target selection particularly when the seed sequence has a weak match with the
target.
3’UTR is an abbreviation for the 3’ untranslated region of an mRNA.
“5'-to-3' mRNA decay pathway” refers to a naturally occurring y for degrading
mRNA that is initiated by the removal of the poly(A) tail by deadenylases. This is followed
by removal of the 5'-cap and subsequent 5' to 3' degradation of the rest of the mRNA.
“Antisense oligos or s” are oligos that are complementary to sense oligos, premRNA
, mRNA or to mature miRNA and which bind to such nucleic acids by means of
complementary base pairing. The antisense oligo need not base pair with every nucleoside in
the target. All that is ary is that there be sufficient binding to provide for a Tm of
greater than or equal to 40 °C under physiologic salt conditions at submicromolar oligo
concentrations unless otherwise stated .
“Algorithms” refers to sets of rules used to design oligo strands for use in the
generation of seqRNAi sets or pairs.
“Antisense strand vehicle” is used to describe an antisense strand structure into which
particular seed sequences can be inserted as a starting point for the design of ss-MiR
compounds. These vehicles are designed and/or selected to minimize off target effects and to
promote efficient RISC loading.
“Architecture” refers to one of the possible architectural configurations of the
seqRNAi-based duplexes formed after a set of seqRNAi strands undergoes complementary
base pairing or it refers to the group of such architectures.
etry rule” refers to the naturally occurring mechanism whereby the likelihood
of a particular strand in a siRNA, miRNA or seqRNAi-based duplex is selected by RISC as
the antisense strand. It has been applied to the design of tional siRNA compounds and
it can apply to seqRNAi compounds. In brief, the relative Tm of the 4 terminal duplexed
nucleosides at one end of the duplex compared to the corresponding nucleosides at the other
terminus of the duplex plays a key role in determining the relative degree to which each
strand will on as the antisense strand in RISC. The strand with its 5’-end ed in
the duplexed terminus with the lower interstrand Tm more likely will be loaded into RISC as
the antisense strand. The Tm effect, however, is not evenly buted across the duplexed
terminal nucleosides because the most terminal is the most important with the successive
nucleosides being progressively less ant with the terminal 4 duplexed nucleosides
being the most significant.
“Backbone” refers to the alternating linker/sugar or sugar substitute structure of oligos
while the normal bases or their substitutes occur as appendages to the backbone.
“Bulge structures or bulge” refers to regions in a miRNA duplex or seqMiR-based
duplex where multiple interior contiguous nucleosides in one strand fail to base pair with the
partner strand in a manner that results in the ion of a bulge in the duplex composed of
these nucleosides. Bulge structures include bulge loops that occur when the nucleosides that
fail to base pair with the partner strand are only in one strand and or loops that occur
when opposing nucleosides in both strands cannot base pair.
“Central region of the nse stand” is defined as nucleosides 9 and 10 from the
5’end along with the adjacent three nucleosideson each side of these including allthe
intervening linkages.
cally modified” is applied to oligos used as conventional antisense oligos,
conventional siRNA, conventional miRNA or seqRNAi (seqsiRNA, seqMiRs, or seqIMiR)
where the term refers to any chemical differences between what appears in such compounds
and the corresponding standard natural components of native RNA and DNA (U, T, A, C and
G bases, ribose or deoxyribose sugar and phosphodiester linkages). During manufacture
chemical modifications of this type do not have to lly be made to native DNA or RNA
components. Also ed in this term are any nucleoside substitutes that can be used as
units in overhang precursors.
“Chimeric oligonucleotides” are ones that containribonucleosides as well as 2’-
deoxyribonucleosides.
“Compounds” refers to compositions of matter that include conventional siRNA,
conventional miRNA, as well as the sense, antisense strands that make up particular seqRNAi
sets in addition to the seqRNAi-based duplexes they can form by complementary base pairing
with each other.
“Conventional antisense oligos” are single stranded oligos that t the expression
of the targeted gene by one of the ing isms: (1) Steric hindrance – e.g., the
antisense oligo eres with some step in the sequence of events involved in gene
expression and/or production of the encoded protein by directly interfering with one of these
steps. Such steps can include transcription of the gene, splicing of the NA and
translation of the mRNA; (2) Induction of enzymatic digestion of the RNA transcripts of the
targeted gene by RNase H; (3) Induction of enzymatic digestion of the RNA ripts of the
targeted gene by RNase L; (4) Induction of enzymatic digestion of the RNA transcripts of the
targeted gene by RNase P: (5) Induction of enzymatic digestion of the RNA ripts of the
targeted gene by double stranded RNase; and (6) Combined steric hindrance and induction of
enzymatic digestion activity in the same antisense oligo.
"Conventional miRNA" are those compounds administered to cells in vitro or in vivo
as an oligo duplex and the term excludes those unusual cases where it is delivered as single
stranded miRNA (ss-miRNA) - i.e., where the antisense stand is administered without a sense
strand and produces a substantial RNAi silencing effect. Administration of conventional
miRNA nearly always es the use of a carrier (in vitro or in vivo) or other means such as
hydrodynamic delivery (in vivo) to get the compound into cells in an active form.
"Conventional siRNA" are those compounds administered to cells in vitro or in vivo
as an oligo duplex and the term excludes those unusual cases where it is delivered as single
stranded siRNA (ss-siRNA) - i.e., where the antisense stand is administered without a sense
strand and produces a ntial RNAi silencing effect. Administration of conventional
siRNA nearly always requires the use of a carrier (in vitro or in vivo) or other means such as
hydrodynamic delivery (in vivo) to get the compound into cells in an active form.
“Duplex vehicle” is used to describe a duplex comprised of a sense and an antisense
strand into which particular seed sequences and their sense strand complement can be
inserted as a starting point for the design of seqMiR compounds. These vehicles are designed
and/or ed to minimize off target effects and to e efficient RISC loading and
retention of the intended antisense .
“Exosomes” are endosome-derived vesicles that transport molecular species such as
miRNA and siRNA from one cell to another. They have a particular composition that reflects
the cells of origin and lly this directs the payload to particular cells. Once these
secondary cells take up the siRNA or miRNA they exert their RNAi functions.
“FANA”refers to a nucleoside modification where the fluorine has the opposite
stereochemical orientation as the hydroxyl in . It can also be referred to as 2’-deoxy-
ro-arabinonucleic acid.
“Gene target” or “target gene” refers to either the DNA sequence of a gene or its RNA
transcript ssed or unprocessed) that is targeted by an RNAi trigger for ssion of
its expression.
“Guide strand” is used interchangeably with antisense strand in the context of dsRNA,
miRNA or siRNA compounds.
"Identity" as used herein and as known in the art, is the relationship between two or
more oligo sequences, and is determined by comparing the sequences. Identity also means the
degree of ce relatedness between oligo sequences, as ined by the match
between strings of such sequences. Identity can be y calculated (see, e.g., Computation
Molecular Biology, Lesk, A. M., eds., Oxford University Press, New York (1998), and
Biocomputing: Informatics and Genome Projects, Smith, D. W., ed., Academic Press, New
York (1993), both of which are incorporated by reference herein). While a number of
methods to measure identity between two polynucleotide ces are available, the term is
well known to skilled artisans (see, e.g., Sequence Analysis in Molecular Biology, von
Heinje, G., Academic Press (1987); and Sequence Analysis Primer, Gribskovm, M. and
Devereux, J., eds., M. Stockton Press, New York (1991)). Methods commonly employed to
determine identity between oligo sequences include, for example, those disclosed in Carillo,
H., and Lipman, D., Siam J. Applied Math. (1988) 48:1073.
“Internal linkage sites” refers to e sites that are not at the 5’ or 3’-ends of an
oligo strand. These sites are ially t to single strand endonuclease attack and to
double strand endonuclease attack if they form a duplex with a partner strand. Such sites may
also be simply referred to as linkage sites.
iPS cell or iPSC are abbreviations for induced pluripotent stem cells. They are created
(induced) from somatic cells by experimental manipulation. Such manipulation has typically
involved the use of expression vectors to cause altered (increased or decreased) expression of
certain genes in the somatic cells. “Pluripotent” refers to the fact that such stem cells can
produce daughter cells committed to one of several possible differentiation programs.
“Linkage site” refers to a particular linkage site or type of linkage site within an oligo
that is defined by the nature of the linkage and the identities of the contiguous 5’ and 3’
nucleosides or nucleoside substitutes. Linkage sites are designated by “X-Y” where X and Y
each represent nucleosides with one of the normal bases (A, C, G, T or U) or nucleoside
tutes and the dash indicates the linkage between them.
“Mismatch" refers to a nucleoside in an oligo that does not undergo complementary
base pairing with a nucleoside in a second nucleic acid or with another nucleoside in the same
oligo and where the effect is to antagonize interstrand or intrastrand duplex formation by
setting up a repulsion of the opposing nucleoside base.
“MicroRNAs (miRNAs)” are a category of lly ing dsRNAs that typically
trigger the post-transcriptional sion of protein encoding genes after one of the strands is
loaded into RISC. This antisense strand can be ed to as mature miRNA. It directs RISC
to specific mRNA targets as recognized by the seed region of the mature miRNA. Most
commonly the seed sequence recognizes complete d sequences in the 3’UTR of
mRNAs transcribed from multiple genes.
“MicroRNA mimics or miRNA mimics” are a category of manufactured compounds
that when administered to cells utilize the cellular mechanisms involved in implementing the
ty of naturally occurring miRNA in order to produce a modulation in the expression of a
particular set of genes. MicroRNA mimics of the present invention can be designed to
modulate some or all of the same genes modulated by a ular naturally occurring miRNA
or be designed to modulate the expression of a set of genes by using a novel seed sequence.
The miRNA mimics of the present invention are referred to as seqMiRs or ss-MiRs
depending on whether they involve one or two strands.
“Modulate”, ating” or “modulation” refer to changing the rate at which a
particular process occurs, inhibiting a particular process, reversing a particular process,
and/or preventing the initiation of a particular process. Accordingly, if the particular process
is tumor growth or metastasis, the term “modulation” includes, without limitation, decreasing
the rate at which tumor growth and/or metastasis occurs; inhibiting tumor growth and/or
metastasis; reversing tumor growth and/or metastasis (including tumor shrinkage and/or
eradication) and/or ting tumor growth and/or asis.
“Native RNA” is naturally occurring RNA (i.e., RNA with normal C, G, U and A
bases, ribose sugar and odiester linkages).
“Nucleoside” is to be interpreted to include the nucleoside analogs provided for
herein. Such analogs can be modified either in the sugar or the base or both. Further, in
particular ments, the nucleotides or nucleosides within an oligo sequence may be
abasic. In overhang precursors and overhangs in RNAi triggers, each nucleoside and its 5’
linkage can be ed to as a unit.
oside substitute” refers to structures with radically different chemistries, such
as the aromatic structures that may appear in the 3’-end overhang precursors or overhangs of
seqRNAi-based siRNA duplexes, but which play at least one role typically undertaken by a
nucleosides. It is to be understood that the scope of the rules that apply to 3’-end overhang
precursors are broader than the rules that apply to structures that occur in the regions of the
seqRNAi strand that would form a duplex with its partner strand(s). In overhang sors
and overhangs each nucleoside tute and its 5’ linkage can be ed to as a unit.
“Oligo(s)” is an abbreviation for oligonucleotide(s).
“Overhang” in the t of conventional siRNA and conventional miRNA refers to
any portion of the sense and/or nse strand that extends beyond the duplex formed by
these strands and that is comprised of nucleoside or nucleoside substitute units.
“Overhang precursor” refers to that portion, if any, of a seqRNAi strand that would
form an overhang when combine with a partner seqRNAi strand to form a seqRNAi-based
duplex. The term also applies to ss-RNAi based on seqRNAi antisense designs where there
are one or more units at the 3’-end of the strand that do not undergo complementary base
pairing with the ed target and which would form an overhang if the strand were
duplexed with a seqRNAi sense strand.
“Passenger strand’” is used interchangeably with “sense strand” in the context of
dsRNA miRNA or siRNA compounds or their components. It forms a x with its
partner guide or antisense strand to form one of these nds.
"Pharmaceutical composition" refers to an entity that comprises a pharmacologically
effective amount of a single or double stranded oligo(s), optionally other ), and a
pharmaceutically acceptable carrier.
"Pharmacologically effective amount," "therapeutically effective amount" or simply
"effective " refers to that amount of an agent effective to e a commercially
viable pharmacological, therapeutic, preventive or other commercial result.
"Pharmaceutically acceptable carrier" refers to a carrier or diluent for administration
of a therapeutic agent. Pharmaceutically acceptable carriers for therapeutic use are well
known in the pharmaceutical art, and are described, for e, in Remington's
Pharmaceutical Sciences, AR Gennaro (editor), 18th edition, 1990, Mack Publishing or
Remington: The Science and Practice of Pharmacy, University of the Sciences in
Philadelphia (editor), 21st edition, 2005, Lippincott ms & Wilkins, which are hereby
incorporated by reference herein.
“Prodrug” refers to a compound that is administered in a form that is inactive but
becomes active in the body after oing chemical modifications typically through
metabolic processes. In the context of RNAi-dependent compounds, prodrug designs have
been proposed as a means of protecting such compounds from nucleases and/or ing
their uptake by cells. As for prodrugs generally any RNAi-dependent prodrugs have to
undergo modification in the body to produce a compound capable of RISC loading and
processing to induce ing the intended target(s).The stration of RNAi-dependent
compounds without 5’-end phosphorylation of the antisense strand is not considered to
constitute the administration of a prodrug.
“RNAi” is an abbreviation for RNA-mediated interference or RNA interference. It
refers to the system of cellular mechanisms that es RNAi triggers and uses them to
implement silencing activity. Multiple types of RNAi activities are recognized with the two
most prominent being siRNA and miRNA. Nearly always the RNAi rs associated with
these activities are double stranded RNA oligos most commonly in the 20mer-size range.
A common feature of the RNAi mechanism is the loading of one of these double stranded
molecules into RISC following by the sense or passenger strand being discarded and the
antisense or guide strand being retained and used to direct RISC to the target(s) to be
“RNAi-dependent” refers to the use of an RNAi based mechanism to e gene
expression. Compounds using this ism include conventional siRNA, shRNA, dicer
substrates, miRNA and the three types of seqRNAi (seqsiRNA, seqMiR and seqIMiR) as
well as ss-siRNA, ss-IMiRs and ss-MiRs.
“RNAi trigger” refers to a double stranded RNA compound most commonly in the
20mer size range that loads into RISC and provides the targeting entity (guide or
antisense ) used to direct RNAi activity.
“Seed sequence or seed region” comprises sides 2-8(or 2-7) counting in from
the 5'-end of the de facto antisense strand of conventional siRNA, miRNA or
nonconventional seqRNAi or ss-RNAi.
“Seed duplex” refers to the duplex formed between the seed sequence in a de facto
antisense stand and its complement in an mRNA 3’UTR.
“Sense oligos or strands” are oligos that are complementary to antisense oligos or
antisense strands of particular genes and which bind to such nucleic acids by means of
complementary base pairing. When g to an nse oligo, the sense oligo need not
base pair with every nucleoside in the antisense oligo. All that is necessary is that there be
sufficient binding to provide for a Tm of greater than or equal to 40 °C under logic salt
conditions at submicromolar oligo concentrations unless otherwise provided for herein.
“Sequential” in the context of the administration of a seqRNAi compound refers to a
“two-step administration or method” where cells are treated with one strand of a
complementary sense and antisense oligo pair and after cellular uptake of this strand, the cells
are treated with the other strand in a manner that also provides for its uptake into the cells.
The two strands then form a onal RNAi trigger intracellularly to inhibit target gene
expression in the cells ning the RNAi trigger.
“SeqIMiRs”are the subtype of seqRNAi nds that are designed to inhibit the
expression and/or function of particular nous miRNAs.
“SeqMiRs” are the subtype of seqRNAi compounds that are designed to mimic
miRNA function. Such mimics may be based on a particular endogenous miRNA seed
sequence. When based on a particular endogenous miRNA seqMiRs are typically ed to
only inhibit a subset of the specific mRNAs inhibited by the endogenous miRNA in on.
SeqMiRs can also be designed with a novel seed sequence and, therefore, not be based on any
given endogenous miRNA.
“SeqRNAi”refers to a novel approach to siRNA and miRNA delivery where the
individual sense and antisense strands making up the duplexes are sufficiently modified to
have sufficient intrinsic nuclease resistance for in vivo sequential administration without a
r or prodrug design and at the same time being able to produce an RNAi-dependent
silencing effect on the intended target gene(s) in a wide range of cell/tissue types. There are
three different types of i RNAs, seqMiRs, and seqIMiRs).
“SeqRNAi-based duplex” refers to the duplex formed when the strands in a seqRNAi
set or pair combine with each other through mentary base pairing.
“SeqRNAi set” or “seqRNAi pair” refers to a group of two or three strands where the
strands can combine to form a seqRNAi-based duplex on the basis of complementary base
pairing.
“SeqsiRNA” is the e of seqRNAi that inhibits the expression of an individual
gene or small number of genes by ing direct ge of the transcripts of the genes by
RISC. The targeting code is primarily composed of the central region of the antisense strand.
Conventional siRNA compounds can be converted to seqsiRNA use or accessible sites in
mRNA for oligo binding can be used as the starting point for designing NA
nds.
“Silencing” refers to the inhibition of gene expression that occurs as a result of RNAi
activity. It is ly expressed as the concentration of the RNAi trigger that produces a
50% tion in the expression of the intended target at the optimum time point.
“Ss-IMiR” refers to an antisense strand that is designed according to the rules
provided herein and is administered to a subject without a carrier or prodrug design and
without the administration of a complementary sense strand. The compound is capable of
being loaded into RISC in a subjects cells and subsequently ing RISC to a specific
miRNA for silencing.
“Ss-MiR” refers to a single stranded miRNA mimic composed of an antisense strand
designed according to the rules provided herein that is capable of being stered to a
subject t a carrier or prodrug design and without a complementary sense strand. It can
be loaded into RISC in subject cells and subsequently directed to a set of targets for silencing
of target gene expression, e.g., inhibition of a particular set of mRNAs containing the
complementary binding sequences in the 3’UTR. The targeting code is primarily or
exclusively ed by the seed ce.
“Ss-miRNA” refers to a single stranded miRNA mimic composed of an antisense or
guide strand that is capable of being loaded into RISC and subsequently directed to a set of
targets for silencing of target gene sion, e.g., inhibition of a particular set of mRNAs
containing the complementary binding sequences in the 3’UTR. The targeting code is
primarily if not exclusively provided by the seed sequence.
“Ss-RNAi” refers to ss-siRNA and/or to ss-miRNA and/or to ss-MiR and/or to
ss-IMiR compounds.
“Ss-siRNA” refers to an antisense strand that is designed according to the rules
provided herein and is administered to a subject without a carrier or prodrug design and
without a complementary sense strand. Further, the compound is capable of being loaded
into RISC in subjects cells and uently directing RISC to the transcript(s) of one or at
most a small number of mRNA types for silencing of target gene expression. The targeting
code is primarily or exclusively composed of the central region of the strand and it typically
directs AGO-2 to an mRNA target(s) that is d by this enzyme.
“Stem cell” refers to a rare cell type in the body that exhibits a capacity for selfrenewal.
Specifically when a stem cell divides the resulting daughter cells are either
ted to undergoing a particular differentiation program or they undergo self-renewal in
which case they produce a replica of the parent stem cell. By undergoing enewal, stem
cells function as the source material for the maintenance and/or expansion of a particular
tissue or cell type.
ct”refers to a mammal including man.
"Substantially identical," as used herein, means there is a very high degree of
homology preferably >90% sequence identity between two nucleic acid sequences.
"Synthetic" means chemically manufactured by man.
“Targeting code” refers to a contiguous nucleoside sequence that is a subset of the
guide or antisense strand sequence of a siRNA, miRNA or seqRNAi compound that is
primarily or exclusively responsible for directing RISC to a specific target(s). Targeting
codes typically can be distinguished on the basis of their particular positions within the guide
or antisense strand relative to its 5'-end.
“Tm” or g temperature is the midpoint of the temperature range over which an
oligo separates from a complementary nucleotide sequence. At this ature, 50% helical
(hybridized) and 50% coiled (unhybridized) forms are present. Tm is measured by using the
UV spectrum to determine the formation and breakdown (melting) of hybridization using
techniques that are well known in the art. There are also formulas available for estimating Tm
on the basis of nearest or considerations or in the case of very short duplexes in
accordance with the relative G:C and U:A content. For the purposes of the present invention
Tm measurements are based on physiological pH (about 7.4) and salt concentrations (about
150mM).
"Treatment" refers to the application or administration of a single or double stranded
oligo(s) or another drug to a subject or patient, or application or administration of an oligo or
other drug to an isolated tissue or cell line from a subject or patient, who has a medical
condition, e.g., a e or er, a symptom of disease, or a predisposition toward a
disease, with the purpose to inhibit the expression of one or more target genes for research
and pment purposes or to cure, heal, ate, e, alter, remedy, ameliorate,
improve, or affect the disease, the symptoms of disease, or the predisposition toward disease.
Tissues or cells or cell lines grown in vitro may also be ed” by such compounds for
these purposes.
“Unit” refers to the nucleoside or nucleoside substitutes that appear in overhang
precursors and overhangs along with their 5’-end linkage. Nucleosides may appear in 5’-end
or 3’-end overhangs but nucleoside substitutes can only appear in 3’-end overhang sors
and overhangs.
“Unlocked c acids” (UNA) are a new class of oligos that contain sides
with a modification to the ribose sugar such that the ring becomes c by virtue of lacking
the bond between the 2' and 3' carbon atoms. The term can also be applied to individual
nucleosides with this cation.
“Upstream” and “Downstream” respectively refer to moving along a nucleotide strand
in a 3’ to 5’ direction or a 5’ to 3’ direction respectively.
“Vehicle” refers a substance of no therapeutic value that is used to convey an active
medicine or compound for administration to a subject in need thereof.
C. The Embodiments
In one embodiment, novel complementary sense and antisense oligo compounds are
sequentially administered to a subject in a two-step sequential procedure whereby one strand
is administered without a carrier or prodrug design and taken up by cells expressing the RNA
target(s), ed by administration of the second complementary strand without a carrier or
prodrug design which is taken up by the same cells resulting in the silencing of the function
of specific RNA target(s) by an RNAi-dependent mechanism. Thus, the individual strands are
taken up intact by a wide variety cell/tissue types in vivo in sufficient amounts in a
bioavailable manner that allows them to generate commercially useful ependent
silencing activity against the intended RNA target(s). The types of RNA targets in question
include, for example, pre-mRNA, mRNA and miRNA although in principle any RNA type
could be targeted.
In a d embodiment, s and algorithms are provided for modifying known
conventional siRNA nds to render them suitable for use in the sequential two-step
sequential administration method described above. In particular these methods and
algorithms provide for the creation of complementary sense and nse strands that can be
sequentially administered to ts without a carrier or prodrug design and where they
exhibit the following properties: (1) exhibit sufficient intrinsic nuclease resistance to survive
long enough to carry out their intended drug function; (2) are widely taken up by many
cell/tissue types in a manner that renders them bioavailable; and (3) produce the intended
RNAi-dependent silencing ty in cells/tissues that express the relevant RNA target(s).
This silencing ty is enhanced relative to the effects seen when the strands are
administered without the partner strand or compared to the sequence identical conventional
RNAi-dependent compound that has not been modified in accordance with the present
invention and is delivered without a carrier.
In another ment, the methods and algorithms provided are applied to
complementary sense and antisense strands that are not known tional siRNA
compounds. These same methods and design algorithms are also le for the generation
of novel compounds that inhibit ular miRNAs. This approach can be applied to
generating tors of any RNA target(s) in subjects where RNAi is desirable. What is
required is that the portion of the target be accessible to complementary base pairing by an
antisense strand that along with a complementary sense strand, are suitable for being
configured in accordance with guidance provided with the present invention. The means for
determining those portions of the intended RNA target which are ible to
complementary base g are well known in the art. Conventional antisense oligo which
have activity against RNA target(s) provide direct evidence of the particular binding site(s)
on an RNA target accessible to such complementary base pairing. It also follows that
conventional antisense oligos can be reconfigured as compounds of the present invention. In
a preferred version of this ment an antisense strand compound of the present invention
is directed to a hotspot in gene target mRNA transcripts where the hotspot is defined in US
7,517,644.
In yet another embodiment, algorithms, methods and compositions of matter are
ed for achieving miRNA mimic ty in cells/tissues in subjects using the sequential
delivery method of suitably designed sense and antisense strands. In one version of this
approach a particular endogenous miRNA is subjected to the methods and thms of the
present invention. In a variant of this, the ing code sequence of the endogenous miRNA
is adjusted to improve the silencing profile of the compound for a ular commercial
purpose.
In a related embodiment, algorithms, methods and compositions of matter are
provided for achieving miRNA-like activity in cells/tissues in subjects using the sequential
delivery method where the sense and antisense strands are not based on a particular
endogenous miRNA. Nevertheless, these compounds are also referred to herein as miRNA
. The starting point for these compounds is a novel seed sequence selected to target
the 3’-UTR of one or more mRNA types of commercial interest for silencing. This novel seed
sequence along with its sense strand complement is inserted into the riate regions of a
duplex that is capable of ently loading its antisense strand into RISC (duplex vehicle)
and the resulting duplex is ted to cation in accordance with the present
invention.
In yet r embodiment an algorithm is used to further modify the antisense
strands of the present invention so that they can induce the intended RNAi-dependent activity
in subjects in the e of a partner sense .
In a final embodiment, carriers are employed with individual strands in cases where it
is desirable to restrict the cell and/or tissue types targeted in subjects in vivo as the same
silencing effect in another cell/tissue type can produce an undesirable side effect. The
rationale for and means to achieve this type of cell/tissue targeting is well understood in the
art including its application to single strand oligo drugs (antisense or aptamers). In extensive
review of carriers suitable for use with single strand oligos and for the targeting of particular
cell/tissue types is provided in . Such relatively small and simple
established carriers are to be contrasted with those in development for the delivery of
conventional siRNA and tional miRNA.
D. Overview of ion Details
1. Comments on Terminology:
The term “nucleoside” is to be interpreted to cover normal ribonucleosides and
deoxyribonucleosides as well as the nucleoside analogs provided. It is to be understood that
the stereochemical orientations of the compound referred to are t to the same
assumptions as are found in the literature generally when short hand terminology is used, for
example, when ribose is referred to it is to be understood as being D-ribose or when
arabinonucleic acids (ANA) are referred to the are D-arabinonucleic acids.
“Nucleoside substitute” refers to ures with chemistries radically different from
nucleosides, but which play at least one role undertaken by a nucleoside in other situations.
In addition, it is to be understood that the scope of the modifications that apply to 3’-end
overhangs are broader than those applying to structures that occur in the s of the
seqRNAi strand that will form a duplex with its partner (s).
Statements such as “unless otherwise specified” or “unless otherwise ed for”
refer to other specified modifications described herein that provide for a different
modification(s) under certain circumstances. In these and in other instances where two or
more rules specifying different modifications for the same entity, the more narrowly
applicable rule (applies to fewer seqRNAi strands) will dominate. For example, rules
applicable to a particular architecture dominate architectural independent rules.
The terms “preferred” and “most preferred” are used to designate the optimal range of
configurations for strands for the majority of possible seqRNAi sets. In some ces, due
to factors such as those arising from sequence specific differences, the optimal variant for a
particular specification will not be what is generally red or most preferred. In such
instances the selected variant still will fall within the more general range of variants provided
for herein. Any such decision related to the use of variants that are not otherwise preferred or
most preferred will be primarily based on balancing the desired level of silencing potency for
the intended target along with the d duration of this silencing vs. reductions in get
effects. Off-target effects include minimizing the suppression of the expression of
unintended targets and minimizing unintended modulation of innate immunity. These
red s are commonly associated with conventional siRNA es and/or their
component strands. They can be measured using methods well known in the art.
“Silencing activity” refers to a level of silencing activity which is substantially
specific to the intended target while minimizing off target effects. Preferably the target is
silenced at greater than 50%, 60% , or 70% in cases where seqsiRNA, and seqImiRs used. In
cases where seqMiRs are utilized, suppression of expression of at least 25%, 35%, 45% or
>50% of 1, 2, 3, 4 or 5 of the targeted sequences is preferred. In the case of therapeutic
seqRNAi compounds, for example, the commercial purpose is iently suppressing the
intended target to the point a therapeutic benefit is achieved. In the case of onal
genomics, for example, this term refers to those levels of intended silencing activity required
to suppress the target levels to the point that significant ic s can be measured
that allow the biologic role(s) of the target to be better understood.
Rules that are itly stated to be d to seqRNAi strands (sense, antisense or
both) apply to the corresponding , antisense or both) seqsiRNA, seqIMiRs and
seqMiRs strands. Such rules are not to be assumed to apply to ss-RNAi strands unless
otherwise . Some ss-RNAi strand modifications are differentiated on the basis of
whether they are designed to produce type or miRNA-type activity.
Unless otherwise specified it is to be understood that for simplicity certain linkage
atives to the natural phosphodiester that are described herein (chirally specific
phosphorothioate, boranophosphate) can substitute for one or more phosphorothioate linkages
described in ns that refer to phosphorothioates generically. Unless otherwise specified,
however, the es uniquely specified for use in seqRNAi strands that will become 3’-end
overhangs in the seqRNAi-based siRNA duplex will only be applied in the context of 3’-end
overhang protection (phosphonoacetate, thiophosphonoacetate, amide, carbamate and urea).
When a linkage is not specified, it is assumed to be odiester.
2. Basic Design Considerations:
It is well established in the art that the types of chemical modifications used in
seqRNAi strands to achieve nuclease resistance and to provide other essential features also
have the potential to adversely affect function. For example, they can reduce and even to
eliminate the silencing activity seen in a corresponding unmodified siRNA or miRNA
duplex. r, the proper use of modifications depends on factors such as the underlying
sequence, which strand is being considered (sense or antisense) the frequency of use of a
particular modification, the nature of the other chemical modifications being used, the overall
placements of al modifications in the strand, the effects of such factors in one strand
on the partner strand and the regional as well as overall interstrand thermodynamics
generated when a duplex is formed. In addition to silencing activity these erations also
have a major impact on other functional features of seqRNAi strands and seqRNAi-based
duplexes such as the extent to which ial off-target effects are engendered or suppressed.
It follows that the greater level of chemical modification that is required for seqRNAi s
compared to the strands in conventional siRNA and conventional miRNA must be more
highly orchestrated such that potentially competing objectives are harmonized. This
harmonization can be achieved though the use of the algorithms provided herein.
seqRNAi sets are ucted by applying a series of algorithms in a logical order.
Some thms, such as the one dealing with nuclease resistance are always applied while
the application of others depends on particular preferences. A general ple for
prioritizing the rules in particular combinations of algorithms applied to the design of a
particular seqRNAi set is that more restrictive rule te less restrictive rules. Rules can
be more restrictive in the sense of providing fewer options for the cation of a ular
structure and/or they can be more restrictive in application. In practice once the ces for
a particular seqRNAi set is selected the appropriate series of algorithms directing design of
the final seqRNAi s are most efficiently d in a logical order. For example the
order for the application of particular algorithms could be the following: (1) providing for
nuclease resistance other than resistance to double strand endoribonucleases; (2) providing
for certain other essential/preferred architecture-independent rules; (3) providing for a
selected stand alone architecture (canonical, blunt-ended, tric or small internal
segmented); (4) optional application of forked t to any of these architectures except the
small internally segmented; (5) provide for l and al interstrand thermodynamic
optimization; (6) provide for double strand endoribonuclease protection if needed; and (7)
possibly select other optional ectural independent rules.
Each of the possible seqRNAi-based duplex architectures has advantages and
disadvantages over the others and a number of these attributes are presented in Table 1. For
general purposes the asymmetric architectural design with only the 3’-end overhang is most
preferred.
TABLE 1
SUMMARY OF seqRNAi-BASED DUPLEX ARCHITECTURES
THAT CAN BE FORMED IN CELLS FOLLOWING
SINGLE STRAND ADMINISTRATION TO SUBJECTS
Duplex
Architecture General
Potential Advantages Potential Disadvantages
Generated in Comments
Cells
Presence of overhangs adds
versatility with respect to
factors such as duration of
silencing and/or increased
Based on the
3’exonuclease protection as a
architecture of
function of various possible
naturally occurring Sense strand overhang can help
chemical modifications. In
Canonical siRNA that includes e its being loaded into
addition, cytoplasmic
the presence of RISC as an antisense strand.
duplexes with overhangs tend
overhangs in both
to be less immunostimulatory
strands.
than those with blunt-ends.
The presence of n types
of overhangs may promote the
export of siRNA duplexes out
of the nucleus.
Potential to n duration Compared to the canonical
of silencing affect other architecture this architecture
factors being equal. This can tends to be more
Lacks overhangs in be an age in some stimulatory when
Blunt-ended
both strands commercial applications such present in the cytoplasm. The
as when ged silencing lack of overhangs may impede
may result in undesirable side the transport of siRNA duplexes
effects. out of the nucleus.
When the d antisense
strand has a 3'-end overhang
and the sense stand does not
the probability the desired
antisense strand will load into
RISC for target recognition
Characterized by can be increased. The
antisense strand presence of a 3'-end overhang
having 3' and/or 5'- also adds ility with
Asymmetric end overhangs while respect to factors such as
the sense strand does duration of silencing on the
not have any basis of various overhang
overhang(s). chemistries. In some instances
the selection preference for
the desired antisense strand
may be further increased
through the use of a 5'-end
overhang in the antisense
strand.
Increases the number of sites
on the RNA target suitable for
siRNA attacks. This occurs
because the forked variant
provides the means to promote
RISC loading of the desired
A variant of
antisense strand in situations
Canonical, Bluntwhere
the terminal sequences
ended and one type
are otherwise poorly
of Asymmetric
compatible with the normal
architecture (one
loading preference mechanism
without 5’-end
that is the basis for the
overhang) where the
asymmetry rule. An advantage
forked design
of this t appears in
involves the use of
situations where the choice of
Forked Variant mismatches in the
a site(s) on the RNA target is
3'-end of the sense
restricted to those that cannot
strand with the
meet the design preferences
complimentary
ated with the basic
antisense strand. It is
ectures. For example, it
applied where the
might be desirable to cleave
conditions for the
an mRNA target between a
asymmetry rule are
primary and a ary
particularly
translational start site so that a
unfavorable.
truncated protein is produced.
As another e, it might
be desirable to cleave an
abnormal mRNA while
g the normal mRNA. In
either of these situations the
available target sites may not
readily t the favorable
thermodynamic asymmetry
between the duplexed termini
that is required for ent
silencing by the standard
architectures unless the forked
variant is used.
Two sense strands eliminates
possibility that the intended By having two short strands the
sense strand will be loaded binding affinity of each of the
Characterized by use
into RISC as the antisense two strands for the
of two sense strands
strand and reduces or complementary strand is
in combination with
eliminates the importance of substantially reduced and may
a single
the asymmetry rule. Two be inadequate for efficient
mentary
antisense s eliminate duplex ion. This situation
antisense strand. In
Small Internally any le contribution of tends to limit the sites on the
the case of seqMiRs
Segmented the antisense strand forming a RNA target for antisense/RISC
there can be two
duplex with the 5’-end half of binding to ones that are
antisense strands
the sense strand from relatively G/C rich. This can at
and a single sense
buting to target least partially be compensated
strand.
recognition. This can simplify for by using affinity increasing
the design of effective modifications such as LNA.
seqMiRs.
Index 1 provides a key for the modifications that can be made to the strands that
applies to some but not all of the figures. Index 2 illustrates some of the more sophisticated
approaches to the design of seqMiR sets that do not apply to other seqRNAi types. To
illustrate the l design process a conventional siRNA directed to mouse PTEN has been
ed along with the microRNA let-7i. The former compound is used to illustrate the
design of a seqsiRNA or seqIMiR set of molecules and the latter compound is used to
illustrate the design of a seqMiR set of molecules. The unmodified strands of the selected
es are shown in Indices 3 and 4. The al removal of bulge structures, mismatches
and/or wobble base pairs is the first design step in the uction of a seqMiR set. In the
case of let-7i there are no bulge structures but there are five wobble base pairs in the duplex
and one mismatch. The removal of these is illustrated in Index 5 and the effect on the specific
nuclease resistance and certain other essential/preferred cations is shown in Index 7.
Indices 6 to 19 illustrate different aspects of the design process based on the chosen
examples. Indices 8 and 9 are particularly noteworthy in that they provide examples of
strands exhibiting the minimal requirements to qualify as a seqRNAi set of molecules.
E. Algorithm: Generally Applicable Architectural Independent rules - Achieving
Nuclease Resistance
All the sense and antisense strands of the present invention (seqsiRNA, seqIMiR,
seqMiR, ss-siRNA, ss-IMiR and ss-MiR) e certain chemical modifications that provide
for nuclease protection while simultaneously being compatible with or supportive of other
essential and optional cations required for additional desirable properties. The required
nuclease protections for certain linkage sites in a seqRNAi or ss-RNAi strand are the
following:
1) tion of certain internal linkage sites from single strand endonuclease attack;
2) Protection of es between the terminal two or more nucleosides or nucleoside
substitutes at the 3’-end of the strand from 3’-end exonuclease attack depending on
the size and nature of the 3’-end overhang precursor(s), if any;
3) tion of the linkage site at the 5’-end of the strand from 5’-end exonuclease
attack; and
4) Protection of certain linkage sites in seqRNAi strands that will form a seqRNAi-based
duplex from double strand endoribonuclease attack where the needed modifications, if
any, t the strand(s) in the duplex.
The protection of particular al linkage sites can be relaxed, if necessary, for the
central region of NA, seqIMiR, ss-siRNA and ss-IMiR as well as for the seed sequence
of seqMiR and ss-MiR antisense strands ed to the rest of the antisense strand. These
regions of the antisense strands ily, if not exclusively, represent the targeting codes and
they can be more sensitive to the chemical modifications used to generate se resistance
than the rest of the antisense or sense strand.
The internal linkage sites to be protected in order to establish nuclease ance are
defined by the ribonucleosides that bracket a given linkage. Thus, the frequency and
positioning of the protective chemical cations are affected by the underlying strand
sequence. For general use the linkage sites (reading 5’ to 3’) to be protected from single
strand endoribonucleases are those where:
1) A pyrimidine (U, C or T) containing ribonucleoside is followed by a purine (G or A)
except C-G.
2) A linkage sites is defined by C-C and U-C.
3) A linkage sites is defined by C-G, A-C and A-U.
Hence, of the 16 possible linkage sites involving ribonucleosides with one or two of the 4
normally occurring bases in RNA (A, U, C and G) only half of them need to be protected to
achieve the stipulated nuclease protection. In contrast the linkage sites that do not have to be
protected from single strand endoribonucleases are A-A, U-U, G-G, G-C, G-U, G-A, A-G
and C-U. T may replace U in a ribonucleoside in some applications bed herein and
when it does the nuclease protection rules treat it as a uridine.
Approaches for protecting particular linkage sites from single strand
bonucleases include the following:
1) The 5’ nucleoside member of the e has a sugar that is ed from the
group consisting of 2’-fluoro, ethyl or xyribose unless otherwise
specified.
2) When there are two or more contiguous nucleosides and one is preferably a 2’-
0-methyl and the uous nucleosides include C then it is preferred that the
C the be 2’methyl unless otherwise specified.
3) When the 5’ nucleoside sugar is 2’-fluoro it is preferred that the intervening
linkage with the 3’ nucleoside be phosphorothioate particularly when the
3’nucleoside is 2’-fluoro or ribose.
4) The intervening linkage can be phosphorothioate or phosphodiester when the
’ nucleoside has a 2’methyl or 2’-deoxyribose sugar with the
orothioate possibly providing added protection.
) The phosphorothioate is preferred when the linkage site is defined in group 1
(U-G, U-A, C-A) or group 2 (C-C and U-C). In group 3 when the first
nucleoside is 2’-fluoro or ribose (C-G, A-C and A-U) the orothioate is
preferred when the 3’-nucleoside in the linkage pair is ribose or roro.
6) Unless otherwise specified, the 3’ nucleoside member of the linkage site can
have a sugar that is selected from the group consisting of ribose, 2’-fluoro, 2’-
0-methyl or 2’-deoxyribose.
In the case of the central region of seqsiRNA, seqIMiR, ss-siRNA and ss-IMiR
antisense strands all the indicated modifications can frequently be accommodated without an
undo negative effect on the intended silencing activity. When an undo negative effect is seen
then the order in which the linkage site protections are removed to achieve a higher silencing
effect will be in the reverse of what is listed (i.e. group 3 then 2 then 1). So, for example, the
protection of the C-G, A-C and A-U linkage sites (group 3) is the least important.
In the case of the seed ce of seqMiR and ss-MiR antisense s the chemical
modifications involved in generating nuclease resistance can affect the range of mRNA types
suppressed by a endogenously occurring or novel seed sequence and may affect the levels of
silencing ty caused by particular miRNA types. When these affects are adverse to the
intended commercial purpose, they can be avoided by ng the level of nuclease
protection. As for the central region of the other seqRNAi and ss-RNAi types, reducing the
level of nuclease protection against endonucleases follows the reverse order in which they are
presented with the third group being the least important.
The general means for protecting a strand of the present ion from single strand
3’-end exoribonucleases independently of any selected architecture requires that at a
minimum the terminal 2 nucleosides or nucleoside substitutes (the maximum is 4) and at a
minimum the terminal two es (the maximum is 4) to be ones that provide for nuclease
ance. Limiting the modifications to two nucleosides or nucleoside substitutes and two
linkages is preferred.
The required 3’end exonuclease tion is provided by the following:
1) In the absence of a 3’-end overhang precursor the required 3’end protection
can be provided by the use of two terminal nucleosides that are individually
selected from the group 2’-fluoro, 2’methyl or 2’-deoxyribose. Strands that
have a 3’ terminal oro modification, however, can have a reduced yield
with current manufacturing methods.
2) In the absence of a 3’-end overhang precursor the terminal two linkages will
be phosphorothioate.
3) The 3’-end exonuclease protection can also be achieved in part or fully by the
use of 3’-end overhang precursors as bed in the section by that name.
The ng precursor can be 1-4 units long with 2 units being preferred.
When there is only one unit the uous nucleoside is selected from the
group 2’-fluoro, 2’methyl or 2’-deoxyribose and the upstream linkage is
phosphorothioate.
The terminal 5’end linkage site is protected entirely or in part as follows:
1) The 5’-end terminal nucleoside is selected from the group consisting of
nucleosides with the following cations: oro, 2’methyl or 2’-
deoxyribose unless otherwise ied.
2) When the 5’ nucleoside to be modified is cytidine, 2’methyl is preferred
unless otherwise stipulated.
3) The 3’ member of the linkage site can have a sugar that is selected from the
group consisting of ribose, 2’-fluoro, 2’methyl or 2’-deoxyribose.
4) The intervening linkage can be phosphodiester or phosphorothioate unless
otherwise specified but when the 5’ nucleoside is 2’-fluoro it is preferred that
the intervening linkage be phosphorothioate.
Protection from double strand endoribonucleases is important for the brief period
between the formation of the seqRNAi-based duplex in cells and RISC association and
processing. The relevant enzymes digest both strands of normal RNA duplexes. When a
segment in a i strand (single strand t) possesses four sequential
phosphodiester linkages contiguous to normal ribonucleosides forms a duplex with a
complementary RNA strand and is base paired with such a t of the same or longer size
in the mentary strand, the ing double strand segment can support low-level
ion by these enzymes. Shorter double strand ts than four do not support
digestion. These enzymes, however, are significantly more active when such double strand
segments have five to six or more phosphodiester linkages contiguous with normal
cleosides in opposition in each strand when the duplex is formed. These enzymes can
also digest a single unprotected single strand segment in a duplex if phosphorothioate
linkages t the complementary RNA segment in the seqRNAi partner strand.
Modified nucleosides and 2’-deoxynucleotides of the types described herein, when
employed in the single strand segment of at least one strand of a seqRNAi pair forming such
a double stranded segment substantially inhibits digestion of the single strand segments of
both strands by double strand endonucleases. Thus, seqRNAi strands are designed as follows:
1) When they form a seqRNAi-based duplex in cells with their partner strand
there will be no complementary double stranded segments comprising 5 or
more utive phosphodiester linkages contiguous with normal
ribonucleosides in both strands and preferably no segment with 4 or more.
2) One or more modified nucleosides will be supplied to break up any single
strand segment(s) in a seqRNAi strand(s) ise capable of forming any
such double strand segment(s) with its partner strand such that the length of
the double strand segment will be limited in length as described.
3) Such modifications can be limited to a single strand segment in one of the
two strands in the resulting seqRNAi-based duplex or appear in both.
Alternatively, or in addition, duplexed segments of these sizes can be broken
up using phosphorothioate linkages, but if this is the only method of
protection then it must be applied to the duplexed segments of both strands.
The rules for protecting seqRNAi-based duplexes from double strand
endoribonuclease attack is different from the rules for protection from other nucleases in that
they are applied after the modifications based on all the nt rules are applied to a given
seqRNAi set. This will help prevent the use of unnecessary modifications.
F. thms: Generally Applicable Architectural Independent Rules– Other
1. Essential/preferred modifications
a) Applicable to seqRNAi Sense and Antisense s as well as to ss-siRNA, ss-
IMiR and ss-MiR:
i) Unless ise ied, it is preferred that within the seqRNAi-based
duplex that any 2' ribose modified nucleoside in one strand is opposed to a
nucleoside in the complementary strand that has a different ribose
modification or is a normal ribonucleoside or 2'-deoxyribonucleoside.
ii) It is preferred that uracil not be paired with ribose in the same nucleoside.
When uracil is paired with 2’-deoxyribose then it is preferred that the any
uous nucleoside not be a 2'-deoxyribonucleoside(s).
iii) It is preferred that any guanine containing 2'-deoxyribonucleoside not be
used on the 3' side of a contiguous cytosine containing2'-deoxyribonucleoside
unless the cytosine is methylated.
iv) When the use of phosphorothioates for nuclease protection s in less
than half the linkages being of this type it is red that additional
phosphorothioates be inserted to achieve this level.
b) Applicable to seqRNAi Sense Strands:
i) It is preferred that there are no more than three e containing
nucleosides in a row in any given sense strand but when four are required then
one of the four preferably will be 7-deazaguanosine.
ii) When a mismatch is indicated by a rule and multiple nucleosides with a
standard base (A, T, U, C or G) can fill the role then the preferred
nucleoside(s) is the one that es the most stable linkage site against
nuclease attack. For example G-G is more stable than C-G.
iii) When the introduction of a ch is indicated by a rule and the
nucleoside selected for a base change to generate a mismatch is an A then the
nucleoside is preferred to be changed to one of the following:
• a T is preferred and it is further preferred that the sugar be
2’deoxyribonuclotide if it is in a position where that sugar is permitted
by the applicable rules.
• a C is preferred and it is further preferred that the sugar be 2’methyl
if it is in a position where that sugar is permitted by the applicable
rules
• a U is acceptable but not preferred and if used it is red that the
sugar be 2’methyl if it is in a position where that sugar is ted
by the applicable rules.
c) Applicable to seqRNAi Antisense s:
i) The antisense strand is 16 to 23 nucleosides in length excluding any 3’-end
overhang precursor unit(s) that may be employed.
ii) More than four guanine-containing nucleosides in a row are not permitted.
It is preferred that there are no more than three guanine-containing sides
in a row outside the central region but when four are required then one of the
four preferably will be 7-deazaguanosine. Four guanine-containing
nucleosides in a row or more are not permitted in the central region of the
antisense strand.
d) able to NA and seqIMiR Antisense Strands:
i) In the central region preferably none of the nucleoside positions are
occupied by entities that would reduce the binding affinity with the intended
target compared to a perfectly complementary central region comprised of the
common normal nucleosides. es of excluded modifications are UNA
and abasic entities as well as nucleosides with mismatched bases with the
target RNA.
ii) ably no more than two contiguous nucleosides in the central region
have the 2'methyl cation.
iii) There are no restrictions on the number or positions of nucleosides in a
seed sequence that can be a 2'-deoxyribonucleoside, however, there is a limit
of no more than 40% of an antisense strand, exclusive of any overhang
precursors, can be 2'-deoxyribonucleoside. In addition it is preferred that there
is a limit of two such nucleosides in the central region and when there are two
they are not contiguous. In the rest of the strand, exclusive of any overhang
precursor(s), there is a limit of one such side.
e)Applicable to seqMiR and ss-MiR Antisense Strands:
i) LNA(s) can be used in the seed sequence, as needed, to increase the binding
affinity with the mRNA 3’-UTR target sequence(s) with a maximum of three
per seed sequence. It is preferred that when there are multiple LNAs in a given
seed sequence that they be separated by at least one nucleoside that does not
have the LNA modification. Note T can substitute for U in LNA.
ii) A 2-thiouracil containing LNA can be used in place of uridine LNA to
further boost seed sequence binding affinity with its mRNA target when the
corresponding base in the target is e.
iii) LNA or other ribose modified ribose nucleosides of the type provided for
herein normal ribose nucleosides can be used in the seed sequence and paired
with the following modified bases when the base is complementary to the
ponding base in the target: 2,6-diaminopurine (pairs with adenine), 2-
thiouracil, 4-thiouracil, 2-thiothymine.
iv) It is red there not be any G:U base pairs between the seed sequence
and the intended target sequence(s).
v) It is preferred that there are no 2'-deoxyribonucleosides in the seed
sequence particularly if there are no LNA modifications in the seed sequence.
There is a limit of four 2'-deoxyribonucleosides in the central region and when
there are more than two they are not contiguous. In the rest of the strand,
exclusive of any overhang precursor(s), there is a limit of one 2'-
deoxyribonucleoside.
vi) It is red that the second nucleoside from the 5’end not be ethyl
or LNA and that it be 2’-fluoro or ribose.
The application of the nuclease resistance and the essential/preferred architectural
ndent rules to illustrative seqsiRNA and seqMiR es is provided in Indices 6 and
7 respectively.
2. Nonessential/optional modifications:
The level of nuclease resistance for seqRNAi strands and seqRNAi-based duplexes
can be adjusted through the selective use of chirally specific phosphorothioate linkages. The
Sp diastereoisomer phosphorothioate linkage is much more nuclease resistant than the Rp
diastereoisomer. The mixed chirality of the standard phosphorothioate linkages results in
sites where the Rp es are cleaved first in susceptible linkage sites. Given that there are
often le susceptible linkage sites the overall ity of a strand or duplex is thus
substantially d ed to an Sp chirally pure strand. Hence, when higher levels of
nuclease resistance are desired for a particular commercial purpose, compared to what is
provided by the standard chirally mixed phosphorothioate linkages, Sp linkages are
preferably used to protect those linkage sites susceptible to cleavage.
r possible alternative to the standard phosphorothioate linkage is the
boranophoshate linkage with the Sp stereoisomer configuration being preferred.
Boranophosphate linkages, (Figure 1) differ from native DNA and RNA in that a borane
(BH3-) group replaces one of the non-bridging oxygen atoms in the native odiester
linkage. Such es can be inserted in oligos via two general methods: (1) te
directed enzymatic polymerization; and (2) chemical synthesis using solid supports. A
boranophosphate nucleoside monomer is illustrated in Figure 2.
phosphate oligo production can be achieved by a variety of solid phase
chemical synthetic s including methods that involve modifications to the very
commonly used approaches employing phosphoramidites or H-phosphonates in the
tion of phosphodiesters, phosphorothioates and phosphorodithioates among other
chemistries (Li et al., Chem Rev 107: 4746, 2007). Other solid phase synthesis techniques
more precisely directed to boranophosphates have also been developed over the last few
years. Wada and his gues, for example, have developed what they call the
boranophosphotriester method that can make use of H-phosphonate intermediates (Shimizu et
al., J Org Chem 71: 4262, 2006; Kawanaka et al., Bioorg Med Chem Lett 18: 3783, 2008).
This method can also be applied to the synthesis of diastereometically pure boranophosphates
(Enya et al., Bioorg Med Chem 16: 9154, 2008).
The generation of oligos with mixed linkages such as boranophosphate and phosphate
linkages has been accomplished by several solid phase methods including one involving the
use of bis(trimethylsiloxy)cyclododecyloxysilyl as the 5’protecting group (Brummel and
Caruthers, Tetrahedron Lett 43: 749, 2002). In another example the 5’-hydroxyl is initially
protected with a benzhydroxybis(trimethylsilyloxy)silyl group and then deblocked by
Et3N:HF before the next cycle (McCuen et al., J Am Chem Soc 128: 8138, 2006). This
method can result in a 99% coupling yield and can be applied to the synthesis of oligos with
pure boranophosphate linkages or boranophosphate mixed with phosphodiester,
orothioate, phosphorodithioate or methyl phosphonate linkages.
The boranophosphorylating reagent 2-(4-nitrophenyl)ethyl ester of
boranophosphoramidate can be used to produce boranophosphate linked oligoribonucleosides
(Lin, Synthesis and properties of new s of boron-containing nucleic acids, PhD
Dissertation, Duke University, Durham NC, 2001). This reagent readily reacts with a
hydroxyl group on the nucleosides in the presence of 1H-tetrazole as a st. The 2-(4-
nitrophenyl)ethyl group can be removed by azabicyclo[5.4.0]undecene (DBU)
through beta-elimination, ing the corresponding nucleoside boranomonophosphates
(NMPB) in good yield.
The -controlled synthesis of oligonucleotide boranophosphates can be achieved
using an adaptation of the oxathiaphospholane approach originally developed for the stereocontrolled
synthesis of phosphorothioates (Li et al., Chem Rev 107: 4746, 2007). This
method involves a tricoordinate phosphorus intermediate that allows for the introduction of a
borane group. Other approaches include stereo-controlled synthesis by means of chiral
indole-oxazaphosphorine or chiral oxazaphospholidine. Both of these approaches initially
used for the stereocontrolled synthesis of phosphorothioates have been successfully adapted
to boranophosphates (Li et al., Chem Rev 107: 4746, 2007). In yet another approach to the
production of the stereocontrolled sis of oligos linked by boranophosphates involves
the use of H-phosphonate intermediates (Iwamato et al., Nucleic Acids Sym Ser 53: 9, 2009).
Modifications Applicable to seqRNAi Sense and Antisense Strands as well as to ss-siRNA, ss-
IMiR and :
a) Unless otherwise provided for the terminal 3'-end nucleoside cation in a
seqRNAi strand is preferably not 2'-fluoro. This is a manufacturing and not a
onal issue. Using existing standard sis methods strands having a 2’-
fluoro at the 3’-end terminus typically results in a reduced yield.
b) Phosphorothioate linkages can be used to e odiesters in positions
where they are not ed to increase nuclease resistance. This can be done, for
example, to se the stickiness of an oligo for certain proteins such as albumin.
c) The Sp diastereoisomer phosphorothioate linkage can be used in linkage sites
selected for protection from nuclease cleavage in accordance with the present
ion rather than the standard chirally mixed phosphorothioate es when a
higher level of nuclease resistance is desired.
d) Boranophosphate linkages may e some or all phosphorothioate linkages.
Applicable to seqRNAi Antisense Strands:
The 5’-end nucleoside can be phosphorylated at the 5’ ribose position.
G. Thermodynamic erations
1. Overview:
dynamic considerations related to complementary base pairing are of
importance in the design of seqRNAi strands. Most importantly, efficient silencing activity
for all the classes of seqRNAi compounds is dependent on optimizing thermodynamic
parameters. Such parameters also play a key role in the optimization of the design of seqMiR
seed sequences for particular commercial purposes. Thermodynamic stability is reflected in
the g temperature (Tm) or the standard free energy change (ΔG) for duplex formation.
These parameters are highly correlated with each other and can be calculated using well
established nearest neighbor calculations or be experimentally determined.
The starting point for constructing strands with the desired thermodynamic properties
for use in the present invention is the basic RNA sequence of the strand where it is comprised
of the normal ribonucleosides with the most common bases (U, C, G and A) and
phosphodiester linkages. Nearest-neighbor calculations can be used to calculate the l
Tm(s) of the strand with its partner strand under physiologic conditions as well as its ability
to interact with itself through n and dimer formation (Panjkovich and Melo
Bioinformatics 21: 711, 2005; Freier et al., Proc Natl Acad Sci USA 83: 9373, 1986; Davis &
Znosko, Biochemistry 46: 13425, 2007; Christiansen & Znosko, Nuc Acids Res published
online June 9, 2009). Nearest-neighbor ations can be aken through the use a
number of readily available computer programs for oligo analysis.
Regional trand Tms play an important role in the design of seqRNAi
compounds. Individually these regions can be too short for the nearest-neighbor calculation
to be reliably applied. When this is the case a basic Tm ation based on A:U and G:C
content can be applied using the following formula where w, x, y and z are the number of
bases of the indicated type: Tm = 2(wA+xU)+4(yG+zC)
Tm calculations are adjusted using the approximations shown in Table 2 which
accounts for the effects of particular chemical modifications. The table can then be used as
guide for making design adjustments to the strands that will result in the desired overall and
regional Tms when they combine to form a duplex with the selected architecture.
TABLE 2
Approximation of Effects of Particular Chemical Modification to an RNA Oligo
on Tm Measured when Duplexed with a Complementary Native RNA Oligo
Degrees
Change in
Modification Comments
Tm per
Modification
plus 1.0 – plus
2’-fluoro
plus 0.5 – plus
2’methyl
Deoxyribose
Any terminal 5’-end duplexed LNA is poorly
stabilizing as are terminal 3’-end duplexed uracil
LNAs. These are excluded from the indicated Tm
range and are not red. LNA with adenine has
about one-half of the stabilizing effect of LNAs
plus 4.0 – plus with other standard bases. Using 2,6-
8.0 diaminopurine or replacing a complementary uracil
containing nucleoside with an LNA with a e
base can reverse this. Using a 2-thiothymine
replacement for a thymine can increase the affinity
of a LNA brining it to the upper end of the
indicated Tm range.
Replacement of e with 2,6-diaminopurine
increases the Tm. It can be paired with any of the
plus 1.0 – plus
2,6-diaminopurine ribose modifications provided for herein to form a
side. The mentary partner nucleoside
can have uracil or e.
2-thiouracil can be paired with any of the ribose
plus 2.0 - plus modifications provided for herein to form a
2-thiouracil
6.0 nucleoside. The complimentary nucleoside in the
partner strand should contain adenine rather than
guanine when the goal is to optimize stability. The
most stabilizing nucleosides have 2-thiouridine
paired with LNA where the use of this base further
increases the izing effect of LNA. Internal 2-
thiouridine containing nucleosides are more than
two fold more stable than are ones found at the
most minal position of an oligo duplex. 2-
thiouridine containing nucleosides at the most 3’-
terminal position in an oligo duplex have little or
no stabilizing effect.
4-thiouracil can be paired with any of the ribose
modifications provided for herein to form a
nucleoside. The complimentary nucleoside in the
partner strand should contain guanine rather than
plus 3.0 - plus
4-thiouracil adenine when the goal is to increase stability. The
most izing nucleosides have uracil
paired with LNA where the use of this base further
increases the izing effect of the LNA
modification.
2-thiothymine can be paired with any of the ribose
modifications ed for herein to form a
plus 2.0 - plus nucleoside. The most stabilizing nucleosides have
2-thiothymine
6.0 2-thiothymine paired with LNA where the use of
this base further increases the stabilizing effect of
LNA.
A single UNA nucleoside will reduce the Tm for
the seqRNAi duplex with lower Tm reductions for
minus 2.0 –
UNA UNA placed near the termini and higher Tm
minus 10.0
reductions for UNA placed near the center of the
duplex
Arabinonucleoside (ANA) minus 0
The effect of the same mismatch depends on the
nature of the mismatch and on where it falls in the
duplex with internal mismatches being two fold or
more destabilizing than mismatches at the
Mismatch duplexed termini. Substitution of a nucleoside with
minus 2.0 – an adenine for one with a guanine will at most
(involving nucleosides with minus 12.0 reduce the Tm about 1.0 degree given that a
standard A, C, G, U or T bases) partner nucleoside with a uracil has a wobble base.
This will have little if any effect. Individual LNA
mismatches are about one-third less destabilizing
than mismatches involving nucleosides with 2’-
modifications to the ribose or with ribose itself.
minus 0.4 –
Phosphorothioate
minus 1.2
* Tm is measured in degrees centigrade under physiologic conditions. The numbers provided
are approximations and the actual affects on Tm are influenced by a number of parameters
including but not limited to the length of the , the position of the modification in the
duplex and the presences of other modifications in the strand. It is to be assumed that the
affinity effects of the indicated nucleoside modifications are with t to a complementary
nucleoside in an oligonucleotide strand unless the cation is specifically stated to be a
mismatch.
2. l and Regional Interstrand Binding Affinities:
The overall Tm for the seqRNAi-based duplex formed by a particular seqRNAi set is
ant. As the Tm increases above about 55 degrees centigrade, for example, the
hood that AGO-2 will be preferentially loaded into RISC relative to the other argonautes
increases. AGO-2 is the only argonaute with the catalytic activity that is important for
NA and seqIMiR activity. In contrast, the large majority of s are relatively
erent to which argonaute is incorporated into RISC, however, loading of AGO-2 has the
potential to generate off target s by these compounds if it’s catalytic activity is not
blocked using the appropriate design considerations. Accordingly, overall Tms of about 65
degrees centigrade and above are preferred for NA and seqIMiR sets to optimize
AGO-2 loading. Lower Tms are preferred for seqMiRs unless the direct catalytic activity of
AGO-2 is inhibited. The latter can be achieved by preventing the nucleosides in ons 10
and/or 11 from the 5’-end of the antisense strand from effectively base paring with an
nded target.
Certain relative differences in interstrand affinities in particular regions of the
seqRNAi-based duplex (regions explicitly defined in Table 3) are also important for all the
seqRNAi-based duplex architectural variants other than small internally segmented. The three
regions itly defined by Table 3 with respect to the sense strand are the areas in the
duplex where collectively a relatively lower binding affinity ed to the overall
interstrand affinity can promote efficient RISC loading and retention of the antisense strand
with the removal of the sense strand. Lower Tms in s 1 and 3 appear to promote
unwinding of the duplex and a substantially lower Tm in region 2, such as can be produced
by a mismatch, UNA or abasic nucleoside can help promote removal of the passenger strand.
When AGO-2 is loaded into RISC and there is an appropriate cleavage site in the sense strand
(opposite the linkage between nucleosides 10 and 11 of the nse strand), however, it can
promote the efficient removal of the sense strand when there is no mismatch, UNA or an
abasic nucleoside to region 2.
These are also the primary regions to look to for affinity lowering modifications
particularly in the sense strand when it is important to reduce the l Tm of a seqRNAi
duplex if it is above the preferred range. The overall Tm of a seqRNAi-based duplex can be
too high to be directly measured (over about 95 degrees centigrade under physiologic
conditions), however, and the compound can still produce the desired ing effect if these
regional interstrand affinities are properly managed.
The general rule is that it is preferable for the combined three regions explicitly
d by Table 3 to have a lower Tm than the combined intervening regions when both are
considered as a continuous sequence and are ted for any size difference. These
combined sequences are large enough to be evaluated using the more accurate nearest
or calculation. It is also preferred that all three of the explicitly defined regions will
have a relatively lower Tm corrected for size than the Tm of the combined intervening
sequences. The small size of the dual regions itly defined by Table 3, however,
requires the use of a basic Tm calculation that does not take the nearest-neighbor effects into
account.
When the overall Tm for the compete duplex is above the preferred upper level
modifications to reduce it should be preferentially made in the regions explicitly defined by
the Table. Even when the overall duplex Tm is in the preferred range mismatch(s) with the
antisense strand, a single UNA or a single abasic nucleoside in one or more of these regions
can e the intended silencing activity. In seqsiRNA/seqIMiR sets, however, a low
relative Tm in region 2 can be less important when the positions in the sense strand te
positions 10 and 11 counting from the 5’-end of the antisense strand have a phosphodiester
linkage and the nucleoside on the 5’side of this linkage site in the sense strand is not 2’
methyl and is preferably ribose or 2’-fluoro. This configuration facilitates the cleavage of the
sense strand by AGO-2 and in turn this facilitates the removal of the sense strand from RISC.
TABLE 3
Regions Suitable for Modifications that Provide
for Regional Reductions in Interstrand ty (Tm) in seqRNAi-based
Duplexes
Length of Sense
Strand Nucleoside Position Counting from 5’-end of Sense Strand
(exclusive of any
Region 1 Region 2 Region 3
precursor)
23 4 – 7 14 - 16 21 - 23
22 4 – 7 13 - 15 20 - 22
21 4 - 7 12 - 14 19 - 21
4 – 7 11 - 13 18 - 20
19 4 – 7 10 - 12 17 - 19
18 4 – 6 9 - 11 16 - 18
17 4 – 5 8 - 10 15 - 17
16 4 7 - 9 14 - 16
* It is to be understood that the regions being identified include the corresponding ed
n of the antisense strand. The sense strand is used as reference because the widest range
of possible chemical modifications and other manipulations, such as mismatches, that can be
used to reduce the interstrand affinity in these regions can be applied to the sense strand
without reducing silencing activity. The indicated length of the sense strand is exclusive of
any 3’-end nucleosides or nucleoside tutes that will form an overhang precursor. The
range of indicated nucleoside positions includes all of those indicated in the given region.
So, for example, 4-7 is to be read to include both the 4th and 7th nucleosides.
Designs for the strands that make up a seqRNAi set of les must e means
to promote the selection of the d antisense strand by RISC from the seqRNAi-based
duplex. One of the means used to e the intended antisense strand being loaded into
RISC as the de facto antisense strand is based on the primary mechanism for antisense strand
ion from nous siRNA and miRNA duplexes. The principle behind this
ism is sometimes referred to as the asymmetry rule. According to this rule the
relative Tm of the 4 terminal duplexed nucleosides at one end of the duplex compared to the
corresponding nucleosides at the other end of the duplex plays a key role in determining the
relative degree to which each strand will function as the nse strand in RISC. The strand
with its 5’-end involved in the duplexed terminus with the lower Tm more likely will be
loaded into RISC as the antisense strand. The Tm effect, however, is not evenly distributed
across the ed terminal nucleosides because the most terminal nucleoside is the most
important with the successive nucleosides being progressively less important. Violations to
this rule do not necessarily render a particular siRNA or miRNA duplexe nonfunctional but
they likely will exhibit suboptimum activity because there will be more loading of the
intended sense strand into RISC as the de facto antisense strand and loading of the intended
sense strand can increase the likelihood of off target effects.
The asymmetry rule is important for the majority of seqRNAi architectural types. The
st way of establishing it for a seqRNAi set against a particular target is simply to select
sequences that will result in compliance with the asymmetry rule following the application of
the necessary rules for chemical modifications to the strand. When necessary the information
in Table 2 can be used to bring a strand set into compliance with the asymmetry rule. In
situations where the strands are exceptionally out of compliance with the asymmetry rule the
forked-variant can be employed with most of the architectures.
The two 4 nucleoside duplexes involved in determining compliance with the
try rule are too short to apply the nearest neighbor calculation with a reasonable
degree of confidence in determining the Tm values. Instead the more basic calculation can be
used to approximate the Tms for the unmodified duplexes. Once the Tm for the unmodified
es is determined then it can be adjusted based on the Tm affects of the modifications
ed in Table 2. This determination, however, does not take into account the decreasing
importance of the nucleosides as one moves away from the terminus. To account for this in a
simple way it is preferred that the overall Tm for the 4 nucleoside duplex be lower for the one
ning the 5’end of the antisense strand and that the most al two nucleoside pairs
of this duplex have a lower affinity for their partner nucleoside than the corresponding pairs
at the other terminus.
RISC requires that the selected antisense strand be phosphorylated at the 5’ CH2OH
position of the 5’-end ribose or ribose substitute in order for the strand to be active in
silencing.
Thus the simplest method to inhibit the loading of the desired sense strand into RISC
as the antisense strand is to 5'-methylate the sense strand at this position. The d
antisense strand can be manufactured to be 5'-phosphorylated or an intracellular enzyme can
be relied on to provide the phosphorylation after the strand has entered the cell. This is to be
used as a supplement to the entation of the asymmetry rule in strands ed with
particular architectures in mind.
Methods for measuring the relative contributions of each of the strands in a siRNA or
miRNA duplex to silencing are well established in the art. These techniques can also be
applied to seqRNAi-based es to ensure that the intended antisense strand is being
efficiently used by RISC. For example, expression s with a read out protein such as
luciferase or enhanced green fluorescent protein can be constructed with target sequences
capable of being recognized by the targeting code for any strand that s RISC silencing.
Two such vectors with read out ns that can be discriminated in the same cells can be
constructed where each one responds to a different strands in a seqRNAi pair. Next these
expression vectors can be transfected into a cell line along with or just prior to the
administration of the seqRNAi-based duplex that is comprised of the test strands. By
measuring the relative level of silencing of each of the read out proteins it is possible to
determine the relative efficiencies with which each of the strands silences their tive
targets. Such an assay provides the means to evaluate the extent to which an intended sense
strand is being loaded into RISC as an antisense strand.
3. ing Codes and Targets:
The central region and the seed sequence are the principal if not exclusive targeting
codes for conventional siRNA and miRNA respectively. Modifications to these regions of the
antisense strand, therefore, are particularly momentous in terms of their ability to affect the
silencing of the intended target(s). These basic concepts also apply to seqRNAi, ss-siRNA,
R and ss-MiR nse strands.
siRNA, seqsiRNA, seqIMiR, ss-siRNA and ss-IMiR antisense strands are most
effective when they are loaded into RISC with AGO-2 because this argonaute is unique in
having catalytic activity against the RISC target. AGO-2 ically cleaves the target
mRNA at the linkage opposite the one g nucleoside positions 10 and 11 counting from
the 5’-end of the nse strand. To be effective the sides in positions 10 and 11
along with several of the contiguous nucleosides must be fully complementary with the
mRNA target. Thus, mismatches in the central region of the antisense strand in particular will
undermine the intended silencing ty. The binding affinity of the central region for the
mRNA target, however, appears to be comparatively unimportant for ing activity within
the range of affinities generated by the types of chemistries allowed by the present invention.
Outside the central region of the antisense strand and exclusive of any overhangs it is
able that the sequence have a high degree of complementarity with the mRNA target. A
small number of mismatches, however, typically can be tolerated.
The typical normal endogenous mechanisms that support miRNA, seqMiR and ss-
MiR activity involve the induction of mRNA degradation processes where the antisense
strand loaded RISC acts simply to recognize particular mRNA types as targets. Once this
occurs other cellular elements form complexes with RISC that result in mRNA degradation
that often starts with the poly-A tail. In this context, the details of the thermodynamic
interactions involved in the complementary base g between the seed sequence and the
complementary sequence in the mRNA 3’-UTR require more attention than the
complementary base g between the central region of other RNAi types and their mRNA
target.
One way to construct seqMiRs is simply to apply the key architectural ndent
thms and a selected architectural dependent algorithm to a particular endogenous
miRNA or a version of it that has been stripped of bulge structures, other mismatches
between the otherwise complementary s and/or wobble base pairings. Alternatively, the
seed sequence from a particular endogenous miRNA or a novel seed sequence can be placed
in a duplex vehicle along with a complementary sequence into the corresponding area of the
sense . Any AGO-2 based tic activity exhibited by the duplex vehicle can be
inhibited, for example, by replacing nucleosides 10 and/or 11 counting from the 5’-end of the
antisense strand with ones that are abasic, UNA and/or FANA. The abasic nucleosides can
have any of the sugar modifications ed for herein including the unlocked variant (the
sugar in UNA), 2-deoxyribose and FANA. Abasic nucleosides preferably are joined to
adjacent nucleosides by phosphorothioate linkages.
Novel seed sequences can be constructed for particular purposes using a combination
of recently developed computer and molecular biologic techniques that have been used to
study the details of the interactions of the seed sequence of endogenous miRNAs and the
complementary sequences in mRNA s that are subject to silencing (Chi et al., Nature
Structural & Mol Biol 19: 321, 2012 provides some specific examples). Potential novel seed
sequences initially can be identified by examining the 3’-UTRs for complementary ces
in the collection of mRNAs that are of interest for silencing. These complementary sequences
will have to meet certain thermodynamic criteria as described below. Next a prototype of the
novel miRNA can be constructed, for example, by placing the seed sequence in a ed
antisense strand that meet the design criteria for seqMiR and ss-MiR compounds. The y
of the prototype seqMiR to physically recognize the collection of mRNAs of interest is then
analyzed. Prototype compounds e of g to a desired collection of mRNAs can be
then tested in ing studies. Finally, ments in the binding affinity of the seed
ce for its mRNA target sequences can then be made as needed.
There is a substantial literature that describes the ctions of the seed sequence of
endogenous miRNA with its mRNA targets. It has also been discovered that the seed
sequence in conventional siRNA is a common major contributor to the off-target effects seen
with this class of RNAi. Thus, it is clear siRNA can also function as a novel type of miRNA
albeit one where the resulting silencing activity is usually not desired. It follows from this
that the sequences of particular miRNA antisense strands that lie outside the seed sequence
are not ed for achieving miRNA-type silencing.
Ui-Tei et al., (Nucleic Acids Research 36: 7100, 2008) have illuminated some key
thermodynamic considerations that affect the cy of particular seed sequences in siRNA
with respect to engendering miRNA-type activity against mRNA targets. They demonstrated
that the thermodynamic stability of the duplex formed between the seed sequence and the
mRNA target sequence has a strong positive correlation with the degree of seed sequence
dependent silencing. The range of calculated seed /mRNA target duplexes tested
ranged from -10°C to 36°C while the corresponding ΔG values ranged from -16 to -7
kcal/mol. This trates there is roughly a 5°C increase in Tm per -1 kcal/mol change in
ΔG. The ΔG value can be converted to the dissociation constant for the seed duplex using the
ished formula ΔG = -RTln(1/Kd) where T is 298.15 K. The results showed that there is
a 106 fold difference in the dissociation constant between the seed/target duplex with the
highest ΔG value and the lowest.
All of the 26 siRNA compounds tested had seed region dependent off target effects
when used at high concentration (50nM) but only 5 of 26 (35%) had off-target effects when
used at a low dose (0.5nM). These siRNA compounds were divided into two groups based on
whether they resulted in greater than or less than 50% seen region based target suppression.
It was found that a calculated Tm of 21.5 s centigrade for the seed duplex
distinguished the two groups with the higher Tm positively correlating with the higher
silencing activity (r = -0.72 in linear regression analysis of silencing ty vs. Tm). This
high level of correlation is surprising given the fact each of the siRNAs tested were distinctly
different compounds that could be expected to vary in terms of factors such as the efficiency
of antisense strand loading into RISC.
The seed duplex Tm calculated in y the same way for 733 human miRNAs in
the miRBase database showed that 75% of them had values above 21.5 degrees centigrade.
Twenty percent were above 40 degrees centigrade and 5% were below 10 degrees. Indeed, 13
of the 733 (2%) had calculated seed duplex Tms above 50 degrees centigrade.
These thermodynamic parameters assist in the optimization of seqMiRs and ss-MiRs
that are based on a particular endogenous miRNA seed sequences or to te miRNA
activity based on a novel seed sequence. When they are based on a seed sequence from
nous mRNA the overall level of silencing activity can be increased or decreased by
increasing or decreasing respectively the l seed duplex Tm with respect to the mRNA
types to be silenced. When the complementary sequence to the seed sequence in the mRNA
3’UTRs varies the relatively affinity of the seed sequence for such target sequences can be
adjusted to have a higher affinity for some and a lower affinity for others based on the desired
pattern of silencing activity. Based on the Ui-Tei et al. (2008) data it is clear that seed duplex
ty between a seqMiR or ss-MiR seed sequence and its mRNA target ce is
preferably above 21.5 degrees centigrade for Tm and/or below a ΔG of -12 for those mRNAs
that are to be silenced and preferably below 15 degrees Tm and above -11 ΔG for those that
are not to be silenced.
The basis for ing the binding ty for a particular seed sequence and its
mRNA target sequence(s) are the chemical and other modifications provided herein that
affect complementary base pairing affinity. Approaches for a number of these modifications
are provided in Table 2. The use of these modifications must also take into eration all
the other design rules that apply to seqMiRs and ss-MiRs including other dynamic
considerations. The seed region of an antisense strand involves nucleoside positions 2-8
counting from the 5’-end and the asymmetry rule, where it applies, involves nucleosides 1-4
from the 5’end and in the case of the forked variant nucleosides 1-6 from the 5’end. Any
modifications to the overlapping side positions must be made compatible. Another
example is the preference for a comparatively low interstrand affinity in region 3 defined by
Table 3. This also puts an ty preference on seqRNAi-based duplexes that involves the
seed ce of the antisense strand that potentially conflicts with any desire to boost the
affinity of the seed sequence with its mRNA 3’UTR target.
The solution to these ial conflicts is to design seqMiR strands so that any
modifications to the seed sequence that increase binding affinity for the mRNA 3’UTR target
sequence do not proportionally increase the l or regional interstrand affinity with the
seqMiR partner sense strand. For example, one or more LNA modifications can be used in
the antisense strand seed sequence where they are compensated for by mismatches, UNA,
abasic nucleosides or other permissible affinity lowering modifications in the corresponding
area of the partner sense strand. With this type of compensation it is preferred that the
affinity ng modification involves either the binding partner or a nucleoside contiguous
with the binding partner that has the affinity increasing modification.
The seed sequences, mRNA 3’-UTR sequences, calculations and experimental design
used by Ui-Tei et al., (2008) can be used to help illustrate aspects of the design and testing of
seqMiR compounds including those based on novel seed sequences (i.e., ones not found in
endogenous miRNA). The particular methods used in the e are not meant to be
limiting but rather to show one approach to reducing some of the design ts for
s reduced to practice. The seed sequences taken from Ui-Tei et al., have little
commercial value but are valuable as an example given that they have been used to generate
real data that ground the example in actual facts. The same basic approach can be used with
novel or endogenous miRNA seed sequences that are directed to the 3’UTRs of actual mRNA
types that are to be silenced by a seqMiR compound.
Index 2A summarizes some of the data from Ui-Tei et al., (2008). The first column
lists the names of 26 different siRNA compounds. The next two columns list the seed
sequences from each of these compounds and the sequence containing the complement to the
seed sequence that was constructed for insertion into an expression . The fourth column
provides the calculated Tm for the seed duplex and the final column provides the t
suppression of the expression vector product produced by the siRNA when transfected into
cells that s it. As previously stated there is a strong ve correlation between a
higher Tm for the seed duplex and a higher level of target suppression.
Key observations based on these data include the following: (1) the fact the binding
affinity of the seed duplex appears to be a much more ant determinant of the level of
target suppression than is the nature of the rest of the siRNA compound; and (2) a specific
seed sequence from an endogenous miRNA antisense strand is not necessary in order to
obtain miRNA-like silencing activity. So what appears to be important with respect to the
duplex is that it simply has the necessary properties to result in the loading of the desired
antisense strand into RISC. Indeed, it is not even necessary for the duplex structure to mimic
any particular features of endogenous miRNA duplexes that are different from siRNA
compounds in order to get miRNA-like silencing activity.
The mental design upon which the suppression data shown Index 2A were
generated involves the use of expression vectors for a gene with an easily quantifiable
product. Ui-Tei et al., (2008) used the a luc gene inserted into the cially
available psiCHECK-1 plasmid (Promega). Twenty-one nucleoside sequences, shown in
column 3 of Index 2A, that include an 8 nucleoside stretch complementary to the 5’-end
nucleoside and the contiguous seed sequence were ed in the plasmid in the 3’UTR of
the luc gene in the plasmid as three tandem s. The remaining 13 nucleosides in the
inserted target sequence had no homology to the rest of the siRNA nse strand. This was
repeated for each of the 26 siRNA compounds involved in the evaluation and listed in
column 1 of the index. These plasmids were then transfected into HeLa cells that were
subsequently treated with the siRNA compound with the seed sequence matching the target
sequence in the transfected plasmid. The ability of the siRNA to ss the luc gene
product was determined for various doses and the 5.0 nM dose result is shown in the fifth
column of Table A in Index 2.
Index 2B provides a table that rates two possible steps in the modification of
seed sequences for use in seqMiR or ss-MiR compounds. In the actual ce of producing
commercially useful compounds the seed sequences can come from endogenous miRNA
antisense strands or they can be novel seed sequences designed to target a particular group of
endogenous mRNA types. The basic rules provided for achieving nuclease resistance and the
other ial/preferred architectural-independent rules are applied to the seed sequences
shown in the first column and the results are shown in the second column. The sugar in the
most 5’ nucleoside in the seed ce can be ribose or 2’-fluoro depending on the intrinsic
se stability of the first two linkage sites in the strand. Since this cannot be fully
determined without knowing the 5-end nucleoside in the strand the examples all have the 2’-
fluoro modification in the first seed position. The modifications, if any, to the most 3’
nucleoside in the seed sequence and the nature of its linkage to the contiguous nucleoside that
is not part of the seed sequence y depends on the nature of the contiguous non-seed
side. For the sake of this illustration it is assume the contiguous nucleoside is a G
because this s the situation if either of the negative control duplexes shown in Index
2D are used as the duplex vehicle. To indicate this situation a G is shown in parenthesis in
column 2 of Index 2B. If another duplex vehicle were used the contiguous nucleoside with
the 3-end of the seed sequence could be U, C or A. In the case of the siRNA based duplex
vehicle shown in Index 2D the contiguous nucleoside would be U. In column 3 examples of
le modifications selected from Table 2 that can be added to substantially increase the
Tm of the seed sequence with the target. The estimated increase in Tm compared to the
unmodified sequence is shown in column 4. In the actual practice of producing cially
useful seqMiR compounds the particulars of such modifications, if any, would be tailored to
optimize the ing of the intended group of mRNA types.
Index 2C provides a table that illustrates two possible steps in the modification of the
portion of the sense strand for use in seqMiR compounds that corresponds to the seed
sequence of the complementary strand. The principal goal here is to reduce the effect of the
affinity enhancing modifications made to the seed sequence in Index 2B on the regional and
overall affinity of the sense and antisense components of the seqMiR compound. The
preferred level of Tm ion in practice will depend on the exact structure of the seqMiR-
based duplex. Examples of possible modifications are shown in column 3 and the estimated
ion in Tm between the modified sense and antisense s is shown in column 4.
Since the preferred way to reduce affinity in this situation is to introduce mismatches the
nuclease resistance modifications may have to change accordingly. Further, the
modifications, if any, to the most 3’ nucleoside in the sense strand sequence in column 2 and
the nature of its linkage to the contiguous 3’ nucleoside (not shown) that is not part of this
section of the sense strand ce can depend on the nature of the contiguous 3’
nucleoside. This occurs if there is an overhang precursor in the sense strand. If so then the
rules ed to e endonuclease protection apply to the 3’end of the sense sequence
shown in column 2. In the absence of an overhang precursor then the rules for protecting the
3’end of the strand in the absence of an overhang precursor apply. This is the case with the
example in Indices 2B, 2C and 2D because the strand lacks an ng precursor. As a
consequence the sense strand sequences shown in 2C must end with a modified nucleoside
and be connected to the contiguous 3’ nucleoside (not shown) by a phosphorothioate linkage.
Finally, in the actual practice of producing commercially useful seqMiR compounds such
modifications to this portion of the sense strand would be ed to a particular duplex
vehicle and the full complement of design requirements ed herein as applied to the
entire duplex vehicle with the desired seed sequence inserted.
Index 2D provides three examples of duplex vehicles that are used to illustrate
features of the design of seqMiR compounds that make use of such structures. These
examples are based on two established negative controls for le species including mouse
and human and a siRNA targeting human and mouse Apo-B. As shown these parent
compounds have been modified in accordance with the essential/preferred architectural
independent rules (from sections E and F). The question marks indicate places where the
preceding nucleoside and/or its 3’ e modification cannot be determined in the absence
of a specific insert sequence. Each of the duplex vehicles is shown with and without a
modification in the antisense strand intended to t catalytic AGO-2 based silencing
activity. In these instances this is specifically illustrated by the placement of an abasic
2’deoxyribonucleoside in position 11 counting from the 5’-end of the antisense strand. In
practice the means to inhibit AGO-2 catalytic activity can be prophylactically made to the
strand or only be made if the need arises.
The portions of the strands to be replaced by the ed seed sequence and the
ponding sense strand sequence are underlined. As shown the rules for generating
nuclease resistance along with the essential/preferred architectural-independent rules have
been applied to the strands of the duplex vehicles with the ion of the underlined
portion. After the selected seed sequence and the corresponding sequence in the sense strand
have been inserted and an architecture selected then the design of a ular seqMiR
compound can be finalized. es of seed sequences and the ponding sense strand
sequences for the purposes of this ration are provided by Indices 2B and 2C
respectively. The insertion of a new seed sequence into a negative control has the potential to
generate a compound with off target AGO-2 catalytic activity. If this occurs it can be
inhibited by the methods provide .
In the actual practice of producing commercially useful seqMiR compounds the pool
of potential duplex es can be comprised of any duplex capable of meeting the design
ia provide herein and where the duplex results in the ent loading of the duplex and
retention of the desired antisense strand by RISC. Sources of duplex vehicles include
endogenous miRNA duplexes, conventional siRNA compounds and es that are
established to be miRNA/siRNA ve controls for the subject species of interest for
treatment with seqMiR compounds. Negative controls will need to be ked for a lack of
induction of unintended siRNA-based silencing activity once the selected seed sequence and
corresponding sense strand sequence are inserted. Any AGO-2 based catalytic silencing
activity generated by a duplex e can be inhibited by replacing the nucleosides in
positions 10 and/or 11 counting from the 5’-end of the antisense strand with modified
nucleosides that will inhibit this catalytic ty without preventing duplex formation by the
s. Suitable modifications for this purpose include abasic, UNA and FANA. The abasic
nucleosides can have any of the sugar modifications provided for herein including the
unlocked variant (i.e., the sugar in UNA), 2-deoxyribose and FANA. Abasic nucleosides
preferably are joined to nt nucleosides by phosphorothioate linkages.
Index 2E provides another seqMiR design variant that is based on the use of a dimer
forming antisense strand. One of the ways this variant is unusual is that it functions as a
seqMiR but only requires a single strand. This design involves placing both the seed
sequence and the complementary sequence in the same strand rather than separating them
between a sense and an antisense strand.
In the illustrative example shown in Index 2E seed sequence number 12 (from siRNA
ITGA10-2803) in the Table in 2B and the corresponding portion of the sense sequence shown
in Index 2C are placed in the antisense strand in the first duplex vehicle shown in Index 2D.
The placement of the sequence previously associated with the sense strand is placed in same
position in the antisense strand that it would be in a sense strand. These seed and
corresponding sense strand sequences are underlined in the first illustration in Index 2E.
Two things are immediately clear from Index 2E: (1) The nse strand forms a
dimer or more ically a duplex with itself: and (2) The antisense stand will also form a
hairpin with itself. These factors will also be true of any other seqMiR designed in this
manner. The ated overall Tm for the unmodified two-stranded duplex is 58 degrees
centigrade under physiological salt conditions and 50nM compound concentration using the
nearest-neighbor calculation. The portion of the strand ting the hairpin is represented
along with the intervening unpaired loop.
Two potential advantages to this design are the following: (1) Only one strand has to
be used in treatment; and (2) The hairpin can provide nuclease protection to the seed
sequence. As a result the seed sequence does not have to be chemically modified to protect it
from se . This would allow, for e, seed sequences from endogenous
miRNA to be used without al modification. A disadvantage of this design is that it is
cannot be efficiently administered to the circulation e the kidneys will rapidly clear the
double strand duplexed portion of the interchanging double and single strand forms. This
approach is more likely to be most useful in situations were the compound is inserted into
comparatively static environments such as the cerebral spinal fluid, joint fluids, ascites and
bladder rather than into the circulation. Here the double strand species in effect serves as a
reservoir for the single strand species that can be more efficiently taken up by cells.
This approach can be used with architectures other than small internally segmented
and the asymmetric variant where there is a 5’-end overhang. The asymmetry rule that
applies to these architectures, however, has to be ed because it does matter which
strand is loaded since they are the same. Thus, the requirement for a differential Tm n
the duplex termini is lowered in this situation. The concept that the 4 most terminal
nucleosides have a graded affinity with the lowest affinity being relegated to the 2 most
terminal nucleosides, however, is retained. Since the 5’end terminal nucleoside is not part of
the seed region it can be configured as a ch with the 3’end terminal nucleoside with no
effect on the seed duplex Tm. This is preferred when the one or both of the nucleosides in the
2 terminal positions are G and/or C. The most 5’ of the seed sequence nucleosides can also be
mismatched with the corresponding nucleoside on the 3’-end but not with the target
sequence. This is preferred if the seed sequence starts with Gs and Cs in the initial 2
positions from the 5’end.
It is also preferred that the strands be inhibited from supporting AG0-2 catalytic
activity that could generate off target effects. This can be achieved by replacing the
nucleosides in positions 10 and/or 11 from the 5’-end with modified nucleosides that will
inhibit this catalytic activity without preventing duplex formation by the strands. le
modifications for this purpose include abasic, UNA and FANA. The abasic sides can
have any of the sugar modifications provided for herein including the unlocked variant (i.e.,
the sugar in UNA), 2-deoxyribose and FANA. Abasic nucleosides preferably are joined to
adjacent nucleosides by phosphorothioate linkages. The design rules affecting regional
interstrand affinities just discussed in this and the preceding paragraph also fulfill the
ence for lower regional affinities in regions 1, 2 and 3 defined by Table 3.
In the illustration in Index 2E, the A in position 10 and the U in position 11 are
rendered abasic 2’-deoxyribonucleotides as indicated by the 0D subscript (Index 1). Such
modifications involving two positions can result in overall Tm drops of 10-20 degrees
centigrade. When required such a drop can be compensated for by using a slightly longer
strand and/or by adding one or more modifications that increase Tm. This is not necessary in
the present example given the starting Tm of 58 and the increases to Tm provided by the
other modified nucleotides. It is also not necessary if the compound does not produce
unacceptable off-target s due to AGO-2 catalytic activity.
As for seqMiR sets lly, cations can be made to the seed ce that
will se the Tm of the seed duplex without undermining important thermodynamic
considerations with respect to overall and regional interstrand affinities. This is achieved by
making compensatory changes in the sequence complementary with the seed sequence in the
seqMiR strand set that in this case is in the same strand. Various means to enhance or reduce
interstrand or antisense strand/target affinities are listed in Table 2.
One specific e or increasing the Tm of the seed duplex out of the numerous
possibilities is shown in the last illustration in Index 2E. Here the LNA modification is used
in positions 5 and 8 counting from the 5’-end. These are sated for by the UOD in
position 11 and by the use of a mismatch in position 15. The UOD in position 11 is contiguous
with the binding r for the LNA in position 8 and the mismatch in position 15 is the
binding partner for the LNA in position 5. This illustrates that this type of compensation can
involve either the g partner or a nucleoside contiguous with the binding partner.
Index 2F provides examples of the application of these design principles to a seed
sequence taken from an endogenous miRNA that has potential relevance for drug
development. Let-7 family members can act as anti-oncogenes and the levels of one or more
family members is suppressed in a number of cancer types. mentally increased levels
of the suppressed family member(s) has been shown to produce a y of anticancer
effects.
The seed sequence illustrated in Index 2F is common to le members of the let-7
miRNA family and to multiple s such as human and mouse. By inserting this sequence
and the corresponding sense strand ce into a duplex vehicle a seqMiR can be
constructed that can mimic features of multiple let-7 family members. Further, the affinity of
this seed ce for the target mRNAs can be increased with a resulting increase in
silencing ty. Five examples of this are shown along with 5 examples of compensatory
reductions in binding affinity capacity in the corresponding area of the sense strand.
In Index 2G these sequences are ed into the appropriate places in the duplex
vehicle shown in 2D that is based on a siRNA to Apo-B. The nse strands are shown
with and without examples of blocking AGO-2 catalytic activity against any unintended
mRNA target. Further, the antisense strands are shown with 2 overhang unit precursors.
These can be selected from those ed in the overhang precursor section, for example,
~U~U or ~dT~dT.
Examples of dimer forming single strands based on the antisense strands shown in 2G
are illustrated in 2H. As described in the description associated with 2E such dimer forming
single strands are most suitable for used in compartments, such as the CNS, in subjects other
than the circulation where the dimer form can be cleared in a matter of minutes by the
kidneys.
4. Summary of minimal essential rules for seqRNAi compounds:
In addition to the essential/preferred architectural-independent rules provided in
sections E and F there are minimal thermodynamic ements for the most basic seqRNAi
compound suitable for use in accordance with the present invention. The stand-alone
architectures provided differ in the ing: (1) whether or not they provide for an
overhang precursor(s) in strands and if so how many units are there and where are they; and
(2) whether or not they provide for one sense strand and one antisense strand or for two sense
strands and one antisense strand or for two antisense s and one sense strand as members
of the same seqRNAi set. It is obviously ary for a seqRNAi-based duplex to have an
architecture. From a thermodynamic point of view the blunt-ended architecture is the
simplest in terms of describing the minimal set or rules for a seqRNAi set. This is because
dual sense or nse strands in the same i set require additional thermodynamic
considerations and an overhang longer than one unit has the potential to affect interstrand
binding affinity of the seqRNAi-based duplex. This can occur when the ng is long
enough to double back on the duplex and interact with it. The overhang effect, however, is
typically not a major concern and can be d in general design considerations. Thus,
nearly all situations the cal and asymmetric architecture (with only a 3’-end overhang
precursor) are no more thermodynamically complex in terms of the rules presented than the
end architecture.
Given these ations the minimal requirements for seqRNAi compounds requires
the essential/preferred architectural-independent rules provided in ns E and F along
with the essential/preferred rules for the blunt-end architecture. In this simplest case the
length of the strands will be assumed to be 19-mers since this length corresponds to that of
the largest proportion of tional siRNA and miRNA compounds exclusive of any
overhangs. The architectural-dependent algorithms include rules with additional
thermodynamic considerations that are not considered here as the simplest case. The
dynamic rules for the simplest case seqRNAi set can be summarized as follows:
1) Table 3 explicitly defines three regions in a seqRNAi-based duplex based on the sense
strand where it is preferred that the ed contribution of the three regions have a
Tm that is lower than the Tm for the overall duplex when corrected for the smaller
number of contributing nucleosides. It is preferred that all three regions have
relatively lower Tms but they are individually too short to allow for reasonably
reliable Tm determinations. Adjustments in affinity can be achieved by using affinitylowering
modifications in the sense strand portion of one of these explicitly defined
regions and/or by increasing the affinity in the intervening areas in the sense strand.
When the overall Tm of a seqRNAi duplex is above the preferable range then the use
of affinity lowering modifications to reduce the overall Tm preferably are made to
one or more of the regions explicitly defined in Table 3. The general steps involved in
achieving these goals are the following:
a. The collective interstrand duplex Tm for the 3 regions explicitly d by
Table 3 and the overall duplex Tm are determined for the unmodified strands
using the t-neighbor calculation.
b. Next the effects of the al modifications on the regional and overall Tms
are adjusted for the modifications made following the applications of the
se resistance and essential/preferred architectural-independent rules
using the information in Table 2.
c. Finally, the information in Table 2 is used to reduce the combined regional Tm
and/or to increase the intervening Tms as needed. These modifications should
be evenly distributed as much as possible. The modifications are made to the
sense strand.
2) The asymmetry rule is applied next.
a. The Tm n the duplexed 4 nucleosides at each terminus based on the
unmodified RNA sequence is estimated using the following equation:Tm =
2(wA+xU)+4(yG+zC), where w, x, y and z are the numbers of the ted
nucleosides in the 4 nucleoside duplex.
b. Table 2 is used to make adjustments in the overall 4 nucleoside duplex Tm
based on the modifications applied to these nucleosides and to the ening
linkages following the applications of the nuclease resistance,
essential/preferred architectural-independent and the thermodynamic rules just
provided in (1).
c. The determinations in (a) and (b), r, do not take into account the
decreasing importance of the nucleosides as one moves away from the
terminus. To account for this in a simple way it is preferred that the overall
Tm for the 4 nucleoside duplex be lower for the one containing the 5’end of
the antisense strand and that the most terminal two nucleoside pairs of this
duplex have a lower affinity for their partner nucleoside than the
corresponding pairs at the other terminus. If it is necessary to make an
adjustment either in one or both of the terminal nucleoside pairs or in the
overall Tm for the terminal 4 nucleosides the needed modification information
can be obtained from Table 2. In general, the magnitude of the modification
should be in alignment with the magnitude of the needed adjustment.
d. When major affinity adjustments of this type are in order mismatches are
preferred over UNA and abasic and they are made to the sense strand.
Not all the permitted strand modifications ed for herein have been well
terized with respect to their impact on interstrand or antisense /target affinity and
they do not appear in Table 2. Those that have been characterized lly vary in their
effect with their position within the strand (terminal positions, for example, typically result in
a reduced effect) and by other details of the adjacent /duplex context.
The next most basic considerations to seqRNAi set design involve adding the
essential/preferred rules for the targeting codes. These are the central region of the nse
strand of seqsiRNA and seqIMiRs and the seed sequence of seqMiRs. These rules also apply
to the corresponding ss-siRNA, ss-IMiR and ss-MiR antisense strands respectively.
The application of these essential rules to an example of an seqsiRNA (seqIMiRs
follow the same design process only the type of target RNA is different) in Index 8 where the
target is mouse PTEN and in Index 9 where the seqMiR example is based on let-7i. These
s illustrate the essential basic design of seqsiRNA/seqIMiR and seqMiR compounds. In
standard practice the some or all of the thermodynamic rules can be left to later in the design
Index 8 carries over the three strands from Index 6 as a starting point. The three
regions defined by Table 3 are underlined in the sense strand. The sequence of the combined
three regions are shown next followed by the ed intervening regions. Table 4 provides
the Tm calculation results for the overall duplex and for the combined al and combined
intervening sequences with and with out adjustments for the modifications made to the
strands. Table 2 is used to provide the estimated effects of the various modifications on the
Tm. The combined regions 1-3 sequence is 10 nucleosides in length while the combined
intervening sequence is 9 sides in length so the Tm for the former has been
proportionally decreased.
TABLE 4
Duplex (degrees centigrade)
Unmodified Modified
Overall 70 79
Combined Regions 1-3 34* 38*
Combined ening
37 41
Regions
*Reduced 10% to compensate for longer length ed to combined intervening regions
It can be seen in Table 4 that both the differential Tms for the two combined regions
and the overall Tm are within the preferred parameters without further modification. Further,
the Tm calculations for the two termini of the duplex meet the requirements of the asymmetry
rule. The terminus with the 5’-end of the sense strand has a calculated Tm of 28 degrees that
increases to 32 with the modifications while the other us has a calculated Tm of 20
s that increases to 22 degrees with the modifications. In l practice, the
asymmetry rule would not be applied at this point if the small internally segmented or
asymmetric architecture with a 5’-end overhang had been selected as part of the design.
Index 9 s over the three strands from Index 7 as a ng point except the
overhang precursors have been removed because the simplest case is being ered in the
example. The three regions defined by Table 3 are underlined in the n of the sense
strand that has the wobble base pairs and mismatch with the nse strand removed. The
sequences of the combined three regions are shown next ed by the combined
intervening regions. Table 5 provides the Tm calculation results for the overall duplex and for
the combined regional and combined intervening sequences with and with out adjustments
for the cations made to the strands. Table 2 is used to provide the estimated effects of
the various modifications on the Tm.
The data shows that the estimated overall duplex Tm is high (82 degrees) so there will
be an expected preference for loading AGO-2. This can increase the likelihood that this
seqMiR compound without further modification could have off-target siRNA like activity. If
this is a problem for the intended commercial purpose the overall Tm of the duplex can be
d to the preferred range or the nucleosides in ons 10 and/or 11 from the 5’-end of
the antisense strand can be modified to inhibit AGO-2 from carrying out a direct cleavage of
an unintended mRNA target(s).
The data also shows that combined Tm of the three regions defined by Table 3 is
lower than the Tm of the combined intervening region. Thus, this duplex meets this
thermodynamic preference without further modification.
TABLE 5
Duplex (degrees centigrade)
Unmodified Modified
Overall 70 82
Combined Regions 1-3 30 36
ed Intervening
41 47
Regions
Index 9 also provides the 4-nucleoside duplexes from each terminus for consideration
of their compatibility with the asymmetry rule. The terminus with the 5’-end of the sense
strand has a calculated Tm of 14 degrees centigrade unmodified and 16 degrees with the
modifications shown while the other terminus has Tms of 12 degrees and 14 s
respectively. Thus, termini are in general compliance with the broader requirement of the
asymmetry rule, but the second pair of nucleosides from the termini are suboptimum in that
the pair in the terminus with the 5’end of the antisense strand has a comparatively higher
affinity than the corresponding pair in the other terminus. Given that the terminus with the
5’end of the sense strand already has a high Tm with 3 of the 4 nucleoside pairs being G:C
the second pair in the other terminus can equally well have an A or a G to replace the C but G
is selected for this example. The indifference to the A or G replacement is that r
provides an advantage over the other with respect to introducing a more nuclease ant
linkage pair.
H. Algorithms: Architectural Dependent - cal
1.Description:
Canonical is the naturally occurring siRNA ecture. It is also the commonly used
ecture for manufactured conventional siRNA. This architecture is defined by
the ce of 1 to 4 nucleosides or nucleoside substitutes called ngs on the 3'-
ends of both strands that extend beyond the duplexed portion of the compound. It is
generally preferred that overhangs be 2-3 nucleosides or nucleoside substitutes in
number.
With the seqRNAi approach the compounds delivered to subjects are single
strands rather than duplexes so it is meaningless to talk about such strands having
overhangs. Instead they have overhang precursors and in the case of the canonical
architecture format both i strands have overhang precursors. Exclusive of the
overhang precursors the two strand of a given seqRNAi set have the same length.
Overhang sors are discussed in more detail in the section by that name.
The asymmetry rule is important for the canonical ecture. This and other
thermodynamic considerations relevant to the canonical architecture are considered in
more detail in the thermodynamics section.
The application of the canonical architecture dependent algorithm to the
rative seqsiRNA and seqMiR examples is provided in Indices 10 and 11
respectively.
The sense and nse strands from Index 8 are carried over as the starting
point for the modifications introduced in Index 10. The latter Index illustrates 7 of the
sense strand variants and 3 of the antisense strand variants that are consistent with the
canonical architecture. Any of these sense strands can be used with any antisense
strand. As required by the canonical architecture both strand types are shown with
overhang precursors. These can be any of those described in the n by that name.
For the sake of illustration those in the e can be said to be ~UF~UM. The same
strands can be used according to the blunt-end architecture simply by dropping the
overhang precursors.
Index 11 carries over the adjusted sense strand and the antisense strand from
Index 9. The sense strand with the wobble bases and mismatch retained could be used
but it is not continued to simply the illustration. The cal architecture requires
3’-end overhang precursors on both the sense and nse strands. In the illustration
2 overhang units are shown since this is the preferred number. The units and the
intervening linkages can be any of those provided for in the overhang precursor
section. For the sake of illustration those in the example can be said to be .
Two es are shown to illustrate the two principal ways that unintended
off target effects due to a siRNA-like activity can be reduced in a seqMiR set. In
duplex one the overall Tm is reduced to below 60 degrees centigrade. One additional
mismatch and one abasic side are added to the mismatch inserted in the sense
strand in accordance with the asymmetry rule. The new modifications are within the
regions 1 and 2 that are explicitly defined by Table 3. These will have the effect of
reducing the 82 degree Tm to a Tm under 60 degrees. In the second duplex position
11 from the 5’end of the antisense strand is converted to an abasic nucleoside.
2. Applicable to seqRNAi Sense Strands:
a) The strand is required to have at least one overhang precursor unit at the 3’-end.
b) Unless otherwise provided for the strand can have one modification per region in
one or more of the three regions explicitly defined by Table 3 where the modifications
are selected from the group consisting of a nucleoside mismatched with its partner
(opposite) nucleoside in the antisense strand, an abasic nucleoside, UNA and ANA.
When a UNA is used in region 1 it is preferred that it be in the most downstream
position from the 5’-end that is allowed by the Table. Abasic nucleosides preferably
are joined to nt nucleosides by phosphorothioate linkages.
c) Except when one of the modifications just bed in (b) is used in region 2, the
ing is preferred: The two nucleoside positions opposite positions 10 and 11
from the 5'-end of the antisense strand when the strands are duplexed is joined by a
phosphodiester linkage and the nucleoside in the sense strand opposite position 11 in
the antisense strand is selected from the group consisting of ribose and oro and
the nucleoside in on 11 is selected from the group consisting of ribose, 2’-fluoro
or 2methyl. So, for example, if the sense strand is a 19-mer exclusive of any
overhang precursors then position 9 from the 5’-end of the sense strand would be
opposite position 11 in the antisense strand. Further, when the linkage site opposite
positions 10 and 11 of the antisense strand is so configured, it is preferred that the
four sense strand nucleoside positions opposite nucleoside ons 9-12 from the 5'-
end of the antisense strand when the strands are duplexed not have any ches
with the antisense strand.
d) When the strand has only one 3’-end overhang precursor unit then the 3’-end
terminal nucleoside or nucleoside substitute and the terminal two linkages are
ed by the 3’-end overhang section herein and the nucleoside next to the
overhang sor will be selected from the group 2’-fluoro, 2’methyl or 2’-
deoxyribose.
e) When the strand has 3’end overhang precursors that are at least two nucleoside or
nucleoside substitute units in length the required 3’-end lease protection is
provided by the 3’-end ng designs described herein.
f) The terminal 5’-end nucleoside preferably is chemically modified, for example, by
methylation to prevent its 5’ ribose position from being orylated by
endogenous enzymes.
g) Should they occur, undesirable off target silencing due to the seed sequence
promoting miRNA-like activity can be inhibited using one or more of three
alternatives that can inhibit the interaction with the unintended mRNA target(s): (i)
one or both of the following stipulations are met: the second nucleoside from the 5'-
end is not ribose or ro and ably is 2'methyl and/or one of the
sides in positions 3-7 from the 5'-end is UNA or . Destabilizing
modifications, r, should not fall in the central region of the antisense strand;
(ii) If the target sequence in the unintended mRNA target site(s) complementary to the
seed sequence has one or more U and/or G containing nucleosides then the seed
sequence can be adjusted to generate at least one G:U wobble base pair between it and
the target sequence; or (3) a multiplicity of the nucleosides in the seed sequence can
be 2’deoxyribonucleosides. The presence of 5 or more consecutive2’-
deoxyribonucleosides is discouraged, however, since it has the potential to promote
RNaseH based degradation of endogenous RNA complementary to the strand. Abasic
nucleosides preferably are joined to adjacent nucleosides by phosphorothioate
linkages.
3. able to i nse Strands:
a) The strand is required to have at least one but not more than four overhang
precursor units at the 3’-end with two units being preferred.
b) When the strand has only one 3’-end overhang precursor unit then the 3’-end
terminal nucleoside or nucleoside substitute and the terminal two linkages are
provided by the 3’-end overhang section herein and the nucleoside next to the
overhang precursor will be selected from the group oro, 2’methyl or 2’-
deoxyribose.
c) When the strand has 3’end ng precursors that are at least two nucleoside or
nucleoside substitute units in length the required 3’-end exonuclease protection is
provided by the 3’-end overhang designs described herein.
4. Applicable to seqsiRNA and seqIMiR Antisense Strands:
Should they occur, undesirable off target silencing due to the seed sequence
promoting miRNA-like activity can be inhibited using one of two atives that can inhibit
the interaction with the unintended mRNA target(s): (i) one or both of the following
ations are met: the second nucleoside from the 5'-end is not ribose or 2-fluoro and
preferably is 2'methyl and/or one of the nucleosides in positions 3-7 from the 5'-end is
UNA or abasic; or (ii) If the target sequence in the nded mRNA target site(s)
complementary to the seed sequence has one or more U and/or G containing nucleosides then
the seed sequence can be adjusted to generate at least one G:U wobble base pair between it
and the target sequence. Abasic nucleosides preferably are joined to adjacent nucleosides by
phosphorothioate linkages.
. Applicable to seqMiR nse Strands:
Particularly, for strands that will generate an overall Tm of greater than 60 degrees
centigrade with their partner strand it is red that any catalytic activity of AGO-2
directed against an endogenous RNA target by the antisense strand is inhibited. This can be
achieved through making certain modifications to the nucleosides in positions 10 and/or 11
from the 5’-end of the antisense strand. When off target activity against a known target is to
be avoided this can be achieved by making one or both of the indicated nucleosides be
mismatches with the target. It is red in this situation that there not be a single A:C
mismatch. Any AGO-2 based catalytic silencing activity can be inhibited by replacing the
nucleosides in positions 10 and/or 11 with modified nucleosides that will inhibit this tic
activity without preventing duplex formation by the s. Suitable modifications for this
purpose include abasic, UNA and FANA. The abasic nucleosides can have any of the sugar
modifications provided for herein including the unlocked variant (i.e., the sugar in UNA), 2-
deoxyribose and FANA. Abasic nucleosides preferably are joined to adjacent sides by
phosphorothioate linkages.
6. Applicable to NA-based and seqIMiR-based Duplexes:
The overall Tm, under physiological conditions, will be at least 55 and preferably at
least 65 degrees but preferably under about 95 degrees rade. The means to adjust
overall Tm is presented in the thermodynamics section.
7. Applicable to seqMiR-based Duplexes:
The overall Tm under logical conditions will be at least 45 and preferably
under 60 s centigrade unless the antisense strand is modified to t AGO-2 from
having a direct tic action on mRNA when it is loaded as such into RISC. In the latter
case the preference for an overall Tm limit of 60 degrees is removed.
I. Algorithms: Architectural Dependent - Blunt-end
1. Description:
Sense and antisense s for a given seqRNAi set have the same length and do not
have 3’-end overhang precursors. The asymmetry rule is important for the blunt-end
architecture. This and other thermodynamic considerations relevant to the blunt architecture
are considered in more detail in the thermodynamics section. The ation of the blunt-end
architecture dependent algorithm to the illustrative seqsiRNA and seqMiR is the same as the
canonical rated in Indices10 and 11 respectively except there are no overhang
precursors.
2. Applicable to seqRNAi Sense s:
a) the required 3’end protection from exonuclease attack can be provided by the use
of two terminal nucleosides that are individually ed from the group 2’-fluoro,
2’methyl or 2’-deoxyribose and where the terminal two linkages will be
phosphorothioate. Strands that have a 3’ terminal 2’-fluoro modification, however,
often have a reduced yield with t manufacturing methods so this modification is
not preferred in this position.
b) In other respects the rules for the canonical architecture apply here except the
strand lacks an overhang precursor.
3. Applicable to seqsiRNA and seqIMiR Antisense Strands
a) the required 3’end protection from exonuclease attack can be provided by the use
of two terminal nucleosides that are individually selected from the group 2’-fluoro,
2’methyl or 2’-deoxyribose and where the terminal two linkages will be
orothioate. Strands that have a 3’ terminal 2’-fluoro cation, however,
often have a reduced yield with current manufacturing methods so this modification is
not preferred in this position.
b) In other ts the rules for the canonical architecture apply here except the
strand lacks an ng precursor.
4. Applicable to seqMiR Antisense Strands:
a) the required 3’end protection from lease attack can be provided by the use
of two terminal nucleosides that are individually selected from the group 2’-fluoro,
2’methyl or xyribose and where the terminal two linkages will be
phosphorothioate. s that have a 3’ terminal 2’-fluoro modification, however,
often have a reduced yield with current manufacturing methods so this modification is
not preferred in this position.
b) In other respects the rules for the canonical architecture apply here except the
strand lacks an ng precursor.
J. Algorithms: Architectural Dependent - Asymmetric
1. Description:
seqRNAi antisense strands have 1-4 unit overhang precursors at the 5’ or 3’ ends or
both while the sense strands in the same set do not have overhang precursors. With respect to
antisense strands with 3’-end overhang precursors the terminal sense strand 5-end nucleoside
preferably is paired with the 3’-end nucleoside in the antisense strand that is contiguous with
the overhang precursor. It is preferred for most strand sequences that the overhang precursor
only occurs at the 3'-end of the antisense strand. When there is only a 3’-end overhang
precursor, it is preferred that it be 2-3 sides and/or nucleoside substitutes in .
5’-end overhang precursors follow the same rules that apply to the rest of the strand save the
3’-end overhang precursor that can follow other rules. Overhang precursors are sed in
more detail in the section by that name.
The asymmetry rule applies to seqRNAi strand sets designed according to the
asymmetric architecture when the antisense strand lacks a 5’-end overhang sor. When
the asymmetric architecture provides for a 5’-end overhang precursor with or without a 3’-
end overhang precursor the importance of the asymmetry rule basis for antisense strand
selection is nullified. As a consequence, the importance of other factors that affect the level
of efficiency in the removal of the intended sense strand and the retention of the intended
antisense strand by RISC is increased, for e, by introducing reductions in interstrand
affinities in particular s explicitly defined by the Table 3 relative to other interstrand
areas particularly in region 2.These and other thermodynamic considerations relevant to the
tric architecture are considered in more detail in the thermodynamics section.
Hence, all three forms of the asymmetric architecture have essentially the same
antisense strands differing only in having a 3’-end overhang precursor or not. The ted
canonical or blunt-end antisense strands can simply be transposed to the asymmetric
architecture. The sense strands used in the asymmetric architecture are either simply
transposed from the blunt-end architecture or they are d at the 3’end to generate a 5’-
end overhang precursor in the r antisense strand when the duplex forms. When the
sense strand is truncated in this way, it is particularly preferred that regions 1 and 2, defined
in Table 3, have vely low Tms compared to the rest of the strand unless the result is to
reduce the overall interstrand Tm below the preferred range. The oning of regions 1 and
2 in this case are based on the length of the ended sense strand even though this sense
strand is truncated at the 3’-end.
Thus it is only necessary to show the seqsiRNA and seqMiR sets in Indices 12 and13
that only illustrate the case where the sense strand is shortened at the 3’-end. In the specific
examples used it is shortened by 3 nucleosides. The antisense strand partner is rated as
having either a 3’-end overhang or being blunt-ended with the 5’-end of the sense strand.
Where the 3’-end has been modified the appropriate changes have been made to comply with
the nuclease resistance and essential/preferred architectural independent rules.
2. Applicable to seqRNAi Sense s that are paired with Antisense Strands without a 5’-
end Overhang Precursor:
Same rules apply as for end architecture.
3. Applicable to seqRNAi Sense Strands that are paired with Antisense Strands with a 5’-
endoverhang precursor with or without a 3’-end Overhang Precursor:
a) Is at least 13 nucleosides long and is no more than 6 nucleosides shorter than the
antisense strand in the set. It is preferred that the 3’end be d by no more than 3
nucleosides and that the 5’-end not be shortened.
b) Unless otherwise provided for the strand can have one modification per region in
one or more of the three regions explicitly described by Table3 where the
modifications are selected from the group consisting of a nucleoside mismatched with
its partner (opposite) nucleoside in the antisense strand, an abasic nucleoside, UNA
and an ANA. When a UNA is used in region 1 it is preferred that it be in the most
downstream position from the 5’-end that is allowed by the Table. Abasic nucleosides
preferably are joined to adjacent nucleosides by phosphorothioate linkages.
4. able to seqsiRNA and seqIMiR Antisense s:
Same rules apply as for canonical or blunt-end architecture depending on whether or
not there is a 3’-end overhang precursor.
. Applicable to seqMiR Antisense Strands:
Same rules apply as for canonical or blunt-end architecture depending on whether or
not there is a 3’-end overhang precursor.
K. Algorithms: Architectural Dependent - Forked-variant
1. Description:
The -variant algorithm is the most radical solution to fulfilling the asymmetry
rule for those seqRNAi architectures where it is important. Thus, its use is limited to being a
supplemental variant of these architectures. It is applied to strands that will form seqRNAibased
es where the asymmetry between the duplexed i is so severely the
opposite of what is desired that it cannot be corrected by using the types of chemical
modifications used to achieve nuclease resistance in accordance with the present invention.
Instead, it es interrupting the complementary base pairing n some or all of the
terminal 6 nucleosides at the 3'-end of the sense strand with the 5'-end of the otherwise
complimentary nse strand by introducing between 2 and 6 mismatches in the sense
strand. Thus, the forked variant is an ion to the general rule that destabilizing
modifications are not preferred between regions 2 and 3 as defined by Table 3. The specific
thermodynamic considerations are discussed in more detail in the section by that name.
The application of the forked-variant architecture dependent algorithm to the
rative seqsiRNA and seqMiR examples is provided in Indices 14 and 15 respectively.
Index 14 carries over the canonical architecture sense and antisense strands from
Index 10. In the discussion of Index 8 it was pointed out the terminal duplex differential Tm
for the seqsiRNA Mouse PTEN compounds serves the asymmetry rule well without any
added modification. Nevertheless it is conceivable that a modest application of the forked
variant could further boost the activity of this these highly related compounds. ingly,
the AR in position 14 and the CR in position 16 of the sense strand are changed to CM and GR
respectively.
Index 15 carries over the two duplexes from Index 11 using the canonical architecture
as the example of an architecture where the asymmetry rule is applicable. These duplexes
have already been adjusted for the asymmetry rule in Index 9 but conceivably could t
r from having a greater ential between the two termini. Accordingly a second
mismatch is introduced into position 17 of the sense strands counting from the 5’-end.
2. Applicable to seqRNAi Sense Strands that form a seqRNAi-based Duplex with their
Partner Strand that has an Architecture where the try Rule is Important ularly
when the Given Duplex is Too out of Alignment with the Rule to be Corrected by Less
l Means:
The complementary base pairing between some or all of the terminal 6 nucleosides at
the 3'-end of the sense strand (exclusive of any overhang precursor) with the ponding
nucleosides in the 5'-end of the antisense partner strand is interrupted by introducing between
2 and 6 mismatches in the sense strand.
L. Algorithms: Architectural Dependent - Small Internally ted
1. Description:
The more general form of this architecture is characterized by the use of two short
sense strands that are complementary to a single antisense . In the case of seqMiRs this
arrangement can be reversed, i.e., there can be two short antisense strands that are
complementary to a single sense strand. In either case these short strands are separated by no
more than two nucleoside positions when they form a seqRNAi-based duplex with their
partner . It is preferred that the short strands be immediately contiguouswhen duplexed
with the partner strand. This can be achieved by simply omitting one e in what would
ise be a single seqRNAi sense strand.
Further, the opposing termini of short strands as they appear in the duplex with the
partner strand can be modified to prevent the possibility that they will be ligated in vivo. The
hood of this occurring, however, has not been established. One method to prevent the
possibility of RNA ligation is to use an inverted abasic residue (such as 3’-2’ or 3’-3’) at one
of the ng termini or to have a one or two nucleoside separation between the short
strands when they form a duplex with the partner strand.
For more general use in seqsiRNA and seqIMiRs this architecture has the effect of
essentially eliminating the possibility that the d sense strand is loaded into RISC as the
antisense strand. In the case of seqMiRs the use of two short antisense strands can ate
any contribution of 3'-supplementary sites to mRNA target recognition. In instances where a
3'-supplementary site would otherwise be used, for example, this approach can be employed
to restrict the range of targets being recognized particularly in cases when the restriction
reduces the number of undesired targets.
The short size of the two sense or antisense strands can reduce their ty with the
partner strand to the point that the resulting duplex is not ently stable. Often this can be
compensated for by judiciously using modifications to the sense strand(s) that are particularly
efficacious in increasing the affinity between them and the full-length partner strand.
Thermodynamic considerations are discussed in more detail in the section by that name.
The application of the small internally segmented ecture dependent thm to
the illustrative seqsiRNA and seqMiR examples is provided in Indices 16 and 17
respectively.
The starting two sense and three antisense strands for the application of the small
internally segmented ecture as shown in Index 16 come from Index 10. The sense
strand only differed with respect to the presence or absence of overhang sors were
divided into two strands by removing the linkage n nucleoside positions 9 and 10.
Next the nuclease resistance rules were applied to the two new termini. The Tms for each of
these dual sense strands was determined using the nearest neighbor calculation followed by
an adjustment for the chemical modifications. The final Tms were 51 degrees and 34 degrees
for the sense strand forming a duplex with the 3’end of the antisense strand or the 5’-end of
the antisense strand tively. To bring the second sense strand above the 40 degree lower
limit and to make the Tms similar, the LNA modification was used in positions 4 and 7
counting from the 5’-end of the second sense strand.
In Index 17 the starting sense s for the application of this architecture are the
sense strand with the wobble base pairings and mismatches removed in Index 9. If the design
began with an endogenous miRNA with a bulge structure(s) this ure would also have
been removed at the start of the ation of the small internally segmented architecture.
The two antisense s come from Index 11. One of these strands has a modification that
inhibits AGO-2 tic activity while the other does not.
The sense strand is split between ons 10 and 11 as indicated by &. The
calculated Tm for the unmodified dual sense strands is 32 or 39 and 42 degrees respectively
for the strands with the single strand 5’-end and 3’-end. The basis for the alternative Tms for
the sense strand with the former single sense strand 5’-end is the presence (Duplex #1) or
absence (Duplex #2) of the abasic nucleoside in the antisense strand. The 3’-end nucleosides
in each of the sense strands are modified and phosphorothioate linkages are added between
nucleoside positions 8-9 and 9-10. These modifications are in keeping with the nuclease
resistance rules and the preference for 2’methyl modifications in the terminal nucleoside
where there is no overhang sor with based on a chemistry not ted in the
duplex.The 5-end nucleoside in the antisense strand is change to a 2’-fluoro to meet the
preference for 2’methyls to not be in both members of a complementary nucleoside pair.
The chemical modifications add about 5 degrees in Tm to each of the sense strands with their
partner antisense . To increase the Tms for the two sense strands two LNA
modifications are added to the first strand and one to the second.
Splitting the antisense strand in Index 17 into two strands at the 10-11 linkage does
not alter the basic Tm calculations made for the dual sense strands since the deleted linkage
in each case opposes the other. The single sense strand in Duplex 3 has the same LNA
modifications and the switch of the AF for an AM at the terminal 3’-position and a switch in
the UM in position11 for UF to accommodate the change in the complementary nucleoside in
the antisense strand. In keeping with the nuclease resistance rules the A in position 10
s ethyl, the G in position 11 becomes 2’-fluoro and phosphorothioate linkages
are inserted between positions 8-9 and 11-12 basing the count on a single antisense strand.
2. able to seqRNAi Sense Strands when Two Sense Strands are Used:
a) It is ed that there be two sense s that are separated by no more than two
nucleoside positions when they form a seqRNAi-based duplex with their r
antisense strand but it is preferred that they be contiguous. An inverted abasic residue
(such as 3’-2’ or 3’-3’) can be used to replace a nucleoside at one of the two termini
that will be in opposition when the seqRNAi-based duplex is formed.
b) The sequence of the s and their chemical modifications determine the Tm of
each of the strands with the partner antisense strand. These factors must result in a
minimum Tm of 40 degrees centigrade for each sense strand with the antisense strand
under physiologic conditions with 50-65 degrees being preferred. It is also preferred
the Tms for each of the sense strands with the partner antisense strand be at most only
a few degrees apart.
c) LNA(s) can be used in one or both sense strands, as needed, to stabilize the
seqRNAi-based duplex under physiologic conditions with a m of three per
strand. It is preferred that: (1) when there are two or three LNAs in a given strand that
they be separated by at least one nucleoside that does not have the LNA modification;
(2) LNAs not be in the first position at the 5’-end of the strand; (3) they not be in the
terminal 3’-end position if the base is a uracil; and (4) ering the two sense
strands as a single unit LNAs preferably are placed between the three regions
explicitly defined by Table 3.
d) A 2-thiouridine containing nucleoside can be used in place of LNA to boost
interstrand binding affinity when the nucleoside in question has a uracil base and it
forms a complementary base pair with an e containing nucleoside in the
antisense strand. In such an instance the nature of any modifications to the sugar in
this nucleoside will follow the relevant ectural independent rules provided
herein.
e) The sense strand undergoing complementary base pairing with the 5’-end of the
antisense strand can have an overhang precursor.
3. Applicable to seqRNAi nse Strand when Two Sense Strands are Used:
Can follow the rules relevant for the canonical, end or asymmetric architectures
ing on the presence or absence of 5’ and/or 3’-end overhang precursors. A 2-
3-unit3’-end overhang precursor is preferred.
4. Applicable to seqsiRNA and seqIMiR Antisense Strands when Two Sense s are
Used:
Can follow the rules relevant for the canonical, blunt-end or asymmetric architectures
depending on the presence or absence of 5’ and/or 3’-end overhang precursors.
5. Applicable to seqMiR Antisense Strand when Two Sense Strands are Used:
Can follow the rules relevant for the canonical, blunt-end or asymmetric architectures
depending on the presence or absence of 5’ and/or 3’-end overhang precursors.
6. Applicable to seqMiR Sense Strand when Two Antisense Strands are Used:
a) The ce of the strands and their chemical modifications determine the Tm of
the strand with the two partner antisense strands. These factors must result in a
minimum Tm of 40 degrees centigrade for each antisense strand with the sense strand
under physiologic conditions with 50-65 degrees being preferred. It is also preferred
the Tms for each of the antisense strands with the partner sense strand be at most only
a few degrees apart.
b) LNA(s) can be used in one or both sense strands, as needed, to stabilize the
i-based duplex under physiologic conditions with a maximum of three per
strand. It is preferred that: (1) when there are two or three LNAs in a given strand that
they be ted by at least one nucleoside that does not have the LNA modification;
(2) LNAs not be in the first position at the 5’-end of the strand; (3) they not be in the
terminal 3’-end position if the base is a uracil; and (4) considering the two sense
s as a single unit LNAs are placed between the three regions explicitly defined
by Table 3 if le.
c) A 2-thiouridine containing nucleoside can be used in place of LNA to boost
interstrand binding affinity when the nucleoside in question has a uracil base and it
forms a complementary base pair with an adenine containing nucleoside in the
antisense strand. In such an instance the nature of any modifications to the sugar in
this nucleoside will follow the relevant architectural independent rules provided
herein.
d) The terminal 5’-end nucleoside preferably is ally modified, for example, by
methylation to prevent its 5’ ribose on from being phosphorylated by
endogenous enzymes.
e) In other respects the sense strand will follow the design of the canonical or bluntend
architectures depending on whether it has an overhang precursor or not.
7. Applicable to seqMiR Antisense Strands when Two are Used:
a) It is required that there be two antisense s that are ted by no more than
two nucleoside positions when they form a seqRNAi-based duplex with their partner
sense strand but it is preferred that they be contiguous. An inverted abasic residue
(such as 3’-2’ or 3’-3’) can be used to e a nucleoside at one of the two termini
that will be in opposition when the seqRNAi-based duplex is formed.
b) It can otherwise follow the rules relevant for the canonical or blunt-end architecture
depending on the presence or absence of a 3’-end overhang precursor.
M. Algorithms: Architectural Dependent –seqRNAi Antisense Strand Based ss-RNAi
1. Description:
A seqRNAi antisense strand based ss-RNAi has three general features: (1) it can be
administered to a subject with out a carrier or g ; (2) a complementary partner
sense strand is not administered to the same subject over a timeframe where both strands can
combine in the subject’s cells; and (3) it es the intended silencing effect in cells in a
subject. Such antisense s occur in three specific versions: ss-MiR, ss-IMiR and ss-
siRNA depending on r the antisense strand functions as a miRNA mimic, miRNA
inhibitor or a siRNA when loaded into RISC.
The application of the ss-RNAi architecture dependent algorithm to the illustrative sssiRNA
and ss-MiR examples is provided in Indices 18 and 19 respectively.
Index 18 shows how the antisense strands shown in Index 10 can be adjusted for ss-
siRNA use.
Index 19 shows es of several variants of a ss-MiR based on let-7i with and
without potential AGO-2 catalytic activity prevented prophylactically and with and without
modifications that increase the binding affinity of the seed sequence for its targets. The
starting strands came from the antisense strands in Index 11 that illustrate the application of
the canonical architecture.
3. Applicable to ss-RNAi
a) The 5’-end nucleoside is phosphorylated at the 5’ ribose position.
b) Preferably the strand is 16-20 nucleosides in length with a 2-3 unit overhang
precursor for a total length of 18-23. Most preferred are ng precursors that have
a relatively high affinity for the PAZ domain of RISC. These can be distinguished by
their ability to extend the duration of the intended silencing activity.
4. Applicable to ss-siRNA and Rs:
The nuclease resistance rules, the ial/preferred architecturally independent rules
and the canonical or blunt ended rules appropriate to a seqsiRNA/seqIMiR antisense strand
are applied. However, 2’-fluoro modifications are preferred over other modifications save
ribose and save the overhang precursors if any. There are two exceptions as follows: (1) the
use of a minimal number of 2’methyl modifications, if needed, to reduce activation of any
unacceptable innate immune response; and (2) the use of an UNA in the seed regionand/or a
2’methyl in position 2 from the 5’-end to inhibit miRNA-like off target effects.
. Applicable to s:
The nuclease resistance rules, the essential/preferred architecturally independent rules
and the canonical or blunt ended rules riate to a seqMiR antisense strand are applied.
However, 2’-fluoro modifications are preferred over other modifications save ribose and save
the overhang precursors if any. There are three exceptions as follows: (1) the use of a
minimal number of ethyl modifications, if needed, to reduce tion of any
unacceptable innate immune response; (2) the use of modifications such as LNA in the seed
sequence to increase the seed duplex Tm; and (3) the use of the modifications ed herein
to inhibit the catalytic activity of AGO-2 against nded RNA targets.
N. ng Precursors
Overhangs in naturally occurring siRNA are typically complementary to their target
RNA. Overhangs, however, appear to play little, if any, role in target recognition. The oldest
and most used conventional siRNA architecture (canonical) for synthetic compounds is
comprised of a 19-mer duplex with two deoxythymidine 3'-end ngs (dTdT) on both
strands. These overhangs were selected because of their convenience and low cost. se
resistant linkages to protect against the 3’ -end leases in biologic fluids commonly join
the nucleosides in overhangs.
It was originally thought that overhangs were required for siRNA activity in all cell
types and that they could be comprised of any native ribonucleoside or ibonucleoside
without affecting activity. Subsequently, it was discovered that 3’-end overhangs were not
required for siRNA ty in mammalian cells when it was shown siRNA with a blunt-end
architecture is e of producing substantial silencing activity against the intended target.
Endogenous miRNAs have 3’-end overhangs that are generated during the processing
of miRNA precursors to become ed miRNA that is ready for RISC loading. As for
siRNA the overhangs in miRNA are not involved in recognizing the target. Instead the 3’-end
antisense strand overhang in siRNA or miRNA has been shown to interact with the PAZ
domain in the RNA binding pocket of RISC in a manner that prevents interaction with the
target transcript. As a result of this interaction this 3’end ng can affect RISC loading
and nse strand ion.
Variations in overhang design and chemistry, as well as the option of not using
ngs, can be used to modulate the activity of seqRNAi compounds in commercially
useful ways. For example, i treatments that sensitize cancers to other therapeutics
(typically targeting molecules that inhibit apoptosis) would only be required to be active
during the comparatively short period of time required for producing such sensitization. By
limiting the duration of such an effect some possible side effects might be reduced or
eliminated. In st, it would generally be advantageous to structure seqRNAi strands to
produce a comparatively long silencing effect when treating chronic diseases such as diabetes
or cardiovascular diseases such as atherosclerosis. In addition, particular overhang
precursors and designs can be used to promote the selection of the desired antisense stand by
RISC and/or to boost the peak silencing activity of the antisense strand/RISC complex as well
as its duration.
Overhang precursors in seqRNAi can be of 1 to 4 nucleosides in length, can involve
neither, either or both of the 3’-ends of a strand pair as well as the 5’-end of the antisense
strand. 3'-end overhangs can have substantially different chemical modifications compared to
the rest of the strand while 5'-end overhangs are based on the same nucleoside and linkage
chemistries as the portion of the strand that forms a duplex with its partner strand.
The 3’-end overhang precursors in seqRNAi can be sed of any of the naturally
occurring deoxyribonucleosides. In on, several groups have described variations in
overhang design/chemistry that can affect the duration of the silencing effect of conventional
siRNA. These same structures can be used as overhang precursors in seqRNAi strands.
Zhang et al., (Bioorganic & Medicinal Chemistry 17: 2441, 2009), for example, showed that
two nucleoside 3'-end ngs with line rings replacing the ribose in both the sense
and antisense strands or just the nse strands of conventional siRNA can result in a
longer lasting silencing effect than the same siRNA with the standard dTdT overhangs.
s et al., (Nucl Acids Res 38: 4788, 2010), in another example, found that the dTdT
ngs were associated with a significantly reduced silencing period both in vitro and in
vivo compared to the other overhang types tested. The latter consisted of the ing: two
2'methyl uridines; two 2'methyl modified nucleosides complementary to the RNA
target; or unmodified ribonucleosides complementary to the RNA target. Differences in
duration of effect were found to not be due to either a difference in IC50 values or to variable
degrees of maximal target silencing. These data suggest that ribonucleosides may have a
stronger binding to the PAZ domain than deoxyribonucleosides.
Numerous other 3'-end ng precursor chemistries can promote i ty
and nuclease resistance. These include but are not limited to the following where the
indicated nucleoside analog chemistries can be used with any of the normal bases: (1) 2'
Methyl; (2) 2'-fluoro; (3) FANA; (4) 2'methyoxyethyl (5) LNA; (6) morpholino; (7)
tricyclo-DNA (Ittig et al., Artif DNA, PNA & XNA 1: 9, 2010); (8) ribo-difluorotoluyl (Xia
et al., ACS Chem Biol 1: 176, 2006); (9) 4'-thioribonucleotides (Hoshika et al., Chem Bio
Chem 8: 2133, 2007); (10) 2'methyl-4'-thioribonucleotide (Takahashi et al., Nucleic Acids
Res 37: 1353, 2009; Matsuda, Yakugaku Zasshi 131: 285, 2011); (11) altritol-nucleoside
(ANA) (Fisher et al., Nucleic Acids Res 35: 1064, 2007); (12) cyclohexenyl-nucleoside
(CeNA) (Nauwelaerts et al., J Am Chem Soc 129; 9340, 2007; (13) piperazine (US patent
675); and (14) 5-bis(aminoethyl) aminoethylcarbamoylmethyl-2'-deoxyuridine or 5-
bis(aminoethyl) aminoethylcarbamoylmethyl-thymidine (Masud et al., Bioorg Med Chem
Lett 21: 715, 2010).
The nucleosides used in overhang precursors in seqRNAi strands can be used in
various combinations in 3'-end overhangs and are preferably joined er and to the
adjacent non-overhang nucleoside by a se ant linkage such as orothioate,
phosphonoacetate, thiophosphonoacetate, methylborane phosphine, amide, carbamate or urea
(Sheehan et al., Nucleic Acids Res 31: 4109, 2003; Krishna & ers, J Amer Chem Soc
133: 9844, 2011; Iwase et al., Nucleic Acids Symposium Series 50: 175, 2006; Iwase et al.,
Nucleosides Nucleotides Nucleic Acids 26: 1451, 2007; Iwase et al., Nucleic Acids
ium Series 53: 119, 2009; Ueno et al. Biochem Biophys Res Comm 330: 1168,
2005). In addition unmodified nucleosides can be used in overhangs when they are joined
together using these linkages but preferably not orothioate with ribonucleosides.
These linkages can also be used in 5'-end overhangs but preferably the nucleosides are
d to the following: (1) 2'Methyl; (2) 2'-fluoro; (3) FANA; and (4) RNA (native
ribose). In the case of seqMiRs, however, such 5’-end cations have to be evaluated for
their effects on what mRNAs will be targeted for silencing.
Further, 3'-end overhang precursors can be sed of certain hydrophobic
aromatic moieties. For example, those that are comprised of one to three units containing
two six membered rings joined by phosphodiester or one of the other es just listed
where the unit(s) are attached to the ucleotide by the same linkage and when multiple
units are used they are also joined by the same linkage. Two unit structures are preferred.
Suitable ring structures include benzene, pyridine, morpholine and piperazine (US patent
6,841,675). Structures based on the benzene and pyridine rings have been previously
described for 3'-end overhang use in conventional siRNA by Ueno et al., (Bioorg Med Chem
Lett 18:194, 2008; Bioorganic & Medicinal Chemistry 17: 1974, 2009). Specifically, these
units are 1,3-bis(hydroxymethyl)benzene, 1,3-bis(hydroxymethyl)pyridine and 1,2-
bis(hydroxymethyl)benzene. These are also suitable for seqRNAi use as overhang
precursors.
In another example of possible non-nucleoside overhang precursors the aromatic
es can be biaryl units where the linkages holding the units together and to the oligo are
covalently attached to benzene rings where the benzene ring is further covalently attached to
a non-bridging moiety selected from the group benzene, naphthalene, threne, and
pyrene. Further, one such biaryl group may be attached to the 5'-end of the intended sense
strand to substantially reduce the hood it will be selected as the antisense strand by
RISC once the complementary seqRNAi strands form a duplex in cells. (Ueno et al., Nucleic
Acids Symposium Series 53: 27, 2009; Yoshikawa et al., Bioconjugate Chem 22: 42, 2011)
When these units are used as overhang precursors one to three units are red and two are
most preferred.
In addition, the 3'-end overhangs, or lack thereof, can affect the distribution of
seqRNAi-based duplexes between the cytoplasm and s. Individual i strands
released into the asm and the duplexes formed by a seqRNAi strand pair can diffuse
into the nucleus. Once in the nucleus individual seqRNAi strands can form seqRNAi-based
duplexes and any duplexes that were formed in the cytoplasm that subsequently diffused into
the nucleus can be expelled from the nucleus by Exportin-5 (Exp-5). This activity of Exp-5
can be rate-limiting for silencing activity at low doses of duplexes. Exp-5 binds to the first
two nucleosides or their analogs in any 3'-end overhang(s) while possibly binding more
weakly to the ed portion. Thus, seqRNAi strands designed to have 3'-end overhang
precursors comprising nucleosides have a potential advantage over seqRNAi strands that do
not have overhang precursors because they can produce a greater duplex presence in the
cytoplasm particularly at lower seqRNAi concentrations. Finally, the nature of the 3’-end
overhang precursors, if any, affects the l and regional interstrand affinities of seqRNAibased
duplexes. This topic is discussed in the section dealing with thermodynamics.
O. Methods of stration of the single strand oligo compounds of the Invention
A major age of the present invention in effecting RNAi is that many of the
modifications described employ chemistries commonly used in conventional antisense oligos
where the pharmacology and toxicology of the compounds is already largely understood
described in the ture. References that summarize much of pharmacology for a range of
ent types of oligo therapeutics includes the following: Antisense Drug Technology:
Principles, gies, and Applications, 2nd ed., Stanley T. Crooke (ed.) CRC Press July
2007; Encyclopedia of Pharmaceutical Technology, - 6 Volume Set, J Swarbrick (Editor) 3rd
edition, 2006, Informa HealthCare; Pharmaceutical Perspectives of Nucleic Acid-Based
Therapy, RI Mahato and SW Kim (Editora) 1 edition, 2002, CRC press; Pharmaceutical
s of Oligonucleotides, P ur and C Malvy rs) 1st edition, 1999, CRC
press; Therapeutic Oligonucleotides (RSC Biomolecular Sciences) (RSC Biomolecular
Sciences) (Hardcover) by Jens Kurreck (Editor) Royal Society of Chemistry; 1 edition, 2008,
CRC press; Clinical Trials of Genetic Therapy with nse DNA and DNA Vectors, E
Wickstrom (Editor) 1st edition, 1998, CRC press.
The fact the compounds of the present ion are sequentially delivered does add
an additional complication. There must be a long enough period between the administration
of the first strand and the second for cells to have taken up most of the first strand. The
periods of time involved have been worked out for conventional antisense oligos and can be
applied here. For example, when these compounds are infused into the circulation the
clearance time half-life from the plasma to the tissues is about 20 minutes. Thus, after one
hour most of the compound is in the tissues. The tissue retention time s on dose but
within the dose range commonly used to treat subjects the tissue retention can be measured in
days or weeks. The nd in the tissues is distributed between a bioavailable form and a
unavailable form, but it is clear the former can exist at effective levels for days or weeks
based on the protracted suppression of the target in tissues.
It follows, therefore, that the seqRNAi compounds of the present invention will be
given to subjects in the dose range established for conventional antisense oligos and that the
spacing between the two strands for i.v. or i.a. administration will range from about one hour
to a week, but 4 hours to 24 hours between strand administrations is preferred. For most
systemic in vivo purposes stration of a strand over one hour at an infusion rate of up to
6 mg/kg/h is appropriate.
The timing of strand administration i.v. or i.a. can also serve for a number of other
strative routes where the nds are juxtaposed to the target tissue such as i.p.,
hecal, intraocular and intravesical. The treatment regimens will for the seqRNAi
compounds will also mirror those used for tional antisense oligos. For the ss-RNAi
compounds of the t invention the sequential delivery related issues do not apply so they
can be fully treated like conventional nse oligos.
In certain embodiments, (e.g., for the treatment of lung disorders, such as pulmonary
fibrosis or asthma or to allow for self administration for local or systemic es) it may
desirable to deliver the oligos described herein in aerosolized form. A pharmaceutical
composition comprising at least one oligo can be administered as an aerosol ation that
contains the oligos in dissolved, suspended or emulsified form in a propellant or a mixture of
solvent and propellant. The aerosolized formulation is then administered through the
respiratory system or nasal passages.
An l formulation used for nasal administration is lly an aqueous solution
designed to be administered to the nasal passages as drops or sprays. Nasal solutions are
generally prepared to be similar to nasal secretions and are generally isotonic and slightly
buffered to maintain a pH of about 5.5 to about 6.5, although pH values outside of this range
can also be used. Antimicrobial agents or preservatives can also be included in the
formulation.
An aerosol ation for use in inhalations and inhalants is designed so that the
oligos are d into the respiratory tree of the patient. See (WO 01/82868; WO 01/82873;
WO 01/82980; WO 02/05730; WO 02/05785. Inhalation solutions can be administered, for
example, by a nebulizer. Inhalations or insufflations, comprising finely powdered or liquid
drugs, are delivered to the respiratory system as a pharmaceutical aerosol of a solution or
suspension of the drug in a lant.
An aerosol formulation generally contains a propellant to aid in disbursement of the
oligos. Propellants can be liquefied gases, including halocarbons, for e, fluorocarbons
such as fluorinated chlorinated hydrocarbons, hydrochlorofluorocarbons, and
hydrochlorocarbons as well as hydrocarbons and hydrocarbon ethers (Remington's
Pharmaceutical Sciences 18th ed., Gennaro, A.R., ed., Mack Publishing Company, Easton,
Pa. (1990)).
Halocarbon propellants useful in the invention e fluorocarbon propellants in
which all hydrogens are replaced with fluorine, hydrogen-containing fluorocarbon
propellants, and en-containing chlorofluorocarbon propellants. Halocarbon
propellants are described in Johnson, U.S. Pat. No. 5,376,359, and Purewal et al., U.S. Pat.
No. 5,776,434.
arbon propellants useful in the invention include, for example, propane,
isobutane, n-butane, pentane, isopentane and neopentane. A blend of arbons can also
be used as a propellant. Ether propellants include, for example, dimethyl ether as well as
numerous other ethers.
The oligos can also be dispensed with a compressed gas. The compressed gas is
generally an inert gas such as carbon dioxide, nitrous oxide or nitrogen.
An aerosol ation of the invention can also n more than one
propellant. For example, the aerosol formulation can contain more than one propellant from
the same class such as two or more fluorocarbons. An l formulation can also contain
more than one propellant from different classes. An aerosol formulation can contain any
combination of two or more propellants from different classes, for example, a
fluorohydrocarbon and a hydrocarbon.
Effective aerosol formulations can also e other components, for example,
ethanol, isopropanol, propylene glycol, as well as surfactants or other components such as
oils and detergents (Remington's Pharmaceutical Sciences, 1990; Purewal et al., U.S. Pat. No.
,776,434). These l components can serve to stabilize the formulation and lubricate
valve components.
The aerosol formulation can be packaged under pressure and can be formulated as an
aerosol using solutions, sions, emulsions, powders and semisolid preparations. A
solution aerosol consists of a solution of an active ingredient such as oligos in pure propellant
or as a mixture of propellant and solvent. The solvent is used to dissolve the active ingredient
and/or retard the evaporation of the lant. Solvents useful in the invention include, for
example, water, ethanol and glycols. A on aerosol contains the active ingredient
peptide and a propellant and can include any combination of solvents and preservatives or
antioxidants.
An aerosol formulation can also be a dispersion or suspension. A suspension aerosol
formulation will generally contain a suspension of an effective amount of the oligos and a
dispersing agent. Dispersing agents useful in the invention include, for example, sorbitan
trioleate, oleyl l, oleic acid, lecithin and corn oil. A suspension aerosol ation
can also include lubricants and other aerosol components.
An l formulation can similarly be formulated as an emulsion. An emulsion can
include, for example, an alcohol such as ethanol, a surfactant, water and propellant, as well as
the active ingredient, the . The surfactant can be nonionic, anionic or cationic. One
example of an emulsion can include, for example, ethanol, surfactant, water and
propellant. Another e of an on can include, for example, vegetable oil, glyceryl
monostearate and propane.
Oligos may be formulated for oral delivery (Tillman et al., J Pharm Sci 97: 225, 2008;
Raoof et al., J Pharm Sci 93: 1431, 2004; Raoof et al., Eur J Pharm Sci 17: 131, 2002; US
6,747,014; US 2003/0040497; US 2003/0083286; US 2003/0124196; US 2003/0176379; US
2004/0229831; US 2005/0196443; US 2007/0004668; US 2007/0249551; WO 02/092616;
WO 03/017940; WO 03/018134; WO 99/60012). Such ations may incorporate one or
more permeability enhancers such as sodium caprate that may be incorporated into an
enteric-coated dosage form with the oligo.
There are also delivery mechanisms applicable to oligos with or without rs that
can be applied to particular parts of the body such as the CNS. These include the use of
convection-enhanced delivery methods such as but not limited to intracerebral clysis
(convection-enhanced microinfusion into the brain – Jeffrey et al., Neurosurgery 46: 683,
2000) to help deliver the cell-permeable carrier/NABT x to the target cells in the CNS
as described in .
Drug delivery mechanisms based on the exploitation of so-called leverage-mediated
uptake mechanisms are also suitable for the practice of this invention (Schmidt and Theopold,
Bioessays 26: 1344, 2004). These mechanisms involve targeting by means of e
adhesion molecules (SAMs) such as tetrameric lectins, linked membrane-anchored
molecules (MARMs) around lipoproteins or bulky hinge les leveraging MARMs to
cause a local inversion of the cell membrane curvature and formation of an internal
endosome, lysosome or phagosome. More specifically leverage-mediated uptake involves
lateral clustering of MARMs by SAMs thus generating the configurational energy that can
drive the reaction towards internalization of the oligo carrying complex by the cell. These
compositions, methods, uses and means of production are provided in .
As for many drugs, dose schedules for ng patients with oligos can be readily
extrapolated from animal studies. The extracellular concentration that must be generally
achieved with highly active conventional antisense or complementary sense and antisense
oligos for use in the two-step method is in the 1-200 nanomolar (nM) range. Higher
extracellular levels, up to 1.5 micromolar, may be more appropriate for some applications as
this can result in an increase in the speed and the amount of the oligos driven into the tissues.
Such levels can readily be achieved in the plasma.
For in vivo applications, the concentration of the oligos to be used is readily
calculated based on the volume of physiologic ed-salt solution or other medium in
which the tissue to be d is being bathed. With fresh , 1-1000 nM ents the
concentration extremes needed for oligos with moderate to excellent activity. Two hundred
nanomolar (200 nM) is a generally serviceable level for most applications. With most cell
lines a r will typically be needed for in vitro administration. tion of the tissue
with the oligos at 5% rather than atmospheric (ambient) oxygen levels may improve the
results significantly.
Pharmacologic/toxicologic studies of phosphorothioate , for example, have
shown that they are tely stable under in vivo conditions, and that they are y taken
up by all the tissues in the body following ic administration with a few exceptions
such as the central nervous system (Iversen, Anticancer Drug Design 6:531, 1991; Iversen,
Antisense Res. Develop. 4:43, 1994; Crooke, Ann. Rev. Pharm. Toxicol. 32: 329, 1992;
Cornish et al., Pharmacol. Comm. 3: 239, 1993; Agrawal et al., Proc. Natl. Acad. Sci. USA
88: 7595, 1991; Cossum et al., J. Pharm. Exp. Therapeutics 269: 89, 1994). These
compounds readily gain access to the tissue in the central nervous system in large amounts
following injection into the cerebral spinal fluid (Osen-Sand et al., Nature 364: 445, 1993;
Suzuki et al., Amer J. Physiol. 266: R1418, 1994; Draguno et al., eport 5: 305, 1993;
Sommer et al., Neuroreport 5: 277, 1993; Heilig et al., Eur. J. Pharm. 236: 339, 1993;
Chiasson et al., Eur J. Pharm. 227: 451, 1992). Phosphorothioates per se have been found to
be relatively non-toxic, and the class specific adverse effects that are seen occur at higher
doses and at faster infusion rates than is needed to obtain a therapeutic effect with a well-
chosen sequence. In addition to providing for nuclease resistance, one potential advantage of
phosphorothioate and boranophosphate linkages over the odiester linkage is the
promotion of binding to plasma proteins and albumin in particular with the resulting effect of
an increased plasma half-life. By retaining the oligo for a longer period of time in plasma the
oligo has more time to enter tissues as opposed to being excreted by the kidney. Oligos with
primarily or exclusively phosphodiester linkages have a plasma half-life of only a few
minutes. Thus, they are of little use for in vivo applications when used without a carrier. In
the case of oligos with a preponderance of or exclusively phosphodiester es, plasma
protein binding can be improved by covalently attaching the oligo a molecule that binds a
plasma protein such as serum n. Such molecules include, but are not limited to, an
arylpropionic acid, for example, ibuprofen, suprofen, ketoprofen, pranoprofen, tiaprofenic
acid, naproxen, flurpibrofen and carprofen (US 6,656,730). As for other es that might
be linked to the oligos suitable for use with the present invention the preferred site is the 3’-
end of the oligo. Intravenous strations of oligos can be continuous for days or be
administered over a period of minutes depending on the particular oligos and the medical
indication. Phosphorothioate-containing oligos have been tested containing 18 nucleotides
(e.g., oblimersen) to 20 nucleotides (e.g., cenersen, orsen, aprinocarsen, ISIS 14803,
ISIS 5132 and ISIS 2503) in length. When so administered such oligos show an alpha and a
beta phase of elimination from the plasma. The alpha phase oligo half-life is 30 to 60 minutes
while the beta phase is longer than two weeks for oligos with both orothioate linkages
and 2’-0 substitutions in at least the terminal four nucleosides on each end of the oligo.
The most ent toxicities associated with intravenous administration of
orothioates have been related to the chemical class and generally independent of the
mRNA target sequence and, therefore, independent of hybridization. The observed and
measured toxicities have been consistent from drug to drug pre-clinically and clinically, with
non-human primates being most similar to humans for certain key toxicities.
The class-related toxicities that have been most compelling in choosing dose and
schedule for pre-clinical and clinical evaluation occur as a function of binding to ic
plasma proteins and include transient inhibition of the clotting cascade and activation of the
complement cascade. Both of these toxicities may be d to the polyanionic nature of the
les.
The effect of phosphorothioates on the clotting e results in plasma
tration-related prolongation of the activated partial thromboplastin (aPPT) time.
Maximum prolongation of the aPTT correlates closely with the maximum plasma
concentration so doses and schedules that avoid high peak trations can be selected to
avoid significant effects on the aPTT. Because the plasma half-life of these drugs is short
(30 to 60 minutes), the effect on clotting is transient. Several of these drugs have been
evaluated in the clinic with prolonged intravenous infusions lasting up to 3 weeks. r
IV infusions (e.g., 2 hours) have also been studied. For example, aprinocarsen (ISIS 3521)
and ISIS 5132 were studied with both 2 hour and 3-week continuous infusion schedules. At a
dose of 3 mg/kg/dose over 2 hours, transient prolongation of the aPTT was observed. When
3 mg/kg was given daily by continuous infusion for 21 days, there was no effect on aPTT.
The effect of nse molecules of this chemical class on the clotting cascade is consistent.
Similarly, the activation of complement is a consistent observation; however, the
relationship between plasma concentration of oligonucleotides and complement activation is
more complex than the effect on clotting. Also, while the effect on clotting is found in rats as
well as monkeys, the effect on the complement cascade has only been ed in monkeys
and humans.
When these drugs are given to cynomolgus monkeys by 2-hour infusion, increases in
complement split products (i.e., C3a, C5a, and Bb) occur only when plasma concentrations
exceed a threshold value of 40-50 mg/mL. In monkeys, there is a low incidence of
vascular collapse associated with increases in these proteins. For the most part, clinical
investigations of orothioates have been designed to avoid these high plasma
concentrations.
When ISIS 3521 was given as a weekly 24 hour infusion at doses as high as 24 mg/kg
(1 mg/kg/hour x 24 hours), the steady state plasma concentrations reached imately 12
mg/mL at the high dose. On this schedule, however, there were substantial increases in C3a
and Bb even though these plasma levels were much lower than those seen with the shorter
infusions. Thus, activation of complement may be associated with both dose and le
where plasma trations that are well tolerated over shorter periods of time (e.g. 2
hours), are associated with toxicity when the plasma trations are ined for
longer. This likely provides the explanation for the findings with cenersen in rhesus monkeys
where complement activation was observed at concentrations of 14-19 mg/mL.
When ISIS 3521 was given at 1.0 and 1.25 mg/kg/hour x 2 hours, the mean peak
plasma concentrations were 11.1+0.98 and 6.82+1.33 μg/mL, respectively. There was no
complement activation at these or other higher doses and no other safety issues. It is
expected that the maximum peak plasma concentrations for similarly sized phosphorothioate
given at 1.2 hour x 1 hour would be similar to that ed with ISIS 3521.
Thus, limiting infusion rates for orothioates to 3.6 mg/kg/h or less is highly
preferred. With somewhat higher infusion rates the effects of complement activation can be
expected. Decisions made about the sequential shortening of the infusion below one hour
using a constant total dose of approximately 22 mg/kg should be readily achieved based on
review of the safety information, including evaluation of complement split products.
The following examples are provided to illustrate certain embodiments of the present
invention. They are not intended to limit the invention in any way.
EXAMPLE I
APPLICATIONS FOR seqsiRNA
The seqsiRNA genes targeted for silencing are shown in Table 6 and in the examples.
They are not meant to provide an exhaustive set of illustrations of how the designs presented
herein can be d in general or in particular. One skilled in the art can readily use the
design principles and the examples provided herein to arrive at a very limited set of
compounds that can be generated in ance with the present invention using any given
gene target in a subject.
TABLE 6
EXAMPLES OF COMMERCIAL APPLICATIONS FOR NA INHIBITORS
FOR ILLUSTRATIVE GENE TARGETS
MEDICAL CONDITIONS TO BE TREATED OR OTHER
GENE TARGET
COMMERCIAL OBJECTIVES FOR seqsiRNA p53 INHIBITORS
Atherosclerosis; tive heart failure; Familial hypercholesterolemia; Statin
Apoliprotein B (Apo B) resistant hypercholesterolemia; HDL/LDL cholesterol imbalance; dyslipidemias;
ed hyperlipidemia; Coronary artery disease; Thrombosis
Myocardial tion; Fatty liver disease; ant hepatitis; Cirrhosis of the
liver; Alcoholic hepatitis; Cholestatic liver injury; Acute liver failure; Cystic
FAS/APO-1 fibrosis; Systemic lupus erythematosus; Arthritis; Parkinson’s Disease;
(CD-95; Tnfrsf6) Autoimmune diabetes; l nervous system injuries, inating es;
Stroke; Chemotherapy-induced neuropathy; Neurodegenerative diseases; Spinal
cord injury; Ischemia –reperfusion injury
p53 Sensitize cancers with wild type p53 to cytotoxic therapies; Cancers with mutant
p53; Sensitize cancers with mutant p53 to the induction of apoptosis by
anyapoptosis inducer; Stem cell quiescence including malignant stem cells
(expand normal stem cells and progeny or put malignant stem cells in cycle so
they can be attacked by cell cycle dependent anti-cancer agents; Heart failure;
Medical conditions where sis is promoted; Inhibiting sis in nonmalignant
stem cells; Huntington’s disease; Diamond-Blackfan syndrome;
Shwachman Diamond Syndrome and other disorders involving defective
ribosomes and/ or imbalances in ribosomal components (ribosomopathies); Fatty
liver disease; Stress induced immunosuppression; lae associated with
chnoid hemorrhage; Pathologic hyperpigmentation; Hyperkeratosis; Toxic
effects of cancer chemotherapy and radiation including but not limited to the
following: hair loss, tis, myelosupression, hearing loss, peripheral nerve
damage, ed brain function and kidney damage; Inflammatory bowel disease;
Crohn’s disease; ARDS; Multiple organ failure; Sensitize cancers to cytotoxic
treatments dependent on cell proliferation and/or DNA replication; Amyloid
deposition; Neurodegenerative diseases; Ischemia-reperfusion injury; Avoidance
of effects of xic therapy due to quiescence of malignant stem cells; Reduced
expansion of non-malignant tissue due to stem cell quiescence; Prevent
demyelination; Multiple sclerosis; Alzheimer’s Disease; Parkinson’s disease;
Prevent cell death associated with diabetic ischemia; Spontaneous apoptosis, cell
cycle arrest, ence and differentiation in stem cells including embryonic stem
cells and iPS such as reduces the efficiency of preparing such cells for
transplantation organ generation, the generation of animals or for use in ific
research; Prevent cell death associated with cerebral ischemia; Prevent cell death
associated with myocardial infarction including uent heart wall rupture;
Schizophrenia; Psoriasis; AIDS; Prevent rupture of atherosclerotic plaques;
Prevent aneurysm rupture; Graft vs host disease; Systemic lupus erythematosus;
Promote healing of hard to heal wounds; Capillary leak syndrome; Emphysema;
Reduce enodosomal, lysosomal or phagosomal sequestration of oligo therapeutics
with the effect of increasing their biologic activity; Promote proliferation of stem
cells such as hematopoietic or neural; Diabetes mellitus including insulin resistant
diabetes; 5q- syndrome; Porokeratosis; Ferritin induced cell death such as occurs
in iron overload; Anemia; Dyskeratosis congentia including that form with
telomerase insufficiency; Prevent emphysema; Prevent COPD; Insulin resistance
in heart failure
Atherosclerosis; Hypercholesterolemia; Statin resistant hypercholesterolemia;
PCSK9
HDL/LDL terol imbalance; dyslipidemias; Acquired hyperlipidemia;
(NARC-1)
ry artery e
Cancers with mutated p53; te cell proliferation including poietic
PTEN
stem and progenitor cells; Increase efficiency of gene er including into
(MMAC1; TEP1)
hematopoietic stem and progenitor cells; Nerve cell regeneration
PTP-1B Insulin resistance; Type II Diabetes
Stat3 Cancer, Autoimmune disease
A. Compounds for Down-regulating p53 Expression
p53 is involved in the regulation of a variety of cellular ms including those
involving stem cell self-renewal, cellular proliferation and viability such as proliferation,
differentiation, apoptosis, senescence, mitotic catastrophe and autophagy. Indices 24-30, 61
and 62 provide compounds suitable for use in accordance with the present invention.
The pathological expression or failure of expression of such ms, and the death
programs in particular, underlie many of the morbidities associated with a wide variety of
medical conditions where blocking p53 function can prevent much if not all of such
morbidity.
In cancer, for e, both wild type and mutant p53 play key roles in tumor
maintenance that include increasing the threshold for the ion of programs that can lead
to the death of the cancer cells. Typically the use of a p53 inhibitor, such as a siRNA directed
to the p53 gene target, in combination with an inducer of a cell death program, such as a
DNA damaging agent, can be used to promote the death of cancer cells. At the same time
inhibition of p53 protects many normal tissues from the toxic s of many such second
agents including herapy and radiation.
Further, the present inventor has found that Boron Neutron e Therapy (BNCT)
can be used in combination with ss-siRNA, double stranded siRNA or conventional antisense
oligos that inhibit p53 (such as but not limited to those described in PCT/US09/02365) as a
method for treating cancer (Brownell et al., “Boron Neutron Capture Therapy” In; “Therapy
of Nuclear ne,” RP Spencer (ed), Grune and Stratton, NY, 1978; Barth et al. Cancer
Res 50: 1061, 1990; Summers and Shaw, Curr Med Chem 8: 1147, 2001). Specifically, the
10B atom undergoes fission to generate 7Li and energetic alpha (helium) particles following
capturing a thermal neutron. Within their 10-14mm path, such particles cause DNA and other
types of damage that enhance apoptosis and other inactivating effects on cancer cells when
wild type or mutated p53 is inhibited.
The use of conventional antisense oligos which function using an RNAse H
mechanism of action and ed to the p53 gene target have been studied in vitro and in
patients. These oligos have been shown to promote the anti-cancer effects of certain
conventional treatments and to protect normal tissues from genome damaging agents. Few
cell types, with the exception of stem cells, s sufficient levels of RNase H to support
tional antisense oligos dependent on this enzyme for their activity. Consequently,
RNAi directed to the p53 gene target which are not dependent on RNAse H ty for
function offer the potential advantage of being active in vivo in a broader range of cell types
while still being catalytic. As for RNAi, generally this potential is severely limited by the
well known problems associated with the poor uptake of conventional siRNA uptake in vivo
and the lack of carriers that can broadly address this problem.
Molitoris et al. (J Am Soc Nephrol 20: 1754, 2009) ts data showing that
tional siRNA directed to the p53 gene target can attenuate cisplatin induced kidney
damage in rats. The siRNA described was a blunt ended 19-mer with alternating 2’
methy/native ribose nucleosides. A carrier was not needed because the proximal tubule cells
in the kidney are both a major site of kidney injury associated with ischemia or
nephrotoxicity such as that caused by cisplatin and is the site of oligo reabsorption by the
kidney. Thus, this carrier free approach with conventional siRNA is of very limited use for
preventing the pathologic effects of p53-dependent programs that kill cells or otherwise
incapacitate them, but it does illustrate the potential usefulness of inhibiting p53 for this
medical indication.
Zhao et al. (Cell Stem Cell 3: 475, 2008) trated that inhibiting p53 expression
with siRNA can be used to enhance the production of iPSC. Human fibroblasts, for example,
were ted to iPSC by using sion vectors for several genes to gain their expression
in the cells. The efficiency of iPSC production was very low but was increased approximately
two logs when shRNA directed to the p53 gene target was installed in the cells using a
iral . The approach bed herein provides the means to transiently suppress
p53 compared to the long term suppression ed by shRNA. This is important when the
iPSC are to be induced to differentiate into particular cell type such as would be needed in
tissue repair applications. As described herein the two-step administration approach
combined with the linkage of a short cell penetrating peptide (CPP) to each strand provides
an ent way to obtain RNAi activity in stem cells in vitro with minimal carrier related
toxicity.
RNAi compounds directed to the human p53 gene target that can be reconfigured for
use in the two-step method provided by the present invention are found in ,
US 2009/0105173 and US 2004/0014956.
Table 6 lists a variety of disorders that would benefit with treatment of the p53
directed compounds described herein. For example, heart failure is a s condition that
results from various cardiovascular diseases. p53 plays a significant role in the development
of heart failure. Cardiac angiogenesis directly related to the maintenance of c function
as well as the pment of cardiac hypertrophy induced by pressure-overload.
Upregulated p53 d the tion from cardiac hypertrophy to heart failure through the
suppression of hypoxia inducible factor-1(HIF-1), which tes angiogenesis in the
hypertrophied heart. In addition, p53 is known to promote sis, and apoptosis is thought
to be involved in heart failure. Thus, p53 is a key molecule that triggers the development of
heart failure via multiple mechanisms.
Accordingly, the p53 directed compounds of the ion can be employed to
diminish or alleviate the pathological symptoms associated with cardiac cell death due to
apoptosis of heart cells. Initially the compound(s) will be incubated with a cardiac cell and
the ability of the oligo to modulate p53 gene function (e.g., reduction in production p53,
apoptosis, improved cardiac cell signaling, Ca++ ort, or morphology etc.) can be
assessed. For example, the H9C2 cardiac muscle cell line can be obtained from American
Type e Collection (Manassas, VA, USA) at passage 14 and cultured in DMEM
complete culture medium (DMEM/F12 supplemented with 10% fetal calf serum (FCS), 2
mM α-glutamine, 0·5 mg/l Fungizone and 50 mg/l gentamicin). This cell line is suitable for
terizing the inhibitory functions of the p53 directed compounds of the invention and
for characterization of modified versions thereof. HL-1 cells, described by Clayton et al.
(1998) PNAS 95:2979-2984, can be edly passaged and yet in a cardiac-specific
phenotype. These cells can also be used to further characterize the s of the oligos
described herein.
It appears that expression of the apoptosis regulator p53 is governed, in part, by a
molecule that in mice is termed murine double minute 2 (MDM2), or in man, human double
minute 2 (HDM2), an E3 enzyme that targets p53 for ubiquitination and proteasomal
processing, and by the deubiquitinating enzyme, herpesvirus-associated ubiquitin-specific
protease (HAUSP), which rescues p53 by removing ubiquitin chains from it. Birks et al.
(Cardiovasc Res. 2008 Aug 1;79 (3):472-80) examined whether elevated expression of p53
was ated with dysregulation of ubiquitin-proteasome system (UPS) components and
activation of downstream effectors of sis in human dilated cardiomyopathy (DCM). In
these studies, left ventricular myocardial samples were obtained from patients with DCM (n =
12) or from non-failing (donor) hearts (n = 17). Western blotting and immunohistochemistry
revealed that DCM tissues contained elevated levels of p53 and its regulators HDM2, MDM2
or the gs f found in other species, and HAUSP (all P < 0.01) compared with
non-failing hearts. DCM tissues also contained elevated levels of polyubiquitinated proteins
and possessed enhanced 20S-proteasome chymotrypsin-like ties (P < 0.04) as measured
in vitro using a fluorogenic substrate. DCM s contained activated caspases 9 and 3 (P <
0.001) and reduced expression of the caspase ate PARP-1 (P < 0.05). Western blotting
and histochemistry ed that DCM tissues ned elevated expression levels
of caspaseactivated DNAse (CAD; P < 0.001), which is a key effector of DNA
fragmentation in sis and also contained elevated expression of a potent inhibitor of
CAD (ICAD-S; P < 0.01). These investigators concluded that expression of p53 in human
DCM is associated with dysregulation of UPS components, which are known to regulate p53
stability. Elevated p53 expression and caspase activation in DCM was not associated with
activation of both CAD and its inhibitor, ICAD-S. These findings are consistent with the
concept that apoptosis may be upted and therefore potentially reversible in human HF.
In view of the foregoing, it is clear that the p53 directed compounds provided herein
should exhibit efficacy for the treatment of heart failure. Accordingly, in one embodiment of
the invention, p53 directed compounds are administered to patients to t c cell
apoptosis, thereby reducing the incidence of heart failure.
Cellular transformation during the development of cancer involves multiple
alterations in the normal n of cell growth regulation and dysregulated transcriptional
control. Primary events in the process of carcinogenesis can involve the activation of
oncogene function by some means (e.g., amplification, mutation, chromosomal
rearrangement) or altered or nt expression of transcriptional regulator functions, and in
many cases the removal of anti-oncogene function. One reason for the enhanced growth and
invasive properties of some tumors may be the acquisition of increasing numbers of
mutations in oncogenes and anti-oncogenes, with cumulative effect (Bear et al., Proc. Natl.
Acad. Sci. USA 86:7495-7499, 1989). Alternatively, insofar as oncogenes function h
the normal cellular ing pathways required for organismal growth and cellular on
(reviewed in McCormick, Nature 363:15-16, 1993), onal events corresponding to
mutations or deregulation in the nic signaling pathways may also contribute to tumor
malignancy (Gilks et al., Mol. Cell Biol. 13:1759-1768, 1993), even though ons in the
signaling pathways alone may not cause cancer.
p53 provides a powerful target for efficacious anti-cancer agents. Combination of the
p53 directed compounds with one or more therapeutic agents that promote apoptosis
effectively induces cell death in cancer cells. Such agents include but are not limited to
conventional chemotherapy, radiation and biologic agent such as monoclonal antibodies and
agents that manipulate hormone pathways.
p53 protein is an important transcription factor which plays a central role in cell cycle
tion mechanisms and cell proliferation control. Baran et al. performed studies to
fy the expression and localization of p53 protein in lesional and non-lesional skin
samples taken from psoriatic ts in comparison with healthy controls (Acta
Dermatovenerol Alp Panonica . ( 2005) 83). Sections of psoriatic lesional and
non-lesional skin (n=18) were examined. A control group (n=10) of healthy volunteers with
no al and family history of psoriasis was also examined. The expression of p53 was
demonstrated using the avidin-biotin complex immunoperoxidase method and the
monoclonal antibody DO7. The count and localization of cells with stained nuclei was
evaluated using a light microscope in 10 fields for every skin biopsy. In lesional psoriatic
skin, the count of p53 ve cells was significantly higher than in the skin samples taken
from healthy individuals (p<0.01) and non-lesional skin taken from psoriatic patients
(p=0.02). No significant difference between non-lesional psoriatic skin and normal skin was
observed (p=0.1). A strong positive correlation between mean count and mean per cent of
p53 positive cells was found (p<0.0001). p53 positive cells were located most commonly in
the basal layer of the epidermis of both healthy skin and non-lesional psoriatic skin. In
lesional psoriatic skin p53 positive cells were present in all layers of the epidermis. In view
of these data, it is clear that p53 protein appears to be an important factor in the pathogenesis
of psoriasis. ingly, compounds which effectively down te p53 expression in
the skin used alone or in combination with other agents used to treat psoriasis should alleviate
the symptoms of this painful and unsightly disorder.
B. Compounds for Down-regulating Fas (Apo-1 or CD95) sion
Fas (APO-1 or CD95) is a cell e or that controls a y leading to cell
death via apoptosis. This pathway is involved in a number of medical conditions where
ng fas function can provide a clinical benefit. See Table 6. Fas-mediated apoptosis, for
example, is a key contributor to the pathology seen in a broad spectrum of liver diseases
where inhibiting hepatocyte death can be life saving. Indices 22 and 31-35 provide novel
compositions of matter that include many of the features heretofore described for increasing
cellular uptake and/or stability for down modulating fas expression in target cells.
Lieberman and her associates have studied the effects of siRNA directed to the
murine fas receptor gene target in murine models of fulminant hepatitis and renal ischemiareperfusion
injury (Song et al., Nature Med 9: 347, 2003; Hamar et al., Proc Natl Acad Sci
USA 101: 14883, 2004). siRNA delivered by a ynamic transfection method showed
that such siRNA protects mice from concanavalin A generated hepatocyte apoptosis as
evidenced by a reduction in liver fibrosis or from death associated with injections of a more
hepatotoxic fas specific antibody. In the second study, siRNA was shown to protect mice
from acute renal failure after clamping of the renal .
RNAi compounds directed to the human fas (apo-1 or CD95) receptor or ligand gene
target are provided in , US 2005/0119212, and US
2008/0227733.
Recently, Feng et al. reported that during myocardial ischemia, cardiomyocytes can
o apoptosis or compensatory hypertrophy (Coron Artery Dis. 2008 Nov;19(7):527-34).
Fas expression is upregulated in the myocardial ischemia and is d to both apoptosis
and hypertrophy of cardiomyocytes. Some reports suggested that Fas might induce
myocardial hypertrophy. Apoptosis of ischemic cardiomyocytes and Fas expression in the
nonischemic myocytes occurs during the early stage of ic heart failure.
Hypertrophic cardiomyocytes easily undergo apoptosis in response to ischemia, after which
apoptotic cardiomyocytes are replaced by fibrous tissue. In the late stage of ischemic heart
e, hypertrophy, apoptosis, and fibrosis are thought to accelerate each other and might
thus form a vicious circle that eventually results in heart failure. Based on these
observations, it is clear that Fas directed compounds provide useful therapeutic agents for
ameliorating the pathological effects associated with myocardial ischemia and hypertrophy.
Accordingly, fas directed oligos will beadministered cardiac cells and their effects on
apoptosis assessed. As discussed above, certain modifications of the fas ed compounds
will also be assessed. These include conjugation to heart homing peptides, inclusion of
CPPs, as well as encapsulation in liposomes or nanoparticles as appropriate.
In their article entitled, “Fas Pulls the r on Psoriasis”, Gilhar et al. describe an
animal model of psoriasis and the role played by Fas mediated signal transduction (2006)
Am. J. Pathology 168:170-175). Fas/FasL signaling is best known for induction of sis.
However, there is an alternate pathway of Fas signaling that induces inflammatory cytokines,
particularly tumor necrosis factor alpha (TNF-α) and interleukin-8 . This pathway is
prominent in cells that express high levels of anti-apoptotic molecules such as Bcl-xL.
Because TNF-α is central to the pathogenesis of psoriasis and tic epidermis has a low
tic index with high expression of Bcl-xL, these authors esized that
inflammatory Fas signaling mediates induction of psoriasis by activated lymphocytes.
Noninvolved skin from sis patients was grafted to beige-severe combined
immunodeficiency mice, and psoriasis was induced by ion of FasL-positive autologous
natural killer cells that were activated by IL-2. Induction of sis was inhibited by
injection of a blocking as (ZB4) or anti-FasL (4A5) antibody on days 3 and 10 after
natural killer cell ion. as monoclonal antibody significantly reduced cell
proliferation (Ki-67) and epidermal thickness, with inhibition of epidermal expression of
TNF-α, IL-15, HLA-DR, and ICAM-1. Fas/FasL signaling is an essential early event in the
induction of psoriasis by activated lymphocytes and is necessary for ion of key
inflammatory cytokines ing TNF-α and IL-15.
Such data provide the rationale for therapeutic regimens entailing topical
administration of Fas directed compounds and/or BCL-xL directed compounds for the
treatment and alleviation of symptoms associated with psoriasis.
C. nds for Down-regulating Apo-B Expression
Apolipoprotein B (apoB) is an essential protein for the formation of low-density
lipoproteins (LDL) and is the ligand for LDL receptor. LDL is responsible for carrying
cholesterol to tissues. High levels of apoB can lead to plaques that cause atherosclerosis.
Accordingly, ng apo B expression is a useful treatment modality for a variety of
medical disorders including those listed in Table 6. Indices 20, 36-44, 63 and 64 provide
compounds suitable for use in accordance with the present invention to silence apoB
expression.
Soutschek et al. (Nature 432: 173, 2004) have described two siRNA compounds
simultaneously ed to both the murine and human apoB gene s suitable for use in
the present invention. These compounds have 21-mer passenger and 23-mer guide strands
with cholesterol conjugated to the 3’-ends of the passenger strand. The cholesterol promoted
both nuclease resistance and cellular uptake into the target tissues. The reductions in apoB
sion in liver and jejunum were associated with reductions in plasma levels of apoB-100
protein and LDL. The authors indicated that the unconjugated compounds (lacking
cholesterol) were inactive and concluded that the conjugated compounds need further
optimization to achieve improved in vivo potency at doses and dose regimens that are
clinically able.
The same group of investigators filed US20060105976, WO06036916 and US
7,528,118 that also provide siRNA compounds suitable for down ting both human and
mouse apoB gene expression. Eighty-one distinct RNAi compounds with demonstrated
ty in the human HepG2 and/or the murine liver cell line NmuLi that expresses apoB
were described. -seven of these double stranded siRNA compounds were found to
reduce apoB protein expression in HepG2 cells to less than 35% of control. One of these
siRNA was tested in human apoB-100 transgenic mice where following three daily tail vein
ions, the siRNA reduced mouse apoB mRNA levels 43+/- 10% in liver and 58 +/-12%
in jejunum and also reduced human apoB mRNA in livers to 0%. Other siRNA
compounds ed to apoB suitable for use in the present invention have been disclosed in
US 2006/0134189. These have been described for use in ation with the SNALP
(stable nucleic acid lipid particles) delivery technology.
Conventional antisense oligos ed to gene targets such as the apoB can be
converted to RNAi compounds in accordance with the present invention and can be used as
described herein. A series of conventional antisense oligos directed to apoB and suitable for
use with the present invention have been described in Merki et al., Circulation 118: 743,
2008; Crooke et al., J Lipid Res 46: 872, 2005; Kastelein et al., Circulation 114: 1729, 2006;
US 7,407,943, US 2006/0035858 and .
The conventional antisense oligos described in filing are 8
mers. It is known that guide s r than 15-mers are not active. Further 16-mer guide
strands are the shortest suggested for use with the present invention. Thus, the compounds
listed in this filing that are le for use in the present example are limited to 16-mers or to
15mers that are extended to 16-mers using the human ApoB sequence. Such 16-mers can
be further lengthened by the use of ngs which as described herein do not necessarily
need to base pair with the gene target.
A number of treatment regimens suitable for use with such tional antisense
oligos or for use with the two-step administration described by the present invention are
provided in .The sequence used for human ApoB is provided in k,
Accession No. X04714.1.
Atherosclerosis is a ion in which vascular smooth muscle cells are
pathologically rammed. Fatty material collects in the walls of arteries and there is
typically c inflammation.This leads to a situation where the vascular wall thickens,
hardens, forms plaques, which may eventually block the arteries or promote the blockage of
arteries by promoting clotting. The latter becomes much more prevalent when there is a
plaque rupture.
If the coronary arteries become narrow due to the effects of the plaque formation,
blood flow to the heart can slow down or stop, causing chest pain (stable angina), shortness
of breath, heart attack, and other symptoms. Pieces of plaque can break apart and move
through the bloodstream. This is a common cause of heart attack and stroke. If the clot moves
into the heart, lungs, or brain, it can cause a stroke, heart attack, or pulmonary sm.
Risk factors for atherosclerosis include: diabetes, high blood pressure, high
cholesterol, high-fat diet, obesity, personal or family history of heart e and smoking.
The following conditions have also been linked to sclerosis: cerebrovascular disease,
kidney disease involving dialysis and peripheral vascular disease. Down modulation of apoB
s can have a beneficial therapeutic effect for the treatment of atherosclerosis and associated
pathologies. WO/2007/030556 provides an animal model for assessing the effects of apoB
directed compounds on the formation of atherosclerotic lesions.
D. Compounds for Down-regulating PCSK9 Expression
Protein convertase subtilisin-like kexin type 9 (PCSK9) is a serine protease that
destroys LDL receptors in liver and consequently the level of LDL in plasma. PCSK9
mutants can have gain-of-function attributes that promote certain medical disorders
associated with alterations in the proportions of plasma lipids. Agents that inhibit PCSK9
function have a role to play in the treatment of such medical disorders including those listed
in Table 6. Indices 21 and 45-51 provide compounds suitable for use in accordance with the
present invention to silence PCSK9 sion.
Frank-Kamenetsky et al. (Proc Natl Acad Sci USA 105: 11915, 2008) have described
four siRNA compounds suitable for use in the present invention with three different
sequences directed to the PCSK9 gene targets of human, mouse, rats, and nonhuman es
(and have characterized their activity in model systems. These siRNA were selected from a
group of 150 by screening for activity using HepG2 cells. These compounds were
formulated in lipidoid nanoparticles for in vivo testing. These nds reduced PCSK9
expression in the livers of rats and mice by 50-70% and this was associated with up to a 60%
reduction in plasma cholesterol levels. In transgenic mice carrying the human PCSK9 gene
siRNA compounds were shown to reduce the levels of the transcripts of this gene in livers by
>70%. In nonhuman primates after a single bolus injection of PCSK9 siRNA the ve
effect on PCSK9 expression lasted 3 weeks. During this time apoB and LDL cholesterol
(LDLc) levels were reduced. There were no detectable effects on HDL cholesterol or
cerides. US2008/0113930 and disclose additional PCSK9 RNAi
compounds which can be modified as disclosed herein.
Conventional antisense oligos directed to the PCSK9 gene target provide another
example g how conventional antisense oligos can be reconfigured to provide novel
compositions of matter suitable for use in the present invention. Such a reconfiguration is
useful in situations where siRNA has advantages over conventional antisense oligos as
described . A series of tional nse oligos directed to human PCSK9 and
suitable for use with the present invention have been described in . These
ces were among the most active of those that were screened for PCSK9 inhibiting
activity in vitro using the Hep3B cell line. The tional antisense oligos described in this
filing are 8mers. It is known that guide strands shorter than 15-mers are not .
Further 16-mer guide strands are the shortest suggested for use with the present invention.
Such 16-mers can be further lengthened by the use of overhangs which as described herein do
not necessarily need to base pair with the gene target in the case of the guide strand.
A number of treatment regimens suitable for use with such conventional antisense
oligos or for use with the two-step strationof strands capable of forming siRNA in
cells and where the guide strand is directed to PCSK9 are described in WO 18883. The
conventional antisense oligos in this filing are targeted to apoB but the tissues involved and
the therapeutic purposes involving PCSK9 are the same and thus essentially the same
treatment regimens can be used.
This protein plays a major regulatory role in cholesterol homeostasis. PCSK9 binds to
the epidermal growth factor-like repeat A (EGF-A) domain of the low-density lipoprotein
receptor (LDLR), inducing LDLR degradation. d LDLR levels result in decreased
metabolism of low-density lipoproteins, which could lead to hypercholesterolemia. Inhibition
of PSCK9 function provides a means of ng cholesterol levels. PCSK9 may also have a
role in the differentiation of cortical neurons.
Further, the usefulness of conventional antisense oligos directed to the murine PCSK9
gene target for the ent of hypercholesterolemia has been demonstrated by Graham et al.
(J lipid Res 48: 763, 2007). A series of antisense oligos were screened for activity and the
most active (ISIS 394814) selected for in vivo studies. Administration of ISIS 394814 to high
fat fed mice for 6 weeks resulted in a 53% reduction in total plasma cholesterol and a 38%
reduction in plasma LDL. This was accompanied by a 92% reduction in liver PCSK9
expression.
E. Compounds for Down-regulating Phosphatase and Tensin Homolog (PTEN)
Expression
PTEN is a phosphatase (phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase) that
is frequently mutated in cancers with wild type p53 where the effect or the mutation is to
inhibit its tic ty. In this context, PTEN is t to function as a tumor
suppressor. In cancers with mutated p53, however, PTEN supports the viability and growth of
the tumor in part by increasing the levels of gain-of-function p53 mutants (Li et al., Cancer
Res 68: 1723, 2008). PTEN also modulates cell cycle regulatory proteins with the effect of
inhibiting cell proliferation. Thus, PTEN inhibitors have a role in the treatment of some
cancers and in ing cell eration such as expanding cell populations for purposes
such as transplantation. Indices 8, 10, 12, 14, 16, 18, 52, 53 and 55-57 provide compounds
suitable for use in accordance with the t invention to e PTEN sion.
In vivo regeneration of peripheral neurons is constrained and rarely complete, and
unfortunately patients with major nerve trunk transections experience only limited recovery.
Intracellular inhibition of neuronal growth signals may be among these constraints. Christie
et al. igated the role of PTEN (phosphatase and tensin homolog deleted on chromosome
) during regeneration of peripheral neurons in adult Sprague Dawley rats (J. Neuroscience
:9306-9315 (2010). PTEN inhibits phosphoinositide 3-kinase (PI3-K)/Akt signaling, a
common and central outgrowth and survival y downstream of neuronal growth factors.
While PI3-K and Akt outgrowth signals were expressed and activated within adult peripheral
neurons during regeneration, PTEN was similarly expressed and poised to inhibit their
support. PTEN was sed in neuron perikaryal cytoplasm, nuclei, regenerating axons,
and Schwann cells. Adult sensory neurons in vitro responded to both graded pharmacological
inhibition of PTEN and its mRNA knockdown using siRNA. Both approaches were
associated with robust rises in the plasticity of neurite outgrowth that were independent of the
mTOR (mammalian target of rapamycin) pathway. Importantly, this accelerated outgrowth
was in addition to the increased outgrowth generated in neurons that had undergone a
preconditioning lesion. Moreover, following severe nerve ction injuries, local
pharmacological inhibition of PTEN or siRNA knockdown of PTEN at the injury site
accelerated axon outgrowth in vivo. The findings indicated a remarkable impact on peripheral
neuron plasticity through PTEN inhibition, even within a complex regenerative milieu.
Overall, these findings identify a novel route to propagate intrinsic regeneration pathways
within axons to benefit nerve . In view of these findings, it is clear that the PTEN
directed compounds of the invention can be useful for the treatment of nerve injury and
damage. In a preferred embodiment, such agents would be administered intrathecally as
described for insulin in Toth et al., Neuroscience(2006) 139:429-49.Czauderna et al. (Nuc
Acids Res 31: 2705, 2003) have described an active siRNA compound that is directed to the
human PTEN gene target which is le for use in accordance with the present ionas
described herein. Allerson et al. (J Med Chem 48: 901, 2005) have described two siRNA
nds le for use in the present invention that are targeted to human PTEN.
F. nds for Down-regulating PTP1B Expression
PTP1B, a ansmembrane protein tyrosine phosphatase that has long been studied
as a negative regulator ofinsulin and leptin ing, has received renewed ion as an
unexpected positive factor in genesis. These dual characteristics make PTP1B a
particularly attractive therapeutic target for diabetes, obesity, and perhaps breast cancer.
Indices 54, 59, 60 and 65 provide compounds suitable for use in accordance with the present
ion to silence PTP1B expression.
In the case of insulin signaling, PTP1B dephosphorylates the insulin receptor (IR) as
well as its primary substrates, the IRS proteins; by contrast, in leptin signaling a downstream
element, the tyrosine kinase JAK2(Janus kinase 2), is the primary target for
dephosphorylation.However, hints that PTP1B might also play a positive signaling role in
cell eration began to emerge a few years ago, with the finding by a number of groups
that PTP1B dephosphorylates the inhibitory Y529 site in Src, thereby activating this kinase.
Other PTP1B substrates might also contribute to owth effects. Indeed, the idea that
PTP1B can serve as a signaling stimulant in some cases ed key confirmation in
previous work that showed PTP1B plays a positive role in a mouse model of ErbB2-induced
breast cancer. See Yip et al. Trends in Biochemical Sciences 35:442-449 (2010). For these
reasons, PTP1B has attracted particular attention as a potential therapeutic target in obesity,
diabetes, and now, cancer. Accordingly, the compounds directed at PTP1B can be used to
advantage for the treatment of such disorders.
EXAMPLE II
ATIONS FOR Rs
MiRNAs have been shown to have wide ranging effects on gene expression. In
certain instances, these effects are detrimental and related to certain pathologies.
Accordingly, specific miRNA inhibitors which target such miRNAs for degradation are
highly desirable. The present or has devised strategies for the synthesis of miRNA
inhibitors suitable for in vivo delivery which exhibit enhanced stability, the ability to form
active duplexes in cells, which act in turn to inhibit the activity of endogenous miRNAs
associated with disease. These design paradigms and the resulting miRNA inhibitors are
described herein below.
Table 7 provides a listing of some of the medical uses of the seqIMiRs ed to the
indicated miRNAs. Indices 66-79 provide pairs of seqIMiR strands that are effective to
inhibit the actions of these miRNA targets. The methods of the present invention, however,
can be used to te Rs against any miRNA. Methods for administration of the
oligos of the invention are provided in detail above.
TABLE 7
MICRORNA TARGETS FOR INHIBITION BY seqIMiRs
AND COMMERCIAL APPLICATIONS
Medical Conditions to be Treated using the
MicroRNA Targets
seqIMiR nds of the Invention
miR-24 Treat cancer ing hormone resistant prostate
miR-29a Inhibit pathologic sis including that due to ia reperfusion
injury such as occurs after the removal of a clot
miR-29b Inhibit pathologic apoptosis
miR-29c Inhibit pathologic apoptosis including that due to ischemia reperfusion
injury such as occurs after the removal of a clot
miR-33 Raise good cholesterol (HDL) levels
2 Hepatitis C
miR-155 Arthritis; Autoimmune inflammation including that associated with
cystic fibrosis; Atopic itis
miR-208a Chronic heart failure
Conventional antisense oligos of different types are under development for potential use
as competitive inhibitors of ular endogenous miRNAs for research, development and
therapeutic purposes. Such oligos are designed to bind particularly tightly one strand of the
miRNA whose actions are to be inhibited. These oligos work by a steric hindrance
mechanism.
Elevated levels of miR-21, for example, occur in us cancers where it promotes
oncogenesis at least in part by preventing the translation and accumulation of PDCD4.
Another example is miR-122 a liver specific miRNA that promotes replication of the
hepatitis C virus. Conventional antisense oligos that inhibit these miRNAs are in
development as potential therapeutic agents.
ed to antisense oligos that engender catalytic activity t their s,
such as those that are RNase H dependent, the nse oligos that function as competitive
inhibitors must be used at substantially higher concentrations. In vivo various tissues take up
oligos in widely ranging amounts. For example, liver and kidney take up vely large
s while resting lymphocytes, testis, skeletal muscle the CNS and other tissues take up
much smaller amounts. Further, antisense oligos that have a itive inhibitor function
have been shown to perform poorly in tissues that do not avidly take up oligos. Therefore, it
would be highly desirable to have oligonucleotide based miRNA inhibitors that have a
catalytic activity against them so that a wider range of tissues types can be subject to ent
miRNA inhibition. The present invention provides a solution to this pressing need.
EXAMPLE III
EXAMPLES OF APPLICATIONS FOR seqMiRs
Table 8 below es a g of miRNAs for which examples of specific seqMiR
compounds have been provided herein. The methods of the present invention can be used to
mimic any endogenous miRNA, to improve on the mRNA type silencing pattern of an
endogenous miRNA for commercial purposes and can be used to generate designer novel
miRNA-like compounds.
TABLE 8
MICRORNAS MIMICKED BY seqMiRs AND COMMERCIAL APPLICATIONS
MicroRNA Medical Conditions to be Treated using the seqMiR Compounds
Mimicked by of the Invention
seqMiR
Let-7i and Let-7 family Cancer
generally
miR1 Ischemia reperfusion injury including that associated with myocardial
infarction; Diabetes
miR2 Ischemia usion injury including that associated with myocardial
infarction; Diabetes
miR-26a-1 Cancer including liver, head and neck, breast
a-2 Cancer including liver, head and neck, breast
miR-29a Fibrosis including liver, lung, kidney and heart; Systemic sis; Cancers
ing lung, liver, chronic lymphocytic ia; Osteoporosis; ic
sclerosis;
miR-29b-1 Fibrosis including liver, lung, kidney and heart; Systemic sclerosis; s
including lung, liver, colon breast, chronic lymphocytic leukemia, acute myeloid
leukemia
miR-29b-2 is including liver, lung, kidney and heart; Systemic sclerosis; Cancers
including lung, liver, colon, breast, rhabdomyosarcoma, chronic lymphocytic
leukemia, acute myeloid leukemia;
miR-29c is including liver, lung, kidney and heart; Systemic sclerosis; Cancers
including lung, liver, rhabdomyosarcoma, chronic lymphocytic leukemia;
miR-34a Cancer including prostate, ovarian, non-small cell lung cancer, pancreatic
cancer, stomach cancer, retinoblastoma and chronic lymphocytic leukemia;
miR-34b Cancer including prostate, ovarian, non-small cell lung cancer, pancreatic
, stomach cancer, retinoblastoma and chronic lymphocytic leukemia;
miR-34c Cancer ing prostate, ovarian, non-small cell lung cancer, pancreatic
cancer, stomach , retinoblastoma and chronic lymphocytic leukemia;
miR-122 Cancer including liver, lung and cervical;
miR-146a Atherosclerosis
miR-203 Sensitize cancers with mutant p53 including colon cancer to chemotherapy
including taxanes
miR-214 Nerve regeneration; Diabetes including type 2;
miR-499 Myocardial infarction including the ischemia-reperfusion injury related to
reversing vessel occlusion;
It is now well established that post-transcriptional gene silencing (PTGS) by miRNA
and other ssociated pathways represents an essential layer of complexity to gene
regulation.Gene silencing using RNAi additionally trates huge potential as a
therapeutic strategy for eliminating gene sion associated with the pathology underlying
a number of different disorders.
A number of conventional miRNA compounds closely based on their endogenous
miRNA counterparts are in development as possible therapeutic agents. Cancer is one area of
focus since it has been found that several different miRNAs are expressed at very low levels
in cancer cells compared to their normal counterparts. Further, it has been shown that
ing these miRNAs can have profound anticancer effects. Several ic examples are
provided in the Table. Indices 2, 9, 11, 13, 15, 17, 19 and 80-95 provide a variety of different
seqMiR compounds, including potential anticancer agents that are based on the endogenous
miRNAs shown in Table 8 that should be useful for the treatment of the indicated conditions.
The miRNA mimics provided should also be effective in cell culture in vitro. In this
approach, the first strand can be transfected into the target cells following by subsequent
ection of the second strand after a certain time frame has elapsed. This method should
facilitate drug discovery efforts, target validation and also provide the means to reduce or
eliminate any undesirable off target effects.
ed ents from original figures
1. KEY TO STRAND MODIFICATIONS
Each of the possible strand modifications in a number of figures will be designated according
to the ing abbreviations as subscripts that follow the letter (A, T, U, C or G) indicating
the base being used or substituted for. When there are two modifications they will both be
indicated as subscripts.
BASES:
1) Abasic is 0
2) 2,6-Diaminopurine is 2
3) 2-thiouracil is 3
4) 4-thiouracil is 4
) 2-thiothymidine is 5
SUGARS:
1) ANA is B
2) DNA is D
3) FANA is H
4) 2’-Fluoro is F
) LNA is L (note TL can substitute for ULeven if the sequence is written with
6) 2’Methyl is M
7) Ribose is R
8) UNA is N
’-END TERMINAL MODIFICATIONS:
1) When the 5’ -end of the antisense strand is orylated a P precedes the
terminal nucleoside designation.
2) When the 5’-end of the sense strand is methylated a Yprecedes the terminal
nucleoside designation.
3’- END OVERHANG SORS:
An overhang precursor unit that is not used in hairpin formation is capital X
1) Phosphodiester is - - or no linkage indicated
2) Phosphorothioate is ~
3) Overhang precursor linkages of other types are a double colon ::
4) A missing linkage is &
2. ILLUSTRATIONS OF DESIGN OF seqMiR COMPOUNDS WITH NOVEL SEED
SEQUENCES
2A. Summary of Some of the Data from Ui-Tei et al., (2008)
4. Tm
3. Sequence with Seed Sequence
. Luc
2. Seed Calculated
1. siRNA ssio
Sequence Target Site that was Inserted into Seed
n at 5.0 nM
the Expression Vector Duplex
Designation
(5’-3’)
(5’-3’) (degrees
centigrade)
1. PLS3-1657 AUUAAAU UCGUGCUGAAAGUAUUUAAUUGA -10 0
2. CTLCAAUUUAU
ACUUGCUCGAGUCAUAAAUUAGA -10 <10
4819
3.Luc-309 UAUAAAU CCCUAAUAUUUAUAAUG -8 25
4. CLTCUAAUAUA
CACUUGCCACUCAUAUAUUAACC -6 20
3114
.GRK4-934 AUAUUCU AGGCAAGCGGCGAAGAAUAUUCU +3 0
6. VIM-1261 UUAGUUU CAUGUCAUUACACAAACUAAUCU +5 25
7.VIM-812 U CUAGGUGAAACUUAUAUGAAAGU +5 22
8.KIF23-430 CGUUUAG GAAUGCGCAACACCUAAACGAUA +12 50
9. OCT-821 UCUUUUG GCGGUUUCAAAAGAUCA +12 22
. TUBA2-
CAAAUCG CUAUGACCGGCACCGAUUUGACG +14 20
11. LUC-774 UUAAGAC UAGGAUGCCAUCGGUCUUAAUGU +15 22
12. -
AUUGGAU ACGUAUGAACUGGAUCCAAUAUG +20 35
2803
13. LUC2-
CGAAGUA AAGCGGUGCCAAGUACUUCGAAA +21 35
14. VIMAUUCACG
GAGGCAAAUGACGCGUGAAUACC +21 <10
1128
.MC4RAUGAUGA
CAUCCUCUGGUUUUCAUCAUAAG +22 >90
16.CCNCAUCAUGA
CUCUCGAUCAUGAUAGC +22 75
17.OCT-670 AUGCUAG UACCUACACUAAUCUAGCAUUGA +25 90
18. OCT-797 ACAGAAC GCUGAAGCUAGUAGUUCUGUAAC +26 45
19. VIM-270 UGAACUC AAGGAAGGGAGAGGAGUUCAAGA +26 85
. VIM-596 G CGUUACUCUCGGAGCAAUCUUUC +26 40
21. VIM-269 GAACUCG CAAUGAUGCACCAGGAGUUCAAG +27 90
-36 CUUCCAG CUUUGGAUGAAACCUGGAAGAUG +28 25
23. PLS3-
CCAUCUC GGUUAUCUCUUCCGAGAUGGUCA +31 60
1528
24. CLTCAGUCGAC
CCGAGCAAGUGGUGUCGACUUCC +33 85
2416
. PLS3-
ACUCCAG GCCAAUAUCGAUCCUGGAGUAAG +35 42
1310
26. VIM-805 UGCUGAC GGUGCCCAAGGAAGUCAGCAAUA +36 90
2B. Modifications to Seed Sequences
3. Examples of Modification(s)
1. Seed 2. Nuclease Resistance Rules 4. Estimated
to Seed ce to
Sequence Applied to Seed Sequence Tm
Increase Tm of Seed Duplex
(5’-3’) (5’-3’) Increase with
Target
(5’-3’)
Sequence
~AF~UFUM~ARARAFUM~(G) ~AF2~UFUM~ALARAFUL4~ +25
~AFAMUFUMUF~AMUF~(G) ~AFAMULUMUL~AMUL~ +20
AAUUUAU
~UF~AMUF~AMARAF~UM~(G) ~UF~ALUF~AMARLF~UM~ +15
UAUAAAU
~UF~ARAFUM~AFUM~AF(G) ~UF~ARALUM~ALUM~AL +20
UAAUAUA
~AFUF~AMUFUM~CMUF~(G) ~AFUL~AMULUM~CMUL~ +20
~UFUM~AFGRUMUFUM~(G) ~UFUM~AF2GLUMUFUL~ +20
~UFUM~CM~AFUM~AFUM~(G) ~UFUM~CL~AF2UM~ALUM~ +15
UUCAUAU
~CFGRUMUFUM~ARGF(G) ~CFGRUMULUM~ARGL~ +15
CGUUUAG
~UF~CMUFUMUFUM~GF(G) ~UF~CMULUMULUM~GL~ +20
UCUUUUG
~CF~ARARAMUF~CMGR(G) ~CF~AR2ARALUF~CMGL +20
CAAAUCG
~UFUM~ARARGRAFCM(G) ~UFUM~ALAR2GRALCM +15
UUAAGAC
F~GRGRAMUR~(G) ~AFULUF~GLGRAMUL~ +20
AUUGGAU
~CFGRARARGRUM~AF(G) ~CFGRALARGRUL~AF +15
CGAAGUA
~AFUMUF~CM~AFCMGF(G) ~AFUMUL~CM~AFCMGL +15
AUUCACG
~AFUM~GRAFUM~GRAF(G) ~AFUM~GRAFUM~GRAF +15
AUGAUGA
~AFUMCF~ARUM~GFAM(G) ~AFUMCL~ARUM~GFAL +15
AUCAUGA
~AFUM~GRCRUM~ARGR(G) ~AFUM~GLCRUM~ALGR +15
AUGCUAG
~AFCM~ARGRARAFCM(G) ~AFCL~ARGRALAFCL +20
ACAGAAC
~UF~GRARAF~CRUMCF(G) ALAFCRUMCL +15
~GFCRUFUMUFUM~GF(G) GFCRULUMULUM~GL +20
~GFARAMCRUM~CF~GR(G) ~GFARALCRUM~CFGL +15
GAACUCG
~CFUFUM~CF~CM~ARGR(G) ~CFULUM~CL~CM~ARGL +20
CUUCCAG
~CFCM~AFUM~CRUF~CM(G) ~CFCM~ALUM~CRUL~CM +15
CCAUCUC
~AFGRUM~CRGRAFCM(G) ~AFGLUM~CRGRALCM +15
AGUCGAC
~AF~CRUM~CF~CM~ARGR(G) M~CL~CM~ARGL +20
ACUCCAG
~UF~GRCRUM~GRAFCM(G) ~UF~GRCRUM~GLAFCM +10
UGCUGAC
2C. Modifications to Area of Sense Strand Corresponding to Seed Sequence
3. Examples of Modification(s) to
2. Nuclease Resistance Rules 4. Estimated Tm
1. Seed Corresponding Sense Strand
Applied to Sense Strand
Sequence Region to Reduce
Sequence Decrease with
Senses/Antisense Interstrand Tm Seed Sequence
(5’-3’)
(5’-3’) Partner
AF~UMUFUM~ARAM~UM~ ~GR~ARAF~UM~ -15
AUUAAAU
AMUF~ARARAMUFUM~ AMUF~AMCMCMGRUM -15
AAUUUAU
AF~UMUMUF~AMUF~AM~ AFGRUM~GRARGF~AM -15
UAUAAAU
UM~AFUM~AFUMUF~AM~ UM~GFUM~GFUM~GFAM~ -20
UAAUAUA
AMGRARAFUM~AFUM~ AMGRAFCMUF~CM~AM~ -20
AUAUUCU
AFARAFCMUM~AFAM~ AFCMAFGRUM~AFAM~ -15
UUAGUUU
AFUM~AFUM~GFAFAM~ AFUM~AFUM~CRUF~AM~ -15
UUCAUAU
CMUM~AFARAMCFGM~ GMUM~AF~CR~AMCFGM~ -15
CGUUUAG
RARARGRAM~ GRARARAFUMUF~AM~ -20
UCUUUUG
CMGRAMUFUMUF~GM~ UGUMUF~GM~ -20
CAAAUCG
GFUM~CRUFUM~AFAM~ GFAM~CRUF~AM~AFAM~ -15
UUAAGAC
AMUF~CM~CF~ARAFUM~ TDUF~GMCF~ARTDUM~ -20
AUUGGAU
UM~AF~CFUMUF~CMGM~ UM~TD~CFUMGF~CMGM~ -15
CMGFUM~GFARAFUM~ GMGFUM~GFCRAFUM~ -15
AUUCACG
UMCM~AFUMCM~AFUM~ UMCM~TDUMCM~TDUM~ -15
AUGAUGA
UFCM~AFUM~GRAFUM~ FUM~CM~AFUM~ -15
AUCAUGA
CMUM~AFGFCM~AFUM~ CMGR~AFGFGR~AFUM~ -15
AUGCUAG
GRUMUMCRUM~GRUM~ CRUM~GRCRUM~CRUM~ -20
ACAGAAC
UMUMCF~AM~ UM~ARGRUM~GFCM~AF~ -15
UGAACUC
CM~ARARARARGRCM~ GRAFTD~ARTD~GRCM~ -20
GCUUUUG
CMGMAFGRUFUM~CM~ GRGMAFGRAFUM~CM~ -15
GAACUCG
CRUM~GRGRARARGM~ CM~ARGRCM~AFCMGM~ -20
CUUCCAG
GFAMGFAMUM~GFGM~ GFCMGFAMAMGFGM~ -15
CCAUCUC
MGRAF~CRUM~ GFAMCMGRAFGRUM~ -15
AGUCGAC
CMUM~GFGRARGRUM~ GRUM~GFCMARCMUM~ -20
ACUCCAG
M~AFGRCM~AM~ GFUM~GRAFGRCM~AM~ -10
UGCUGAC
2D. Examples of Possible Duplex Vehicles for the Seed Sequences and
Corresponding Sense Sequences
NEGATIVE CONTROL DUPLEX #1SELECTED FOR USE AS A DUPLEX VEHICLE
Sense strand (UU 3’-end overhang in parent compound is not retained):
UF~GMUM~ARUF~GRCMGRAMUM~C?G- -C- -A- -G- -A- -C- -U~AM
Antisense strand (UU 3’-end overhang in parent nd is ed):
UF~A- -G- -U- -C- -U- -G- -C?GRAF~UF~CMGFCM~AMUF~AF~CF~AM~UF~UM
NEGATIVE CONTROL DUPLEX #1 MODIFIED TO BLOCK ANTISENSE STRAND AGO-2
CATALYTIC ACTIVITY
Antisense :
UF~A- -G- -U- -C- -U- -G- -C?GRAF~U0D~CMGFCM~AMUF~AF~CF~AM~UF~UM
NEGATIVE CONTROL DUPLEX #2 SELECTED FOR USE AS A DUPLEX VEHICLE
Sense strand (5’ al nucleoside [C] in parent is removed):
GF~UM~GRAFCM~AFCMGRUMUF~C?G- -G- -A- -G- -A- -A- -U~UM
Antisense strand (3’ terminal nucleoside [G] in parent is removed and two unit overhang precursor
added):
AF~A- -U- -U- -C- -U- -C- -C?GRARAFCMGRUM~GRUM~CM~AF~CM:X:X
NEGATIVE CONTROL DUPLEX #2 MODIFIED TO BLOCK ANTISENSE STRAND AGO-2
CATALYTIC ACTIVITY
Antisense strand:
AF~A- -U- -U- -C- -U- -C- -C?GRAR~A0D~CMGRUM~GRUM~CM~AF~CM:X:X
siRNA DIRECTED TO HUMAN AND MOUSE APO-B
Sense strand (parent has no overhang):
CM~AMUF~CM~AFCM~AF~CRUM~GFA?A- -U- -A- -C- -C- -A- -A~UM
Antisense strand (parent has ~A~C 3’-end ng that is replaced by a unit overhang precursor):
AF~U- -U- -G- -G- -U- -A- -U?UF~CM~AFGRUM~GRUM~GRAMUF~GRAF~CM:X:X
siRNA DIRECTED TO HUMAN AND MOUSE APO-B MODIFIED TO BLOCK ANTISENSE
STRAND AGO-2 CATALYTIC ACTIVITY
Antisense strand:
AF~U- -U- -G- -G- -U- -A- -U?UF~CM~A0D~GRUM~GRUM~GRAMUF~GRAF~CM:X:X
2E. Example ofSelf-Dimer Forming Antisense Strand
Unmodified:
5’ AUGAUAUCCAAUAUU 3’
3’ UUAUAACCUAUAGUAGGUUAU 5’
Calculated dominant hairpin duplex:
’ UAUUGGA 3’
3’ AUAACCU 5’
Calculated dominant hairpin unpaired loop:
’ UGAUA 3’
Modified according to essential/preferred ectural-independent rules and for prevention
of ARO-2 catalytic activity against the target:
’PUM~AF~UFUM~GRGRAM~UF~GM~A0D~U0D~AMUF~CM~CM~ARAMUM~AF~UF~UM 3’
Further modified for increased seed duplex affinity for :
’ PUM~AF~UFUM~GLGRAM~UL~GM~A0D~U0D~AMUF~CM~AMARAMUM~AF~UF~UM 3’
2F. Examples of Possible Modifications to the Seed Sequence found in Multiple Let-7
Family Members and the Corresponding Sense Strand Sequence
Let-7 family seed sequence: GAGGUAG
Let-7 family seed sequence ed for nuclease resistance: GRARGRGRUM~ARGR
Sense strand sequence corresponding to let-7 family seed sequence: CUACCUC
Sense strand sequence corresponding to let-7 family seed sequence modified for nuclease
ance: CRUM~AFCMCRUM~CR
Examples of Modifications to let-7 Seed Sequence
Examples of Modification(s)
to Seed ce to Estimated Tm
Increase Tm of Seed Duplex Increase with
Target
(5’-3’) Sequence
GRALGRGRUL~ARGL +25
GRARGLGRUM~ARGL +15
GRA2GRGLUM~A2GR +15
GRARGRGLUM~ARGR +10
GRARGRGRUL3~ARGR +15
Examples of Modifications to Area of Sense Strand Corresponding to Seed Sequence
Examples of cation(s) to
Estimated Tm
Corresponding Sense Strand
Region to Reduce Decrease with
Senses/Antisense Interstrand Tm Seed Sequence
Partner
(5’-3’)
GRUMTDCM~CR~AM~CR -20
GRUM~AFCMGRUM~CR -15
CM~AMAFGMCRUM~CR -15
CF~CM~CRUM~CR -10
CRUM~AFCN~CRUM~CR -10
Note: the 3’-end C has been converted to a mismatch in section G. in accordance with the
try rule. This will further reduce the estimated Tm by about -5 degrees.
2G. Examples of Let-7 Seed Sequence and Corresponding Sense Stand Sequence
Inserted into a Duplex Vehicle
Duplex #1
Sense strand:
GF~UM~CM~AMUF~CM~AFCM~AF~CRUM~GFARGRUMTDCM~CR~AM~AR~UM
Antisense strand:
AF~GRALGRGRUL~ARGLUF~CM~AFGRUM~GRUM~GRAMUF~GRAF~CM:X:X
Antisense strand (AGO-2 catalytic activity inhibited):
AF~GRALGRGRUL~ARGLUF~CM~AD0~GRUM~GRUM~GRAMUF~GRAF~CM:X:X
Antisense strand (AGO-2 catalytic activity inhibited):
AF~GRALGRGRUL~ARGLUF~CMANGRUM~GRUM~GRAMUF~GRAF~CM:X:X
Duplex #2
Sense strand:
GF~UM~CM~AMUF~CM~AFCM~AF~CRUM~GFARGRUM~AFCMGRUM~GR~UM
Antisense :
AF~GRARGLGRUM~ARGLUF~CM~AFGRUM~GRUM~GRAMUF~GRAF~CM:X:X
nse strand (AGO-2 catalytic activity inhibited):
AF~GRARGLGRUM~ARGLUF~CM~A0~GRUM~GRUM~GRAMUF~GRAF~CM:X:X
Antisense strand (AGO-2 catalytic activity inhibited):
AF~GRARGLGRUM~ARGLUF~CMANGRUM~GRUM~GRAMUF~GRAF~CM:X:X
Duplex #3
Sense strand:
GF~UM~CM~AMUF~CM~AFCM~AF~CRUM~GFAFCM~AMAFGMCRUM~AR~UM
Antisense :
AF~GRAR2GRGLUM~AR2GRUF~CM~AFGRUM~GRUM~GRAMUF~GRAF~CM:X:X
Antisense strand (AGO-2 catalytic activity inhibited):
AF~GRAR2GRGLUM~AR2GRUF~CM~AD0~GRUM~GRUM~GRAMUF~GRAF~CM:X:X
nse strand (AGO-2 catalytic activity inhibited):
AF~GRAR2GRGLUM~AR2GRUF~CMANGRUM~GRUM~GRAMUF~GRAF~CM:X:X
Duplex #4
Sense strand:
GF~UM~CM~AMUF~CM~AFCM~AF~CRUM~GFAMCR~CM~CF~CM~CRUM~GR~UM
Antisense strand:
AF~GRARGRGLUM~ARGRUF~CM~AFGRUM~GRUM~GRAMUF~GRAF~CM:X:X
Antisense strand (AGO-2 catalytic activity inhibited):
AF~GRARGRGLUM~ARGRUF~CM~AD0~GRUM~GRUM~GRAMUF~GRAF~CM:X:X
Antisense strand (AGO-2 catalytic activity inhibited):
AF~GRARGRGLUM~ARGRUF~CMANGRUM~GRUM~GRAMUF~GRAF~CM:X:X
Duplex #5
Sense strand:
GF~UM~CM~AMUF~CM~AFCM~AF~CRUM~GFAMCRUM~AFCNCRUM~AR~UM
Antisense :
AF~GRARGRGRUL3~ARGRUF~CM~AFGRUM~GRUM~GRAMUF~GRAF~CM:X:X
Antisense strand (AGO-2 catalytic activity inhibited):
AF~GRARGRGRUL3~ARGRUF~CM~A0~GRUM~GRUM~GRAMUF~GRAF~CM:X:X
Antisense strand (AGO-2 catalytic activity inhibited):
AF~GRARGRGRUL3~ARGRUF~CMANGRUM~GRUM~GRAMUF~GRAF~CM:X:X
2H. Examples of Let-7 Seed Sequence and Corresponding Sense Stand ce
Inserted into the Same Strand to Generate Dimer Forming Single Strands
Group #1
Antisense strand:
PAF~GRALGRGRUL~ARGLUF~CM~AFGRUM~ARGRUMTDCM~CR~AM~CR~UM:X:X
Antisense strand (AGO-2 catalytic activity inhibited):
PAF~GRALGRGRUL~ARGLUF~CM~AD0~GRUM~ARGRUMTDCM~CR~AM~CR~UM:X:X
nse strand (AGO-2 catalytic activity inhibited):
PAF~GRALGRGRUL~ARGLUF~CMANGRUM~ARGRUMTDCM~CR~AM~CR~UM:X:X
Group #2
Antisense strand:
PAF~GRARGLGRUM~ARGLUF~CM~AFGRUM~GRUM~AFCMGRUM~CR~UM:X:X
Antisense strand (AGO-2 catalytic ty inhibited):
PAF~GRARGLGRUM~ARGLUF~CM~A0~GRUM~GRUM~AFCMGRUM~CR~UM:X:X
Antisense strand (AGO-2 catalytic activity inhibited):
PAF~GRARGLGRUM~ARGLUF~CMANGRUM~GRUM~AFCMGRUM~CR~UM:X:X
Group #3
Antisense strand:
PAF~GRA2GRGLUM~A2GRUF~CM~AFGRUM~CM~AMAFGMCRUM~CR~UM:X:X
Antisense strand (AGO-2 catalytic activity inhibited):
PAF~GRA2GRGLUM~A2GRUF~CM~AD0~GRUM~CM~AMAFGMCRUM~CR~UM:X:X
Antisense strand (AGO-2 catalytic activity inhibited):
PAF~GRA2GRGLUM~A2GRUF~CMANGRUM~CM~AMAFGMCRUM~CR~UM:X:X
Group #4
Antisense strand:
PAF~GRARGRGLUM~ARGRUF~CM~AFGRUM~CR~CM~CF~CM~CRUM~CR~UM:X:X
Antisense strand (AGO-2 catalytic activity inhibited):
PAF~GRARGRGLUM~ARGRUF~CM~AD0~GRUM~CR~CM~CF~CM~CRUM~CR~UM:X:X
Antisense strand (AGO-2 catalytic activity inhibited):
PAF~GRARGRGLUM~ARGRUF~CMANGRUM~CR~CM~CF~CM~CRUM~CR~UM:X:X
Group #5
Antisense strand:
PAF~GRARGRGRUL3~ARGRUF~CM~AFGRUM~CRUM~AFCNCRUM~CR~UM:X:X
Antisense strand (AGO-2 tic activity ted):
PAF~GRARGRGRUL3~ARGRUF~CM~A0~GRUM~CRUM~AFCNCRUM~CR~UM:X:X
Antisense strand (AGO-2 catalytic activity inhibited):
PAF~GRARGRGRUL3~ARGRUF~CMANGRUM~CRUM~AFCNCRUM~CR~UM:X:X
3. UNMODIFIED STRANDS COMPRISING A siRNA COMPOUND DIRECTED
TO MOUSE PTEN
Sense strand:
’ CAGCUAGAACUUA 3’
Antisense strand:
’ UAAGUUCUAGCUGUGGUGG 3’
4. UNMODIFIED STRANDS COMPRISING HUMAN/MOUSE Let-7i
‘Iva?“ ‘4’?!”thgwm L§‘§’ &¥;Mx&wv* ~ I m: TI Wham?
gagmmaéawgsgxgmg
Sense :
’ CUGCGCAAGCUACUGCCUUGCU 3’
Antisense strand:
’ UGAGGUAGUAGUUUGUGCUGUU 3’
. STRANDS COMPRISING HUMAN/MOUSE Let-7i WITH REMOVAL OF
WOBBLE BASE PAIRSAND MISMATCH
v Sense strand (removed wobble base pairings):
’ AAACUACUACCUCACU 3’
Sense strand (removed wobble base pairings and mismatch):
’ CAGCACAAACUACUACCUCACU 3 ’
Antisense strand:
» 5’ UGAGGUAGUAGUUUGUGCUGUU 3’
6. APPLICATION OF NUCLEASE RESISTANCE AND ESSENTIAL/PREFERRED
ECTURAL INDEPENDENT RULES TO STRANDS ILLUSTRATING THE
INITIAL STEPS IN THE DESIGN OF A seqsiRNA SET DIRECTED TO MOUSE
PTEN
Sense strand:
’ CF~CM~AFCM~CM~AFCM~ARGRCRUM~ARGRARAF~CRUM~UF~AM 3’
Antisense strand:
’ UF~AM~AR~GRUMUF~CRUM~ARGRCRUM~GRUM~GRGRUM~GF~GM 3’
7. APPLICATION OF NUCLEASE RESISTANCE AND
ESSENTIAL/PREFERRED ECTURAL INDEPENDENT RULES TO
STRANDS ILLUSTRATING AN EARLY STEP IN THE DESIGN OF A seqMiR
SET BASED ON HUMAN/MOUSE Let-7i
Sense strand:
’ CF~UM~GRCMGRCM~ARARGRCRUM~AF~CRUM~GRCM~CRUMUF~GF~CF~UM 3’
Sense strand (removed wobble base pairings and mismatch):
’ CF~AMGRCM~AFCM~ARARAF~CRUM~AF~CRUM~AFCM~CMUF~CM~AF~CF~UM
Antisense :
’ RGRGRUM~ARGRUM~ARGRURURUM~GRUM~GRCRUF~GM~UF~UM 3’
8. APPLICATION OF THERMODYNAMIC RULES TO NUCLEASE
RESISTANT STRANDS ILLUSTRATING A PREFERRED STEPS IN THE DESIG
Sense strand:
’ CF~CM~AFCM~CM~AFCM~ARGRCRUM~ARGRARAF~CRUM~UF~AM 3’
Sense strand sequence of ed regions 1-3 from Table 3 lined):
’ CCACCUAUUA 3’
Combined intervening sense strand sequence:
’ CCAAGGAAC 3’
Antisense strand:
’ UF~AM~AR~GRUMUF~CRUM~ARGRCRUM~GRUM~GRGRUM~GF~GM 3
Four nucleoside terminus with 5’-end sense strand:
’ CCAC 3’
3’ GGUG 5’
Four nucleoside terminus with 5’-end antisense strand:
’ UAAG3’
3’ AUUC 5’
Adjusted sense strand:
No adjustments required
9. APPLICATION OF THERMODYNAMIC RULES TO NUCLEASE
RESISTANT STRANDS ILLUSTRATING PREFERRED STEPS IN THE DESIGN
OF A seqMiR SET BASED ON HUMAN/MOUSE Let-7i
Sense strand:
’ CF~UM~GRCMGRCM~ARARGRCRUM~AF~CRUM~GRCM~CRUMUF~GM 3’
Sense strand ed wobble base pairings and mismatch):
’ CF~AMGRCM~AFCM~ARARAF~CRUM~AF~CRUM~AFCM~CMUF~CM~AM 3’
Sense strand sequence of combined regions 1-3 from Table 3 (underlined):
’ CACAUACUCA 3’
Combined intervening sense strand sequence:
5’ CAGAACUACC 3’
Antisense strand:
’ UF~GRARGRGRUM~ARGRUM~ARGRURURUM~GRUM~GRCRUF~GM 3’
Four nucleoside terminus with 5’-end sense strand:
5’ CF~AMGRCM 3’
3’ GM~UFCRGR 5’
Four nucleoside terminus with 5’-end antisense strand:
’ UM~GRARGR3’
3’ UFCM 5’
Adjusted sense strand with mismatch introduced:
’ CF~AMGRCM~AFCM~ARARAF~CRUM~AF~CRUM~AFCM~CMUF~GM~AM 3’
. ATION OF CANONICAL ECTURAL-DEPENDENT ALG
Sense strand variants:
’ CF~CM~AFCM~CM~AFCM~ARGRCRUM~ARGRARAF~CRUM~UF~AM:X:X 3’
’ CF~CM~AFCM~CM~AFCM~ARGRGRUM~ARGRARAF~CRUM~UF~AM:X:X 3’
’ CF~CM~AFCM~CM~AFCM~ARGR~CDo~UM~ARGRARAF~CRUM~UF~AM:X:X 3’
’ CF~CM~AFCM~CM~AFCM~ARGRCNUM~ARGRARAF~CRUM~UF~AM:X:X 3’
’ CF~CM~AFCM~GM~AFCM~ARGRGRUM~ARGRARAF~CRUM~UF~AM:X:X 3’
’ AFCM~GM~AFCM~ARGR~CDo~UM~ARGRARAF~CRUM~UF~AM:X:X 3’
’ CF~CM~AFCM~GM~AFCM~ARGRCNUM~ARGRARAF~CRUM~UF~AM:X:X 3’
Antisense strand variants:
’ UF~AM~AR~GRUMUF~CRUM~ARGRCRUM~GRUM~GRGRUM~GF~GM:X:X3
’ UF~AR~AR~GRUMUN~CRUM~ARGRCRUM~GRUM~GRGRUM~GF~GM:X:X 3
’ UF~AM~AR~GRUMUN~CRUM~ARGRCRUM~GRUM~GRGRUM~GF~GM:X:X 3
11. APPLICATION OF CANONICAL ARCHITECTURAL-DEPENDENT ALGORITH
Duplex #1
Sense strand (overall Tm of duplex reduced):
’ CF~AMGRCM~AFGM~ARARAF~CR~UD0~AF~CRUM~AFCM~CMUF~GM~AF:X:X 3’
Antisense strand:
’ UM~GRARGRGRUM~ARGRUM~ARGRURURUM~GRUM~GRCRUF~GM:X:X 3’
Duplex #2
Sense strand:
5’ CF~AMGRCM~AFCM~ARARAF~CRUM~AF~CRUM~AFCM~CMUF~GM~AF:X:X 3’
Antisense strand (AGO-2 catalytic activity against mRNA inhibited):
’ UM~GRARGRGRUM~ARGRUM~AR~GD0~URURUM~GRUM~GRCRUF~GM:X:X 3’
12. APPLICATION OF ASYMMETRIC ARCHITECTURAL-DEPENDENT ALGORITH
Form with 5’ and 3’ overhang precursors in antisense strand
Sense strand variants:
’ CF~CM~AFCM~CM~AFCM~ARGRCRUM~ARGRAR~AF~CM 3’
’ CF~CM~AFCM~CM~AFCM~ARGRGRUM~ARGRAR~AF~CM 3’
’ CF~CM~AFCM~CM~AFCM~ARGR~CDo~UM~ARGRAR~AF~CM 3’
’ CF~CM~AFCM~CM~AFCM~ARGRCNUM~ARGRAR~AF~CM 3’
5’ CF~CM~AFCM~GM~AFCM~ARGRGRUM~ARGRAR~AF~CM 3’
’ AFCM~GM~AFCM~ARGR~CDo~UM~ARGRAR~AF~CM 3’
’ CF~CM~AFCM~GM~AFCM~ARGRCNUM~ARGRAR~AF~CM 3’
Antisense strand variants:
’ UF~AM~AR~GRUMUF~CRUM~ARGRCRUM~GRUM~GRGRUM~GF~GM:X:X 3’
5’ UF~AM~AR~GRUMUF~CRUM~ARGRCRUM~GRUM~GRGRUM~GF~GM3’
’ UF~AR~AR~GRUMUN~CRUM~ARGRCRUM~GRUM~GRGRUM~GF~GM:X:X 3’
’ UF~AR~AR~GRUMUN~CRUM~ARGRCRUM~GRUM~GRGRUM~GF~GM3’
’ UF~AM~AR~GRUMUN~CRUM~ARGRCRUM~GRUM~GRGRUM~GF~GM:X:X 3’
’ UF~AM~AR~GRUMUN~CRUM~ARGRCRUM~GRUM~GRGRUM~GF~GM3’
Form with 3’ overhang sors in antisense strand
Sense strand variants:
’ CF~CM~AFCM~CM~AFCM~ARGRCRUM~ARGRARAF~CRUM~UF~AM 3’
’ CF~CM~AFCM~CM~AFCM~ARGRGRUM~ARGRARAF~CRUM~UF~AM 3’
’ CF~CM~AFCM~CM~AFCM~ARGR~CDo~UM~ARGRARAF~CRUM~UF~AM 3’
5’ CF~CM~AFCM~CM~AFCM~ARGRCNUM~ARGRARAF~CRUM~UF~AM3’
’ CF~CM~AFCM~GM~AFCM~ARGRGRUM~ARGRARAF~CRUM~UF~AM 3’
’ CF~CM~AFCM~GM~AFCM~ARGR~CDo~UM~ARGRARAF~CRUM~UF~AM 3’
’ CF~CM~AFCM~GM~AFCM~ARGRCNUM~ARGRARAF~CRUM~UF~AM 3’
Antisense strand ts:
’ UF~AM~AR~GRUMUF~CRUM~ARGRCRUM~GRUM~GRGRUM~GF~GM:X:X 3’
’ UF~AM~AR~GRUMUF~CRUM~ARGRCRUM~GRUM~GRGRUM~GF~GM3’
’ UF~AR~AR~GRUMUN~CRUM~ARGRCRUM~GRUM~GRGRUM~GF~GM:X:X 3’
’ UF~AR~AR~GRUMUN~CRUM~ARGRCRUM~GRUM~GRGRUM~GF~GM3’
5’ UF~AM~AR~GRUMUN~CRUM~ARGRCRUM~GRUM~GRGRUM~GF~GM:X:X 3’
’ AR~GRUMUN~CRUM~ARGRCRUM~GRUM~GRGRUM~GF~GM3’
13. APPLICATION OF ASYMMETRIC ARCHITECTURAL-DEPENDENT ALGORITH
Duplex #1
Sense strand (overall Tm of duplex reduced):
’ CF~AMGRCM~AFGM~ARARAF~CR~UD0~AF~CRUM~AF~CM~CM 3’
Antisense strand:
’ UM~GRARGRGRUM~ARGRUM~ARGRURURUM~GRUM~GRCRUF~GM:X:X 3’
5’ UM~GRARGRGRUM~ARGRUM~ARGRURURUM~GRUM~GRCR~UF~GM 3’
Duplex #2
Sense strand:
’ RCM~AFCM~ARARAF~CRUM~AF~CRUM~AF~CM~CM 3’
nse strand (AGO-2 catalytic activity against mRNA inhibited):
’ UM~GRARGRGRUM~ARGRUM~AR~GD0~URURUM~GRUM~GRCRUF~GM:X:X 3’
’ UM~GRARGRGRUM~ARGRUM~AR~GD0~URURUM~GRUM~GRCR~UF~GM 3’
Duplex #3
Sense strand:
5’ CF~AMGRCM~AFCM~ARARAF~CRUM~AF~CRUM~AF~CM~CM 3’
Antisense strand:
’ UM~GRARGRGRUM~ARGRUM~ARGRURURUM~GRUM~GRCRUF~GM:X:X 3’
’ UM~GRARGRGRUM~ARGRUM~ARGRURURUM~GRUM~GRCR~UF~GM 3’
14. APPLICATION OF FORKED-VARIANT ARCHITECTURALDEPENDENT
ALGORITHM TO CANONICAL ARCHITECTURE STRANDS ILLUSTRAT
Sense strand variants:
’ AFCM~CM~AFCM~ARGRCRUM~ARGRCMAF~GRUM~UF~AM:X:X 3’
’ CF~CM~AFCM~CM~AFCM~ARGRGRUM~ARGRCMAF~GRUM~UF~AM:X:X 3’
’ AFCM~CM~AFCM~ARGR~CDo~UM~ARGRCMAF~GRUM~UF~AM:X:X 3’
5’ CF~CM~AFCM~CM~AFCM~ARGRCNUM~ARGRCMAF~GRUM~UF~AM:X:X 3’
’ CF~CM~AFCM~GM~AFCM~ARGRGRUM~ARGRCMAF~GRUM~UF~AM:X:X 3’
’ CF~CM~AFCM~GM~AFCM~ARGR~CDo~UM~ARGRCMAF~GRUM~UF~AM:X:X 3’
’ CF~CM~AFCM~GM~AFCM~ARGRCNUM~ARGRCMAF~GRUM~UF~AM:X:X 3’
Antisense strand variants:
’ UF~AM~AR~GRUMUF~CRUM~ARGRCRUM~GRUM~GRGRUM~GF~GM:X:X 3’
’ UF~AR~AR~GRUMUN~CRUM~ARGRCRUM~GRUM~GRGRUM~GF~GM:X:X 3’
’ UF~AM~AR~GRUMUN~CRUM~ARGRCRUM~GRUM~GRGRUM~GF~GM:X:X 3’
. APPLICATION OF FORKED-VARIANT ARCHITECTURALDEPENDENT
ALGORITHM TO CANONICAL ARCHITECTURE STRANDS ILLUSTRAT
Duplex #1
Sense strand (overall Tm of duplex reduced):
’ CF~AMGRCM~AFGM~ARARAF~CR~UD0~AF~CRUM~AFCM~GMUF~GM~AF:X:X 3’
Antisense strand:
’ UM~GRARGRGRUM~ARGRUM~ARGRURURUM~GRUM~GRCRUF~GM:X:X 3’
Duplex #2
Sense strand:
’ CF~AMGRCM~AFCM~ARARAF~CRUM~AF~CRUM~AFCM~GMUF~GM~AF:X:X 3’
Antisense strand (AGO-2 catalytic activity against mRNA inhibited):
’ UM~GRARGRGRUM~ARGRUM~AR~GD0~URURUM~GRUM~GRCRUF~GM:X:X 3’
16. APPLICATION OF SMALL INTERNALLY SEGMENTED
ARCHITECTURAL-DEPENDENT ALGORITHM ILLUSTRATING A STEP
IN THE DESIGN OF A seqsiRNA SET DIRECTED TO MOUSE PTEN
Sense :
5’ CF~CM~AFCM~CM~AFCM~AF~GM&CF~UM~ARGLARAF~CLUM~UF~AM:X:X 3’
’ CF~CM~AFCM~CM~AFCM~AF~GM&CF~UM~ARGLARAF~CLUM~UF~AM 3’
Antisense strand variants:
’ UF~AM~AR~GRUMUF~CRUM~ARGRCRUM~GRUM~GRGRUM~GF~GM:X:X 3
’ UF~AR~AR~GRUMUN~CRUM~ARGRCRUM~GRUM~GRGRUM~GF~GM:X:X 3
5’ UF~AM~AR~GRUMUN~CRUM~ARGRCRUM~GRUM~GRGRUM~GF~GM:X:X 3
17. APPLICATION OF SMALL INTERNALLY TED
ECTURAL-DEPENDENT ALGORITHM ILLUSTRATING A STEP
IN THE DESIGN OF A seqMiR SET BASED ON HUMAN/MOUSE Let-7i
Duplex #1 (Dual Sense Strands)
Sense strand:
’ CF~AMGLCM~AFCM~ARAL~AF~CM&UM~AF~CRUM~AFCL~CMUF~CM~AM 3’
Antisense strand:
’ UF~GRARGRGRUM~ARGRUM~ARGRURURUM~GRUM~GRCRUF~GM:X:X 3’
Duplex #2 (Dual Sense Strands)
Sense strand:
5’ CF~AMGLCM~AFCM~ARAL~AF~CM&UM~AF~CRUM~AFCL~CMUF~CM~AM 3’
Antisense strand (AGO-2 catalytic activity against mRNA inhibited):
’ UF~GRARGRGRUM~ARGRUM~AR~GD0~URURUM~GRUM~GRCRUF~GM:X:X 3’
Duplex #3 (Dual Antisense Strands)
Sense :
’ CF~AMGLCM~AFCM~ARALAF~CRUF~AFCRUM~AFCL~CMUF~CM~AM 3’
Antisense strand:
5’ UF~GRARGRGRUM~ARGR~UM~AM&GF~URURUM~GRUM~GRCRUF~GM:X:X 3’
ATION OF ss-RNAi ARCHITECTURAL-DEPENDENT ALGORITHM
TO AN ANTISENSE STRAND ILLUSTRATING A STEP IN THE DESIGN OF A A
DIRECTED TO MOUSE PTEN
’ PUF~AF~AR~GRUFUF~CRUF~ARGRCRUF~GRUF~GRGRUF~GF~GF:X:X 3
’ PUF~AM~AR~GRUFUN~CRUF~ARGRCRUF~GRUF~GRGRUF~GF~GF:X:X 3
’ ~AR~GRUFUN~CRUF~ARGRCRUF~GRUF~GRGRUF~GF~GF:X:X 3
APPLICATION OF ss-RNAi ARCHITECTURAL-DEPENDENT ALGORITHM TO
AN ANTISENSE STRAND ILLUSTRATING A STEP IN THE DESIGN OF A ss-MiR
BASED ON HUMAN/MOUSE Let-7i
Antisense strand:
’ PUF~GRARGRGRUF~ARGRUF~ARGRURURUF~GRUF~GRCRUF~GF:X:X 3’
nse strand (AGO-2 catalytic activity against mRNA inhibited):
5’ ARGRGRUF~ARGRUF~AR~GD0~URURUF~GRUF~GRCRUF~GF:X:X 3’
Antisense strand (binding affinity for mRNA targets is increased):
’ PUF~GRARGLGRUF~ARGRUF~ARGRURURUF~GRUF~GRCRUF~GF:X:X 3’
Antisense strand (AGO-2 catalytic activity against mRNA inhibited and binding affinity
for mRNA s isincreased):
’ PUF~GRARGLGRUF~ARGRUF~AR~GD0~URURUF~GRUF~GRCRUF~GF:X:X 3’
Antisense strand (binding affinity for mRNA targets is further increased):
’ PUF~GRALGRGRUF~ALGRUF~ARGRURURUF~GRUF~GRCRUF~GF:X:X 3’
Antisense strand (AGO-2 catalytic activity against mRNA inhibited and binding affinity
for mRNA targets is further increased):
’ PUF~GRALGRGRUF~ALGRUF~AR~GD0~URURUF~GRUF~GRCRUF~GF:X:X 3’
. seqsiRNA COMPOUNDS DIRECTED TO MOUSE APO-B
FOR SEQUENTIAL ION OF RNAi ACTIVITY
Canonical architecture
Sense:
’ CF~AMARGRUM~GRUM~CF~ARUF~CM~AF~CM~AF~CRUM~GR~AF~AM:X:X 3’
5’ CF~AMARGRUM~CRUM~CF~ARUF~CM~AF~CM~AF~CRUM~GR~AF~AM:X:X 3’
’ CF~AMARGRUM~GNUM~CF~ARUF~CM~AF~CM~AF~CRUM~GR~AF~AM:X:X 3’
’ CF~AMARGRUM~GRUM~CF~AR~UD0~CM~AF~CM~AF~CRUM~GR~AF~AM:X:X 3’
’ RGRUM~CRUM~CF~AR~UD0~CM~AF~CM~AF~CRUM~GR~AF~AM:X:X 3’
’ CF~AMARGRUM~GNUM~CF~AR~UD0~CM~AF~CM~AF~CRUM~GR~AF~AM:X:X 3’
5’ CF~AMARGRUM~GRUM~CF~ARUN~CM~AF~CM~AF~CRUM~GR~AF~AM:X:X 3’
’ CF~AMARGRUM~CRUM~CF~ARUN~CM~AF~CM~AF~CRUM~GR~AF~AM:X:X 3’
’ CF~AMARGRUM~GNUM~CF~ARUN~CM~AF~CM~AF~CRUM~GR~AF~AM:X:X 3’
Antisense:
’ UF~UM~CF~ARGRUM~GRUM~GRARUF~GRAF~CM~AF~CRUM~UF~GM:X:X 3’
’ UF~UM~CF~ARGRUM~GRUM~GRARUR~GRAF~CM~AF~CRUM~UF~GM:X:X 3’
’ UF~UM~CF~ARGRUM~GRUMGFARUMGFAF~CM~AF~CRUM~UF~GM:X:X 3’
end architecture
Sense:
’ CF~AMARGRUM~GRUM~CF~ARUF~CM~AF~CM~AF~CRUM~GR~AF~AM 3’
’ CF~AMARGRUM~CRUM~CF~ARUF~CM~AF~CM~AF~CRUM~GR~AF~AM 3’
5’ CF~AMARGRUM~GNUM~CF~ARUF~CM~AF~CM~AF~CRUM~GR~AF~AM 3’
’ CF~AMARGRUM~GRUM~CF~AR~UD0~CM~AF~CM~AF~CRUM~GR~AF~AM 3’
’ CF~AMARGRUM~CRUM~CF~AR~UD0~CM~AF~CM~AF~CRUM~GR~AF~AM 3’
’ CF~AMARGRUM~GNUM~CF~AR~UD0~CM~AF~CM~AF~CRUM~GR~AF~AM 3’
’ CF~AMARGRUM~GRUM~CF~ARUN~CM~AF~CM~AF~CRUM~GR~AF~AM 3’
5’ CF~AMARGRUM~CRUM~CF~ARUN~CM~AF~CM~AF~CRUM~GR~AF~AM 3’
’ CF~AMARGRUM~GNUM~CF~ARUN~CM~AF~CM~AF~CRUM~GR~AF~AM 3’
Antisense:
’ UF~UM~CF~ARGRUM~GRUM~GRARUF~GRAF~CM~AF~CRUM~UF~GM 3’
’ UF~UM~CF~ARGRUM~GRUM~GRARUR~GRAF~CM~AF~CRUM~UF~GM 3’
5’ UF~UM~CF~ARGRUM~GRUMGFARUMGFAF~CM~AF~CRUM~UF~GM 3’
Asymmetric architecture
Sense:
’ CF~AMARGRUM~GRUM~CF~ARUF~CM~AF~CM~AF~CRUM~GR~AF~AM 3’
’ CF~AMARGRUM~CRUM~CF~ARUF~CM~AF~CM~AF~CRUM~GR~AF~AM 3’
’ CF~AMARGRUM~GNUM~CF~ARUF~CM~AF~CM~AF~CRUM~GR~AF~AM 3’
’ CF~AMARGRUM~GRUM~CF~AR~UD0~CM~AF~CM~AF~CRUM~GR~AF~AM 3’
5’ CF~AMARGRUM~CRUM~CF~AR~UD0~CM~AF~CM~AF~CRUM~GR~AF~AM 3’
’ CF~AMARGRUM~GNUM~CF~AR~UD0~CM~AF~CM~AF~CRUM~GR~AF~AM 3’
’ CF~AMARGRUM~GRUM~CF~ARUN~CM~AF~CM~AF~CRUM~GR~AF~AM 3’
’ CF~AMARGRUM~CRUM~CF~ARUN~CM~AF~CM~AF~CRUM~GR~AF~AM 3’
’ CF~AMARGRUM~GNUM~CF~ARUN~CM~AF~CM~AF~CRUM~GR~AF~AM 3’
Antisense:
’ CF~ARGRUM~GRUM~GRARUF~GRAF~CM~AF~CRUM~UF~GM:X:X 3’
’ UF~UM~CF~ARGRUM~GRUM~GRARUR~GRAF~CM~AF~CRUM~UF~GM:X:X 3’
’ UF~UM~CF~ARGRUM~GRUMGFARUMGFAF~CM~AF~CRUM~UF~GM:X:X 3’
Forked variant
Sense:
’ CF~AMARGRUM~GRUM~CF~ARUF~CM~AF~CM~AF~GRUM~UM~AF~AM 3’
’ CF~AMARGRUM~CRUM~CF~ARUF~CM~AF~CM~AF~GRUM~UM~AF~AM 3’
5’ CF~AMARGRUM~GNUM~CF~ARUF~CM~AF~CM~AF~GRUM~UM~AF~AM 3’
’ CF~AMARGRUM~GRUM~CF~AR~UD0~CM~AF~CM~AF~GRUM~UM~AF~AM 3’
’ CF~AMARGRUM~CRUM~CF~AR~UD0~CM~AF~CM~AF~GRUM~UM~AF~AM 3’
’ RGRUM~GNUM~CF~AR~UD0~CM~AF~CM~AF~GRUM~UM~AF~AM 3’
’ CF~AMARGRUM~GRUM~CF~ARUN~CM~AF~CM~AF~GRUM~UM~AF~AM 3’
5’ CF~AMARGRUM~CRUM~CF~ARUN~CM~AF~CM~AF~GRUM~UM~AF~AM 3’
’ CF~AMARGRUM~GNUM~CF~ARUN~CM~AF~CM~AF~GRUM~UM~AF~AM 3’
Antisense:
’ UF~UM~CF~ARGRUM~GRUM~GRARUF~GRAF~CM~AF~GRUM~UF~GM:X:X 3’
’ UF~UM~CF~ARGRUM~GRUM~GRARUR~GRAF~CM~AF~GRUM~UF~GM:X:X 3’
5’ UF~UM~CF~ARGRUM~GRUMGFARUMGFAF~CM~AF~GRUM~UF~GM:X:X 3’
Small internally segmented architecture
Sense:
’ CF~AM~ARGRUM~GRUM~CL~AR~UM&CM~AF~CM~AL~CRUM~GR~AF~AM 3’
’ CF~AM~ARGRUM~GRUM~CL~AR~UM&CM~AF~CM~AL~CRUM~GR~AF~AM:X:X 3’
nse:
’ UF~UM~CF~ARGRUM~GRUM~GRARUF~GRAF~CM~AF~GRUM~UF~GM:X:X 3’
5’ UF~UM~CF~ARGRUM~GRUM~GRARUR~GRAF~CM~AF~GRUM~UF~GM:X:X 3’
’ UF~UM~CF~ARGRUM~GRUMGFARUMGFAF~CM~AF~GRUM~UF~GM:X:X 3’
ss-siRNA
’ PUF~UM~CF~ARGRUF~GRUF~GRARUF~GRAF~CF~AF~CRUF~UF~GF:X:X 3’
’ PUF~UM~CF~ARGRUF~GRUF~GRARUR~GRAF~CF~AF~CRUF~UF~GF:X:X 3’
’ PUF~UM~CF~ARGRUF~GRUFGFARUMGFAF~CF~AF~CRUF~UF~GF:X:X 3’
5’ PUF~UF~CF~ARGRUF~GRUF~GRARUF~GRAF~CF~AF~CRUF~UF~GF:X:X 3’
’ PUF~UF~CF~ARGRUF~GRUF~GRARUR~GRAF~CF~AF~CRUF~UF~GF:X:X 3’
’ PUF~UF~CF~ARGRUF~GRUFGFARUMGFAF~CF~AF~CRUF~UF~GF:X:X 3’
21. seqsiRNA COMPOUNDS DIRECTED TO HUMAN/MOUSE PCSK9
FOR TIAL INDUCTION OF RNAi ACTIVITY
Canonical architecture
Sense:
5’ GF~CMGRGRCM~AF~CM~CM~CRUF~CM~AF~UM~ARGRGRCM~CF~UM:X:X 3’
’ GF~CMGRGRCM~AF~CM~CM~CR~UD0~CM~AF~UM~ARGRGRCM~CF~UM:X:X 3’
’ GF~CMGRGRCM~AF~CM~CM~CRUN~CM~AF~UM~ARGRGRCM~CF~UM:X:X 3’
’ RGRCM~AF~CM~CM~CRUF~CM~AF~UM~ARGRGRCM~GF~UM:X:X 3’
’ GF~CMGRGRCM~AF~CM~CM~CR~UD0~CM~AF~UM~ARGRGRCM~GF~UM:X:X 3’
5’ GF~CMGRGRCM~AF~CM~CM~CRUN~CM~AF~UM~ARGRGRCM~GF~UM:X:X 3’
’ GF~CMGRGRCM~AF~GM~CM~CRUF~CM~AF~UM~ARGRGRCM~GF~UM:X:X 3’
’ GF~CMGRGRCM~AF~GM~CM~CR~UD0~CM~AF~UM~ARGRGRCM~GF~UM:X:X 3’
’ GF~CMGRGRCM~AF~GM~CM~CRUN~CM~AF~UM~ARGRGRCM~GF~UM:X:X 3’
Antisense:
5’ AF~GMGRCM~CRUM~AF~UM~GRARGRGRGRUM~GRCM~CF~GF~CM:X:X 3’
’ AF~GM~GRCM~CRUM~AF~UM~GRARGFGRGRUM~GRCM~CF~GF~CM:X:X 3’
’ AF~GM~GRCM~CRUM~AF~UM~GRAFGRGRGRUM~GRCM~CF~GF~CM:X:X 3’
’ AF~GM~GRCM~CRUM~AF~UM~GRAFGFGRGRUM~GRCM~CF~GF~CM:X:X 3’
’ AF~GM~GRCM~CRUM~AF~UM~GRAMGFGRGRUM~GRCM~CF~GF~CM:X:X 3’
5’ AF~GM~GRCM~CRUM~AF~UM~GRAFGMGRGRUM~GRCM~CF~GF~CM:X:X 3’
Blunt-end architecture
Sense:
’ GF~CMGRGRCM~AF~CM~CM~CRUF~CM~AF~UM~ARGRGRCM~CF~UM 3’
’ RGRCM~AF~CM~CM~CR~UD0~CM~AF~UM~ARGRGRCM~CF~UM 3’
’ GF~CMGRGRCM~AF~CM~CM~CRUN~CM~AF~UM~ARGRGRCM~CF~UM 3’
5’ GF~CMGRGRCM~AF~CM~CM~CRUF~CM~AF~UM~ARGRGRCM~GF~UM 3’
’ GF~CMGRGRCM~AF~CM~CM~CR~UD0~CM~AF~UM~ARGRGRCM~GF~UM 3’
’ GF~CMGRGRCM~AF~CM~CM~CRUN~CM~AF~UM~ARGRGRCM~GF~UM 3’
’ GF~CMGRGRCM~AF~GM~CM~CRUF~CM~AF~UM~ARGRGRCM~GF~UM 3’
’ GF~CMGRGRCM~AF~GM~CM~CR~UD0~CM~AF~UM~ARGRGRCM~GF~UM 3’
5’ GF~CMGRGRCM~AF~GM~CM~CRUN~CM~AF~UM~ARGRGRCM~GF~UM 3’
Antisense:
’ AF~GMGRCM~CRUM~AF~UM~GRARGRGRGRUM~GRCM~CF~GF~CM 3’
’ AF~GM~GRCM~CRUM~AF~UM~GRARGFGRGRUM~GRCM~CF~GF~CM 3’
’ AF~GM~GRCM~CRUM~AF~UM~GRAFGRGRGRUM~GRCM~CF~GF~CM 3’
5’ AF~GM~GRCM~CRUM~AF~UM~GRAFGFGRGRUM~GRCM~CF~GF~CM 3’
’ AF~GM~GRCM~CRUM~AF~UM~GRAMGFGRGRUM~GRCM~CF~GF~CM 3’
’ AF~GM~GRCM~CRUM~AF~UM~GRAFGMGRGRUM~GRCM~CF~GF~CM 3’
Asymmetric architecture
Sense:
’ GF~CMGRGRCM~AF~CM~CM~CRUF~CM~AF~UM~ARGRGRCM~CF~UM 3’
’ GF~CMGRGRCM~AF~CM~CM~CR~UD0~CM~AF~UM~ARGRGRCM~CF~UM 3’
’ GF~CMGRGRCM~AF~CM~CM~CRUN~CM~AF~UM~ARGRGRCM~CF~UM 3’
’ GF~CMGRGRCM~AF~CM~CM~CRUF~CM~AF~UM~ARGRGRCM~GF~UM 3’
5’ GF~CMGRGRCM~AF~CM~CM~CR~UD0~CM~AF~UM~ARGRGRCM~GF~UM 3’
’ GF~CMGRGRCM~AF~CM~CM~CRUN~CM~AF~UM~ARGRGRCM~GF~UM 3’
’ GF~CMGRGRCM~AF~GM~CM~CRUF~CM~AF~UM~ARGRGRCM~GF~UM 3’
’ RGRCM~AF~GM~CM~CR~UD0~CM~AF~UM~ARGRGRCM~GF~UM 3’
’ GF~CMGRGRCM~AF~GM~CM~CRUN~CM~AF~UM~ARGRGRCM~GF~UM 3’
Antisense:
’ AF~GMGRCM~CRUM~AF~UM~GRARGRGRGRUM~GRCM~CF~GF~CM:X:X 3’
’ AF~GM~GRCM~CRUM~AF~UM~GRARGFGRGRUM~GRCM~CF~GF~CM:X:X 3’
’ AF~GM~GRCM~CRUM~AF~UM~GRAFGRGRGRUM~GRCM~CF~GF~CM:X:X 3’
’ AF~GM~GRCM~CRUM~AF~UM~GRAFGFGRGRUM~GRCM~CF~GF~CM:X:X 3’
5’ AF~GM~GRCM~CRUM~AF~UM~GRAMGFGRGRUM~GRCM~CF~GF~CM:X:X 3’
’ AF~GM~GRCM~CRUM~AF~UM~GRAFGMGRGRUM~GRCM~CF~GF~CM:X:X 3’
Forked variant
Sense:
’ GF~CMGRGRCM~AF~CM~CM~CRUF~CM~AF~UM~ARGRCF~CM~GF~UM 3’
’ RGRCM~AF~CM~CM~CR~UD0~CM~AF~UM~ARGRCF~CM~GF~UM 3’
’ GF~CMGRGRCM~AF~CM~CM~CRUN~CM~AF~UM~ARGRCF~CM~GF~UM 3’
’ GF~CMGRGRCM~AF~GM~CM~CRUF~CM~AF~UM~ARGRCF~CM~GF~UM 3’
5’ GF~CMGRGRCM~AF~GM~CM~CR~UD0~CM~AF~UM~ARCF~GRCM~GF~UM 3’
’ GF~CMGRGRCM~AF~GM~CM~CRUN~CM~AF~UM~ARGRCF~CM~GF~UM 3’
Antisense:
’ AF~GMGRCM~CRUM~AF~UM~GRARGRGRGRUM~GRCM~CF~GF~CM:X:X 3’
’ AF~GM~GRCM~CRUM~AF~UM~GRARGFGRGRUM~GRCM~CF~GF~CM:X:X 3’
5’ AF~GM~GRCM~CRUM~AF~UM~GRAFGRGRGRUM~GRCM~CF~GF~CM:X:X 3’
’ AF~GM~GRCM~CRUM~AF~UM~GRAFGFGRGRUM~GRCM~CF~GF~CM:X:X 3’
’ AF~GM~GRCM~CRUM~AF~UM~GRAMGFGRGRUM~GRCM~CF~GF~CM:X:X 3’
’ AF~GM~GRCM~CRUM~AF~UM~GRAFGMGRGRUM~GRCM~CF~GF~CM:X:X 3’
Small internally segmented architecture
Sense:
’ GF~CMGRGRCM~AF~CM~CF~CM&UF~CM~AF~UM~ARGRGRCM~CF~UM:X:X 3’
’ RGRCM~AF~CM~CF~CM&UF~CM~AF~UM~ARGRGRCM~CF~UM 3’
’ GF~CMGRGRCM~AF~CM~CF~CM&UF~CM~AF~UM~ALGRGRCM~CF~UM:X:X 3’
5’ GF~CMGRGRCM~AF~CM~CF~CM&UF~CM~AF~UM~ALGRGRCM~CF~UM 3’
Antisense:
’ AF~GMGRCM~CRUM~AF~UM~GRARGRGRGRUM~GRCM~CF~GF~CM:X:X 3’
’ AF~GM~GRCM~CRUM~AF~UM~GRARGFGRGRUM~GRCM~CF~GF~CM:X:X 3’
’ AF~GM~GRCM~CRUM~AF~UM~GRAFGRGRGRUM~GRCM~CF~GF~CM:X:X 3’
5’ AF~GM~GRCM~CRUM~AF~UM~GRAFGFGRGRUM~GRCM~CF~GF~CM:X:X 3’
’ AF~GM~GRCM~CRUM~AF~UM~GRAMGFGRGRUM~GRCM~CF~GF~CM:X:X 3’
’ AF~GM~GRCM~CRUM~AF~UM~GRAFGMGRGRUM~GRCM~CF~GF~CM:X:X 3’
ss-siRNA
’ PAF~GMGRCF~CRUF~AF~UF~GRARGRGRGRUM~GRCF~CF~GF~CF:X:X 3’
’ PAF~GM~GRCF~CRUF~AF~UF~GRARGFGRGRUM~GRCF~CF~GF~CF:X:X 3’
’ PAF~GM~GRCF~CRUF~AF~UF~GRAFGRGRGRUF~GRCF~CF~GF~CF:X:X 3’
5’ PAF~GM~GRCF~CRUF~AF~UF~GRAFGFGRGRUF~GRCF~CF~GF~CF:X:X 3’
’ PAF~GM~GRCF~CRUF~AF~UF~GRAFGFGRGRUF~GRCF~CF~GF~CF:X:X 3’
’ PAF~GM~GRCF~CRUF~AF~UM~GRAFGFGRGRUF~GRCF~CF~GF~CF:X:X 3’
’ GRCF~CRUF~AF~UF~GRARGRGRGRUM~GRCF~CF~GF~CF:X:X 3’
’ PAF~GF~GRCF~CRUF~AF~UF~GRARGFGRGRUM~GRCF~CF~GF~CF:X:X 3’
5’ PAF~GF~GRCF~CRUF~AF~UF~GRAFGRGRGRUF~GRCF~CF~GF~CF:X:X 3’
’ PAF~GF~GRCF~CRUF~AF~UF~GRAFGFGRGRUF~GRCF~CF~GF~CF:X:X 3’
’ PAF~GF~GRCF~CRUF~AF~UF~GRAFGFGRGRUF~GRCF~CF~GF~CF:X:X 3’
’ PAF~GF~GRCF~CRUF~AF~UM~GRAFGFGRGRUF~GRCF~CF~GF~CF:X:X 3’
22. seqsiRNA COMPOUNDS DIRECTED TO MOUSE FAS
FOR SEQUENTIAL INDUCTION OF RNAi ACTIVITY
cal architecture
Sense:
’ GF~UM~GRCM~ARARGRUM~GRCF~ARARAF~CM~CF~ARGR~AF~CM:X:X 3’
’ GF~UM~GRCM~ARARGRUM~GRCF~ARARAF~CM~CF~ARGR~AF~GM:X:X 3’
’ GF~UM~GRCM~ARARGRUM~GR~CD0~ARARAF~CM~CF~ARGR~AF~GM:X:X 3’
5’ GF~UM~GRCM~ARARGRUM~GRCN~ARARAF~CM~CF~ARGR~AF~GM:X:X 3’
nse:
’ GF~UM~CRUM~GRGRURURUF~GRCF~AMCRUM~UF~GRCM~AF~CM:X:X 3’
’ GF~UM~CRUM~GR~GRUR~URUFGRCFAMCRUM~UF~GRCM~AF~CM:X:X 3’
5’ GF~UM~CRUM~GR~GRURURUF~GMCF~AMCR~UM~UF~GRCM~AF~CM:X:X 3’
’ GF~UM~CRUM~GR~GRUR~URUFGMCFAMCRUM~UF~GRCM~AF~CM:X:X 3’
’ GF~UM~CRUM~GR~GRURURUF~GFCM~AMCRUM~UF~GRCM~AF~CM:X:X 3’
’ GF~UM~CRUM~GR~GRUR~URUFGFCMAMCRUM~UF~GRCM~AF~CM:X:X 3’
’ GF~UM~CRUM~GR~GRURURUF~GFCR~AMCRUM~UF~GRCM~AF~CM:X:X 3’
5’ GF~UM~CRUM~GR~GRUR~URUFGFCRAMCRUM~UF~GRCM~AF~CM:X:X 3’
’ GF~UM~CRUM~GR~GRURURUF~GRCR~AMCRUM~UF~GRCM~AF~CM:X:X 3’
’ GF~UM~CRUM~GR~GRUR~URUFGRCRAMCRUM~UF~GRCM~AF~CM:X:X 3’
Blunt-end architecture
Sense:
’ GF~UM~GRCM~ARARGRUM~GRCF~ARARAF~CM~CF~ARGR~AF~CM 3’
’ GF~UM~GRCM~ARARGRUM~GRCF~ARARAF~CM~CF~ARGR~AF~GM 3’
’ GF~UM~GRCM~ARARGRUM~GR~CD0~ARARAF~CM~CF~ARGR~AF~GM 3’
5’ GF~UM~GRCM~ARARGRUM~GRCN~ARARAF~CM~CF~ARGR~AF~GM 3’
Antisense:
’ GF~UM~CRUM~GRGRURURUF~GRCF~AMCRUM~UF~GRCM~AF~CM 3’
’ GF~UM~CRUM~GR~GRUR~URUFGRCFAMCRUM~UF~GRCM~AF~CM 3’
’ GF~UM~CRUM~GR~GRURURUF~GMCF~AMCR~UM~UF~GRCM~AF~CM 3’
5’ GF~UM~CRUM~GR~GRUR~URUFGMCFAMCRUM~UF~GRCM~AF~CM 3’
’ GF~UM~CRUM~GR~GRURURUF~GFCM~AMCRUM~UF~GRCM~AF~CM 3’
’ GF~UM~CRUM~GR~GRUR~URUFGFCMAMCRUM~UF~GRCM~AF~CM 3’
’ CRUM~GR~GRURURUF~GFCR~AMCRUM~UF~GRCM~AF~CM 3’
’ GF~UM~CRUM~GR~GRUR~URUFGFCRAMCRUM~UF~GRCM~AF~CM 3’
5’ GF~UM~CRUM~GR~GRURURUF~GRCR~AMCRUM~UF~GRCM~AF~CM 3’
’ GF~UM~CRUM~GR~GRUR~URUFGRCRAMCRUM~UF~GRCM~AF~CM 3’
Asymmetric architecture
Sense:
’ GF~UM~GRCM~ARARGRUM~GRCF~ARARAF~CM~CF~ARGR~AF~CM 3’
’ GF~UM~GRCM~ARARGRUM~GRCF~ARARAF~CM~CF~ARGR~AF~GM 3’
’ GF~UM~GRCM~ARARGRUM~GR~CD0~ARARAF~CM~CF~ARGR~AF~GM 3’
’ GF~UM~GRCM~ARARGRUM~GRCN~ARARAF~CM~CF~ARGR~AF~GM 3’
Antisense:
’ GF~UM~CRUM~GRGRURURUF~GRCF~AMCRUM~UF~GRCM~AF~CM:X:X 3’
’ GF~UM~CRUM~GR~GRUR~URUFGRCFAMCRUM~UF~GRCM~AF~CM:X:X 3’
’ GF~UM~CRUM~GR~GRURURUF~GMCF~AMCR~UM~UF~GRCM~AF~CM:X:X 3’
’ GF~UM~CRUM~GR~GRUR~URUFGMCFAMCRUM~UF~GRCM~AF~CM:X:X 3’
5’ GF~UM~CRUM~GR~GRURURUF~GFCM~AMCRUM~UF~GRCM~AF~CM:X:X 3’
’ CRUM~GR~GRUR~URUFGFCMAMCRUM~UF~GRCM~AF~CM:X:X 3’
’ GF~UM~CRUM~GR~GRURURUF~GFCR~AMCRUM~UF~GRCM~AF~CM:X:X 3’
’ GF~UM~CRUM~GR~GRUR~URUFGFCRAMCRUM~UF~GRCM~AF~CM:X:X 3’
’ GF~UM~CRUM~GR~GRURURUF~GRCR~AMCRUM~UF~GRCM~AF~CM:X:X 3’
5’ GF~UM~CRUM~GR~GRUR~URUFGRCRAMCRUM~UF~GRCM~AF~CM:X:X 3’
Forked variant
Sense:
5’ GF~UM~GRCM~ARARGRUM~GRCF~ARARAF~CM~CF~AF~CM~AF~GM 3’
’ GF~UM~GRCM~ARARGRUM~GR~CD0~ARARAF~CM~CF~AF~CM~AF~GM 3’
’ GF~UM~GRCM~ARARGRUM~GRCN~ARARAF~CM~CF~AF~CM~AF~GM 3’
Antisense:
’ GF~UM~CRUM~GRGRURURUF~GRCF~AMCRUM~UF~GRCM~AF~CM:X:X 3’
5’ GF~UM~CRUM~GR~GRUR~URUFGRCFAMCRUM~UF~GRCM~AF~CM:X:X 3’
’ GF~UM~CRUM~GR~GRURURUF~GMCF~AMCR~UM~UF~GRCM~AF~CM:X:X 3’
’ CRUM~GR~GRUR~URUFGMCFAMCRUM~UF~GRCM~AF~CM:X:X 3’
’ GF~UM~CRUM~GR~GRURURUF~GFCM~AMCRUM~UF~GRCM~AF~CM:X:X 3’
’ GF~UM~CRUM~GR~GRUR~URUFGFCMAMCRUM~UF~GRCM~AF~CM:X:X 3’
5’ GF~UM~CRUM~GR~GRURURUF~GFCR~AMCRUM~UF~GRCM~AF~CM:X:X 3’
’ GF~UM~CRUM~GR~GRUR~URUFGFCRAMCRUM~UF~GRCM~AF~CM:X:X 3’
’ GF~UM~CRUM~GR~GRURURUF~GRCR~AMCRUM~UF~GRCM~AF~CM:X:X 3’
’ GF~UM~CRUM~GR~GRUR~URUFGRCRAMCRUM~UF~GRCM~AF~CM:X:X 3’
Small internally segmented architecture
Sense:
’ GF~UM~GRCM~ARARGR~UM~GM&CF~ARARAF~CM~CF~ARGR~AF~CM:X:X 3’
’ GF~UM~GRCM~ARARGR~UM~GM&CF~ARARAF~CM~CF~ARGR~AF~CM 3’
’ GF~UM~GRCM~ARARGR~UL~GM&CF~ARARAF~CM~CL~ARGR~AF~CM:X:X 3’
5’ GF~UM~GRCM~ARARGR~UL~GM&CF~ARARAF~CM~CL~ARGR~AF~CM 3’
nse:
’ GF~UM~CRUM~GRGRURURUF~GRCF~AMCRUM~UF~GRCM~AF~CM:X:X 3’
’ GF~UM~CRUM~GR~GRUR~URUFGRCFAMCRUM~UF~GRCM~AF~CM:X:X 3’
’ GF~UM~CRUM~GR~GRURURUF~GMCF~AMCR~UM~UF~GRCM~AF~CM:X:X 3’
5’ GF~UM~CRUM~GR~GRUR~URUFGMCFAMCRUM~UF~GRCM~AF~CM:X:X 3’
’ CRUM~GR~GRURURUF~GFCM~AMCRUM~UF~GRCM~AF~CM:X:X 3’
’ GF~UM~CRUM~GR~GRUR~URUFGFCMAMCRUM~UF~GRCM~AF~CM:X:X 3’
’ GF~UM~CRUM~GR~GRURURUF~GFCR~AMCRUM~UF~GRCM~AF~CM:X:X 3’
’ GF~UM~CRUM~GR~GRUR~URUFGFCRAMCRUM~UF~GRCM~AF~CM:X:X 3’
5’ GF~UM~CRUM~GR~GRURURUF~GRCR~AMCRUM~UF~GRCM~AF~CM:X:X 3’
’ GF~UM~CRUM~GR~GRUR~URUFGRCRAMCRUM~UF~GRCM~AF~CM:X:X 3’
ss-siRNA
5’ PGF~UM~CRUF~GRGRURURUF~GRCF~AFCRUF~UF~GRCF~AF~CF:X:X 3’
’ PGF~UM~CRUF~GR~GRUR~URUFGRCFAFCRUF~UF~GRCF~AF~CF:X:X 3’
’ PGF~UM~CRUF~GR~GRURURUF~GFCF~AFCR~UF~UF~GRCF~AF~CF:X:X 3’
’ PGF~UM~CRUF~GR~GRUR~URUFGFCFAFCRUF~UF~GRCF~AF~CF:X:X 3’
’ PGF~UM~CRUF~GR~GRURURUF~GFCF~AMCRUF~UF~GRCF~AF~CF:X:X 3’
5’ PGF~UM~CRUF~GR~GRUR~URUFGFCFAFCRUF~UF~GRCF~AF~CF:X:X 3’
’ PGF~UM~CRUF~GR~GRURURUF~GFCR~AFCRUM~UF~GRCF~AF~CF:X:X 3’
’ PGF~UM~CRUF~GR~GRUR~URUFGFCRAFCRUF~UF~GRCF~AF~CF:X:X 3’
’ PGF~UM~CRUF~GR~GRURURUF~GRCR~AFCRUF~UF~GRCF~AF~CF:X:X 3’
’ PGF~UM~CRUF~GR~GRUR~URUFGRCRAFCRUF~UF~GRCF~AF~CF:X:X 3’
5’ PGF~UF~CRUF~GRGRURURUF~GRCF~AFCRUF~UF~GRCF~AF~CF:X:X 3’
’ PGF~UF~CRUF~GR~GRUR~URUFGRCFAFCRUF~UF~GRCF~AF~CF:X:X 3’
’ PGF~UF~CRUF~GR~GRURURUF~GFCF~AFCR~UF~UF~GRCF~AF~CF:X:X 3’
23. seqsiRNA COMPOUNDS DIRECTED TO MOUSE STAT3
FOR SEQUENTIAL INDUCTION OF RNAi TY
Canonical architecture
Sense:
5’ M~CF~CM~ARGRGRARCF~GRAMCRUM~UFUM~GR~AF~UM:X:X 3’
’ CF~CMUM~CF~CM~CMGRGRARGF~GRAMCRUM~UFUM~GR~AF~UM:X:X 3’
’ CF~CMUM~CF~CM~CMGRGRAR~CD0~GRAMCRUM~UFUM~GR~AF~UM:X:X 3’
’ CF~CMUM~CF~CM~CMGRGRARCN~GRAMCRUM~UFUM~GR~AF~UM:X:X 3’
Antisense:
5’ AF~UM~CF~ARARARGRUF~CF~GRUF~CM~CRUF~GRGRAF~GF~GM:X:X 3’
’ AF~UM~CF~ARARARGRUF~CF~GRUR~CM~CRUF~GRGRAF~GF~GM:X:X 3’
’ AF~UM~CF~ARARARGRUF~CF~GFUF~CM~CRUF~GRGRAF~GF~GM:X:X 3’
’ AF~UM~CF~ARARARGRUF~CF~GMUF~CM~CRUF~GRGRAF~GF~GM:X:X 3’
’ AF~UM~CF~ARARARGRUF~CF~GFUM~CM~CRUF~GRGRAF~GF~GM:X:X 3’
5’ AF~UM~CF~ARAR~ARGRUF~CFGRUFCM~CRUF~GRGRAF~GF~GM:X:X 3’
’ AF~UM~CF~ARAR~ARGRUF~CF~GRUR~CM~CRUF~GRGRAF~GF~GM:X:X 3’
’ AF~UM~CF~ARAR~ARGRUF~CFGFUFCM~CRUF~GRGRAF~GF~GM:X:X 3’
’ AF~UM~CF~ARAR~ARGRUF~CFGMUFCM~CRUF~GRGRAF~GF~GM:X:X 3’
’ AF~UM~CF~ARAR~ARGRUF~CFGFUMCM~CRUF~GRGRAF~GF~GM:X:X 3’
Blunt-end ecture
Sense:
’ CF~CMUM~CF~CM~ARGRGRARCF~GRAMCRUM~UFUM~GR~AF~UM 3’
’ CF~CMUM~CF~CM~CMGRGRARGF~GRAMCRUM~UFUM~GR~AF~UM 3’
5’ CF~CMUM~CF~CM~CMGRGRAR~CD0~GRAMCRUM~UFUM~GR~AF~UM 3’
’ CF~CMUM~CF~CM~CMGRGRARCN~GRAMCRUM~UFUM~GR~AF~UM 3’
Antisense:
’ AF~UM~CF~ARARARGRUF~CF~GRUF~CM~CRUF~GRGRAF~GF~GM 3’
’ AF~UM~CF~ARARARGRUF~CF~GRUR~CM~CRUF~GRGRAF~GF~GM 3’
5’ AF~UM~CF~ARARARGRUF~CF~GFUF~CM~CRUF~GRGRAF~GF~GM 3’
’ AF~UM~CF~ARARARGRUF~CF~GMUF~CM~CRUF~GRGRAF~GF~GM 3’
’ AF~UM~CF~ARARARGRUF~CF~GFUM~CM~CRUF~GRGRAF~GF~GM 3’
’ AF~UM~CF~ARAR~ARGRUF~CFGRUFCM~CRUF~GRGRAF~GF~GM 3’
’ AF~UM~CF~ARAR~ARGRUF~CF~GRUR~CM~CRUF~GRGRAF~GF~GM 3’
5’ AF~UM~CF~ARAR~ARGRUF~CFGFUFCM~CRUF~GRGRAF~GF~GM 3’
’ AF~UM~CF~ARAR~ARGRUF~CFGMUFCM~CRUF~GRGRAF~GF~GM 3’
’ AF~UM~CF~ARAR~ARGRUF~CFGFUMCM~CRUF~GRGRAF~GF~GM 3’
Asymmetric architecture
Sense:
’ CF~CMUM~CF~CM~ARGRGRARCF~GRAMCRUM~UFUM~GR~AF~UM 3’
’ CF~CMUM~CF~CM~CMGRGRARGF~GRAMCRUM~UFUM~GR~AF~UM 3’
’ CF~CMUM~CF~CM~CMGRGRAR~CD0~GRAMCRUM~UFUM~GR~AF~UM 3’
’ CF~CMUM~CF~CM~CMGRGRARCN~GRAMCRUM~UFUM~GR~AF~UM 3’
Antisense:
’ AF~UM~CF~ARARARGRUF~CF~GRUF~CM~CRUF~GRGRAF~GF~GM:X:X 3’
’ AF~UM~CF~ARARARGRUF~CF~GRUR~CM~CRUF~GRGRAF~GF~GM:X:X 3’
’ AF~UM~CF~ARARARGRUF~CF~GFUF~CM~CRUF~GRGRAF~GF~GM:X:X 3’
’ CF~ARARARGRUF~CF~GMUF~CM~CRUF~GRGRAF~GF~GM:X:X 3’
5’ AF~UM~CF~ARARARGRUF~CF~GFUM~CM~CRUF~GRGRAF~GF~GM:X:X 3’
’ AF~UM~CF~ARAR~ARGRUF~CFGRUFCM~CRUF~GRGRAF~GF~GM:X:X 3’
’ AF~UM~CF~ARAR~ARGRUF~CF~GRUR~CM~CRUF~GRGRAF~GF~GM:X:X 3’
’ AF~UM~CF~ARAR~ARGRUF~CFGFUFCM~CRUF~GRGRAF~GF~GM:X:X 3’
’ AF~UM~CF~ARAR~ARGRUF~CFGMUFCM~CRUF~GRGRAF~GF~GM:X:X 3’
5’ AF~UM~CF~ARAR~ARGRUF~CFGFUMCM~CRUF~GRGRAF~GF~GM:X:X 3’
Forked variant
Sense:
’ CF~CMUM~CF~CM~ARGRGRARCF~GRAMCRUM~AF~UM~CM~AF~UM 3’
’ CF~CMUM~CF~CM~CMGRGRARGF~GRAMCRUM~AF~UM~CM~AF~UM 3’
’ CF~CMUM~CF~CM~CMGRGRAR~CD0~GRAMCRUM~AF~UM~CM~AF~UM 3’
’ CF~CMUM~CF~CM~CMGRGRARCN~GRAMCRUM~AF~UM~CM~AF~UM 3’
Antisense:
’ AF~UM~CF~ARARARGRUF~CF~GRUF~CM~CRUF~GRGRAF~GF~GM:X:X 3’
’ AF~UM~CF~ARARARGRUF~CF~GRUR~CM~CRUF~GRGRAF~GF~GM:X:X 3’
’ AF~UM~CF~ARARARGRUF~CF~GFUF~CM~CRUF~GRGRAF~GF~GM:X:X 3’
’ CF~ARARARGRUF~CF~GMUF~CM~CRUF~GRGRAF~GF~GM:X:X 3’
5’ AF~UM~CF~ARARARGRUF~CF~GFUM~CM~CRUF~GRGRAF~GF~GM:X:X 3’
’ AF~UM~CF~ARAR~ARGRUF~CFGRUFCM~CRUF~GRGRAF~GF~GM:X:X 3’
’ AF~UM~CF~ARAR~ARGRUF~CF~GRUR~CM~CRUF~GRGRAF~GF~GM:X:X 3’
’ AF~UM~CF~ARAR~ARGRUF~CFGFUFCM~CRUF~GRGRAF~GF~GM:X:X 3’
’ AF~UM~CF~ARAR~ARGRUF~CFGMUFCM~CRUF~GRGRAF~GF~GM:X:X 3’
5’ AF~UM~CF~ARAR~ARGRUF~CFGFUMCM~CRUF~GRGRAF~GF~GM:X:X 3’
Small ally segmented architecture
Sense:
’ CF~CMUM~CF~CM~AR~GF~GM&AM~CF~GRAMCRUM~UFUM~GR~AF~UM:X:X 3’
’ CF~CMUM~CF~CL~AR~GF~GM&AM~CF~GRAMCRUL~UFUM~GR~AF~UM:X:X 3’
’ CF~CMUM~CF~CM~AR~GF~GM&AM~CF~GRAMCRUM~UFUM~GR~AF~UM 3’
’ CF~CMUM~CF~CL~AR~GF~GM&AM~CF~GRAMCRUL~UFUM~GR~AF~UM 3’
5’ CF~CMUM~CF~CM~ARGR~GF~AM&CF~GRAMCLUM~UFUL~GR~AF~UM:X:X 3
’ CF~CMUM~CL~CM~ARGR~GF~AM&CF~GRAMCLUM~UFUL~GR~AF~UM:X:X 3
’ CF~CMUL~CF~CM~ARGR~GL~AM&CF~GLAMCLUM~UFUL~GR~AF~UM:X:X 3
’ CF~CMUM~CF~CM~ARGR~GF~AM&CF~GRAMCLUM~UFUL~GR~AF~UM 3
’ CF~CMUM~CL~CM~ARGR~GF~AM&CF~GRAMCLUM~UFUL~GR~AF~UM 3
5’ CF~CMUL~CF~CM~ARGR~GL~AM&CF~GLAMCLUM~UFUL~GR~AF~UM3
Antisense:
’ AF~UM~CF~ARARARGRUF~CF~GRUF~CM~CRUF~GRGRAF~GF~GM:X:X 3’
’ AF~UM~CF~ARARARGRUF~CF~GRUR~CM~CRUF~GRGRAF~GF~GM:X:X 3’
’ AF~UM~CF~ARARARGRUF~CF~GFUF~CM~CRUF~GRGRAF~GF~GM:X:X 3’
5’ AF~UM~CF~ARARARGRUF~CF~GMUF~CM~CRUF~GRGRAF~GF~GM:X:X 3’
’ AF~UM~CF~ARARARGRUF~CF~GFUM~CM~CRUF~GRGRAF~GF~GM:X:X 3’
’ CF~ARAR~ARGRUF~CFGRUFCM~CRUF~GRGRAF~GF~GM:X:X 3’
’ AF~UM~CF~ARAR~ARGRUF~CF~GRUR~CM~CRUF~GRGRAF~GF~GM:X:X 3’
’ AF~UM~CF~ARAR~ARGRUF~CFGFUFCM~CRUF~GRGRAF~GF~GM:X:X 3’
5’ AF~UM~CF~ARAR~ARGRUF~CFGMUFCM~CRUF~GRGRAF~GF~GM:X:X 3’
’ AF~UM~CF~ARAR~ARGRUF~CFGFUMCM~CRUF~GRGRAF~GF~GM:X:X 3’
ss-siRNA
5’ PAF~UM~CF~ARARARGRUF~CF~GRUF~CF~CRUF~GRGRAF~GF~GF:X:X 3’
’ PAF~UM~CF~ARARARGRUF~CF~GRUR~CF~CRUF~GRGRAF~GF~GF:X:X 3’
’ PAF~UM~CF~ARARARGRUF~CF~GFUF~CF~CRUF~GRGRAF~GF~GF:X:X 3’
’ PAF~UM~CF~ARARARGRUF~CF~GFUF~CF~CRUF~GRGRAF~GF~GF:X:X 3’
’ PAF~UM~CF~ARARARGRUF~CF~GFUF~CF~CRUF~GRGRAF~GF~GF:X:X 3’
5’ PAF~UM~CF~ARAR~ARGRUF~CFGRUFCF~CRUF~GRGRAF~GF~GF:X:X 3’
’ PAF~UM~CF~ARAR~ARGRUF~CF~GRUR~CF~CRUF~GRGRAF~GF~GF:X:X 3’
’ PAF~UM~CF~ARAR~ARGRUF~CFGFUFCF~CRUF~GRGRAF~GF~GF:X:X 3’
’ PAF~UM~CF~ARAR~ARGRUF~CFGFUFCF~CRUF~GRGRAF~GF~GF:X:X 3’
’ PAF~UM~CF~ARAR~ARGRUF~CFGFUFCF~CRUF~GRGRAF~GF~GF:X:X 3’
5’ PAF~UF~CF~ARARARGRUF~CF~GRUF~CF~CRUF~GRGRAF~GF~GF:X:X 3’
’ PAF~UF~CF~ARARARGRUF~CF~GRUR~CF~CRUF~GRGRAF~GF~GF:X:X 3’
’ PAF~UF~CF~ARARARGRUF~CF~GFUF~CF~CRUF~GRGRAF~GF~GF:X:X 3’
24. seqRNAi siRNA Compounds Directed to Human p53 for sequential induction of
RNAi
Sense Strands:
’ A~C~C~U~A-U-G-G-A~A~A~C~U~A~C~U~U 3’ (#)
’ C~A~G~A~C~C~U~A-U-G-G-A~A~A~C~U~A~C~U~U 3’ (#)
’ C~A~G~A~C~C~U~A-U-G-G-A~A-A~C~U~A~C~U~U 3’ (#)
5’ C~A~G~A~C~C~U~A-U-Y-G-A~A-A~C~U~A~C~U~U 3’ (#)
’ C~A~G~A~C~C~U~A-U-Y-G-A~A-A~C~U~A~C*~U~U 3’ (#)
’ C~A~G~A~C~C*~U~A-U-Y-G-A~A-A~C~U~A~C*~U~U 3’ (#)
’ C~A~G~A~C~C~U~A~U-Y~G~A~A~A~C~U~A~C*~U~U 3’ (#)
’ C~A~G~A~C~C*~U~A~U~Y~G~A~A~A~C~U~A~C*~U~U 3’ (#)
5’ C~A~G~A~C~C~U~A~U-G*~G~A~A~A~C~U~A~C*~U~U 3’ (#)
’ C~A~G~A~C~C*~U~A~U~G~G*~A~A~A~C~U~A~C*~U~U 3’ (#)
’ C~A~G~A~C~C~U~A~U~GXG~A~A~A~C~U~A~C~U~U 3’ (#)
’ A~C~C~U~A~U~G~G~A~A~A~C~U~A~C 3’ (#)
Antisense Strands:
5' U~A~G-U~U-U-C-C-A-U~A-G~G~U~C~U~G 3' (#)
' A~A~G~U~A~G-U~U-U-C-C-A-U~A-G~G~U~C~U~G 3' (#)
' A~A~G~U~A~G-U~U-U-C-C-A-U~A-G~G~U~C~U~G 3' (#)
' A~A~G~U~A~G-U~U-U-C-C-A-U~A-G~G~U~C~U~G 3' (#)
' A~A~G~U~A~G~U-U-U-C-C-A-U-A~G~G~U~C~U~G 3' (#)
' A~A~G~U*~A~G-U~U-U-C-C-A-U~A-G~G~U~C~U~G 3' (#)
' A~A~G~U~A~G~U*-U-U-C-C-A-U-A~G~G~U~C~U~G 3' (#)
1) The nucleosides shown in bold have the 2’methyl modification, those that are
ined are 2’-fluoro and those that are r bold nor underlined are native ribose.
2) One or more contiguous dashes ent phosphodiester linkages and ~ represents
phosphorothioate linkages
3) Any asterisk after a letter indicates it is an unlocked nucleic acid monomer. These
nucleosides do not have other ribose cations such as 2'-fluro or 2'methyl.
4) Any X indicates the lack of a linkage
5) Any Y indicates an abasic nucleoside
6) The C in any CpG may be methylated at the C5 position
7) The 5'end of the sense strand may have a 5'methyl group
8) The 5'end of an antisense strand may have a 5'-phosphate group
9) The two nucleosides in positions 10 and 11 from the 5'-end of the nse strand
which may be in italics are the ones opposite the argonaute 2 cleavage site
. seqRNAi siRNA Compounds Directed to Human p53 for sequential induction of
RNAi
Sense Strands:
’ C~C~G~U~C~C~C~A-A-G-C-A~A~U~G~G~A~C~G~A 3’ (#)
’ C~C~G~U~C~C~C~A-A-G-C-A~A~U~G~G~A~C~G~A 3’ (#)
’ C~C~G~U~A~C~C~A~A~A~C~A~A~U~G~G~A~U~G~A 3’ (#)
’ C~C~G~U~C~C~C~A-A-Y-C-A~A~U~G~G~A~C~G~A 3’ (#)
5’ C~C~G~U~C~C~C~A-A-Y-C-A~A~U~G~G~A*~C~G~A 3’ (#)
’ C~C~G~U~C~C~C*~A-A-Y-C-A~A~U~G~G~A*~C~G~A 3’ (#)
’ C~C~G~U~C~C~C~A~A~Y~C~A~A~U~G~G~A~C~G~A 3’ (#)
’ C~C~G~U~C~C~C~A~A~Y~C~A~A~U~G~G~A*~C~G~A 3’ (#)
’ C~C~G~U~C~C~C*~A~A~Y~C~A~A~U~G~G~A*~C~G~A 3’ (#)
5’ C~C~G~U~C~C~C~A~A~GXC~A~A~U~G~G~A~C~G~A 3’ (#)
’ G~U~C~C~C~A~A~G~C~A~A~U~G~G~A 3’ (#)
’ G~U~C~C~C~A~A*~G~C~A~A~U~G~G~A 3’ (#)
Antisense Strands:
' U~C~G~U~C~C-A-U-U-G-C-U-U-G-G~G~A~C~G~G 3' (#)
5' U~C~G~U~C~C-A-U-U-G-C-U-U-G-G~G~A~C~G~G 3' (#)
' U~C~G~U~C~C-A-U-U-G-C-U-U-G-G~G~A~C~G~G 3' (#)
' U~C~G~U~C~C-A-U-U-G-C-U-U-G-G~G~A~C~G~G 3' (#)
' U~C~G~U~C~C-A~U-U-G-C-U-U~G-G~G~A~C~G~G 3' (#)
' U~C~G~U*~C~C-A~U-U-G-C-U-U~G-G~G~A~C~G~G 3' (#)
5' U~C~G~U~C~C-A*~U-U-G-C-U-U~G-G~G~A~C~G~G 3' (#)
1) The nucleosides shown in bold have the 2’methyl cation, those that are
underlined are 2’-fluoro and those that are neither bold nor underlined are native ribose.
2) One or more contiguous dashes represent phosphodiester linkages and ~ represents
phosphorothioate linkages
3) Any asterisk after a letter indicates it is an unlocked nucleic acid monomer. These
nucleosides do not have other ribose modifications such as 2'-fluro or 2'methyl.
4) Any X indicates the lack of a linkage
) Any Y indicates an abasic nucleoside
6) The C in any CpG may be methylated at the C5 position
7) The 5'end of the sense strand may have a 5'methyl group
8) The 5'end of an antisense strand may have a 5'-phosphate group
9) The two nucleosides in positions 10 and 11 from the 5'-end of the antisense strand
which may be in italics are the ones opposite the argonaute 2 cleavage site
26. i siRNA Compounds Directed to Human p53 for tial ion of
RNAi
Sense s:
5’ C~C~G~A~G~U~G~G-A-A-G-G~A~A~A~U~U~U 3’ (#)
Antisense Strands:
' A~A~A~U~U-U-C-C-U-U-C-C-A-C~U~C~G~G 3' (#)
1) The sides shown in bold have the 2’methyl modification, those that are
underlined are 2’-fluoro and those that are neither bold nor underlined are native
ribose.
2) One or more contiguous dashes represent phosphodiester linkages and ~ represents
orothioate linkages
3) Any asterisk after a letter indicates it is an unlocked nucleic acid monomer. These
nucleosides do not have other ribose modifications such as 2'-fluro or ethyl.
4) Any X indicates the lack of a linkage
5) Any Y indicates an abasic side
6) The C in any CpG may be methylated at the C5 position
7) The 5'end of the sense strand may have a 5'methyl group
8) The 5'end of an antisense strand may have a 5'-phosphate group
9) The two nucleosides in positions 10 and 11 from the 5'-end of the antisense strand
which may be in italics are the ones opposite the argonaute 2 cleavage site
27. seqRNAi siRNA Compounds Directed to Human p53 for sequential induction of
RNAi
Sense Strands:
5’ G~G~A~G~A~A~U~A-U-U-U-C~A~C~C~C~U~U 3’ (#)
Antisense Strands:
' A~A~G~G~G-U-G-A-A-A-U-A-U-U~C~U~C~C 3' (#)
1) The sides shown in bold have the 2’methyl modification, those that are
ined are 2’-fluoro and those that are neither bold nor underlined are native
ribose.
2) One or more contiguous dashes represent phosphodiester linkages and ~ represents
phosphorothioate linkages
3) Any asterisk after a letter tes it is an unlocked nucleic acid monomer. These
nucleosides do not have other ribose modifications such as 2'-fluro or 2'methyl.
4) Any X tes the lack of a linkage
) Any Y tes an abasic nucleoside
6) The C in any CpG may be methylated at the C5 position
7) The 5'end of the sense strand may have a 5'methyl group
8) The 5'end of an antisense strand may have a 5'-phosphate group
9) The two nucleosides in positions 10 and 11 from the 5'-end of the antisense strand
which may be in italics are the ones opposite the argonaute 2 cleavage site
28. seqRNAi siRNA Compounds Directed to Human p53 for sequential induction of
RNAi
Sense s:
5’ G~G~A~G~G~G~A~G-A-A-U-A~U~U~U~C~A~C~C~C~U 3’ (#)
Antisense Strands:
' G~A~G~G~G-U-G-A-A-A-U-A-U-U-C-U-C-C~C~U~C~C 3' (#)
1) The nucleosides shown in bold have the 2’methyl modification, those that are
underlined are 2’-fluoro and those that are neither bold nor underlined are native
ribose.
2) One or more contiguous dashes represent phosphodiester linkages and ~ represents
phosphorothioate linkages
3) Any asterisk after a letter indicates it is an unlocked nucleic acid monomer. These
sides do not have other ribose modifications such as 2'-fluro or 2'methyl.
4) Any X indicates the lack of a linkage
) Any Y indicates an abasic nucleoside
6) The C in any CpG may be methylated at the C5 position
7) The 5'end of the sense strand may have a 5'methyl group
8) The 5'end of an antisense strand may have a 5'-phosphate group
9) The two nucleosides in positions 10 and 11 from the 5'-end of the antisense strand
which may be in italics are the ones te the argonaute 2 cleavage site
29. seqRNAi siRNA Compounds Directed to Human p53 for tial induction of
RNAi
Sense s:
’ G~G~A~C~G~G~A~A-C-A-G-C~U~U~U~G~A~G~G~U 3’ (#)
Antisense s:
' A~C~C~U~C-A-A-A-G-C-U-G-U-U-C-C~G~U~C~C 3' (#)
1) The nucleosides shown in bold have the 2’methyl modification, those that are
underlined are 2’-fluoro and those that are neither bold nor underlined are native
ribose.
2) One or more contiguous dashes represent phosphodiester linkages and ~ represents
phosphorothioate es
3) Any asterisk after a letter indicates it is an unlocked c acid monomer. These
nucleosides do not have other ribose modifications such as 2'-fluro or 2'methyl.
4) Any X indicates the lack of a linkage
) Any Y indicates an abasic nucleoside
6) The C in any CpG may be methylated at the C5 on
7) The 5'end of the sense strand may have a 5'methyl group
8) The 5'end of an antisense strand may have a 5'-phosphate group
9) The two nucleosides in positions 10 and 11 from the 5'-end of the antisense strand
which may be in italics are the ones opposite the argonaute 2 cleavage site
. i siRNA Compounds Directed to Human p53 for sequential induction of
RNAi
Sense Strands:
’ C~A~U~G~U~U~C~A-A-G-A-C~A~G~A~A~G~G~G~C~C 3’ (#)
nse Strands:
5' G~G~C~C~C-U-U-C-U-G-U-C-U-U-G-A-A~C~A~U~G 3' (#)
1) The nucleosides shown in bold have the 2’methyl modification, those that are
underlined are 2’-fluoro and those that are neither bold nor underlined are native
ribose.
2) One or more contiguous dashes represent phosphodiester linkages and ~ represents
phosphorothioate linkages
3) Any asterisk after a letter indicates it is an unlocked nucleic acid monomer. These
nucleosides do not have other ribose modifications such as 2'-fluro or 2'methyl.
4) Any X indicates the lack of a linkage
) Any Y indicates an abasic nucleoside
6) The C in any CpG may be methylated at the C5 position
7) The 5'end of the sense strand may have a ethyl group
8) The 5'end of an nse strand may have a sphate group
9) The two nucleosides in positions 10 and 11 from the 5'-end of the antisense strand
which may be in italics are the ones opposite the argonaute 2 cleavage site
31. i siRNA Compounds Directed to Human Fas for sequential induction of
RNAi
Sense s:
5’ G~G~A~A~G~A~C~U-G-U-U-A~C~U~A~C~A~G~T~T 3’ (#)
nse Strands:
' A~G~A~C~U-G-U-A-G-U-A-A-C-A-G-U-C~U~U~C~C 3' (#)
1) The nucleosides shown in bold have the 2’methyl modification, those that are
underlined are 2’-fluoro and those that are neither bold nor underlined are native
ribose.
2) One or more contiguous dashes represent phosphodiester linkages and ~ represents
phosphorothioate linkages
3) Any asterisk after a letter indicates it is an unlocked nucleic acid monomer. These
nucleosides do not have other ribose modifications such as 2'-fluro or 2'methyl.
4) Any X indicates the lack of a linkage
) Any Y indicates an abasic nucleoside
6) The C in any CpG may be methylated at the C5 position
7) The 5'end of the sense strand may have a 5'methyl group
8) The 5'end of an antisense strand may have a 5'-phosphate group
9) The two nucleosides in positions 10 and 11 from the 5'-end of the antisense strand
which may be in italics are the ones opposite the argonaute 2 cleavage site
32. seqRNAi siRNA Compounds Directed to Human Fas for tial induction of
RNAi
Sense Strands:
’ G~U~G~A~U~G~A~A-G-G-A-C-A~U~G~G~C~U~U~A 3’ (#)
Antisense Strands:
' U~A~A~G~C-C-A-U-G-U-C-C-U-U-C-A~U~C~A~C 3' (#)
1) The nucleosides shown in bold have the 2’methyl modification, those that are
underlined are 2’-fluoro and those that are neither bold nor ined are native
ribose.
2) One or more uous dashes represent phosphodiester linkages and ~ represents
phosphorothioate linkages
3) Any asterisk after a letter indicates it is an unlocked nucleic acid monomer. These
nucleosides do not have other ribose modifications such as ro or 2'methyl.
4) Any X indicates the lack of a linkage
) Any Y indicates an abasic nucleoside
6) The C in any CpG may be methylated at the C5 position
7) The 5'end of the sense strand may have a 5'methyl group
8) The 5'end of an antisense strand may have a 5'-phosphate group
9) The two nucleosides in positions 10 and 11 from the 5'-end of the antisense strand
which may be in italics are the ones opposite the argonaute 2 cleavage site
33. seqRNAi siRNA nds Directed to Human Fas for sequential induction of
RNAi
Sense Strands:
’ G~C~C~A~U~G~A~A-G-G-A-C~A~U~G~G~C~U~U~A 3’ (#)
Antisense Strands:
' U~A~A~G~C-C-A-U-G-U-C-C-U-U-C-A~U~G~G~C 3' (#)
1) The sides shown in bold have the 2’methyl modification, those that are
ined are 2’-fluoro and those that are neither bold nor underlined are native
ribose.
2) One or more contiguous dashes represent phosphodiester linkages and ~ represents
phosphorothioate linkages
3) Any asterisk after a letter indicates it is an unlocked nucleic acid monomer. These
nucleosides do not have other ribose modifications such as 2'-fluro or 2'methyl.
4) Any X indicates the lack of a linkage
) Any Y indicates an abasic nucleoside
6) The C in any CpG may be ated at the C5 position
7) The 5'end of the sense strand may have a 5'methyl group
8) The 5'end of an antisense strand may have a 5'-phosphate group
9) The two nucleosides in positions 10 and 11 from the 5'-end of the antisense strand
which may be in italics are the ones opposite the ute 2 cleavage site
34. seqRNAi siRNA nds Directed to Human Fas for sequential induction of
RNAi
Sense Strands:
’ G~A~A~G~C~G~U~A-U-G-A-C~A~C~A~U~U~G~A~T 3’ (#)
Antisense Strands:
' A~U~C~A~A-U-G-U-G-U-C-A-U-A-C-G~C~U~U~C 3' (#)
1) The nucleosides shown in bold have the ethyl modification, those that are
ined are 2’-fluoro and those that are neither bold nor underlined are native
ribose.
2) One or more contiguous dashes ent phosphodiester linkages and ~ represents
phosphorothioate linkages
3) Any asterisk after a letter indicates it is an unlocked nucleic acid r. These
nucleosides do not have other ribose cations such as 2'-fluro or 2'methyl.
4) Any X indicates the lack of a linkage
) Any Y indicates an abasic nucleoside
6) The C in any CpG may be methylated at the C5 position
7) The 5'end of the sense strand may have a 5'methyl group
8) The 5'end of an antisense strand may have a 5'-phosphate group
9) The two nucleosides in positions 10 and 11 from the 5'-end of the antisense strand
which may be in italics are the ones opposite the argonaute 2 cleavage site
35. seqRNAi siRNA Compounds Directed to Human Fas for sequential induction of
RNAi
Sense Strands:
’ G~G~A~C~A~U~U~A-C-U-A-G~U~G~A~C~U~C~A 3’ (#)
Antisense Strands:
' U~G~A~G~U-C-A-C-U-A-G-U-A-A-U~G~U~C~C 3' (#)
1) The nucleosides shown in bold have the 2’methyl modification, those that are
underlined are 2’-fluoro and those that are neither bold nor ined are native
ribose.
2) One or more contiguous dashes represent phosphodiester linkages and ~ represents
phosphorothioate linkages
3) Any sk after a letter indicates it is an ed nucleic acid monomer. These
nucleosides do not have other ribose modifications such as 2'-fluro or 2'methyl.
4) Any X indicates the lack of a linkage
5) Any Y indicates an abasic nucleoside
6) The C in any CpG may be methylated at the C5 position
7) The 5'end of the sense strand may have a 5'methyl group
8) The 5'end of an antisense strand may have a 5'-phosphate group
9) The two nucleosides in positions 10 and 11 from the 5'-end of the antisense strand
which may be in italics are the ones te the argonaute 2 cleavage site
36. seqRNAi siRNA Compounds Directed to Murine ApoB for sequential induction
of RNAi
Sense Strands:
' A~C~U~U~C-C-U-G-A~A~U~A~A~C~U~A 3' (#)
Antisense Strands:
' U~A~G~U~U-A-U-U-C-A-G-G-A-A-G~U~C~U~A 3' (#)
1) The nucleosides shown in bold have the 2’methyl modification, those that are
underlined are 2’-fluoro and those that are neither bold nor underlined are native
ribose.
2) One or more uous dashes represent phosphodiester linkages and ~ represents
phosphorothioate linkages
3) Any asterisk after a letter indicates it is an ed c acid monomer. These
nucleosides do not have other ribose modifications such as 2'-fluro or 2'methyl.
4) Any X indicates the lack of a e
) Any Y indicates an abasic nucleoside
6) The C in any CpG may be methylated at the C5 on
7) The 5'end of the sense strand may have a 5'methyl group
8) The 5'end of an antisense strand may have a 5'-phosphate group
9) The two nucleosides in positions 10 and 11 from the 5'-end of the antisense strand
which may be in italics are the ones opposite the argonaute 2 cleavage site
37. seqRNAi siRNA Compounds Directed to Human/Murine ApoB for sequential
induction of RNAi
Sense Strands:
’ A~G~G~G~U~G~U~A-U-G-G-C-U~U~C~A~A~C~C~C~U 3’ (#)
Antisense Strands:
' A~G~G~G~U-U-G-A-A-G-C-C-A-U-A-C-A~C~C~C~U 3' (#)
1) The nucleosides shown in bold have the 2’methyl cation, those that are
underlined are 2’-fluoro and those that are neither bold nor underlined are native
.
2) One or more contiguous dashes represent phosphodiester linkages and ~ represents
phosphorothioate es
3) Any asterisk after a letter indicates it is an unlocked nucleic acid monomer. These
nucleosides do not have other ribose modifications such as 2'-fluro or 2'methyl.
4) Any X indicates the lack of a linkage
) Any Y indicates an abasic nucleoside
6) The C in any CpG may be methylated at the C5 position
7) The 5'end of the sense strand may have a 5'methyl group
8) The 5'end of an antisense strand may have a 5'-phosphate group
9) The two nucleosides in positions 10 and 11 from the 5'-end of the antisense strand
which may be in italics are the ones opposite the ute 2 cleavage site
38. seqRNAi siRNA Compounds ed to Human/Murine ApoB for sequential
induction of RNAi
Sense Strands:
’ G~G~A~G~U~U~U~G-U-G-A-C~A~A~A~U~A~U~G~G~G~C~A 3’ (#)
nse Strands:
' U~G~C~C~C-A-U-A-U-U-U-G-U-C-A-C-A-A-A~C~U~C~C 3' (#)
1) The nucleosides shown in bold have the 2’methyl modification, those that are
underlined are 2’-fluoro and those that are neither bold nor ined are native
ribose.
2) One or more contiguous dashes represent phosphodiester linkages and ~ represents
phosphorothioate linkages
3) Any asterisk after a letter indicates it is an unlocked nucleic acid monomer. These
nucleosides do not have other ribose modifications such as 2'-fluro or 2'methyl.
4) Any X indicates the lack of a linkage
) Any Y tes an abasic nucleoside
6) The C in any CpG may be methylated at the C5 position
7) The 5'end of the sense strand may have a 5'methyl group
8) The 5'end of an antisense strand may have a 5'-phosphate group
9) The two nucleosides in positions 10 and 11 from the 5'-end of the antisense strand
which may be in italics are the ones opposite the argonaute 2 cleavage site
39. seqRNAi siRNA nds Directed to Human/Murine ApoB for sequential
ion of RNAi
Sense s:
’ G~A~U~U~G~A~U~U-G-A-C~C~U~G~U~C~C~A~U~U 3’ (#)
Antisense Strands:
' A~A~U~G~G-A-C-A-G-G-U-C-A-A-U-C~A~A~U~C 3' (#)
1) The sides shown in bold have the ethyl modification, those that are
underlined are 2’-fluoro and those that are neither bold nor underlined are native
ribose.
2) One or more contiguous dashes represent phosphodiester linkages and ~ represents
phosphorothioate linkages
3) Any asterisk after a letter indicates it is an unlocked nucleic acid monomer. These
nucleosides do not have other ribose modifications such as 2'-fluro or 2'methyl.
4) Any X indicates the lack of a linkage
5) Any Y indicates an abasic nucleoside
6) The C in any CpG may be methylated at the C5 position
7) The 5'end of the sense strand may have a 5'methyl group
8) The 5'end of an antisense strand may have a 5'-phosphate group
9) The two nucleosides in positions 10 and 11 from the 5'-end of the antisense strand
which may be in italics are the ones opposite the argonaute 2 cleavage site
40. seqRNAi siRNA Compounds Directed to Human/Murine ApoB for tial
induction of RNAi
Sense Strands:
’ G~U~A~U~U~C~A~C-A-C-U-G~A~A~U~A~C~C~A~A~U 3’ (#)
Antisense Strands:
' A~U~U~G~G-U-A-U-U-C-A-G-U-G-U-G-A~A~U~A~C 3' (#)
1) The nucleosides shown in bold have the 2’methyl modification, those that are
underlined are 2’-fluoro and those that are neither bold nor underlined are native
ribose.
2) One or more contiguous dashes represent phosphodiester linkages and ~ represents
phosphorothioate linkages
3) Any asterisk after a letter indicates it is an ed nucleic acid r. These
nucleosides do not have other ribose modifications such as 2'-fluro or 2'methyl.
4) Any X indicates the lack of a linkage
) Any Y indicates an abasic nucleoside
6) The C in any CpG may be methylated at the C5 on
7) The 5'end of the sense strand may have a 5'methyl group
8) The 5'end of an antisense strand may have a 5'-phosphate group
9) The two nucleosides in positions 10 and 11 from the 5'-end of the antisense strand
which may be in italics are the ones opposite the argonaute 2 ge site
41. seqRNAi siRNA Compounds Directed to Human ApoB for sequential induction
of RNAi
Sense Strands:
’ G~G~U~G~C~G~A~A-G-C-A-G~A~C~U~G~A~G~G~C~T~A 3’ (#)
Antisense Strands:
' T~A~G~C~C-U-C-A-G-U-C-U-G-C-U-U-C-G~C~A~C~C 3' (#)
1) The nucleosides shown in bold have the 2’methyl modification, those that are
underlined are 2’-fluoro and those that are neither bold nor underlined are native
ribose.
2) One or more contiguous dashes represent phosphodiester linkages and ~ represents
phosphorothioate es
3) Any asterisk after a letter tes it is an unlocked nucleic acid r. These
nucleosides do not have other ribose modifications such as 2'-fluro or 2'methyl.
4) Any X indicates the lack of a e
) Any Y indicates an abasic nucleoside
6) The C in any CpG may be methylated at the C5 position
7) The 5'end of the sense strand may have a 5'methyl group
8) The 5'end of an antisense strand may have a 5'-phosphate group
9) The two nucleosides in positions 10 and 11 from the 5'-end of the antisense strand
which may be in italics are the ones opposite the argonaute 2 cleavage site
42. seqRNAi siRNA Compounds Directed to Human ApoB for sequential induction
of RNAi
Sense Strands:
5’ U~G~C~G~A~A~G~C~A~G~A~C~U~G~A 3’ (#)
Antisense Strands:
' G~C~C~U~C-A-G-U-C-U-G-C-U-U-C-G-C~A~G~G~C 3' (#)
1) The nucleosides shown in bold have the 2’methyl cation, those that are
underlined are 2’-fluoro and those that are neither bold nor underlined are native
ribose.
2) One or more contiguous dashes represent odiester es and ~ represents
phosphorothioate linkages
3) Any sk after a letter indicates it is an unlocked nucleic acid monomer. These
nucleosides do not have other ribose modifications such as 2'-fluro or 2'methyl.
4) Any X indicates the lack of a linkage
) Any Y tes an abasic nucleoside
6) The C in any CpG may be methylated at the C5 position
7) The 5'end of the sense strand may have a 5'methyl group
8) The 5'end of an antisense strand may have a 5'-phosphate group
9) The two nucleosides in positions 10 and 11 from the 5'-end of the antisense strand
which may be in italics are the ones opposite the argonaute 2 cleavage site
43. seqRNAi siRNA nds Directed to Human ApoB for sequential induction
of RNAi
Sense Strands:
’ C~G~G~C~A~U~U~C-G-G-C-U~A~U~G~U~G~U~U 3’ (#)
Antisense Strands:
' A~A~C~A-C-A-U-A-G-C-C-G-A-A-U~G~C~C~G 3' (#)
Sense Strands as 16-mer:
’ C~G~G~C~A~U~U~C-G-G-C-U~A~U~G~U 3’ (#)
Antisense Strands as 16-mer:
' A~C~A~U~A-G-C-C-G-A-A-U-G~C~C~G 3'
1) The nucleosides shown in bold have the 2’methyl modification, those that are
underlined are 2’-fluoro and those that are neither bold nor ined are native
ribose.
2) One or more contiguous dashes represent phosphodiester linkages and ~ ents
phosphorothioate es
3) Any sk after a letter indicates it is an unlocked nucleic acid monomer. These
nucleosides do not have other ribose modifications such as 2'-fluro or 2'methyl.
4) Any X indicates the lack of a linkage
) Any Y indicates an abasic nucleoside
6) The C in any CpG may be methylated at the C5 position
7) The 5'end of the sense strand may have a 5'methyl group
8) The 5'end of an antisense strand may have a 5'-phosphate group
9) The two sides in positions 10 and 11 from the 5'-end of the antisense strand
which may be in italics are the ones opposite the argonaute 2 cleavage site
44. seqRNAi siRNA Compounds Directed to Human ApoB for tial induction
of RNAi
Sense Strands:
’ C~A~C~A~G~G~G~C~U~C~A~C~C~C~U 3’ (#)
Antisense Strands:
' U~C~A~G~G-G-U-G-A-G-C-C-C-U-G-U~G~U~G~U 3' (#)
1) The nucleosides shown in bold have the 2’methyl modification, those that are
underlined are 2’-fluoro and those that are neither bold nor ined are native
ribose.
2) One or more contiguous dashes represent odiester linkages and ~ represents
phosphorothioate es
3) Any asterisk after a letter indicates it is an unlocked nucleic acid monomer. These
nucleosides do not have other ribose cations such as 2'-fluro or 2'methyl.
4) Any X indicates the lack of a linkage
) Any Y indicates an abasic nucleoside
6) The C in any CpG may be methylated at the C5 position
7) The 5'end of the sense strand may have a 5'methyl group
8) The 5'end of an antisense strand may have a 5'-phosphate group
9) The two nucleosides in positions 10 and 11 from the 5'-end of the antisense strand
which may be in italics are the ones opposite the argonaute 2 cleavage site
45. seqRNAi siRNA nds Directed to Human/Murine/Rat/Nonhuman
Primate PCSK9 for sequential ion of RNAi
Sense Strands:
5’ C~U~A~G~A~C~C~U-G-U-U-U~U~G~C~U~U~U 3’ (#)
Antisense Strands:
' A~A~A~G~C-A-A-A-A-C-A-G-G-U~C~U~A~G 3' (#)
1) The nucleosides shown in bold have the 2’methyl modification, those that are
underlined are 2’-fluoro and those that are r bold nor ined are native
ribose.
2) One or more contiguous dashes represent phosphodiester linkages and ~ represents
phosphorothioate linkages
3) Any asterisk after a letter indicates it is an unlocked nucleic acid monomer. These
nucleosides do not have other ribose modifications such as 2'-fluro or 2'methyl.
4) Any X indicates the lack of a linkage
) Any Y indicates an abasic nucleoside
6) The C in any CpG may be methylated at the C5 position
7) The 5'end of the sense strand may have a 5'methyl group
8) The 5'end of an antisense strand may have a 5'-phosphate group
9) The two nucleosides in positions 10 and 11 from the 5'-end of the antisense strand
which may be in italics are the ones opposite the argonaute 2 cleavage site
46. seqRNAi siRNA Compounds Directed to Human/Murine/Rat/Nonhuman
Primate PCSK9 for sequential induction of RNAi
Sense Strands:
’ G~A~G~G~U~G~U~A-U-C-U-C~C~U~A~G~A~C~A 3’ (#)
Antisense Strands:
' U~G~U~C~U-A-G-G-A-G-A-U-A-C-A~C~C~U~C 3' (#)
1) The nucleosides shown in bold have the 2’methyl modification, those that are
ined are 2’-fluoro and those that are neither bold nor underlined are native
ribose.
2) One or more contiguous dashes represent phosphodiester linkages and ~ ents
phosphorothioate linkages
3) Any asterisk after a letter indicates it is an unlocked nucleic acid monomer. These
sides do not have other ribose modifications such as 2'-fluro or 2'methyl.
4) Any X indicates the lack of a linkage
) Any Y indicates an abasic side
6) The C in any CpG may be methylated at the C5 position
7) The 5'end of the sense strand may have a 5'methyl group
8) The 5'end of an antisense strand may have a 5'-phosphate group
9) The two nucleosides in positions 10 and 11 from the 5'-end of the antisense strand
which may be in italics are the ones opposite the ute 2 cleavage site
47. seqRNAi siRNA Compounds Directed to Human/Murine/Rat/Nonhuman
Primate PCSK9 for tial induction of RNAi
Sense Strands:
’ G~A~G~G~U~G~U~A-U-C-U-C~C~U~C~G~A~C~A 3’ (#)
Antisense Strands:
' U~G~U~C~G-A-G-G-A-G-A-U-A-C-A~C~C~U~C 3' (#)
1) The nucleosides shown in bold have the 2’methyl modification, those that are
underlined are 2’-fluoro and those that are neither bold nor underlined are native
ribose.
2) One or more uous dashes ent phosphodiester linkages and ~ represents
phosphorothioate linkages
3) Any asterisk after a letter indicates it is an unlocked nucleic acid monomer. These
nucleosides do not have other ribose modifications such as 2'-fluro or 2'methyl.
4) Any X indicates the lack of a linkage
5) Any Y indicates an abasic nucleoside
6) The C in any CpG may be methylated at the C5 on
7) The 5'end of the sense strand may have a 5'methyl group
8) The 5'end of an antisense strand may have a sphate group
9) The two nucleosides in positions 10 and 11 from the 5'-end of the antisense strand
which may be in italics are the ones te the argonaute 2 cleavage site
48. seqRNAi siRNA Compounds Directed to Human PCSK9 for sequential
induction of RNAi
Sense Strands:
’ G~G~G~U~G~G~U~C-A-G-C-G~G~C~C~G~G~G~A~U 3’ (#)
Antisense Strands:
' C~C-G-G-C-C-G-C-U-G-A-C-C~A~C~C~C 3' (#)
1) The nucleosides shown in bold have the 2’methyl modification, those that are
ined are 2’-fluoro and those that are neither bold nor underlined are native
ribose.
2) One or more contiguous dashes represent phosphodiester linkages and ~ ents
orothioate linkages
3) Any asterisk after a letter indicates it is an unlocked nucleic acid monomer. These
nucleosides do not have other ribose modifications such as 2'-fluro or 2'methyl.
4) Any X indicates the lack of a linkage
) Any Y indicates an abasic nucleoside
6) The C in any CpG may be methylated at the C5 position
7) The 5'end of the sense strand may have a 5'methyl group
8) The 5'end of an antisense strand may have a 5'-phosphate group
9) The two nucleosides in positions 10 and 11 from the 5'-end of the antisense strand
which may be in italics are the ones opposite the argonaute 2 cleavage site
49. seqRNAi siRNA Compounds Directed to Human PCSK9 for sequential
induction of RNAi
Sense Strands:
’ G~C~U~G~C~C~C~A-C-G-U-G~G~C~U~G~G~C~A~U 3’ (#)
Antisense Strands:
' A~U~G~C~C-A-G-C-C-A-C-G-U-G-G-G~C~A~G~C 3' (#)
1) The sides shown in bold have the 2’methyl modification, those that are
underlined are 2’-fluoro and those that are neither bold nor underlined are native
ribose.
2) One or more contiguous dashes represent phosphodiester linkages and ~ represents
phosphorothioate linkages
3) Any asterisk after a letter indicates it is an unlocked nucleic acid monomer. These
nucleosides do not have other ribose modifications such as 2'-fluro or ethyl.
4) Any X indicates the lack of a e
) Any Y indicates an abasic nucleoside
6) The C in any CpG may be methylated at the C5 position
7) The 5'end of the sense strand may have a 5'methyl group
8) The 5'end of an antisense strand may have a 5'-phosphate group
9) The two nucleosides in positions 10 and 11 from the 5'-end of the nse strand
which may be in s are the ones opposite the ute 2 cleavage site
50. seqRNAi siRNA Compounds Directed to Human PCSK9 for sequential
induction of RNAi
Sense Strands:
’ G~C~U~G~C~C~C~A~C~G~U~G~G~C~U 3’ (#)
Antisense Strands:
5' C~C~A~G~C-C-A-C-G-U-G-G-G-C-A-G~C~A~G~C 3' (#)
1) The nucleosides shown in bold have the 2’methyl modification, those that are
underlined are 2’-fluoro and those that are neither bold nor ined are native
ribose.
2) One or more contiguous dashes represent odiester linkages and ~ represents
phosphorothioate linkages
3) Any asterisk after a letter indicates it is an unlocked c acid monomer. These
nucleosides do not have other ribose cations such as 2'-fluro or 2'methyl.
4) Any X indicates the lack of a linkage
) Any Y tes an abasic nucleoside
6) The C in any CpG may be methylated at the C5 position
7) The 5'end of the sense strand may have a 5'methyl group
8) The 5'end of an antisense strand may have a 5'-phosphate group
9) The two nucleosides in positions 10 and 11 from the 5'-end of the antisense strand
which may be in italics are the ones opposite the argonaute 2 cleavage site
51. seqRNAi siRNA Compounds Directed to Human PCSK9 for sequential
induction of RNAi
Sense Strands:
5’ G~G~U~G~A~G~G~G~U~G~U~C~U~A~C 3’ (#)
Antisense Strands:
' G~G~C~G~U-A-G-A-C-A-C-C-C-U-C-A-C~C~G~C~C 3' (#)
1) The nucleosides shown in bold have the 2’methyl modification, those that are
underlined are oro and those that are r bold nor underlined are native
ribose.
2) One or more contiguous dashes represent phosphodiester linkages and ~ represents
phosphorothioate linkages
3) Any asterisk after a letter indicates it is an unlocked nucleic acid monomer. These
nucleosides do not have other ribose modifications such as 2'-fluro or ethyl.
4) Any X indicates the lack of a linkage
) Any Y indicates an abasic side
6) The C in any CpG may be methylated at the C5 position
7) The 5'end of the sense strand may have a 5'methyl group
8) The 5'end of an antisense strand may have a 5'-phosphate group
9) The two nucleosides in positions 10 and 11 from the 5'-end of the antisense strand
which may be in italics are the ones opposite the argonaute 2 cleavage site
52. seqRNAi siRNA Compounds Directed to Human PTEN for sequential induction
of RNAi
Sense Strands:
’ C~G~U~U~A~G~C~A-G-A-A-A~C~A~A~A~A~G~G~A 3’ (#)
’ C~G~U~U~A~G~C~A-G-A-A~A-C~A~A~A~A~G~G~A 3’ (#)
’ C~G~U~U~A~G*~C~A-G-A-A~A-C~A~A~A~A~G~G~A 3’ (#)
’ U~A~G*~C~A-G-A-A~A-C~A~A~A~A*~G~G~A 3’ (#)
5’ C~G~U~U~A~G~Y~A-G-A-A-A~C~A~A~A~A~G~G~A 3’ (#)
’ C~G~U~U~A~G~Y~A-G-A-A-A~C~A~A~A~A*~G~G~A 3’ (#)
’ C~G~U~U~A~G~C~A-G-Y-A-A~C~A~A~A~A*~G~G~A 3’ (#)
’ C~G~U~U~A~G*~C~A-G-Y-A-A~C~A~A~A~A*~G~G~A 3’ (#)
’ C~G~U~U~A~G*~C~A~G~Y~A~A~C~A~A~A~A*~G~G~A 3’ (#)
5’ C~G~U~U~A~U~C~A-G-A-A~A-C~A~A~U~A~G~G~A 3’ (#)
’ U~A~U~C~G-G-A-A~A-C~A~A~U~A~G~G~A 3’ (#)
’ C~G~U~U~A~G~C~A~G~AXA~A~C~A~A~A~A~G~G~A 3’ (#)
’ U~A~G~C~A~G~A~A~A~C~A~A~A~A 3’ (#)
’ U~A~G~C~A~G~A+~A~A~C~A~A~A~A 3’ (#)
Antisense Strands:
' U~C~C~U~U-U-U-G-U-U-U-C-U-G-C-U~A~A~C~G 3' (#)
' U~C~C~U~U~U-U-G-U-U-U-C-U-G-C~U~A~A~C~G 3' (#)
' U~C~C~U~U~U-U~G-U-U-U-C-U~G-C~U~A~A~C~G 3' (#)
' U~C~C~U~U~U-U~G-U-U-U-C-U~G-C~U~A~A~C~G 3' (#)
' U~C~C~U~U~U-U~G-U-U-U-C-U~G-C~U~A~A~C~G 3' (#)
' U~C~C~U~U~U-U~G-U-U-U-C-U~G-C~U~A~A~C~G 3' (#)
' U~U~U~U~G-U-U-U-C-U~G~C~U~A~A~C~G 3' (#)
1) The nucleosides shown in bold have the ethyl modification, those that are
underlined are oro and those that are neither bold nor underlined are native
ribose.
2) One or more contiguous dashes represent phosphodiester linkages and ~ represents
phosphorothioate linkages
3) Any asterisk after a letter indicates it is an unlocked nucleic acid monomer. These
nucleosides do not have other ribose modifications such as 2'-fluro or 2'methyl.
4) Any plus after a letter indicates it is an locked c acid monomer (LNA).
) Any X indicates the lack of a linkage
6) Any Y indicates an abasic nucleoside
7) The C in any CpG may be methylated at the C5 on
8) The 5'end of the sense strand may have a 5'methyl group
9) The 5'end of an antisense strand may have a 5'-phosphate group
) The two nucleosides in positions 10 and 11 from the 5'-end of the antisense strand
which may be in italics are the ones opposite the argonaute 2 cleavage site
53. seqRNAi siRNA Compounds ed to Human/Murine PTEN for sequential
induction of RNAi
Sense Strands:
5’ A~A~G~U~A~A~G~G~AXC~C~A~G~A~G~A~C~A~A 3’ (#)
’ G~U~A~A~G~G-A~C~C~A~G~A~G~A~C 3’ (#)
Antisense Strands:
' U~U~G~U~C-U~C-U-G-G-U-C-C~U-U~A~C~U~U 3' (#)
' U~U~G~U~C~U~C-U~G-G-U-C-C~U-U~A~C~U~U 3' (#)
5' U~U~G~U~C~U~C-U~G-G-U-C-C~U-U~A~C~U~U 3' (#)
' U~U~G~U~C~U~C-U~G-G-U-C-C~U-U~A~C~U~U 3' (#)
' U~U~G~U~C~U~C-U~G-G-U-C-C~U-U~A~C~U~U 3' (#)
1) The nucleosides shown in bold have the 2’methyl modification, those that are
underlined are 2’-fluoro and those that are neither bold nor underlined are native
ribose.
2) One or more contiguous dashes represent phosphodiester linkages and ~ represents
orothioate linkages
3) Any asterisk after a letter indicates it is an unlocked nucleic acid monomer. These
sides do not have other ribose modifications such as 2'-fluro or 2'methyl.
4) Any X indicates the lack of a linkage
) Any Y indicates an abasic side
6) The C in any CpG may be methylated at the C5 position
7) The 5'end of the sense strand may have a 5'methyl group
8) The 5'end of an antisense strand may have a 5'-phosphate group
9) The two sides in positions 10 and 11 from the 5'-end of the antisense strand
which may be in s are the ones opposite the argonaute 2 cleavage site
54. seqRNAi siRNA Compounds Directed to Human PTP-1B for sequential
induction of RNAi
Sense Strands:
' U~A~G~G~U~A~C~A-G-A-G~A-C~G~U~C~A~G~U 3' (#)
' U~A~G~G~U~A~C~A-G-A-G-A~C~G~U~C~A~G~U 3' (#)
' U~A~G~G~U~A~C~A-G-A-G-A~C~G~U~C~A~G~U 3' (#)
5' U~A~G~G~U~A*~C~A-G-A-G-A~C~G~U~C~A~G~U 3' (#)
' U~A~G~G~U~A*~C~A-G-A-G-A~C~G~U~C*~A~G~U 3' (#)
' U~A~G~G~U~A~C-Y-G-A-G-A~C~G~U~C~A~G~U 3' (#)
' U~A~G~G~U~A~C-Y-G-A-G-A~C~G~U~C~G~G~U 3' (#)
Antisense Strands:
5' A~C~U~G~A-C-G-U-C-U-C-U-G-U-A~C~C~U~A 3' (#)
' A~C~U~G~A~C-G~U-C-U-C-U-G~U-A~C~C~U~A 3' (#)
' A~C~U~G~A~C-G~U-C-U-C-U-G~U-A~C~C~U~A 3' (#)
' A~C~U~G~A~C-G~U-C-U-C-U-G~U-A~C~C~U~A 3' (#)
' A~C~U~G~A~C~G-U~C-U-C-U~G-U~A~C~C~U~A 3' (#)
1) The nucleosides shown in bold have the 2’methyl modification, those that are
underlined are 2’-fluoro and those that are r bold nor underlined are native
ribose.
2) One or more contiguous dashes represent phosphodiester linkages and ~ represents
phosphorothioate linkages
3) Any asterisk after a letter indicates it is an unlocked nucleic acid monomer. These
nucleosides do not have other ribose modifications such as ro or 2'methyl.
4) Any X tes the lack of a e
) Any Y indicates an abasic nucleoside
6) The C in any CpG may be methylated at the C5 position
7) The 5'end of the sense strand may have a 5'methyl group
8) The 5'end of an antisense strand may have a 5'-phosphate group
9) The two nucleosides in positions 10 and 11 from the 5'-end of the antisense strand
which may be in italics are the ones opposite the argonaute 2 cleavage site
55. seqRNAi siRNA Compounds Directed to Human PTEN for sequential induction
of RNAi
Sense Strands:
5’ G~G~G~A~A~A~A~U~A~C~A~U~U~C~U~U~U~C~C 3’ (#)
’ G~G~G~A~A~A~A~U~A~CXA~U~U~C~U~U~C~C~C 3’ (#)
’ G~G~G~A~A~A~A~U~A~C~A~U~U~C~U~U*~C~C~C 3’ (#)
’ G~G~G~A~A~A~A~U~A~Y~A~U~U~C~U~U*~C~C~C 3’ (#)
’ G~G~G~A~A*~A~A~U~A~Y~A~U~U~C~U~U*~C~C~C 3’ (#)
5’ G~A~A~A~A~U~A~C~A~U~U~C~U~U~C 3’ (#)
Antisense Strands:
' G~G~G~A~A~G-A-A-U-G-U-A-U-U~U~U~C~C~C 3' (#)
' G~G~G~A~A~G-A-A-U-G-U-A-U-U~U~U~C~C~C 3' (#)
' G~G~G~A~A~G-A~A-U-G-U-A-U-U~U~U~C~C~C 3' (#)
5' G~G~G~A~A~G-A~A-U-G-U-A-U-U~U~U~C~C~C 3' (#)
1) The nucleosides shown in bold have the 2’methyl modification, those that are
underlined are 2’-fluoro and those that are neither bold nor underlined are native
ribose.
2) One or more contiguous dashes represent phosphodiester linkages and ~ represents
phosphorothioate es
3) Any sk after a letter indicates it is an unlocked nucleic acid monomer. These
nucleosides do not have other ribose modifications such as 2'-fluro or 2'methyl.
4) Any X indicates the lack of a linkage
) Any Y indicates an abasic side
6) The C in any CpG may be methylated at the C5 position
7) The 5'end of the sense strand may have a 5'methyl group
8) The 5'end of an antisense strand may have a 5'-phosphate group
9) The two nucleosides in positions 10 and 11 from the 5'-end of the nse strand
which may be in s are the ones opposite the argonaute 2 cleavage site
56. seqRNAi siRNA Compounds Directed to Human/Nonhuman Primate PTEN for
sequential induction of RNAi
Sense Strands:
5’ G~G~G~U~A~A~A~U-A-C-A-U-U~C~U~U~C~A~U 3’ (#)
’ G~G~G~U~A~A~A~U-A-Y-A-U-U~C~U~U~C~A~U 3’ (#)
’ U~A*~A~A~U-A-Y-A-U-U~C~U~U~C~A~U 3’ (#)
’ G~G~G~U~A*~A~A~U~A~Y~A~U~U~C~U~U~C~A~U 3’ (#)
’ G~G~G~U~A*~A~A~U-A-Y-A-U-U~C~U~U*~C~A~U 3’ (#)
5’ G~G~G~U~A*~A~A~U~A~Y~A~U~U~C~U~U*~C~A~U 3’ (#)
’ G~G~G~U~A~A~A~U-A-C-A-U-U~C~U~C~C~A~U 3’ (#)
’ G~G~G~C~A~A~A~U-A-C-A-U-U~C~U~C~C~A~U 3’ (#)
’ G~G~G~C~A~A~A~U-A-C-G-U-U~C~U~C~C~A~U 3’ (#)
’ G~G~G~U~A~A~A~U~A~CXA~U~U~C~U~U~C~A~U 3’ (#)
5’ G~U~A~A~A~U~A~C~A~U~U~C~U~U~C 3’ (#)
Antisense Strands:
' A~U~G~A~A-G~A-A-U-G-U-A-U~U~U~A~C~C~C 3' (#)
' A~U~G~A~A~G-A~A-U-G-U-A-U~U-U~A~C~C~C 3' (#)
' A~U~G~A~A~G~A~A~U-G-U-A~U~U~U~A~C~C~C 3' (#)
5' A~U~G~A~A~G~A*~A~U-G-U-A~U~U~U~A~C~C~C 3' (#)
' A~U~G~A~A~G~A~A~U-G-U-A~U~U~U~A*~C~C~C 3' (#)
1) The sides shown in bold have the 2’methyl modification, those that are
underlined are oro and those that are neither bold nor underlined are native
ribose.
2) One or more contiguous dashes represent phosphodiester linkages and ~ represents
phosphorothioate linkages
3) Any asterisk after a letter indicates it is an unlocked nucleic acid monomer. These
nucleosides do not have other ribose modifications such as ro or 2'methyl.
4) Any X indicates the lack of a linkage
5) Any Y indicates an abasic nucleoside
6) The C in any CpG may be methylated at the C5 position
7) The 5'end of the sense strand may have a ethyl group
8) The 5'end of an antisense strand may have a 5'-phosphate group
9) The two nucleosides in positions 10 and 11 from the 5'-end of the antisense strand
which may be in italics are the ones opposite the argonaute 2 cleavage site
57. i siRNA Compounds Directed to Mouse PTEN for sequential induction
of RNAi
Sense Strands:
’ G~G~G~U~A~A~A~U-A-C-G-U-U~C~U~U~C~A~U 3’ (#)
’ G~G~G~U~A~A~A~U-A-Y-G-U-U~C~U~U~C~A~U 3’ (#)
’ G~G~G~U~A*~A~A~U-A-Y-G-U-U~C~U~U~C~A~U 3’ (#)
’ G~G~G~U~A*~A~A~U~A~Y~G~U~U~C~U~U~C~A~U 3’ (#)
5’ G~G~G~U~A*~A~A~U-A-Y-G-U-U~C~U~U*~C~A~U 3’ (#)
’ G~G~G~U~A*~A~A~U~A~Y~G~U~U~C~U~U*~C~A~U 3’ (#)
’ G~G~G~U~A~A~A~U-A-C-G-U-U~C~U~C~C~A~U 3’ (#)
’ G~G~G~C~A~A~A~U-A-C-G-U-U~C~U~C~C~A~U 3’ (#)
’ G~G~G~C~A~A~A~U-A-C-G-U-U~C~U~C~C~A~U 3’ (#)
5’ G~G~G~U~A~A~A~U~A~CXG~U~U~C~U~U~C~A~U 3’ (#)
’ G~U~A~A~A~U~A~C~G~U~U~C~U~U~C 3’ (#)
Antisense Strands:
' A~U~G~A~A-G~A-A-C-G-U-A-U~U~U~A~C~C~C 3' (#)
' A~U~G~A~A~G-A~A-C-G-U-A-U~U-U~A~C~C~C 3' (#)
5' A~U~G~A~A~G~A~A~C-G-U-A~U~U~U~A~C~C~C 3' (#)
' A~U~G~A~A~G~A*~A~C-G-U-A~U~U~U~A~C~C~C 3' (#)
' A~U~G~A~A~G~A~A~C-G-U-A~U~U~U~A*~C~C~C 3' (#)
1) The nucleosides shown in bold have the 2’methyl modification, those that are
underlined are 2’-fluoro and those that are neither bold nor underlined are native
ribose.
2) One or more contiguous dashes represent odiester linkages and ~ represents
phosphorothioate linkages
3) Any sk after a letter indicates it is an unlocked nucleic acid monomer. These
nucleosides do not have other ribose modifications such as 2'-fluro or ethyl.
4) Any X indicates the lack of a linkage
) Any Y indicates an abasic side
6) The C in any CpG may be methylated at the C5 on
7) The 5'end of the sense strand may have a 5'methyl group
8) The 5'end of an antisense strand may have a 5'-phosphate group
9) The two nucleosides in positions 10 and 11 from the 5'-end of the antisense strand
which may be in italics are the ones opposite the argonaute 2 cleavage site
58. seqRNAi siRNA Compounds Directed to Human/Mouse PCSK9 for sequential
induction of RNAi
Sense s:
’ G~C~C~U~G~G~A~G-U-U-U-A~U~U~C~G~G~A~A 3’ (#)
’ G~C~C~U~G~G~A~G-U-U-U-A~U~U~C~G~G~A~A 3’ (#)
5’ G~C~C~U~G~G~A~G-U-U-U-A~U~U~C~G~G~A~A 3’ (#)
’ G~C~C~U~G~G~A~G-U-U-U~A-U~U~C~G~G~A~A 3’ (#)
’ U~G~G*~A~G-U-U-U~A-U~U~C~G~G~A~A 3’ (#)
’ G~C~C~U~G~G*~A~G-U-U-U~A-U~U~C~G*~G~A~A 3’ (#)
’ G~C~C~U~G~G*~A~G-U-Y-U-A~U~U~C~G*~G~A~A 3’ (#)
5’ G~C~C~U~G~G*~A~G~U~Y~U~A~U~U~C~G*~G~A~A 3’ (#)
’ G~C~C~U~G~U~A~G-U-U-U-A~U~U~C~G~U~A~A 3’ (#)
’ G~C~C~U~G~U~A~G~U-C-U~A~U~U~C~G~U~A~A 3’ (#)
’ G~C~C~U~G~G~A~G~U~UXU~A~U~U~C~G~G~A~A 3’ (#)
’ C~U~G~G~A~G~U~U~U~A~U~U~C~G~G 3’ (#)
Antisense Strands:
' U~U~C~C~G-A~A-U-A-A-A-C-U~C-C~A~G~G~C 3' (#)
' U~U~C~C~G-A~A-U-A-A-A-C-U~C-C~A~G~G~C 3' (#)
' U~U~C~C~G-A~A-U-A-A-A-C-U~C-C~A~G~G~C 3' (#)
' U~U~C~C~G-A~A-U-A-A-A-C-U~C-C~A~G~G~C 3' (#)
' U~U~C~C~G~A-A~U-A-A-A-C~U-C~C~A~G~G~C 3' (#)
' U~U~C~C~G*~A-A~U-A-A-A-C~U-C~C~A~G~G~C 3' (#)
' U~U~C~C~G~A-A*~U-A-A-A-C~U-C~C~A~G~G~C 3' (#)
1) The nucleosides shown in bold have the 2’methyl modification, those that are
underlined are oro and those that are neither bold nor underlined are native
ribose.
2) One or more contiguous dashes ent phosphodiester linkages and ~ represents
phosphorothioate es
3) Any asterisk after a letter indicates it is an unlocked nucleic acid monomer. These
nucleosides do not have other ribose modifications such as ro or 2'methyl.
4) Any X indicates the lack of a linkage
) Any Y indicates an abasic nucleoside
6) The C in any CpG may be ated at the C5 position
7) The 5'end of the sense strand may have a 5'methyl group
8) The 5'end of an antisense strand may have a 5'-phosphate group
9) The two nucleosides in positions 10 and 11 from the 5'-end of the antisense strand
which may be in italics are the ones opposite the argonaute 2 cleavage site
59. seqRNAi siRNA Compounds Directed to Mouse PTP1B for sequential induction
of RNAi
Sense Strands:
’ G~A~A~G~C~C~C~A-G-A-G~G-A~G~C~U~A~U~A 3’ (#)
5’ G~A~A~G~C~U~C~A-G-U-G~G-A~U~C~U~A~U~A 3’ (#)
’ G~A~A~G~C~U~C~A-G-A-G-G~A~U~C~U~A~U~A 3’ (#)
’ G~A~A~G~C~C~C-A-Y-A-G~G-A~G~C~U~A~U~A 3’ (#)
’ G~A~A~G~C~C~C~A~Y~A~G~G~A~G~C~U~A~U~A 3’ (#)
’ G~A~A~G~C~C~C~A~Y~A~G~G~A~G~C*~U~A~U~A 3’ (#)
5’ G~A~A~G~C~C~C~A-Y-A-G~G-A~G~C*~U~A~U~A 3’ (#)
’ G~A~A~G~C*~C~C~A-Y-A-G~G-A~G~C*~U~A~U~A 3’ (#)
’ G~C*~C~C~A-G*-A-G~G-A~G~C*~U~A~U~A 3’ (#)
’ G~A~A~G~C*~C~C~A-G-A*-G~G-A~G~C~U*~A~U~A 3’ (#)
’ G~A~A~G~C~C~C~A~GXA~G~G~A~G~C~U~A~U~A 3’ (#)
’ G~C~C~C~A~G~A~G~G~A~G~C~U~A 3’ (#)
Antisense Strands:
' U~A~U~A~G~C-U~C-C-U-C-U-G~G-G~C~U~U~C 3' (#)
' U~A~U~A~G~C-U~C-C-U-C-U-G~G-G~C~U~U~C 3' (#)
' U~A~U~A~G~C-U~C-C-U-C-U-G~G-G~C~U~U~C 3' (#)
1) The nucleosides shown in bold have the 2’methyl modification, those that are
underlined are 2’-fluoro and those that are neither bold nor underlined are native
ribose.
2) One or more uous dashes represent odiester linkages and ~ represents
phosphorothioate linkages
3) Any asterisk after a letter indicates it is an unlocked nucleic acid monomer. These
nucleosides do not have other ribose modifications such as 2'-fluro or 2'methyl.
4) Any X indicates the lack of a linkage
) Any Y indicates an abasic nucleoside
6) The C in any CpG may be methylated at the C5 position
7) The 5'end of the sense strand may have a ethyl group
8) The 5'end of an antisense strand may have a 5'-phosphate group
9) The two nucleosides in positions 10 and 11 from the 5'-end of the antisense strand
which may be in s are the ones opposite the argonaute 2 cleavage site
60. seqRNAi siRNA Compounds Directed to Human/Mouse PTP1B for sequential
induction of RNAi
Sense Strands:
’ U~C~A~A~A~G~U~C-C-G-A-G~A~G~U~C~a~g~g 3’ (#)
5’ U~C~A~A~A~G~U~C-C-G-A-G~A~G~U~C~a~g~g 3’ (#)
’ U~C~A~A~A~G~U~C-C-G-A-G~A~G~U~C~A~G~A 3’ (#)
’ U~C~A~A~A~G~U~C-C-G-A-G~A~G~U~C~A~A~G 3’ (#)
’ U~C~A~A~A~G~U~C-C-G-A-G~A~G~U~C~U~A~G 3’ (#)
’ U~C~A~A~A~G~U~C-C-Y-A-G~A~G~U~C~U~A~G 3’ (#)
5’ A~A~G~U~C-C-G*-A-G~A~G~U~C~U~A~G 3’ (#)
’ U~C~A~A~A~G~U~C~C~G*~A~G~A~G~U~C~U~A~G 3’ (#)
’ U~C~A~A~A~G~U~C~C~G*~A~G~A~G~U~C*~A~G~G 3’ (#)
’ U~C~A~A~A~G*~U~C~C~G*~A~G~A~G~U~C*~A~G~G 3’ (#)
’ U~C~A~A~A~G~U~C~C~GXA~G~A~G~U~C~A~G~G 3’ (#)
5’ A~A~A~G~U~C~C~G~A~G~A~G~U~C~A 3’ (#)
Antisense s:
' C~C~U~G~A~C-U~C-U-C-G-G-A~C-U~U~U~G~A 3' (#)
' C~C~U~G~A~C-U~C-U-C-G-G-A~C-U~U~U~G~A 3' (#)
' C~C~U~G~A~C-U~C-U-C-G-G-A~C-U~U~U~G~A 3' (#)
5' C~C~U~G~A~C~U-C~U-C-G-G~A-C~U~U~U~G~A 3' (#)
' C~C~U~G~A~C~U*-C~U-C-G-G~A-C~U~U~U~G~A 3' (#)
' C~C~U~G~A*~C~U-C~U-C-G-G~A-C~U~U~U~G~A 3' (#)
1) The nucleosides shown in bold have the 2’methyl modification, those that are
underlined are 2’-fluoro and those that are neither bold nor underlined are native
ribose.
2) One or more contiguous dashes represent phosphodiester linkages and ~ represents
phosphorothioate linkages
3) Any sk after a letter indicates it is an unlocked c acid monomer. These
nucleosides do not have other ribose modifications such as 2'-fluro or 2'methyl.
4) Any X indicates the lack of a linkage
) Any Y tes an abasic nucleoside
6) The C in any CpG may be methylated at the C5 position
7) The 5'end of the sense strand may have a 5'methyl group
8) The 5'end of an antisense strand may have a 5'-phosphate group
9) The two nucleosides in positions 10 and 11 from the 5'-end of the antisense strand
which may be in italics are the ones opposite the argonaute 2 cleavage site
) Small letters designate nucleosides that have deoxyribose
61. seqRNAi siRNA Compounds Directed to Human p53 for sequential induction of
RNAi
Sense Strands:
’ U~G~G~A~G~G~A~G-C-C-G-C~A~G~U~C~A~G~A~U 3’ (#)
’ U~G~G~A~G~G~A~G-C-C-G-C~A~G~U~C~A~G~A~U 3’ (#)
’ U~G~G~A~G~G~A~G-C-C-G~C-A~G~U~C~A~G~A~U 3’ (#)
’ U~G~G~A~G~G~A~G-C-C-G-C~A~G~U~C~A~G*~A~U 3’ (#)
5’ U~G~G~A~G~G~A*~G-C-C-G-C~A~G~U~C~A~G*~A~U 3’ (#)
’ U~G~G~A~G~G~A*~G-C-Y-G-C~A~G~U~C~A~G*~A~U 3’ (#)
’ U~G~G~A~G~G~A*~G~C~Y~G~C~A~G~U~C~A~G*~A~U 3’ (#)
’ U~G~G~A~G*~G~A~G~C~Y~G~C~A~G~U~C~A~G*~A~U 3’ (#)
’ U~G~G~A~G~G~A~G~C~CXG~C~A~G~U~C~A~G~A~U 3’ (#)
5’ G~A~G~C~C~G~C~A~G~U~C~A 3’ (#)
’ G~A~G~G~A~G~C~Y~G~C~A~G~U~C~A 3’ (#)
’ G~A~G~G~A~G~C~G~G~C~A~G~U~C~A 3’ (#)
’ G~A~G~G~A~G~C~C*~G~C~A~G~U~C~A 3’ (#)
Antisense Strands:
5' A~U~C~U~G-A~C-U-G-C-G-G-C-U~C-C~U~C~C~A 3' (#)
' A~U~C~U~G-A~C-U-G-C-G-G-C-U~C-C~U~C~C~A 3' (#)
' A~U~C~U~G-A~C-U-G-C-G-G-C-U~C-C~U~C~C~A 3' (#)
' U~G~A-C~U-G-C-G-G-C~U-C~C~U~C~C~A 3' (#)
' A~U~C~U~G~A-C*~U-G-C-G-G-C~U-C~C~U~C~C~A 3' (#)
1) The sides shown in bold have the 2’methyl modification, those that are
underlined are 2’-fluoro and those that are neither bold nor underlined are native
ribose.
2) One or more contiguous dashes represent phosphodiester linkages and ~ ents
phosphorothioate es
3) Any asterisk after a letter indicates it is an unlocked nucleic acid monomer. These
nucleosides do not have other ribose cations such as 2'-fluro or 2'methyl.
4) Any X indicates the lack of a linkage
) Any Y indicates an abasic nucleoside
6) The C in any CpG may be methylated at the C5 position
7) The 5'end of the sense strand may have a 5'methyl group
8) The 5'end of an antisense strand may have a 5'-phosphate group
9) The two nucleosides in positions 10 and 11 from the 5'-end of the antisense strand
which may be in italics are the ones opposite the argonaute 2 cleavage site
62. seqRNAi siRNA Compounds Directed to Human p53 for sequential induction of
RNAi
Sense Strands:
5’ A~U~G~G~A~U~G~A-U-U-U-G~A~U~G~C~U~G~U 3’ (#)
’ A~U~G~G~A~U~G~A-U-U-U-G~A~U~G~C~U~G~U 3’ (#)
’ G~A~U~G~A-U-U-U-G~A~U~G~C~A~G~U 3’ (#)
’ A~U~G~G~A~U~G~A-U-Y-U-G~A~U~G~C~U~G~U 3’ (#)
’ A~U~G~G~A~U~G~A~U~Y~U~G~A~U~G~C~U~G~U 3’ (#)
5’ A~U~G~G~A~U~G~A~U~Y~U~G~A~U~G~C~A~G~U 3’ (#)
’ A~U~G~G~A~U~G~A~U~Y~U~G~A~U~G~C*~U~G~U 3’ (#)
’ A~U~G~G~A~U~G*~A~U~Y~U~G~A~U~G~C*~U~G~U 3’ (#)
’ A~U~G~G~A~U~G~A~U~UXU~G~A~U~G~C~U~G~U 3’ (#)
’ G~G~A~U~G~A~U~U~U~G~A~U~G~C~U 3’ (#)
Antisense Strands:
' A~C~A~G~C~A-U~C-A-A-A-U-C~A-U~C~C~A~U 3' (#)
' A~C~A~G~C~A-U~C-A-A-A-U-C~A-U~C~C~A~U 3' (#)
' A~C~A~G~C~A-U~C-A-A-A-U-C~A-U~C~C~A~U 3' (#)
5' A~C~A~G~C~A-U~C-A-A-A-U-C~A-U~C~C~A~U 3' (#)
' A~C~A~G~C~A-U*~C-A-A-A-U-C~A-U~C~C~A~U 3' (#)
' A~C~A~G*~C~A-U~C-A-A-A-U-C~A-U~C~C~A~U 3' (#)
1) The nucleosides shown in bold have the 2’methyl modification, those that are
underlined are oro and those that are neither bold nor underlined are native
ribose.
2) One or more contiguous dashes represent phosphodiester linkages and ~ represents
phosphorothioate linkages
3) Any asterisk after a letter indicates it is an unlocked nucleic acid monomer. These
nucleosides do not have other ribose modifications such as 2'-fluro or 2'methyl.
4) Any X indicates the lack of a e
) Any Y indicates an abasic nucleoside
6) The C in any CpG may be methylated at the C5 position
7) The 5'end of the sense strand may have a ethyl group
8) The 5'end of an antisense strand may have a 5'-phosphate group
9) The two nucleosides in positions 10 and 11 from the 5'-end of the antisense strand
which may be in italics are the ones opposite the argonaute 2 cleavage site
63. seqRNAi siRNA Compounds ed to Human/Mouse ApoB for sequential
induction of RNAi
Sense Strands:
’ A~U~C~A~C-A-C-U-G~A~A~U~A~C~C~A~A~U 3’ (#)
’ G~U~C~A~U~C~A*~C-A-C-U-G~A~A~U~A~C~C~A~A~U 3’ (#)
5’ G~U~C~A~U~C~A*~C-A-C-U-G~A~A~U~A~C~C*~A~A~U 3’ (#)
’ G~U~C~A~U~C~A~C-A-C-U-G~A~A~U~A~C~C~A~A~U 3’ (#)
’ G~U~C~A~U~C~A*~C-A-C-U-G~A~A~U~A~C~C~A~A~U 3’ (#)
’ G~U~C~A~U~C~A~C-A-C-U-G~A~A~U~A~C~C*~A~A~U 3’ (#)
’ G~U~C~A~U~C~A*~C-A-C-U-G~A~A~U~A~C~C*~A~A~U 3’ (#)
5’ G~U~C~A~U~C~A*~C~A~Y~U~G~A~A~U~A~C~C*~A~A~U 3’ (#)
’ G~U~C~A~U~C~A*~C~A~C~U~G*~A~A~U~A~C~C*~A~A~U 3’ (#)
’ G~U~C~A~U*~C~A~C~A*~C~U~G~A*~A~U~A~C~C*~A~A~U 3’ (#)
’ G~U~C~A~U~C~A~C~A~C~U~G~A~A~U~A~C~C~A~A~U 3’ (#)
’ A~U~C~A~C~A~CXU~G~A~A~U~A~C~C~A~A~U 3’ (#)
5’ C~A~U~C~A~C~A~C~U~G~A~A~U~A~C 3’ (#)
’ C~A~U~C~A~C~A~Y~U~G~A~A~U~A~C 3’ (#)
Antisense Strands:
' A~U~U~G~G~U-A~U-U-C-A-G-U~G-U~G~A~U~G~A~C 3' (#)
' A~U~U~G~G~U-A~U-U-C-A-G-U~G-U~G~A~U~G~A~C 3' (#)
5' A~U~U~G~G~U-A~U-U-C-A-G-U~G-U~G~A~U~G~A~C 3' (#)
' A~U~U~G~G~U-A~U-U-C-A-G-U~G-U~G~A~U~G~A~C 3' (#)
' A~U~U~G~G~U~A~U-U-C-A-G-U~G~U~G~A~U~G~A~C 3' (#)
' A~U~U~G~G~U~A*~U-U-C-A-G-U~G~U~G~A~U~G~A~C 3'
1) The nucleosides shown in bold have the 2’methyl modification, those that are
underlined are 2’-fluoro and those that are neither bold nor underlined are native
ribose.
2) One or more contiguous dashes represent phosphodiester linkages and ~ represents
phosphorothioate linkages
3) Any asterisk after a letter indicates it is an unlocked c acid monomer. These
nucleosides do not have other ribose modifications such as 2'-fluro or 2'methyl.
4) Any X tes the lack of a e
) Any Y indicates an abasic side
6) The C in any CpG may be methylated at the C5 position
7) The 5'end of the sense strand may have a 5'methyl group
8) The 5'end of an antisense strand may have a 5'-phosphate group
9) The two nucleosides in ons 10 and 11 from the 5'-end of the antisense strand
which may be in italics are the ones opposite the argonaute 2 cleavage site
64. seqRNAi siRNA Compounds Directed to Human/Mouse ApoB for sequential
induction of RNAi
Sense Strands:
’ G~G~U~G~U~A~U~G-G-C-U-U~C~A~A~C~C~C~U~G 3’ (#)
’ G~G~U~G~U~A~U~G-G-C-U-U~C~A~A~C~C~C~U~G 3’ (#)
5’ G~G~U~G~U~A~U~G-G-C-U-C~C~A~A~C~C~A~U~G 3’ (#)
’ G~G~U~G~U~A~U~G-G-Y-U-U~C~A~A~C~C~C~U~G 3’ (#)
’ G~G~U~G~U~A~U~G~G~Y~U~U~C~A~A~C~C~C~U~G 3’ (#)
’ G~G~U~G~U~A~U~G~G~Y~U~U~C~A~A~C~C*~C~U~G 3’ (#)
’ G~U~A~U*~G~G~Y~U~U~C~A~A~C~C*~C~U~G 3’ (#)
5’ G~G~U~G~U~A~U~G~G~C*~U~U~C~A~A~C~C*~C~U~G 3’ (#)
’ G~G~U~G~U~A~U*~G~G~C~U*~U~C~A~A~C~C*~C~U~G 3’ (#)
’ G~G~U~G~U~A~U~G-G-C-U-U~C~A~A~C~C*~C~U~G 3’ (#)
’ G~G~U~G~U~A~U~G-GXC-U-U~C~A~A~C~C~C~U~G 3’ (#)
’ G~U~A~U~G~G-C~U~U~C~A~A~C~C~C 3’ (#)
5’ G~U~A~U~G~G-C~U~U*~C~A~A~C~C~C 3’ (#)
nse Strands:
' C~A~G~G~G~U-U-G-A-A-G-C-C-A-U~A~C~A~C~C 3' (#)
' C~A~G~G~G~U-U-G-A-A-G-C-C-A-U~A~C~A~C~C 3' (#)
' C~A~G~G~G~U-U-G-A-A-G-C-C-A-U~A~C~A~C~C 3' (#)
' G~G~U-U~G-A-A-G-C-C~A-U~A~C~A~C~C 3' (#)
' C~A~G~G~G~U~U~G-A-A-G-C-C~A~U~A~C~A~C~C 3' (#)
' C~A~G~G~G~U~U*~G-A-A-G-C-C~A~U~A~C~A~C~C 3' (#)
' C~A~G~G~G~U-U*~G-A-A-G-C-C~A-U~A~C~A~C~C 3' (#)
5' C~A~G~G~G~U-U*~G-A-A-G-C-C~A-U~A*~C~A~C~C 3' (#)
' G*~G~U-U~G-A-A-G-C-C~A-U~A*~C~A~C~C 3' (#)
1) The nucleosides shown in bold have the ethyl modification, those that are
underlined are 2’-fluoro and those that are neither bold nor underlined are native
ribose.
2) One or more contiguous dashes represent phosphodiester linkages and ~ represents
phosphorothioate linkages
3) Any asterisk after a letter indicates it is an unlocked nucleic acid monomer. These
nucleosides do not have other ribose modifications such as 2'-fluro or 2'methyl.
4) Any X indicates the lack of a linkage
) Any Y indicates an abasic nucleoside
6) The C in any CpG may be methylated at the C5 position
7) The 5'end of the sense strand may have a 5'methyl group
8) The 5'end of an antisense strand may have a 5'-phosphate group
9) The two nucleosides in positions 10 and 11 from the 5'-end of the antisense strand
which may be in italics are the ones opposite the argonaute 2 ge site
65. seqRNAi siRNA Compounds Directed to Human PTP1b for sequential induction
of RNAi
Sense Strands:
’ G~G~A~A~G~A~A~A-A-A-G-G~A~A~G~C*~C~C 3’ (#)
’ G~G~A~A~G~A~A~A-A-A-G-G~A~A~G*~C~C~C 3’ (#)
’ G~G~A~A~G~A~A~A-A-A-G-G~A~A~G*~C~C~C 3’ (#)
’ G~G~A~A~G~A~A*~A-A-A-G-G~A~A~G*~C~C~C 3’ (#)
5’ G~G~A~A~G~A~A*~A-A-Y-G-G~A~A~G*~C~C~C 3’ (#)
’ G~G~A~A~G~A*~A~A-A-Y-G-G~A~A~G*~C~C~C 3’ (#)
’ G~G~A~A~G~A*~A~A~A~Y~G~G~A~A~G*~C~C~C 3’ (#)
’ G~G~A~A~G~A~A~A~A~A~G~G~A~A~G~C~C~C 3’ (#)
’ A~G~A~A~A~A~AXG~G~A~A~G~C~C~C 3’ (#)
Antisense Strands:
5' G~G~G~C~U~U-C~C-U-U-U-U-U~C-U~U~C~C 3' (#)
' G~G~G~C~U~U-C~C-U-U-U-U-U~C-U~U~C~C 3' (#)
' G~G~G~C~U~U-C~C-U-U-U-U-U~C-U~U~C~C 3' (#)
' G~G~G~C~U~U-C~C-U-U-U-U-U~C-U~U~C~C 3' (#)
' G~G~G~C~U~U~C-C-U-U-U-U-U-C~U~U~C~C 3' (#)
5' G~G~G~C~U~U-C~C-U-U-U-U-U~C-U~U*~C~C 3' (#)
' G~G~G~C~U~U*-C~C-U-U-U-U-U~C-U~U*~C~C 3' (#)
1) The nucleosides shown in bold have the 2’methyl modification, those that are
underlined are 2’-fluoro and those that are neither bold nor underlined are native
2) One or more contiguous dashes represent odiester linkages and ~ represents
phosphorothioate linkages
3) Any asterisk after a letter indicates it is an unlocked nucleic acid monomer. These
nucleosides do not have other ribose modifications such as 2'-fluro or 2'methyl.
4) Any X indicates the lack of a linkage
5) Any Y indicates an abasic nucleoside
6) The C in any CpG may be methylated at the C5 position
7) The 5'end of the sense strand may have a ethyl group
8) The 5'end of an antisense strand may have a 5'-phosphate group
9) The two nucleosides in positions 10 and 11 from the 5'-end of the antisense strand
which may be in italics are the ones opposite the argonaute 2 cleavage site
66. seqRNAi miRNA Inhibitor Compounds Based on Mouse miR-24 for sequential
administration to inhibit the s f.
Endogenous miRNA antisense strands (overhang in bold):
' AGUUCAGCAGGAACAG 3'
Sense and antisense strands for use in seqRNAi miRNA inhibitors:
Prototype sense strand sequence:
' UGGCUCAGUUCAGCAGGAACAG 3' (#)
Prototype antisense strand sequence:
with G:U intact:
' GUUCCUGCUGAGCUGAGCUAGU 3' (#)
with G:U converted to G:C
' GUUCCUGCUGAACUGAGCCAGU3' (#)
mentary sense and antisense strands for use in accordance with this invention:
Sense strands:
' C~U~G~G~C~U~C~A-G-U-U-C~A~G~C~A~G~G~A~A~C 3' (#)
' C~U~G~G~C~U~C~A-G-U-U-C~A~G~C~A~G~G~A~A~C 3' (#)
' C~U~G~G~C~U~C~A-G-Y-U-C~A~G~C~A~G~G~A~A~C 3' (#)
5' C~U~G~G~C~U~C~A~G~Y~U~C~A~G~C~A~G~G~A~A~C 3' (#)
' C~U~G~G~C~U~C~A-G-Y-U-C~A~G~C~A~G~G~A*~A~C 3' (#)
' C~U~G~G~C~U~C~A~G~Y~U~C~A~G~C~A~G~G~A*~A~C 3' (#)
' C~U~G~G~C~U~C*~A-G-Y-U-C~A~G~C~A~G~G~A*~A~C 3' (#)
5' C~U~G~G~C~U~C*~A~G~Y~U~C~A~G~C~A~G~G~A*~A~C 3' (#)
' C~U~G~G~C~U*~C~A-G-U*-U-C~A~G~C~A~G~G~A*~A~C 3' (#)
' C~U~G~G~C~U*~C~A~G~C~U~C~A~G~C~A~G~G~A*~A~C 3' (#)
' C~U~G~G~C~G~C~A-G-C-U-C~A~G~C~A~G~G~U~A~C 3' (#)
' C~U~G~G~C~G~C~A~G~C~U~C~A~G~C~A~G~G~U~A~C 3' (#)
5' C~U~G~G~C~U~C~A~G~U~UXC~A~G~C~A~G~G~A~A~C 3' (#)
' C~U~G~G~C~U~C~A~G~U~UXC~A~G~C~A~G~G~A~A~C 3' (#)
' C~U~G~G~C~A~C~A~G~U~UXC~A~G~C~A~G~A~A~A~C 3' (#)
' C~U~G~G~C~U~C~A-G-U-U-C~A~G~C~A~G~G~A~A 3' (#)
' G~C~U~C~A-G-U-U-C~A~G~C~A~G~G 3' (#)
5' G~C~U~C~A~G~U~U~C~A~G~C~A~G~G 3' (#)
nse s:
' G~U~U~C~C~U-G~C-U-G-A-A-C-U~G-A~G~C~C~A~G 3' (#)
' G~U~U~C~C~U-G~C-U-G-A-A-C-U~G-A~G~C~C~A~G 3' (#)
' G~U~U~C~C~U-G~C-U-G-A-A-C-U~G-A~G~C~C~A~G 3' (#)
5' G~U~U~C~C~U-G~C-U-G-A-A-C-U~G-A~G~C~C~A~G 3' (#)
' G~U~U~C*~C~U-G~C-U-G-A-A-C-U~G-A~G~C~C~A~G 3' (#)
' G~U~U~C~C~U-G*~C-U-G-A-A-C-U~G-A~G~C~C~A~G 3' (#)
' G~U~U~C~C~U~G-C~U-G-A-A-C~U-G~A~G~C~C~A~G 3' (#)
' G~U~U~C*~C~U~G-C~U-G-A-A-C~U-G~A~G~C~C~A~G 3' (#)
5' G~U~U~C~C~U~G*-C~U-G-A-A-C~U-G~A~G~C~C~A~G 3' (#)
' U~U~C~C~U~G-C~U-G-A-A-C-U-G~A-G~C~C~A~G 3' (#)
' U~U~C~C~U~G-C~U-G-A-A-C-U-G~A-G~C~C~A~G 3' (#)
' C~U~G-C~U-G-A-A-C-U-G~A-G~C~C~A~G 3' (#)
' C~U~G-C~U-G-A-A-C-U-G~A-G~C~C~A~G 3' (#)
' U~U~C~C*~U~G-C~U-G-A-A-C-U-G~A-G~C~C~A~G 3' (#)
' U~U~C~C~U~G-C*~U-G-A-A-C-U-G~A-G~C~C~A~G 3' (#)
5' U~U~C~C~U~G~C-U~G-A-A-C-U~G-A~G~C~C~A~G 3' (#)
' U~U~C~C*~U~G~C-U~G-A-A-C-U~G-A~G~C~C~A~G 3' (#)
' U~U~C~C~U~G~C*-U~G-A-A-C-U~G-A~G~C~C~A~G 3' (#)
) The nucleosides shown in bold have the 2’methyl modification, those that are
underlined are 2’-fluoro and those that are neither bold nor underlined are native ribose.
11) One or more contiguous dashes represent phosphodiester linkages and ~ represents
phosphorothioate linkages
12) Any asterisk after a letter indicates it is an unlocked nucleic acid monomer. These
nucleosides do not have other ribose modifications such as 2'-fluro or 2'methyl.
13) Any X indicates the lack of a e
14) Any Y indicates an abasic side
) The C in any CpG may be methylated at the C5 position
16) The 5'end of the sense strand may have a 5'methyl group
17) The 5'end of an antisense strand may have a 5'-phosphate group
18) The two nucleosides in positions 10 and 11 from the 5'-end of the antisense strand
which may be in italics are the ones opposite the argonaute 2 cleavage site
67. seqRNAi miRNA Inhibitor Compounds Based on Human miR-24 for sequential
administration to t the actions thereof.
Endogenous miRNA antisense strands (overhang in bold):
' UGGCUCAGUUCAGCAGGAACAG 3' (#)
Sense and nse strands for use in seqRNAi miRNA inhibitors:
Prototype sense strand sequence:
5' UGGCUCAGUUCAGCAGGAACAG 3' (#)
ype antisense strand sequence:
with G:U intact:
' UUCCUGCUGAGCUGAGCUAGU 3' (#)
with G:U converted to G:C
5' UUCCUGCUGAACUGAGCCAGU 3' (#)
Complementary sense and antisense strands for use in accordance with this invention:
Sense strands:
Same as mouse miR-24
Antisense strands:
Same as mouse miR-24
1) The nucleosides shown in bold have the 2’methyl modification, those that are
underlined are 2’-fluoro and those that are neither bold nor underlined are native .
2) One or more contiguous dashes represent phosphodiester linkages and ~ represents
phosphorothioate linkages
3) Any asterisk after a letter indicates it is an unlocked nucleic acid monomer. These
nucleosides do not have other ribose modifications such as 2'-fluro or 2'methyl.
4) Any X indicates the lack of a linkage
) Any Y indicates an abasic nucleoside
6) The C in any CpG may be methylated at the C5 position
7) The 5'end of the sense strand may have a 5'methyl group
8) The 5'end of an antisense strand may have a sphate group
9) The two nucleosides in positions 10 and 11 from the 5'-end of the nse strand
which may be in italics are the ones opposite the argonaute 2 cleavage site
68. seqRNAi miRNA Inhibitor nds Based on Mouse miR-29a for
sequential administration to inhibit the actions thereof.
Endogenous miRNA antisense strands ang in bold):
' UAGCACCAUCUGAAAUCGGUUA 3' (#)
Sense and antisense strands for use in seqRNAi miRNA inhibitors:
Prototype sense strand sequence:
' UAGCACCAUCUGAAAUCGGUUA 3' (#)
Prototype antisense strand sequence:
with G:U intact:
' UUCAGAUGGUGUUA 3' (#)
with G:U converted to G:C:
' ACCGAUUUCAGAUGGUGCUA 3' (#)
mentary sense and antisense strands for use in accordance with this invention:
Sense strands:
' G~C~A~C~C~A~U~C-U-G-A-A~A~U~C~G~G~U~U~A 3' (#)
' G~C~A~C~C~A~U~C-U-G-A-A~A~U~C~G~G~U~U~A 3' (#)
' G~C~A~C~C~A~U~C-U-Y-A-A~A~U~C~G~G~U~U~A 3' (#)
' G~C~A~C~C~A~U~C~U~Y~A~A~A~U~C~G~G~U~U~A 3' (#)
5' C~C~A~U~C-U-Y-A-A~A~U~C~G~G*~U~U~A 3' (#)
' G~C~A~C~C~A~U~C~U~Y~A~A~A~U~C~G~G*~U~U~A 3' (#)
' G~C~A~C~C~A~U~C-U-Y-A-A~A~U~C~G~G*~U~U~A 3' (#)
' G~C~A~C~C~A~U~C~U~Y~A~A~A~U~C~G~G*~U~U~A 3' (#)
' G~C~A~C~C~A~U*~C-U-Y-A-A~A~U~C~G~G*~U~U~A 3' (#)
5' G~C~A~C~C~A~U*~C~U~Y~A~A~A~U~C~G~G*~U~U~A 3' (#)
' G~C~A~C~C~A~U*~C-U-G*-A-A~A~U~C~G~G*~U~U~A 3' (#)
' G~C~A~C~C~A~U*~C~U~G*~A~A~A~U~C~G~G*~U~U~A 3' (#)
' G~C~A~C~C~A~G~C-U-U-A-A~A~U~C~G~U~U~U~A 3' (#)
' G~C~A~C~C~A~G~C~U~U~A~A~A~U~C~G~U~U~U~A 3' (#)
5' G~C~A~C~C~A~U~C~U~GXA~A~A~U~C~G~G~U~U~A 3' (#)
' G~C~A~C~C~A~U~C~U~GXA~A~A~U~C~G~G~U~U~A 3' (#)
' G~C~A~C~C~C~U~C~U~GXA~A~A~U~C~G~A~U~U~A 3' (#)
' A~U~C-U-G-A-A~A~U~C~G~G 3' (#)
' A~C~C~A~U~C~U~G~A~A~A~U~C~G~G 3' (#)
Antisense strands:
' U~A~A~C~C~G-A~U-U-U-C-A-G-A~U-G~G~U~G~C 3' (#)
' U~A~A~C~C~G-A~U-U-U-C-A-G-A~U-G~G~U~G~C 3' (#)
' U~A~A~C~C~G-A~U-U-U-C-A-G-A~U-G~G~U~G~C 3' (#)
' U~A~A~C~C~G-A~U-U-U-C-A-G-A~U-G~G~U~G~C 3' (#)
5' U~A~A~C~C~G~A-U~U-U-C-A-G~A-U~G~G~U~G~C 3' (#)
' U~A~A~C~C~G-A*~U-U-U-C-A-G-A~U-G~G~U~G~C 3' (#)
' U~A~A~C~C~G~A*-U~U-U-C-A-G~A-U~G~G~U~G~C 3' (#)
' U~A~A~C*~C~G-A~U-U-U-C-A-G-A~U-G~G~U~G~C 3' (#)
' U~A~A~C*~C~G~A-U~U-U-C-A-G~A-U~G~G~U~G~C 3' (#)
1) The nucleosides shown in bold have the 2’methyl modification, those that are
underlined are 2’-fluoro and those that are r bold nor underlined are native ribose.
2) One or more contiguous dashes represent phosphodiester linkages and ~ represents
phosphorothioate linkages
3) Any asterisk after a letter indicates it is an unlocked nucleic acid r. These
nucleosides do not have other ribose modifications such as 2'-fluro or 2'methyl.
4) Any X tes the lack of a linkage
) Any Y indicates an abasic nucleoside
6) The C in any CpG may be methylated at the C5 position
7) The 5'end of the sense strand may have a 5'methyl group
8) The 5'end of an antisense strand may have a 5'-phosphate group
9) The two nucleosides in positions 10 and 11 from the 5'-end of the antisense strand
which may be in italics are the ones opposite the argonaute 2 cleavage site
69. seqRNAi miRNA Inhibitor Compounds Based on Human miR-29a for
sequential administration to t the actions thereof.
Endogenous miRNA antisense strands ang in bold):
Same as for mouse miR-29a
Sense and antisense strands for use in seqRNAi miRNA inhibitors:
Prototype sense strand ce:
Same as for mouse miR-29a
Prototype antisense strand sequence:
with G:U intact:
Same as for mouse miR-29a
with G:U converted to G:C:
Same as for mouse miR-29a
Complementary sense and antisense s for use in accordance with this invention:
Sense strands:
Same as for mouse miR-29a
nse strands:
Same as for mouse miR-29a
1) The nucleosides shown in bold have the 2’methyl modification, those that are
underlined are 2’-fluoro and those that are neither bold nor underlined are native ribose.
2) One or more uous dashes represent phosphodiester linkages and ~ represents
orothioate linkages
3) Any asterisk after a letter indicates it is an unlocked c acid monomer. These
sides do not have other ribose modifications such as 2'-fluro or 2'methyl.
4) Any X indicates the lack of a linkage
) Any Y indicates an abasic nucleoside
6) The C in any CpG may be ated at the C5 position
7) The 5'end of the sense strand may have a 5'methyl group
8) The 5'end of an antisense strand may have a 5'-phosphate group
9) The two nucleosides in positions 10 and 11 from the 5'-end of the antisense strand
which may be in italics are the ones opposite the argonaute 2 ge site
70. seqRNAi miRNA Inhibitor Compounds Based on Mouse miR-29b for
sequential administration to inhibit the actions thereof.
Endogenous miRNA antisense strands (overhang in bold):
' UAGCACCAUUUGAAAUCAGUGUU 3' (#)
Sense and antisense strands for use in seqRNAi miRNA inhibitors:
Prototype sense strand sequence:
5' UAGCACCAUUUGAAAUCAGUGUU 3' (#)
Prototype antisense strand sequence:
with G:U intact:
' GCUGGUUUCAAAUGGUGCUA 3' (#)
with G:U converted to G:C:
' ACUGAUUUCAAAUGGUGCUA 3' (#)
Complementary sense and antisense strands for use in accordance with this invention:
Sense s:
5' G~C~A~C~C~A~U~U-U-G-A-A~A~U~C~A~G~U~G~U~U 3'
' G~C~A~C~C~A~U~U-U-G-A-A~A~U~C~A~G~U~G~U~U 3'
' G~C~A~C~C~A~U~U-U-Y-A-A~A~U~C~A~G~U~G~U~U 3'
' G~C~A~C~C~A~U~U~U~Y~A~A~A~U~C~A~G~U~G~U~U 3'
' G~C~A~C~C~A~U~U-U-Y-A-A~A~U~C~A~G~U*~G~U~U 3'
5' G~C~A~C~C~A~U~U~U~Y~A~A~A~U~C~A~G~U*~G~U~U 3'
' G~C~A~C~C~A~U*~U-U-Y-A-A~A~U~C~A~G~U*~G~U~U 3'
' G~C~A~C~C~A~U*~U~U~Y~A~A~A~U~C~A~G~U*~G~U~U 3'
' G~C~A~C~C*~A~U~U-U-Y-A-A~A~U~C~A~G~U*~G~U~U 3'
' G~C~A~C~C*~A~U~U~U~Y~A~A~A~U~C~A~G~U*~G~U~U 3'
5' G~C~A~C~A~A~U~U-U-Y-A-A~A~U~C~A~G~C~G~U~U 3'
' G~C~A~C~A~A~U~U~U~Y~A~A~A~U~C~A~G~C~G~U~U 3'
' G~C~A~C~A~A~U~U~U~A~A~A~A~U~C~A~G~C~G~U~U 3'
' G~C~A~C~C~A~U~U~U~GXA~A~A~U~C~A~G~U~G~U~U 3'
' G~C~A~C~C~A~U~U~U~GXA~A~A~U~C~A~G~U~G~U~U 3'
5' G~C~A~C~A~A~U~U~U~GXA~A~A~U~C~A~A~U~G~U~U 3'
' C~C~A~U~U~U~G~A~A~A~U~C~A~G~U 3'
' U~U~U~G~A~A~A~U~C~A~G~U 3'
Antisense strands:
' A~A~C~A~C-U~G-A-U-U-U-C-A-A~A-U~G~G~U~G~C 3'
' A~A~C~A~C-U~G-A-U-U-U-C-A-A~A-U~G~G~U~G~C 3'
' A~A~C~A~C-U~G-A-U-U-U-C-A-A~A-U~G~G~U~G~C 3'
' A~A~C~A~C-U~G-A-U-U-U-C-A-A~A-U~G~G~U~G~C 3'
' A~A~C~A*~C-U~G-A-U-U-U-C-A-A~A-U~G~G~U~G~C 3'
5' A~A~C~A*~C-U~G-A-U-U-U-C-A-A~A-U~G*~G~U~G~C 3'
' A~A~C~A~C~U-G~A-U-U-U-C-A~A-A~U~G~G~U~G~C 3'
' A~A~C~A~C~U-G~A-U-U-U-C-A~A-A~U~G~G~U~G~C 3'
' A~A~C~A*~C~U-G~A-U-U-U-C-A~A-A~U~G~G~U~G~C 3'
' A*~C~U-G~A-U-U-U-C-A~A~A~U~G*~G~U~G~C 3'
5' A~A~C~A~C~U~G~A~U-U-U-C~A~A~A~U~G~G~U~G~C 3'
' A~A~C~A~C~U~G~A~U-U-U-C~A~A~A~U~G~G~U~G~C 3'
' A~A~C~A*~C~U~G~A~U-U-U-C~A~A~A~U~G~G~U~G~C 3'
' A~A~C~A*~C~U~G~A~U-U-U-C~A~A~A~U~G*~G~U~G~C 3'
' A~A~C~A~C~U~G~A~U~U~U~C~A~A~A~U~G~G~U~G~C 3'
5' A~A~C~A~C~U~G~A~U~U~U~C~A~A~A~U~G~G~U~G~C 3'
' A~A~C~A*~C~U~G~A~U~U~U~C~A~A~A~U~G~G~U~G~C 3'
' A~A~C~A*~C~U~G~A~U~U~U~C~A~A~A~U~G*~G~U~G~C 3'
1) The sides shown in bold have the 2’methyl modification, those that are
underlined are 2’-fluoro and those that are r bold nor underlined are native ribose.
2) One or more contiguous dashes represent phosphodiester linkages and ~ represents
phosphorothioate linkages
3) Any asterisk after a letter indicates it is an ed nucleic acid r. These
nucleosides do not have other ribose modifications such as 2'-fluro or 2'methyl.
4) Any X indicates the lack of a linkage
5) Any Y indicates an abasic nucleoside
6) The C in any CpG may be methylated at the C5 position
7) The 5'end of the sense strand may have a 5'methyl group
8) The 5'end of an antisense strand may have a 5'-phosphate group
9) The two nucleosides in positions 10 and 11 from the 5'-end of the antisense strand
which may be in italics are the ones opposite the argonaute 2 cleavage site
71. i miRNA Inhibitor Compounds Based on Human miR-29b for
sequential administration to inhibit the actions thereof.
Endogenous miRNA antisense strands (overhang in bold):
Same as for mouse miR-29b
Sense and antisense strands for use in seqRNAi miRNA inhibitors:
Prototype sense strand sequence:
Same as for mouse miR-29b
Prototype antisense strand sequence:
with G:U intact:
Same as for mouse miR-29b
with G:U converted to G:C:
Same as for mouse miR-29b
Complementary sense and antisense strands for use in accordance with this invention:
Sense s:
Same as for mouse miR-29b
nse strands:
Same as for mouse miR-29b
1) The nucleosides shown in bold have the 2’methyl modification, those that are
underlined are 2’-fluoro and those that are neither bold nor ined are native ribose.
2) One or more contiguous dashes represent phosphodiester linkages and ~ represents
orothioate linkages
3) Any asterisk after a letter indicates it is an unlocked nucleic acid monomer. These
nucleosides do not have other ribose modifications such as 2'-fluro or 2'methyl.
4) Any X indicates the lack of a linkage
) Any Y indicates an abasic side
6) The C in any CpG may be methylated at the C5 position
7) The 5'end of the sense strand may have a 5'methyl group
8) The 5'end of an nse strand may have a 5'-phosphate group
9) The two nucleosides in positions 10 and 11 from the 5'-end of the antisense strand
which may be in italics are the ones opposite the argonaute 2 cleavage site
72. seqRNAi miRNA Inhibitor nds Based on Mouse miR-29c for sequential
administration to inhibit the actions thereof.
Endogenous miRNA antisense s (overhang in bold):
' UAGCACCAUUUGAAAUCGGUUA 3' (#)
Sense and antisense strands for use in seqRNAi miRNA inhibitors:
Prototype sense strand sequence:
' UAGCACCAUUUGAAAUCGGUUA 3' (#)
Prototype antisense strand ce:
with G:U intact:
' UGACCGAUUUCAAAUGGUGUUA 3' (#)
with G:U converted to G:C:
' UAACCGAUUUCAAAUGGUGCUA 3' (#)
Complementary sense and antisense strands for use in accordance with this invention:
Sense strands:
' G~C~A~C~C~A~U~U-U-G-A-A~A~U~C~G~G~U~U~A 3'
5' G~C~A~C~C~A~U~U-U-G-A-A~A~U~C~G~G~U~U~A 3'
' G~C~A~C~C~A~U~U-U-Y-A-A~A~U~C~G~G~U~U~A 3'
' G~C~A~C~C~A~U~U~U~Y~A~A~A~U~C~G~G~U~U~A 3'
' C~C~A~U~U-U-Y-A-A~A~U~C~G*~G~U~U~A 3'
' G~C~A~C~C~A~U~U~U~Y~A~A~A~U~C~G*~G~U~U~A 3'
5' G~C~A~C~C~A~U*~U-U-Y-A-A~A~U~C~G*~G~U~U~A 3'
' G~C~A~C~C~A~U*~U~U~Y~A~A~A~U~C~G*~G~U~U~A 3'
' G~C~A~C~C~A*~U~U-U-Y-A-A~A~U~C~G*~G~U~U~A 3'
' G~C~A~C~C~A*~U~U~U~Y~A~A~A~U~C~G*~G~U~U~A 3'
' G~C~A~C~C~A~U~U-U-G*-A-A~A~U~C~G~G~U~U~A 3'
5' C~C~A~U~U~U~G*~A~A~A~U~C~G~G~U~U~A 3'
' G~C~A~C~C~A~U~U-U-G*-A-A~A~U~C~G*~G~U~U~A 3'
' G~C~A~C~C~A~U~U~U~G*~A~A~A~U~C~G*~G~U~U~A 3'
' G~C~A~C~C~A~U*~U-U-G*-A-A~A~U~C~G*~G~U~U~A 3'
' G~C~A~C~C~A~U*~U~U~G*~A~A~A~U~C~G*~G~U~U~A 3'
5' G~C~A~C~C~A*~U~U-U-G*-A-A~A~U~C~G*~G~U~U~A 3'
' G~C~A~C~C~A*~U~U~U~G*~A~A~A~U~C~G*~G~U~U~A 3'
' G~C~A~C~C~A~U~U-U-A-A-A~A~U~C~G~G~U~U~A 3'
' G~C~A~C~C~A~U~U~U~A~A~A~A~U~C~G~G~U~U~A 3'
' G~C~A~C~C~A~U~U-U-A-A-A~A~U~C~A~G~U~U~A 3'
5' G~C~A~C~C~A~U~U~U~A~A~A~A~U~C~A~G~U~U~A 3'
' G~C~A~C~C~A~C~U-U-A-A-A~A~U~C~A~G~U~U~A 3'
' G~C~A~C~C~A~C~U~U~A~A~A~A~U~C~A~G~U~U~A 3'
' G~C~A~C~C~C~U~U-U-A-A-A~A~U~C~A~G~U~U~A 3'
' G~C~A~C~C~C~U~U~U~A~A~A~A~U~C~A~G~U~U~A 3'
' G~C~A~C~C~A~U~U~U~GXA-A~A~U~C~G~G~U~U~A 3'
' G~C~A~C~C~A~U~U~U~GXA-A~A~U~C~G~G~U~U~A 3'
' G~C~A~C~U~A~U~U~U~GXA-A~A~U~C~U~G~U~U~A 3'
' A~C~C~A~U~U~U~G~A~A~A~U~C~G~G 3'
5' A~C~C~A~U~U~U~G~A~A~A~U~C~G~G 3'
' A~C~C~A~U~U~A~G~A~A~A~U~C~G~G 3'
Antisense strands:
' U~A~A~C~C-G~A-U-U-U-C-A-A-A~U-G~G~U~G~C 3'
5' U~A~A~C~C-G~A-U-U-U-C-A-A-A~U-G~G~U~G~C 3'
' U~A~A~C~C-G~A-U-U-U-C-A-A-A~U-G~G~U~G~C 3'
' C~C-G~A-U-U-U-C-A-A-A~U-G~G~U~G~C 3'
' U~A~A~C~C~G-A~U-U-U-C-A-A~A-U~G~G~U~G~C 3'
' U~A~A~C~C~G-A~U-U-U-C-A-A~A-U~G~G~U~G~C 3'
5' C~C~G-A~U-U-U-C-A-A~A-U~G~G~U~G~C 3'
' U~A~A~C~C~G-A~U-U-U-C-A-A~A-U~G~G~U~G~C 3'
' U~A~A~C~C~G-A*~U-U-U-C-A-A~A-U~G~G~U~G~C 3'
' U~A~A~C~C~G-A*~U-U-U-C-A-A~A-U~G~G~U~G~C 3'
' U~A~A~C~C~G-A*~U-U-U-C-A-A~A-U~G~G~U~G~C 3'
5' U~A~A~C~C~G-A*~U-U-U-C-A-A~A-U~G~G~U~G~C 3'
' U~A~A~C*~C~G-A~U-U-U-C-A-A~A-U~G~G~U~G~C 3'
' U~A~A~C*~C~G-A~U-U-U-C-A-A~A-U~G~G~U~G~C 3'
' U~A~A~C*~C~G-A~U-U-U-C-A-A~A-U~G~G~U~G~C 3'
' U~A~A~C*~C~G-A~U-U-U-C-A-A~A-U~G~G~U~G~C 3'
' U~A~A~C*~C~G-A~U-U-U-C-A-A~A-U~G*~G~U~G~C 3'
' U~A~A~C*~C~G-A~U-U-U-C-A-A~A-U~G*~G~U~G~C 3'
' U~A~A~C*~C~G-A~U-U-U-C-A-A~A-U~G*~G~U~G~C 3'
' U~A~A~C*~C~G-A~U-U-U-C-A-A~A-U~G*~G~U~G~C 3'
1) The nucleosides shown in bold have the 2’methyl modification, those that are
underlined are 2’-fluoro and those that are neither bold nor underlined are native ribose.
2) One or more contiguous dashes represent phosphodiester es and ~ represents
phosphorothioate es
3) Any asterisk after a letter tes it is an unlocked nucleic acid monomer. These
nucleosides do not have other ribose modifications such as 2'-fluro or 2'methyl.
4) Any X indicates the lack of a linkage
) Any Y indicates an abasic nucleoside
6) The C in any CpG may be methylated at the C5 position
7) The 5'end of the sense strand may have a 5'methyl group
8) The 5'end of an antisense strand may have a 5'-phosphate group
9) The two nucleosides in positions 10 and 11 from the 5'-end of the antisense strand
which may be in italics are the ones opposite the argonaute 2 cleavage site
73. i miRNA Inhibitor Compounds Based on Human miR-29c for
sequential stration to t the actions thereof.
Endogenous miRNA antisense strands (overhang in bold):
Same as for mouse miR-29c
Sense and antisense strands for use in seqRNAi miRNA inhibitors:
Prototype sense strand sequence:
Same as for mouse miR-29c
Prototype antisense strand ce:
with G:U intact:
Same as for mouse miR-29c
with G:U converted to G:C:
Same as for mouse miR-29c
Complementary sense and antisense strands for use in accordance with this invention:
Sense strands:
Same as for mouse c
Antisense strands:
Same as for mouse miR-29c
1) The nucleosides shown in bold have the 2’methyl modification, those that are
underlined are 2’-fluoro and those that are neither bold nor underlined are native ribose.
2) One or more contiguous dashes represent phosphodiester linkages and ~ represents
phosphorothioate linkages
3) Any asterisk after a letter indicates it is an unlocked nucleic acid r. These
nucleosides do not have other ribose modifications such as 2'-fluro or ethyl.
4) Any X indicates the lack of a linkage
) Any Y indicates an abasic nucleoside
6) The C in any CpG may be methylated at the C5 on
7) The 5'end of the sense strand may have a 5'methyl group
8) The 5'end of an antisense strand may have a 5'-phosphate group
9) The two nucleosides in positions 10 and 11 from the 5'-end of the antisense strand
which may be in italics are the ones te the argonaute 2 cleavage site
74. i miRNA Inhibitor Compounds Based on Mouse miR-33 for sequential
administration to inhibit the actions thereof.
Endogenous miRNA antisense strands (overhang in bold):
Sense and antisense strands for use in seqRNAi miRNA inhibitors:
Prototype sense strand ce:
Prototype antisense strand sequence:
with G:U intact:
with G:U converted to G:C:
75. seqRNAi miRNA tor Compounds Based on Human miR-33 for sequential
administration to inhibit the s thereof.
1) The nucleosides shown in bold have the 2’methyl modification, those that are
underlined are 2’-fluoro and those that are neither bold nor underlined are native .
2) One or more contiguous dashes represent phosphodiester linkages and ~ represents
phosphorothioate linkages
3) Any asterisk after a letter tes it is an unlocked nucleic acid monomer. These
nucleosides do not have other ribose modifications such as 2'-fluro or 2'methyl.
4) Any X indicates the lack of a e
5) Any Y indicates an abasic nucleoside
6) The C in any CpG may be methylated at the C5 position
7) The 5'end of the sense strand may have a 5'methyl group
8) The 5'end of an antisense strand may have a 5'-phosphate group
9) The two nucleosides in positions 10 and 11 from the 5'-end of the antisense strand
which may be in italics are the ones opposite the ute 2 cleavage site
76. seqRNAi miRNA Inhibitor Compounds Based on Mouse miR-122 for sequential
stration to inhibit the actions thereof.
Endogenous miRNA antisense strands (overhang in bold):
5' UGGAGUGUGACAAUGGUGUUUG 3' (#)
Sense and antisense strands for use in seqRNAi miRNA inhibitors:
Prototype sense strand sequence:
' UGGAGUGUGACAAUGGUGUUUG 3' (#)
Prototype antisense strand sequence:
with G:U intact:
' AAACGCCAUUGUCACACUCC 3' (#)
with G:U converted to G:C:
' AAACACCAUUGUCACACUCC 3' (#)
mentary sense and antisense strands for use in accordance with this invention:
Sense strands:
' G~G~A~G~U~G~U~G-A-C-A-A~U~G~G~U~G~U~U~U 3'
' G~G~A~G~U~G~U~G-A-C-A-A~U~G~G~U~G~U~U~U 3'
5' G~G~A~G~U~G~U~G-A-Y-A-A~U~G~G~U~G~U~U~U 3'
' G~G~A~G~U~G~U~G~A~Y~A~A~U~G~G~U~G~U~U~U 3'
' G~U~G~U~G-A-Y-A-A~U~G~G~U~G*~U~U~U 3'
' G~G~A~G~U~G~U~G~A~Y~A~A~U~G~G~U~G*~U~U~U 3'
' G~G~A~G~U*~G~U~G-A-Y-A-A~U~G~G~U~G*~U~U~U 3'
5' G~G~A~G~U*~G~U~G~A~Y~A~A~U~G~G~U~G*~U~U~U 3'
' G~G~A~G~U~G~U*~G-A-Y-A-A~U~G~G~U~G*~U~U~U 3'
' G~G~A~G~U~G~U*~G~A~Y~A~A~U~G~G~U~G*~U~U~U 3'
' G~G~A~G~U*~G~U~G-A-C*-A-A~U~G~G~U~G*~U~U~U 3'
' G~G~A~G~U*~G~U~G~A~C*~A~A~U~G~G~U~G*~U~U~U 3'
5' G~G~A~G~U~G~U~G-A-G-A-A~U~G~G~U~C~U~U~U 3'
' G~G~A~G~U~G~U~G~A~G~A~A~U~G~G~U~C~U~U~U 3'
' G~G~A~G~C~G~U~G-A-G-A-A~U~G~G~U~C~U~U~U 3'
' G~G~A~G~C~G~U~G~A~G~A~A~U~G~G~U~C~U~U~U 3'
' G~G~A~G~U~G~C~G-A-G-A-A~U~G~G~U~C~U~U~U 3'
5' G~G~A~G~U~G~C~G~A~G~A~A~U~G~G~U~C~U~U~U 3'
' G~G~A~G~C~G~U~G-A-C*-A-A~U~G~G~U~C~U~U~U 3'
' G~G~A~G~C~G~U~G~A~C*~A~A~U~G~G~U~C~U~U~U 3'
' G~G~A~G~U~G~U~G~A~CXA~A~U~G~G~U~G~U~U~U 3'
' G~G~A~G~U~G~U~G~A~CXA~A~U~G~G~U~G~U~U~U 3'
' G~G~A~G~C~G~U~G~A~CXA~A~U~G~G~U~A~U~U~U 3'
' A~G~U~G~U~G~A~C~A~A~U~G~G~U~G 3'
' A~G~U~G~U~G~A~C~A~A~U~G~G~U~G 3'
' A~G~U~G~U~G~A~G~A~A~U~G~G~U~G 3'
Antisense strands:
' A~A~A~C~A-C~C-A-U-U-G-U-C-A~C-A~C~U~C~C 3'
' A~A~A~C~A-C~C-A-U-U-G-U-C-A~C-A~C~U~C~C 3'
' A~A~A~C~A-C~C-A-U-U-G-U-C-A~C-A~C~U~C~C 3'
' A~A~A~C~A-C~C-A-U-U-G-U-C-A~C-A~C~U~C~C 3'
5' A~A~A~C~A~C-C~A-U-U-G-U-C~A-C~A~C~U~C~C 3'
' A~A~A~C~A~C-C~A-U-U-G-U-C~A-C~A~C~U~C~C 3'
' A~A~A~C~A~C-C~A-U-U-G-U-C~A-C~A~C~U~C~C 3'
' A~A~A~C~A~C-C~A-U-U-G-U-C~A-C~A~C~U~C~C 3'
' A~A~A~C*~A~C-C~A-U-U-G-U-C~A-C~A~C~U~C~C 3'
5' A~A~A~C*~A~C-C~A-U-U-G-U-C~A-C~A~C~U~C~C 3'
' A~A~A~C*~A~C-C~A-U-U-G-U-C~A-C~A~C~U~C~C 3'
' A~A~A~C*~A~C-C~A-U-U-G-U-C~A-C~A~C~U~C~C 3'
' A~A~A~C~A~C-C*~A-U-U-G-U-C~A-C~A~C~U~C~C 3'
' A~A~A~C~A~C-C*~A-U-U-G-U-C~A-C~A~C~U~C~C 3'
5' A~A~A~C~A~C-C*~A-U-U-G-U-C~A-C~A~C~U~C~C 3'
' C~A~C-C*~A-U-U-G-U-C~A-C~A~C~U~C~C 3'
' C*~A~C-C~A-U-U-G-U-C~A-C~A*~C~U~C~C 3'
' A~A~A~C*~A~C-C~A-U-U-G-U-C~A-C~A*~C~U~C~C 3'
' A~A~A~C*~A~C-C~A-U-U-G-U-C~A-C~A*~C~U~C~C 3'
' A~A~A~C*~A~C-C~A-U-U-G-U-C~A-C~A*~C~U~C~C 3'
' A~A~A~C~A~C~C~A~U-U-G-U~C~A~C~A~C~U~C~C 3'
' A~A~A~C~A~C~C~A~U-U-G-U~C~A~C~A~C~U~C~C 3'
' A~A~A~C~A~C~C~A~U-U-G-U~C~A~C~A~C~U~C~C 3'
5' A~A~A~C~A~C~C~A~U-U-G-U~C~A~C~A~C~U~C~C 3'
' A~A~A~C*~A~C~C~A~U-U-G-U~C~A~C~A~C~U~C~C 3'
' A~A~A~C*~A~C~C~A~U-U-G-U~C~A~C~A~C~U~C~C 3'
' A~A~A~C*~A~C~C~A~U-U-G-U~C~A~C~A~C~U~C~C 3'
' A~A~A~C*~A~C~C~A~U-U-G-U~C~A~C~A~C~U~C~C 3'
5' A~A~A~C~A~C~C*~A~U-U-G-U~C~A~C~A~C~U~C~C 3'
' A~A~A~C~A~C~C*~A~U-U-G-U~C~A~C~A~C~U~C~C 3'
' A~A~A~C~A~C~C*~A~U-U-G-U~C~A~C~A~C~U~C~C 3'
' A~A~A~C~A~C~C*~A~U-U-G-U~C~A~C~A~C~U~C~C 3'
' A~A~A~C*~A~C~C~A~U-U-G-U~C~A~C~A*~C~U~C~C 3'
5' A~A~A~C*~A~C~C~A~U-U-G-U~C~A~C~A*~C~U~C~C 3'
' C*~A~C~C~A~U-U-G-U~C~A~C~A*~C~U~C~C 3'
' A~A~A~C*~A~C~C~A~U-U-G-U~C~A~C~A*~C~U~C~C 3'
' C~A~C~C~A~U~U~G~U~C~A~C~A~C~U~C~C 3'
' A~A~A~C~A~C~C~A~U~U~G~U~C~A~C~A~C~U~C~C 3'
5' A~A~A~C~A~C~C~A~U~U~G~U~C~A~C~A~C~U~C~C 3'
' A~A~A~C~A~C~C~A~U~U~G~U~C~A~C~A~C~U~C~C 3'
' A~A~A~C*~A~C~C~A~U~U~G~U~C~A~C~A~C~U~C~C 3'
' A~A~A~C*~A~C~C~A~U~U~G~U~C~A~C~A~C~U~C~C 3'
' A~A~A~C*~A~C~C~A~U~U~G~U~C~A~C~A~C~U~C~C 3'
' A~A~A~C*~A~C~C~A~U~U~G~U~C~A~C~A~C~U~C~C 3'
1) The nucleosides shown in bold have the ethyl modification, those that are
underlined are 2’-fluoro and those that are neither bold nor underlined are native ribose.
2) One or more contiguous dashes represent phosphodiester linkages and ~ represents
phosphorothioate linkages
3) Any asterisk after a letter indicates it is an unlocked nucleic acid monomer. These
nucleosides do not have other ribose modifications such as ro or 2'methyl.
4) Any X indicates the lack of a linkage
5) Any Y indicates an abasic nucleoside
6) The C in any CpG may be methylated at the C5 position
7) The 5'end of the sense strand may have a 5'methyl group
8) The 5'end of an antisense strand may have a 5'-phosphate group
9) The two sides in positions 10 and 11 from the 5'-end of the antisense strand
which may be in italics are the ones opposite the argonaute 2 cleavage site
77. seqRNAi miRNA Inhibitor Compounds Based on Human miR-122 for
sequential administration to inhibit the actions thereof.
Endogenous miRNA antisense strands (overhang in bold):
' UGGAGUGUGACAAUGGUGUUUG 3' (#)
Sense and antisense strands for use in i miRNA inhibitors:
Prototype sense strand ce:
Same as mouse miR-122
Prototype antisense strand sequence:
with G:U intact:
Same as mouse miR-122
with G:U converted to G:C:
Same as mouse miR-122
Complementary sense and antisense strands for use in accordance with this ion:
Sense strands:
Same as mouse miR-122
Antisense strands:
Same as mouse miR-122
1) The nucleosides shown in bold have the 2’methyl modification, those that are
underlined are 2’-fluoro and those that are r bold nor underlined are native ribose.
2) One or more contiguous dashes represent phosphodiester linkages and ~ represents
phosphorothioate linkages
3) Any asterisk after a letter indicates it is an unlocked nucleic acid monomer. These
nucleosides do not have other ribose modifications such as ro or 2'methyl.
4) Any X indicates the lack of a e
) Any Y indicates an abasic nucleoside
6) The C in any CpG may be methylated at the C5 position
7) The 5'end of the sense strand may have a ethyl group
8) The 5'end of an nse strand may have a 5'-phosphate group
9) The two nucleosides in positions 10 and 11 from the 5'-end of the antisense strand
which may be in italics are the ones opposite the argonaute 2 cleavage site
78. seqRNAi miRNA Inhibitor Compounds Based on Mouse miR-155 for
sequential administration to inhibit the actions thereof.
Endogenous miRNA antisense strands (overhang in bold):
Sense and antisense strands for use in seqRNAi miRNA inhibitors:
Prototype sense strand sequence:
Prototype antisense strand sequence:
with G:U intact:
with G:U converted to G:C
1) The nucleosides shown in bold have the 2’methyl modification, those that are
underlined are oro and those that are neither bold nor underlined are native ribose.
19) One or more contiguous dashes represent phosphodiester linkages and ~ represents
phosphorothioate linkages
) Any asterisk after a letter indicates it is an unlocked nucleic acid monomer. These
nucleosides do not have other ribose modifications such as 2'-fluro or 2'methyl.
21) Any X indicates the lack of a linkage
22) Any Y indicates an abasic nucleoside
23) The C in any CpG may be ated at the C5 position
24) The 5'end of the sense strand may have a 5'methyl group
) The 5'end of an antisense strand may have a 5'-phosphate group
26) The two nucleosides in positions 10 and 11 from the 5'-end of the antisense strand
which may be in italics are the ones opposite the ute 2 ge site
79. seqRNAi miRNA Inhibitor Compounds Based on Human 5 for
sequential administration to inhibit the actions thereof.
80. miRNA Mimic Compounds Based on Mouse miR-24 for use in the tial
administration method described herein.
miR1 hairpin (unmatched nucleosides are offset - U may pair with G):
g g a ua ucuca
cucc gu ccu cugagcuga ucagu u
|||| || ||| ||||||||| ||||| u
gagg ca gga gacuugacu gguca u
a a c -c cacac
miR2 hairpin (unmatched nucleosides are offset - U may pair with G):
- ucu ---- ccgc c g a aa ug u
gcc cucc gggcu cucc gu ccu cugagcuga cagu au c
||| |||| ||||| |||| || ||| ||||||||| |||| ||
cgg gagg cccga gagg ca gga gacuugacu guca ug c
a -uc aucc -ccu a a c cg cg a
Endogenous sense strand top and antisense strand bottom with unmatched nucleosides
indicated by both italics and underline, with G:U matches underlined and overhangs in
bold. X represents no corresponding nucleoside:
miR1
5' GUGCCUACUGAGCUGAUAUCAGU3' (#)
3' GACAAGGACGACUUGACUXCGGU 5'
miR2
' GUGCCUACUGAGCUGAAACAGU 3' (#)
3' GACAAGGACGACUUGACUCGGU 5'
Sense strand top and antisense strand bottom where sense strand has been ed to
have only matched nucleosides with the antisense strand and includes G:U matches
indicated by underline and overhang is ted in bold:
miR1
' GUUCCUGCUGAGCUGAGCUAGU 3' (#)
3' GACGACUUGACUCGGU 5'
miR2
' GUUCCUGCUGAGCUGAGCCAGU 3' (#)
3' GACAAGGACGACUUGACUCGGU 5'
Sense strand top and nse strand bottom where sense strand has been adjusted to
have only matched nucleosides where G:U eliminated by adjusting sense strand to have
standard match to the corresponding antisense strand nucleoside the overhang is shown
in bold:
miR1
' GUUCCUGCUGAACUGAGCCAGU3' (#)
3' GACAAGGACGACUUGACUCGGU 5'
miR2
' GUUCCUGCUGAACUGAGCCAGU 3' (#)
3' GACAAGGACGACUUGACUCGGU 5'
Endogenous nse strand with overhang shown in bold and shown written in both
directions:
' UGGCUCAGUUCAGCAGGAACAG 3' (#)
3' GACAAGGACGACUUGACUCGGU 5'
s modified for seqRNAi miRNA use (note these compounds based on mouse miR-
24 may also be effectively used with other species including human). Any sense strand
can be used with a complementary antisense strand:
Set 1 Sense strands:
miR1 sense strands based on:
' GUGCCUACUGAGCUGAUAUCAGU 3'
Related strands ed for seqRNAi use:
' G~U~G~C~C~U~A~C-U-G-A~G~C-U~G~A~U~A~U~C~A~G~U 3' (#)
' G~U~G~C~C~U~A~C-U-G-A-G~C~U~G~A~U~A~U~C~A~G~U 3' (#)
' G~U~G~C~C~U~A~C-U-G-A~G~C-U~G~A~U~A~U~C~A~G~U 3' (#)
' G~U~G~C~C~U~A~C-U-G-A-G~C~U~G~A~U~A~U~C~A~G~U 3' (#)
5' G~U~G~C~C~U~A~C-U-G-A-G~C~U~G~A~U~A~U~C~A~G~U 3' (#)
' G~U~G~C~C~U~A~C-U-G-A-G~C~U~G~A-U-A-U-C~A~G~U 3' (#)
' G~U~G~C~C~U~A~C~U~GXA~G~C~U~G~A~U~A~U~C~A~G~U 3' (#)
' G~U~G~C~C~U~A~C-U-Y-A-G~C~U~G~A~U~A~U~C~A~G~U 3' (#)
' G~U~G~C~C~U~A~C~U~Y~A~G~C~U~G~A~U~A~U~C~A~G~U 3' (#)
' G~U~G~C~C~U~A~C-U-G*-A-G~C~U~G~A~U~A*~U~C~A~G~U 3' (#)
' G~U~G~C~C*~U~A~C-U-G*-A-G~C~U~G~A~U~A*~U~C~A~G~U 3' (#)
5' G~U~G~C*~C~U~A~C*-U-G-A-G~C*~U~G~A~U~A~U*~C~A~G~U 3' (#)
' G~U~G~C*~C~U~A~G-U-G-A-G~C*~U~G~A~U~A~G~C~A~G~U 3' (#)
' G~U~G~C~C~U~A*~C-U-G-A-G~C~U~G~A~U~A~U~C*~A~G~U 3' (#)
' C~C~U~A~C~U~G~A~G~C~U~G~A~U~A~U 3' (#)
' C~C~U~A~C~U~G~A~G~C~U~G*~A~U~A~U 3' (#)
5' C~C~U~A~C~U~G~A~G*~C~U~G~A~U~A~U 3' (#)
27) The nucleosides shown in bold have the ethyl modification, those that are
underlined are 2’-fluoro and those that are neither bold nor underlined are native ribose.
28) One or more contiguous dashes represent phosphodiester linkages and ~ represents
phosphorothioate linkages
29) Any asterisk after a letter indicates it is an ed nucleic acid monomer. These
nucleosides do not have other ribose cations such as 2'-fluro or 2'methyl.
) Any X indicates the lack of a linkage
31) Any Y indicates an abasic nucleoside
32) The C in any CpG may be methylated at the C5 position
33) The 5'end of the sense strand may have a 5'methyl group
Set 2 Sense strands:
miR1 sense strands based on:
' GCUGAGCUGAGCUAGU 3'
Related s modified for seqRNAi use:
5' G~U~U~C~C~U~G~C-U-G-A~G~C-U~G~A~G~C~U~A~G~U 3' (#)
' G~U~U~C~C~U~G~C-U-G-A-G~C~U~G~A~G~C~U~A~G~U 3' (#)
' G~U~U~C~C~U~G~C-U-G-A~G~C-U~G~A~G~C~U~A~G~U 3' (#)
' G~U~U~C~C~U~G~C-U-G-A-G~C~U~G~A~G~C~U~A~G~U 3' (#)
' G~U~U~C~C~U~G~C-U-Y-A-G~C~U~G~A~G~C~U~A~G~U 3' (#)
' G~U~U~C~C~U~G~C~U~Y~A~G~C~U~G~A~G~C~U~A~G~U 3' (#)
5' G~U~U~C~C*~U~G~C~U~Y~A~G~C~U~G~A~G~C*~U~A~G~U 3' (#)
' C~C*~U~G~C~U~G*~A~G~C~U~G~A~G~C*~U~A~G~U 3' (#)
' G~U~U~C~C*~U~G~C-U-G*-A-G~C~U~G~A~G~C*~U~A~G~U 3' (#)
' G~U~U~C~C*~U~G~C~U-G*-A-G~C~U~G*~A~G~C*~U~A~G~U 3' (#)
' G~U~U~C~C*~U~G~C~U-G*-A-G~C~U~C~A~G~C*~U~A~G~U 3' (#)
5' G~U~U~C~G~U~G~C~U~G*~A~G~C~U~G~A~G~G~U~A~G~U 3' (#)
' G~U~U~C~C~U~G~C~U~GXA~G~C~U~G~A~G~C~U~A~G~U 3' (#)
' C~C~U~G~C~U~G~A~G~C~U~G~A~G~C 3' (#)
' G~C~U~G*~A~G~C~U~G~A~G~C 3' (#)
1) The nucleosides shown in bold have the 2’methyl modification, those that are
underlined are 2’-fluoro and those that are neither bold nor underlined are native ribose.
2) One or more contiguous dashes represent phosphodiester linkages and ~ represents
phosphorothioate linkages
3) Any asterisk after a letter indicates it is an unlocked nucleic acid monomer. These
nucleosides do not have other ribose modifications such as ro or 2'methyl.
4) Any X indicates the lack of a linkage
) Any Y indicates an abasic nucleoside
6) The C in any CpG may be methylated at the C5 position
7) The 5'end of the sense strand may have a 5'methyl group
Set 3 Sense s:
miR1 sense strands based on:
' GCUGAACUGAGCCAGU 3'
d strands modified for seqRNAi use:
' G~U~U~C~C~U~G~C-U-G-A~A~C-U~G~A~G~C~C~A~G~U 3' (#)
' G~U~U~C~C~U~G~C-U-G-A-A~C~U~G~A~G~C~C~A~G~U 3' (#)
5' G~U~U~C~C~U~G~C-U-G-A~A~C-U~G~A~G~C~C~A~G~U 3' (#)
' G~U~U~C~C~U~G~C-U-G-A-A~C~U~G~A~G~C~C~A~G~U 3' (#)
' G~U~U~C~C~U~G~C-U-Y-A-A~C~U~G~A~G~C~C~A~G~U 3' (#)
' G~U~U~C~C~U~G~C~U~Y~A~A~C~U~G~A~G~C~C~A~G~U 3' (#)
' G~U~U~C~C*~U~G~C~U~Y~A~A~C~U~G~A~G~C*~C~A~G~U 3' (#)
5' G~U~U~C~C*~U~G~C~U~G*~A~A~C~U~G~A~G~C*~C~A~G~U 3' (#)
' G~U~U~C~C*~U~G~C-U-G*-A-A~C~U~G~A~G~C*~C~A~G~U 3' (#)
' G~U~U~C~C*~U~G~C~U-G*-A-A~C~U~G*~A~G~C*~C~A~G~U 3' (#)
' G~U~U~C*~C~U~G~C*~U-G-A-A~C*~U~G~A~G*~C~C~A~G~U 3' (#)
' G~U~U~C~G~U~G~C~U~G*~A~A~C~U~G~A~G~G~C~A~G~U 3' (#)
5' G~U~U~C~C~U~G~C~U~GXA~A~C~U~G~A~G~C~C~A~G~U 3' (#)
' C~C~U~G~C~U~G~A~A~C~U~G~A~G~C 3' (#)
' G~C~U~G~A*~A~C~U~G~A~G~C 3' (#)
1) The nucleosides shown in bold have the 2’methyl cation, those that are
underlined are 2’-fluoro and those that are neither bold nor underlined are native ribose.
2) One or more contiguous dashes represent phosphodiester linkages and ~ represents
phosphorothioate linkages
3) Any asterisk after a letter indicates it is an unlocked nucleic acid monomer. These
nucleosides do not have other ribose modifications such as 2'-fluro or 2'methyl.
4) Any X indicates the lack of a linkage
) Any Y indicates an abasic nucleoside
6) The C in any CpG may be methylated at the C5 position
7) The 5'end of the sense strand may have a 5'methyl group
Set 4 Sense strands:
miR2 sense strands based on:
' GUGCCUACUGAGCUGAAACAGU 3'
Related strands ed for seqRNAi use:
' G~U~G~C~C~U~A~C-U-G-A~G~C-U~G~A~A~A~C~A~G~U 3' (#)
5' G~U~G~C~C~U~A~C-U-G-A-G~C~U~G~A~A~A~C~A~G~U 3' (#)
' G~U~G~C~C~U~A~C-U-G-A~G~C-U~G~A~A~A~C~A~G~U 3' (#)
' G~U~G~C~C~U~A~C-U-G-A-G~C~U~G~A~A~A~C~A~G~U 3' (#)
' G~U~G~C~C~U~A~C~U~GXA~G~C~U~G~A~A~A~C~A~G~U 3' (#)
' C~C~U~A~C-U-Y-A-G~C~U~G~A~A~A~C~A~G~U 3' (#)
5' G~U~G~C~C~U~A~C~U~Y~A~G~C~U~G~A~A~A~C~A~G~U 3' (#)
' G~U~G~C~C~U~A~C-U-G*-A-G~C~U~G~A~A~A~C~A~G~U 3' (#)
' G~U~G~C~C*~U~A~C-U-G*-A-G~C~U~G~A~A~A*~C~A~G~U 3' (#)
' G~U~G~C~C~U~A~C-U-G*-A-G~C~U~G~A~A~A*~C~A~G~U 3' (#)
' G~U~G~C~C~U~A*~C-U-G-A-G~C~U~G~A~A~A~C~A~G~U 3' (#)
5' C~C~U~A~C~U~G~A~G~C~U~G~A~A~A~C 3' (#)
1) The sides shown in bold have the 2’methyl modification, those that are
underlined are 2’-fluoro and those that are neither bold nor underlined are native ribose.
2) One or more contiguous dashes represent phosphodiester linkages and ~ represents
phosphorothioate linkages
3) Any asterisk after a letter indicates it is an unlocked nucleic acid r. These
nucleosides do not have other ribose modifications such as 2'-fluro or 2'methyl.
4) Any X tes the lack of a linkage
) Any Y indicates an abasic nucleoside
6) The C in any CpG may be ated at the C5 position
7) The 5'end of the sense strand may have a 5'methyl group
Set 5 Sense strands:
miR2 sense strands based on:
' GUUCCUGCUGAGCUGAGCCAGU 3'
Related strands modified for seqRNAi use:
' G~U~U~C~C~U~G~C-U-G-A~G~C-U~G~A~G~C~C~A~G~U 3' (#)
' G~U~U~C~C~U~G~C-U-G-A-G~C~U~G~A~G~C~C~A~G~U 3' (#)
5' G~U~U~C~C~U~G~C-U-G-A~G~C-U~G~A~G~C~C~A~G~U 3' (#)
' G~U~U~C~C~U~G~C-U-G-A-G~C~U~G~A~G~C~C~A~G~U 3' (#)
' G~U~U~C~C~U~G~C-U-Y-A-G~C~U~G~A~G~C~C~A~G~U 3' (#)
' G~U~U~C~C~U~G~C~U~Y~A~G~C~U~G~A~G~C~C~A~G~U 3' (#)
' C~C*~U~G~C~U~Y~A~G~C~U~G~A~G~C*~C~A~G~U 3' (#)
5' G~U~U~C~C*~U~G~C~U~G*~A~G~C~U~G~A~G~C*~C~A~G~U 3' (#)
' G~U~U~C~C*~U~G~C-U-G*-A-G~C~U~G~A~G~C*~C~A~G~U 3' (#)
' G~U~U~C~C*~U~G~C~U-G*-A-G~C~U~G*~A~G~C*~C~A~G~U 3' (#)
' G~U~U~C~G~U~G~C~U~G*~A~G~C~U~G~A~G~G~C~A~G~U 3' (#)
' G~U~U~C~C~U~G~C~U~GXA~G~C~U~G~A~G~C~C~A~G~U 3' (#)
' C~C~U~G~C~U~G~A~G~C~U~G~A~G~C 3'
' C~C~U~G~C~U~G~A*~G~C~U~G~A~G~C 3'
1) The sides shown in bold have the 2’methyl modification, those that are
ined are 2’-fluoro and those that are neither bold nor underlined are native ribose.
2) One or more contiguous dashes represent phosphodiester linkages and ~ represents
phosphorothioate linkages
3) Any asterisk after a letter indicates it is an unlocked nucleic acid r. These
nucleosides do not have other ribose modifications such as 2'-fluro or 2'methyl.
4) Any X indicates the lack of a linkage
) Any Y indicates an abasic side
6) The C in any CpG may be methylated at the C5 position
7) The 5'end of the sense strand may have a 5'methyl group
Set 6 Sense strands:
miR2 sense strands based on:
' GUUCCUGCUGAACUGAGCCAGU 3'
Related s modified for seqRNAi use:
Same as Set 3 for miR1
Set 7 Sense strands:
These sense strands have been designed to be complementary to the miR-24 antisense
strands that form hairpins. They will produce activity in both mouse and human cells
and in cells from any other species that has the same miR-24 antisense strand.
' C~G~G~C~U~C~C~G-G-C-U~G-A~A-C~U~G~A~G~C~C~A 3' (#)
5' C~G~G~C~U~C~C~G-G-Y-U~G-A~A-C~U~G~A~G~C~C~A 3' (#)
' C~G~G~C~U~C~C~G~G~Y~U~G~A~A~C~U~G~A~G~C~C~A 3' (#)
' C~G~G~C~C~C~C~G~G~Y~U~G~A~A~C~U~G~A~G~A~C~A 3' (#)
' C~G~G~C~U~C~C~G~G~C*~U~G~A~A~C~U~G~A~G~C~C~A 3' (#)
' C~G~G~C~U~C~C~G~G~C*~U~G~A~A~C~U~G~A~G*~C~C~A 3' (#)
' C~U~C~C~G~G~C~U~G~A~A~C~U~G~A~G 3' (#)
5' C~U+~C~C~G~G~C~U~G~A~A~C~U~G~A+~G 3' (#)
1) The sides shown in bold have the 2’methyl cation, those that are
underlined are 2’-fluoro and those that are neither bold nor underlined are native ribose.
2) One or more contiguous dashes represent phosphodiester linkages and ~ represents
phosphorothioate linkages
3) Any asterisk after a letter indicates it is an unlocked nucleic acid monomer. These
nucleosides do not have other ribose modifications such as ro or 2'methyl.
4) Any + after a letter indicates the nucleoside is an LNA
) Any Y indicates an abasic nucleoside
6) The C in any CpG may be methylated at the C5 position
7) The 5'end of the sense strand may have a 5'methyl group
Antisense strands for both miR1 and miR2 all sense strand sets:
miR-24 antisense s (both miR1 and 2 for both mouse and human) based on:
' UGGCUCAGUUCAGCAGGAACAG 3' (seed region is underlined)
Related strands modified for seqRNAi use:
Group 1 (alternating oro modified nucleosides with native ribose):
' U~R~G-C-U-C-A-G-U-U~C~A~G~C~A~G~G~A~A~C~A~G 3' (#)
' U~R~G~C-U-C-A-G-U-U~C~A~G~C~A~G~G~A~A~C~A~G 3' (#)
' U~R~G-C-U-C-A-G-U~U~C~A~G~C~A~G~G~A~A~C~A~G 3' (#)
5' U~R~G~C-U-C-A-G-U-U~C~A~G~C~A~G~G~A~A~C~A~G 3' (#)
' U~R~G~C-U-C-A-G~U~U~C~A~G~C~A~G~G~A~A~C~A~G 3' (#)
' U~R~G~C~U-C-A-G~U~U~C~A~G~C~A~G~G~A~A~C~A~G 3' (#)
' U~R~G~C~U~C-A-G~U~U~C~A~G~C~A~G~G~A~A~C~A~G 3' (#)
' U~R~G~C~U~C~A-G~U~U~C~A~G~C~A~G~G~A~A~C~A~G 3' (#)
5' U~R~G~C~U~C~A~G~U~U~C~A~G~C~A~G~G~A~A~C~A~G 3' (#)
Group 2 (alternating 2'-fluoro with 2'methyl modified nucleosides):
' U~R~G-C-U-C-A-G-U-U~C~A~G~C~A~G~G~A~A~C~A~G 3' (#)
' U~R~G~C-U-C-A-G-U-U~C~A~G~C~A~G~G~A~A~C~A~G 3' (#)
' U~R~G-C-U-C-A-G-U~U~C~A~G~C~A~G~G~A~A~C~A~G 3' (#)
5' U~R~G~C-U-C-A-G-U~U~C~A~G~C~A~G~G~A~A~C~A~G 3' (#)
' U~R~G~C-U-C-A-G~U~U~C~A~G~C~A~G~G~A~A~C~A~G 3' (#)
' U~R~G~C~U-C-A-G~U~U~C~A~G~C~A~G~G~A~A~C~A~G 3' (#)
' U~R~G~C~U~C-A-G~U~U~C~A~G~C~A~G~G~A~A~C~A~G 3' (#)
' U~R~G~C~U~C~A-G~U~U~C~A~G~C~A~G~G~A~A~C~A~G 3' (#)
5' C~U~C~A~G~U~U~C~A~G~C~A~G~G~A~A~C~A~G 3' (#)
' U-R-G-C-U-C-A-G-U-U~C~A~G~C~A~G~G~A~A~C~A~G 3' (#)
' U~R-G~C-U~C-A~G-U~U~C~A~G~C~A~G~G~A~A~C~A~G 3' (#)
' U~R~G-C-U-C-A-G-U-U~C~A~G~C~A~G~G~A~A~C~A~G 3' (#)
' C-U-C-A-G-U-U~C~A~G~C~A~G~G~A~A~C~A~G 3' (#)
5' U~R~G-C-U-C-A-G-U~U~C~A~G~C~A~G~G~A~A~C~A~G 3' (#)
' U~R~G~C-U-C-A-G-U~U~C~A~G~C~A~G~G~A~A~C~A~G 3' (#)
' U~R~G~C-U-C-A-G~U~U~C~A~G~C~A~G~G~A~A~C~A~G 3' (#)
' U~R~G~C~U-C-A-G~U~U~C~A~G~C~A~G~G~A~A~C~A~G 3' (#)
' U~R~G~C~U~C-A-G~U~U~C~A~G~C~A~G~G~A~A~C~A~G 3' (#)
5' U~R~G~C~U~C~A-G~U~U~C~A~G~C~A~G~G~A~A~C~A~G 3' (#)
' U~R~G~C~U~C~A~G~U~U~C~A~G~C~A~G~G~A~A~C~A~G 3' (#)
' U-R-G-C-U-C-A-G-U-U~C~A~G~C~A~G~G~A~A~C~A~G 3' (#)
' U~R-G~C-U~C-A~G-U~U~C~A~G~C~A~G~G~A~A~C~A~G 3' (#)
Group 3 (hair pin design):
' U-G-G-C-U-C-A-G-U-U-C~A~G~C~C~U~G~A~G~C~C~G 3' (#)
' U-G-G-C-U-C-A-G-U-U-C~A~G~C~C~G~G~A~G~C~C~G 3' (#)
' U-G-G-C-U-C-A-G-U-U-C~A~G~C~C~U~G~A~A~C~C~G 3' (#)
' U-G-G-C-U-C-A-G-U-U-C~A~G~C~C~U~G~A~G~C~C~G 3' (#)
5' U-G-G-C-U-C-A-G-U-U-C~A~G~C~C~G~G~A~G~C~C~G 3' (#)
' C-U-C-A-G-U-U-C~A~G~C~C~U~G~A~A~C~C~G 3' (#)
' U~G~G-C-U-C-A-G-U-U-C~A~G~C~C~G~G~A~G~C~C~G 3' (#)
' U~G~G-C-U-C-A-G-U-U-C~A~G~C~C~U~G~A~A~C~C~G 3' (#)
' U~G~G-C-U-C-A-G-U-U-C~A~G~C~C~U~G~A~G~C~C~G 3' (#)
5' U~G~G~C-U-C-A-G-U-U-C~A~G~C~C~U~G~A~A~C~C~G 3' (#)
' U~G~G~C-U-C-A-G-U-U-C~A~G~C~C~G~G~A~G~C~C~G 3' (#)
' U~G~G~C-U-C-A-G-U-U-C~A~G~C~C~U~G~A~A~C~C~G 3' (#)
' U~G~G~C-U-C-A-G-U-U-C~A~G~C~C~U~G~A~G~C~C~G 3' (#)
' U~G~G-C-U-C-A-G-U-U-C~A~G~C~C~U~G~A~A~C~C~G 3' (#)
5' U~G~G-C-U-C-A-G-U-U-C~A~G~C~C~U~G~A~G~C~C~G 3' (#)
' U~G~G-C-U-C-A-G-U-U-C~A~G~C~C~U~G~A~A~C~C~G 3' (#)
' U~G~G-C-U-C-A-G-U-U-C~A~G~C~C~U~G~A~G~C~C~G 3' (#)
1) The nucleosides shown in bold have the 2’methyl modification, those that are
underlined are 2’-fluoro and those that are neither bold nor ined are native ribose.
2) One or more contiguous dashes represent phosphodiester linkages and ~ represents
orothioate linkages
3) Any asterisk after a letter tes it is an unlocked nucleic acid monomer. These
nucleosides do not have other ribose modifications such as ro or 2'methyl.
4) The C in any CpG may be methylated at the C5 position
5) The 5'end of the antisense strand may have a 5'-phosphate group
6) R is G (ribose), G (2'-fluoro), U (ribose) or U (2'-fluoro)
81. seqRNAi miRNA Mimic Compounds Based on Human miR-24 for use in the
sequential stration method described herein.
miR1 hairpin (unmatched nucleosides are offset - U may pair with G):
g g a ua ucuca
cucc gu ccu cugagcuga ucagu u
|||| || ||| ||||||||| ||||| u
gagg ca gga gacuugacu gguca u
a a c -c cacau
miR2 hairpin (unmatched nucleosides are offset - U may pair with G):
cc cg -cu --aa u
cucug ucc ugc acugagcug acacag u
||||| ||| ||| ||||||||| |||||| g
gggac agg acg ugacucggu uguguu g
-a -- acu caca u
Endogenous sense strand top and antisense strand bottom with unmatched nucleosides
indicated by both italics and underline, with G:U matches underlined and overhangs in
bold. X represents no corresponding nucleoside:
miR1
' UGCCUACUGAGCUGAUAUCAGU 3' (#)
3' GACAAGGACGACUUGACUXCGGU 5'
miR2
' UGCXCUACUGAGCUGAAACACAG 3' (#)
3' GACAAGGACGACUUGACUCGGU 5'
Sense strand top and antisense strand bottom where sense strand has been adjusted to
have only matched nucleosides with the antisense strand and includes G:U matches
indicated by underline and overhang is indicated in bold:
miR1
5' UUCCUGCUGAGCUGAGCUAGU 3' (#)
3' GACGACUUGACUCGGU 5'
Sense strand top and antisense strand bottom where sense strand has been adjusted to
have only matched nucleosides where G:U ated by adjusting sense strand to have
standard match to the corresponding antisense strand side the overhang is shown
in bold:
miR1
' UUCCUGCUGAACUGAGCCAGU 3' (#)
3' GACAAGGACGACUUGACUCGGU 5'
Endogenous antisense strand with overhang shown in bold and shown written in both
directions:
' UGGCUCAGUUCAGCAGGAACAG 3' (#)
3' GACAAGGACGACUUGACUCGGU 5'
s modified for seqRNAi miRNA use:
Set 1 Sense strands:
miR1 sense strands based on:
' UGCCUACUGAGCUGAUAUCAGU 3'
Related strands modified for seqRNAi use:
' U~G~C~C~U~A~C-U-G-A~G~C-U~G~A~U~A~U~C~A~G~U 3' (#)
' C~U~A~C-U-G-A-G~C~U~G~A~U~A~U~C~A~G~U 3' (#)
' U~G~C~C~U~A~C-U-G-A~G~C-U~G~A~U~A~U~C~A~G~U 3' (#)
' U~G~C~C~U~A~C-U-G-A-G~C~U~G~A~U~A~U~C~A~G~U 3' (#)
5' U~G~C~C~U~A~C-U-G-A-G~C~U~G~A~U~A~U~C~A~G~U 3' (#)
' U~G~C~C~U~A~C-U-G-A-G~C~U~G~A-U-A-U-C~A~G~U 3' (#)
' U~G~C~C~U~A~C~U~GXA~G~C~U~G~A~U~A~U~C~A~G~U 3' (#)
' U~G~C~C~U~A~C-U-Y-A-G~C~U~G~A~U~A~U~C~A~G~U 3' (#)
' U~G~C~C~U~A~C~U~Y~A~G~C~U~G~A~U~A~U~C~A~G~U 3' (#)
5' U~G~C~C~U~A~C-U-G*-A-G~C~U~G~A~U~A*~U~C~A~G~U 3' (#)
' U~G~C~C*~U~A~C-U-G*-A-G~C~U~G~A~U~A*~U~C~A~G~U 3' (#)
' U~G~C*~C~U~A~C*-U-G-A-G~C*~U~G~A~U~A~U*~C~A~G~U 3' (#)
' U~G~C*~C~U~A~G-U-G-A-G~C*~U~G~A~U~A~G~C~A~G~U 3' (#)
' U~G~C~C~U~A*~C-U-G-A-G~C~U~G~A~U~A~U~C*~A~G~U 3' (#)
5' C~U~A~C~U~G~A~G~C~U~G~A~U~A~U 3' (#)
' C~U~A~C~U~G~A~G~C~U~G*~A~U~A~U 3' (#)
' C~U~A~C~U~G~A~G*~C~U~G~A~U~A~U 3' (#)
1) The nucleosides shown in bold have the 2’methyl cation, those that are
underlined are 2’-fluoro and those that are neither bold nor underlined are native ribose.
2) One or more contiguous dashes represent phosphodiester linkages and ~ represents
phosphorothioate linkages
3) Any asterisk after a letter indicates it is an unlocked c acid monomer. These
nucleosides do not have other ribose modifications such as 2'-fluro or 2'methyl.
4) Any X tes the lack of a linkage
5) Any Y indicates an abasic nucleoside
6) The C in any CpG may be methylated at the C5 position
7) The 5'end of the sense strand may have a 5'methyl group
Set 2 Sense strands:
miR1 sense strands based on:
5' CUGAGCUGAGCUAGU 3'
Related strands ed for seqRNAi use:
' U~U~C~C~U~G~C-U-G-A~G~C-U~G~A~G~C~U~A~G~U 3' (#)
' U~U~C~C~U~G~C-U-G-A-G~C~U~G~A~G~C~U~A~G~U 3' (#)
5' U~U~C~C~U~G~C-U-G-A~G~C-U~G~A~G~C~U~A~G~U 3' (#)
' U~U~C~C~U~G~C-U-G-A-G~C~U~G~A~G~C~U~A~G~U 3' (#)
' U~U~C~C~U~G~C-U-G-Y-G~C~U~G~A~G~C~U~A~G~U 3' (#)
' U~U~C~C~U~G~C~U~G~Y~G~C~U~G~A~G~C~U~A~G~U 3' (#)
' U~U~C~C*~U~G~C~U~G~Y~G~C~U~G~A~G~C*~U~A~G~U 3' (#)
' U~U~C~C*~U~G~C~U~G~A*~G~C~U~G~A~G~C*~U~A~G~U 3' (#)
5' U~U~C~C*~U~G~C-U-G-A*-G~C~U~G~A~G~C*~U~A~G~U 3' (#)
' U~U~C~C*~U~G~C~U-G-A*-G~C~U~G*~A~G~C*~U~A~G~U 3' (#)
' U~U~C~C*~U~G~C~U-G-A*-G~C~U~C~A~G~C*~U~A~G~U 3' (#)
' U~U~C~G~U~G~C~U~G~A*~G~C~U~G~A~G~G~U~A~G~U 3' (#)
' U~U~C~C~U~G~C~U~G~AXG~C~U~G~A~G~C~U~A~G~U 3' (#)
5' C~C~U~G~C~U~G~A~G~C~U~G~A~G~C 3' (#)
' C~C~U~G~C~U~G~A*~G~C~U~G~A~G~C 3' (#)
1) The nucleosides shown in bold have the 2’methyl modification, those that are
underlined are oro and those that are neither bold nor underlined are native ribose.
2) One or more contiguous dashes ent phosphodiester linkages and ~ represents
phosphorothioate es
3) Any asterisk after a letter indicates it is an unlocked nucleic acid monomer. These
nucleosides do not have other ribose modifications such as 2'-fluro or 2'methyl.
4) Any X indicates the lack of a linkage
) Any Y indicates an abasic nucleoside
6) The C in any CpG may be methylated at the C5 position
7) The 5'end of the sense strand may have a 5'methyl group
Set 3 Sense strands:
miR1 sense strands based on:
' UUCCUGCUGAACUGAGCCAGU 3'
Related s modified for seqRNAi use:
' U~U~C~C~U~G~C~U-G-A-A~C-U~G~A~G~C~C~A~G~U 3' (#)
' U~U~C~C~U~G~C~U-G-A-A~C~U~G~A~G~C~C~A~G~U 3' (#)
' U~U~C~C~U~G~C~U-G-A-A~C-U~G~A~G~C~C~A~G~U 3' (#)
' U~U~C~C~U~G~C~U-G-A-A-C~U~G~A~G~C~C~A~G~U 3' (#)
' U~U~C~C~U~G~C~U-G-Y-A-C~U~G~A~G~C~C~A~G~U 3' (#)
5' U~U~C~C~U~G~C~U~G~Y~A~C~U~G~A~G~C~C~A~G~U 3' (#)
' U~U~C~C~U*~G~C~U~G~Y~A~C~U~G~A~G~C*~C~A~G~U 3' (#)
' U~U~C~C~U*~G~C~U~G~A*~A~C~U~G~A~G~C*~C~A~G~U 3' (#)
' U~U~C~C*~U~G~C-U-G-A*-A~C~U~G~A~G~C*~C~A~G~U 3' (#)
' U~U~C~C*~U~G~C~U-G-A*-A~C~U~G*~A~G~C*~C~A~G~U 3' (#)
5' U~U~C*~C~U~G~C*~U-G-A*-A~C*~U~G~A~G*~C~C~A~G~U 3' (#)
' U~U~C~G~U~G~C~U~G~A*~A~C~U~G~A~G~G~C~A~G~U 3' (#)
' U~U~C~C~U~G~C~U~G~AXA~C~U~G~A~G~C~C~A~G~U 3' (#)
' C~C~U~G~C~U~G~A~A~C~U~G~A~G~C 3' (#)
' C~C~U~G~C~U~G~A~A*~C~U~G~A~G~C 3' (#)
1) The nucleosides shown in bold have the 2’methyl modification, those that are
underlined are 2’-fluoro and those that are neither bold nor underlined are native ribose.
2) One or more uous dashes represent phosphodiester linkages and ~ represents
orothioate linkages
3) Any asterisk after a letter indicates it is an unlocked nucleic acid monomer. These
nucleosides do not have other ribose cations such as 2'-fluro or 2'methyl.
4) Any X indicates the lack of a linkage
) Any Y indicates an abasic nucleoside
6) The C in any CpG may be methylated at the C5 position
7) The 5'end of the sense strand may have a ethyl group
Set 4 Sense strands:
miR2 sense strands based on:
Mouse set 4 sense strand without 5'-end G
Related s modified for seqRNAi use:
' U~G~C~C~U~A~C~U-G-A-G~C-U~G~A~A~A~C~A~G~U 3' (#)
5' U~G~C~C~U~A~C~U-G-A-G-C~U~G~A~A~A~C~A~G~U 3' (#)
' U~G~C~C~U~A~C~U-G-A-G~C-U~G~A~A~A~C~A~G~U 3' (#)
' U~G~C~C~U~A~C~U-G-A-G-C~U~G~A~A~A~C~A~G~U 3' (#)
' U~G~C~C~U~A~C~U~G~AXG~C~U~G~A~A~A~C~A~G~U 3' (#)
' C~U~A~C-U-G-Y-G~C~U~G~A~A~A~C~A~G~U 3' (#)
5' U~G~C~C~U~A~C~U~G~Y~G~C~U~G~A~A~A~C~A~G~U 3' (#)
' U~G~C~C~U~A~C-U-G-A*-G~C~U~G~A~A~A~C~A~G~U 3' (#)
' U~G~C~C*~U~A~C-U-G-A*-G~C~U~G~A~A~A*~C~A~G~U 3' (#)
' U~G~C~C~U~A~C-U-G-A*-G~C~U~G~A~A~A*~C~A~G~U 3' (#)
' U~G~C~C~U~A~C*-U-G-A-G~C~U~G~A~A~A~C~A~G~U 3' (#)
5' C~C~U~A~C~U~G~A~G~C~U~G~A~A~A~C 3'
1) The nucleosides shown in bold have the 2’methyl modification, those that are
underlined are 2’-fluoro and those that are neither bold nor underlined are native ribose.
2) One or more uous dashes represent phosphodiester linkages and ~ represents
phosphorothioate linkages
3) Any asterisk after a letter indicates it is an unlocked nucleic acid monomer. These
nucleosides do not have other ribose modifications such as 2'-fluro or ethyl.
4) Any X indicates the lack of a e
) Any Y indicates an abasic nucleoside
6) The C in any CpG may be methylated at the C5 position
7) The 5'end of the sense strand may have a 5'methyl group
Set 5 Sense strands:
miR2 sense strands based on:
Mouse set 4 sense strand without 5'-end G
Related strands modified for seqRNAi use:
' U~U~C~C~U~G~C~U-G-A-G~C-U~G~A~G~C~C~A~G~U 3' (#)
5' U~U~C~C~U~G~C~U-G-A-G-C~U~G~A~G~C~C~A~G~U 3' (#)
' U~U~C~C~U~G~C~U-G-A-G~C-U~G~A~G~C~C~A~G~U 3' (#)
' U~U~C~C~U~G~C~U-G-A-G-C~U~G~A~G~C~C~A~G~U 3' (#)
' U~U~C~C~U~G~C~U-G-Y-G-C~U~G~A~G~C~C~A~G~U 3' (#)
' C~U~G~C~U~G~Y~G~C~U~G~A~G~C~C~A~G~U 3' (#)
5' U~U~C~C~U*~G~C~U~G~Y~G~C~U~G~A~G~C*~C~A~G~U 3' (#)
' U~U~C~C~U*~G~C~U~G~A~G*~C~U~G~A~G~C*~C~A~G~U 3' (#)
' U~U~C~C~U*~G~C-U-G-A-G*~C~U~G~A~G~C*~C~A~G~U 3' (#)
' U~U~C~C~U*~G~C~U-G-A-G*~C~U~G*~A~G~C*~C~A~G~U 3' (#)
' U~U~C~G~U~G~C~U~G~A~G~C~U~G~A~G~G~C~A~G~U 3' (#)
5' C~U~G~C~U~G~AXG~C~U~G~A~G~C~C~A~G~U 3' (#)
' C~C~U~G~C~U~G~Y~G~C~U~G~A~G~C 3' (#)
' G~C~U~G~Y~G~C~U~G~A~G~C 3' (#)
1) The nucleosides shown in bold have the 2’methyl modification, those that are
underlined are 2’-fluoro and those that are neither bold nor underlined are native ribose.
2) One or more contiguous dashes represent phosphodiester linkages and ~ represents
phosphorothioate linkages
3) Any asterisk after a letter indicates it is an unlocked nucleic acid r. These
nucleosides do not have other ribose modifications such as 2'-fluro or 2'methyl.
4) Any X indicates the lack of a linkage
) Any Y indicates an abasic nucleoside
6) The C in any CpG may be methylated at the C5 position
7) The 5'end of the sense strand may have a ethyl group
Set 6 Sense s:
miR2 sense strands based on:
' UUCCUGCUGAACUGAGCCAGU 3'
Related strands modified for seqRNAi use:
Same as human Set 3 for miR1
Set 7 Sense strands:
These sense strands have been designed to be complementary to the miR-24 antisense
strands that form hairpins. They will produce activity in both mouse and human cells
and in cells from any other species that has the same miR-24 antisense strand.
These are the same as the mouse miR-24 Set 7 sense strands
1) The nucleosides shown in bold have the 2’methyl cation, those that are
underlined are 2’-fluoro and those that are neither bold nor underlined are native ribose.
2) One or more contiguous dashes represent phosphodiester es and ~ represents
phosphorothioate linkages
3) Any asterisk after a letter indicates it is an unlocked nucleic acid monomer. These
nucleosides do not have other ribose cations such as 2'-fluro or 2'methyl.
4) Any + after a letter indicates the nucleoside is an LNA
) Any Y indicates an abasic nucleoside
6) The C in any CpG may be methylated at the C5 position
7) The 5'end of the sense strand may have a 5'methyl group
Antisense strands for both miR1 and miR2 all sense strand sets:
miR-24 antisense strands (both miR1 and 2 for both mouse and human) based on:
' UGGCUCAGUUCAGCAGGAACAG 3' (seed region is ined)
Related strands modified for seqRNAi use:
Group 1 (alternating 2'-fluoro ed nucleosides with native ribose):
Same as for mouse miR-24
Group 2 nating 2'-fluoro with 2'methyl modified nucleosides):
Same as for mouse miR-24
Group 3 (hair pin design):
Same as for mouse miR-24
1) The nucleosides shown in bold have the 2’methyl modification, those that are
underlined are 2’-fluoro and those that are neither bold nor underlined are native ribose.
2) One or more contiguous dashes represent odiester linkages and ~ ents
orothioate linkages
3) Any asterisk after a letter indicates it is an unlocked c acid monomer. These
nucleosides do not have other ribose modifications such as 2'-fluro or 2'methyl.
4) The C in any CpG may be methylated at the C5 position
) The 5'end of the antisense strand may have a 5'-phosphate group
6) R is G (ribose), G (2'-fluoro), U (ribose) or U (2'-fluoro)
82. seqRNAi miRNA Mimic Compounds Based on Mouse miR-26a for use in the
sequential stration method described herein.
miR-26a-1 hairpin (unmatched nucleosides are offset - U may pair with G):
a - g u c g gca g
aggcc gug ccucgu caaguaauc aggauaggcu u g u
||||| ||| |||||| ||||||||| |||||||||| | |
uccgg cgc ggggca guucauugg ucuuauccgg g c c
g g a c u g -aa c
miR-26a-2 hairpin (unmatched nucleosides are offset - U may pair with G):
g gg ug uu c -- uc
gcugc c ga caaguaauc aggauaggcu gug c
||||| | || ||||||||| |||||||||| |||
cgacg g cu guucauuag ucuuguccgg uac g
g ga gu uu u ag cu
Endogenous sense strand top and antisense strand bottom with unmatched sides
indicated by both italics and underline, with G:U matches underlined and overhangs in
bold:
miR-26a-1
5' CCUAUUCUUGGUUACUUGCACG 3' (#)
3' UCGGAUAGGACCUAAUGAACUU 5'
miR-26a-2
' CCUGUUCUUGAUUACUUGUUUC3' (#)
3' UCGGAUAGGACCUAAUGAACUU 5'
Sense strand top and antisense strand bottom where sense strand has been adjusted to
have only matched nucleosides with the antisense strand and includes G:U s
indicated by underline and overhang is indicated in bold:
miR-26a-1
' CCUAUUCUGGGUUACUUGAACG 3' (#)
3' UCGGAUAGGACCUAAUGAACUU 5'
miR-26a-2
' CCUGUUCUGGAUUACUUGAAUC3' (#)
3' AGGACCUAAUGAACUU 5'
Sense strand top and antisense strand bottom where sense strand has been adjusted to
have only matched nucleosides where G:U ated by adjusting sense strand to have
standard match to the corresponding antisense strand nucleoside the overhang is shown
in bold:
miR-26a-1
' CCUAUCCUGGAUUACUUGAACG 3' (#)
3' AGGACCUAAUGAACUU 5'
miR-26a-2
5' CCUAUCCUGGAUUACUUGAAUC3' (#)
3' AGGACCUAAUGAACUU 5'
Endogenous antisense strand with overhang shown in bold and shown written in both
directions:
' UUCAAGUAAUCCAGGAUAGGCU 3' (#)
3' UCGGAUAGGACCUAAUGAACUU 5'
Strands modified for seqRNAi miRNA use:
Set 1 Sense strands:
miR-26a-1 sense strands based on:
' CCUAUUCUUGGUUACUUGCACG 3'
Related strands modified for seqRNAi use:
' C~C~U~A~U~U~C~U-U-G-G~U~U-A~C~U~U~G~C~A~C~G 3' (#)
' C~C~U~A~U~U~C~U-U-G-G-U~U~A~C~U~U~G~C~A~C~G 3' (#)
' C~C~U~A~U~U~C~U-U-G-G~U~U-A~C~U~U~G~C~A~C~G 3' (#)
5' C~C~U~A~U~U~C~U-U-G-G-U~U~A~C~U~U~G~C~A~C~G 3' (#)
' C~C~U~A~U~U~C~U-U-Y-G-U~U~A~C~U~U~G~C~A~C~G 3' (#)
' C~C~U~A~U~U~C~U~U~Y~G~U~U~A~C~U~U~G~C~A~C~G 3' (#)
' C~C~U~A~U*~U~C~U~U~Y~G~U~U~A~C~U~U~G*~C~A~C~G 3' (#)
' C~C~U~A~U*~U~C~U~U~G*~G~U~U~A~C~U~U~G*~C~A~C~G 3' (#)
' C~C~U~A~U*~U~C~U-U-G*-G-U~U~A~C~U~U~G*~C~A~C~G 3' (#)
5' C~C~U~A~U*~U~C~U~U-G*-G-U~U~A~C*~U~U~G*~C~A~C~G 3' (#)
' C~C~U~A*~U~U~C~U*~U-G-G-U~U*~A~C~U~U*~G~C~A~C~G 3' (#)
' C~C~U~A~G~U~C~U~U~G*~G~U~U~A~C~U~U~A~C~A~C~G 3' (#)
' A~U~U~C~U~U~GXG~U~U~A~C~U~U~G~C~A~C~G 3' (#)
' A~U~U~C~U~U~G~G~U~U~A~C~U~U~G 3' (#)
5' A~U~U~C~U~U~G~G*~U~U~A~C~U~U~G 3' (#)
1) The nucleosides shown in bold have the 2’methyl cation, those that are
ined are 2’-fluoro and those that are neither bold nor underlined are native ribose.
2) One or more contiguous dashes represent phosphodiester linkages and ~ represents
phosphorothioate linkages
3) Any asterisk after a letter indicates it is an unlocked nucleic acid r. These
nucleosides do not have other ribose modifications such as 2'-fluro or 2'methyl.
4) Any X indicates the lack of a linkage
) Any Y indicates an abasic nucleoside
6) The C in any CpG may be methylated at the C5 position
7) The 5'end of the sense strand may have a 5'methyl group
Set 2 Sense strands:
miR-26a-1 sense strands based on:
' CCUAUUCUGGGUUACUUGAACG 3'
Related strands ed for seqRNAi use:
' C~C~U~A~U~U~C~U-G-G-G~U~U-A~C~U~U~G~A~A~C~G 3' (#)
' C~C~U~A~U~U~C~U-G-G-G-U~U~A~C~U~U~G~A~A~C~G 3' (#)
' C~C~U~A~U~U~C~U-G-G-G~U~U-A~C~U~U~G~A~A~C~G 3' (#)
' C~C~U~A~U~U~C~U-G-G-G-U~U~A~C~U~U~G~A~A~C~G 3' (#)
' C~C~U~A~U~U~C~U-G-Y-G-U~U~A~C~U~U~G~A~A~C~G 3' (#)
5' C~C~U~A~U~U~C~U~G~Y~G~U~U~A~C~U~U~G~A~A~C~G 3' (#)
' C~C~U~A~U*~U~C~U~G~Y~G~U~U~A~C~U~U~G*~A~A~C~G 3' (#)
' C~C~U~A~U*~U~C~U~G~G*~G~U~U~A~C~U~U~G*~A~A~C~G 3' (#)
' C~C~U~A~U*~U~C~U-G-G*-G-U~U~A~C~U~U~G*~A~A~C~G 3' (#)
' C~C~U~A~U*~U~C~U~G-G*-G-U~U~A~C*~U~U~G*~A~A~C~G 3' (#)
5' C~C~U~A*~U~U~C~U*~G-G-G-U~U*~A~C~U~U*~G~A~A~C~G 3' (#)
' C~C~U~A~G~U~C~U~G~G*~G~U~U~A~C~U~U~A~A~A~C~G 3' (#)
' C~C~U~A~U~U~C~U~G~GXG~U~U~A~C~U~U~G~A~A~C~G 3' (#)
' A~U~U~C~U~G~G~G~U~U~A~C~U~U~G 3' (#)
' C~U~G~G~G*~U~U~A~C~U~U~G 3' (#)
1) The nucleosides shown in bold have the 2’methyl modification, those that are
underlined are 2’-fluoro and those that are neither bold nor ined are native ribose.
2) One or more uous dashes represent phosphodiester linkages and ~ represents
orothioate linkages
3) Any asterisk after a letter indicates it is an unlocked nucleic acid monomer. These
nucleosides do not have other ribose modifications such as 2'-fluro or 2'methyl.
4) Any X indicates the lack of a linkage
) Any Y indicates an abasic nucleoside
6) The C in any CpG may be methylated at the C5 position
7) The 5'end of the sense strand may have a 5'methyl group
Set 3 Sense strands:
miR-26a-1 sense strands based on:
' CUGGAUUACUUGAACG 3'
Related strands ed for seqRNAi use:
' C~C~U~A~U~C~C~U-G-G-A~U~U-A~C~U~U~G~A~A~C~G 3' (#)
5' A~U~C~C~U-G-G-A-U~U~A~C~U~U~G~A~A~C~G 3' (#)
' C~C~U~A~U~C~C~U-G-G-A~U~U-A~C~U~U~G~A~A~C~G 3' (#)
' C~C~U~A~U~C~C~U-G-G-A-U~U~A~C~U~U~G~A~A~C~G 3' (#)
' C~C~U~A~U~C~C~U-G-Y-A-U~U~A~C~U~U~G~A~A~C~G 3' (#)
' C~C~U~A~U~C~C~U~G~Y~A~U~U~A~C~U~U~G~A~A~C~G 3' (#)
5' C~C~U~A~U*~C~C~U~G~Y~A~U~U~A~C~U~U~G*~A~A~C~G 3' (#)
' C~C~U~A~U*~C~C~U~G~G*~A~U~U~A~C~U~U~G*~A~A~C~G 3' (#)
' C~C~U~A~U*~C~C~U-G-G*-A-U~U~A~C~U~U~G*~A~A~C~G 3' (#)
' C~C~U~A~U*~C~C~U~G-G*-A-U~U~A~C*~U~U~G*~A~A~C~G 3' (#)
' C~C~U~A*~U~C~C~U*~G-G-A-U~U*~A~C~U~U*~G~A~A~C~G 3' (#)
5' C~C~U~A~G~C~C~U~G~G*~A~U~U~A~C~U~U~A~A~A~C~G 3' (#)
' C~C~U~A~U~C~C~U~G~GXA~U~U~A~C~U~U~G~A~A~C~G 3' (#)
' A~U~C~C~U~G~G~A~U~U~A~C~U~U~G 3' (#)
' A~U~C~C~U~G~G~A*~U~U~A~C~U~U~G 3' (#)
1) The nucleosides shown in bold have the 2’methyl modification, those that are
underlined are 2’-fluoro and those that are neither bold nor underlined are native ribose.
2) One or more contiguous dashes represent phosphodiester linkages and ~ represents
phosphorothioate linkages
3) Any sk after a letter indicates it is an unlocked nucleic acid monomer. These
nucleosides do not have other ribose modifications such as 2'-fluro or 2'methyl.
4) Any X indicates the lack of a linkage
) Any Y indicates an abasic nucleoside
6) The C in any CpG may be methylated at the C5 position
7) The 5'end of the sense strand may have a 5'methyl group
Set 4 Sense strands:
miR-26a-2 sense strands based on:
' CCUGUUCUUGAUUACUUGUUUC3'
Related strands ed for seqRNAi use:
' C~C~U~G~U~U~C~U-U-G-A~U~U-A~C~U~U~G~U~U~U~C 3' (#)
' C~C~U~G~U~U~C~U-U-G-A-U~U~A~C~U~U~G~U~U~U~C 3' (#)
' C~C~U~G~U~U~C~U-U-G-A~U~U-A~C~U~U~G~U~U~U~C 3' (#)
' C~C~U~G~U~U~C~U-U-G-A-U~U~A~C~U~U~G~U~U~U~C 3' (#)
5' C~C~U~G~U~U~C~U-U-Y-A-U~U~A~C~U~U~G~U~U~U~C 3' (#)
' C~C~U~G~U~U~C~U~U~Y~A~U~U~A~C~U~U~G~U~U~U~C 3' (#)
' C~C~U~G~U*~U~C~U~U~Y~A~U~U~A~C~U~U~G*~U~U~U~C 3' (#)
' C~C~U~G~U*~U~C~U~U~G*~A~U~U~A~C~U~U~G*~U~U~U~C 3' (#)
' C~C~U~G~U*~U~C~U-U-G*-A-U~U~A~C~U~U~G*~U~U~U~C 3' (#)
5' C~C~U~G~U*~U~C~U~U-G*-A-U~U~A~C*~U~U~G*~U~U~U~C 3' (#)
' C~C~U~G*~U~U~C~U*~U-G-A-U~U*~A~C~U~U*~G~U~U~U~C 3' (#)
' G~G~U~C~U~U~G*~A~U~U~A~C~U~U~A~U~U~U~C 3' (#)
' C~C~U~G~U~U~C~U~U~GXA~U~U~A~C~U~U~G~U~U~U~C 3' (#)
' G~U~U~C~U~U~G~A~U~U~A~C~U~U~G 3' (#)
' G~U~U~C~U~U~G~A*~U~U~A~C~U~U~G 3' (#)
1) The nucleosides shown in bold have the 2’methyl modification, those that are
underlined are 2’-fluoro and those that are r bold nor underlined are native ribose.
2) One or more contiguous dashes represent phosphodiester linkages and ~ represents
phosphorothioate linkages
3) Any asterisk after a letter indicates it is an unlocked nucleic acid monomer. These
nucleosides do not have other ribose modifications such as ro or 2'methyl.
4) Any X tes the lack of a linkage
5) Any Y indicates an abasic nucleoside
6) The C in any CpG may be methylated at the C5 position
7) The 5'end of the sense strand may have a ethyl group
Set 5 Sense strands:
miR-26a-2 sense strands based on:
5' CCUGUUCUGGAUUACUUGAAUC3'
Related strands modified for seqRNAi use:
' C~C~U~G~U~U~C~U-G-G-A~U~U-A~C~U~U~G~A~A~U~C 3' (#)
' C~C~U~G~U~U~C~U-G-G-A-U~U~A~C~U~U~G~A~A~U~C 3' (#)
' C~C~U~G~U~U~C~U-G-G-A~U~U-A~C~U~U~G~A~A~U~C 3' (#)
5' C~C~U~G~U~U~C~U-G-G-A-U~U~A~C~U~U~G~A~A~U~C 3' (#)
' C~C~U~G~U~U~C~U-G-Y-A-U~U~A~C~U~U~G~A~A~U~C 3' (#)
' G~U~U~C~U~G~Y~A~U~U~A~C~U~U~G~A~A~U~C 3' (#)
' C~C~U~G~U*~U~C~U~G~Y~A~U~U~A~C~U~U~G*~A~A~U~C 3' (#)
' C~C~U~G~U*~U~C~U~G~G*~A~U~U~A~C~U~U~G*~A~A~U~C 3' (#)
5' C~C~U~G~U*~U~C~U-G-G*-A-U~U~A~C~U~U~G*~A~A~U~C 3' (#)
' C~C~U~G~U*~U~C~U~G-G*-A-U~U~A~C*~U~U~G*~A~A~U~C 3' (#)
' G*~U~U~C~U*~G-G-A-U~U*~A~C~U~U*~G~A~A~U~C 3' (#)
' C~C~U~G~G~U~C~U~G~G*~A~U~U~A~C~U~U~A~A~A~U~C 3' (#)
' C~C~U~G~U~U~C~U~G~GXA~U~U~A~C~U~U~G~A~A~U~C 3' (#)
' G~U~U~C~U~G~G~A~U~U~A~C~U~U~G 3' (#)
5' G~U~U~C~U~G~G~A*~U~U~A~C~U~U~G 3' (#)
1) The nucleosides shown in bold have the 2’methyl cation, those that are
underlined are oro and those that are neither bold nor underlined are native ribose.
2) One or more contiguous dashes represent odiester linkages and ~ represents
phosphorothioate linkages
3) Any asterisk after a letter indicates it is an unlocked nucleic acid monomer. These
sides do not have other ribose modifications such as 2'-fluro or 2'methyl.
4) Any X indicates the lack of a linkage
) Any Y indicates an abasic nucleoside
6) The C in any CpG may be methylated at the C5 position
7) The 5'end of the sense strand may have a 5'methyl group
Set 6 Sense strands:
miR-26a-2 sense strands based on:
' CCUAUCCUGGAUUACUUGAAUC3' (#)
Related strands modified for seqRNAi use:
5' C~C~U~A~U~C~C~U-G-G-A~U~U-A~C~U~U~G~A~A~U~C 3' (#)
' C~C~U~A~U~C~C~U-G-G-A-U~U~A~C~U~U~G~A~A~U~C 3' (#)
' C~C~U~A~U~C~C~U-G-G-A~U~U-A~C~U~U~G~A~A~U~C 3' (#)
' C~C~U~A~U~C~C~U-G-G-A-U~U~A~C~U~U~G~A~A~U~C 3' (#)
' C~C~U~A~U~C~C~U-G-Y-A-U~U~A~C~U~U~G~A~A~U~C 3' (#)
5' C~C~U~A~U~C~C~U~G~Y~A~U~U~A~C~U~U~G~A~A~U~C 3' (#)
' C~C~U~A~U*~C~C~U~G~Y~A~U~U~A~C~U~U~G*~A~A~U~C 3' (#)
' C~C~U~A~U*~C~C~U~G~G*~A~U~U~A~C~U~U~G*~A~A~U~C 3' (#)
' A~U*~C~C~U-G-G*-A-U~U~A~C~U~U~G*~A~A~U~C 3' (#)
' C~C~U~A~U*~C~C~U~G-G*-A-U~U~A~C*~U~U~G*~A~A~U~C 3' (#)
' A*~U~C~C~U*~G-G-A-U~U*~A~C~U~U*~G~A~A~U~C 3' (#)
5' C~C~U~A~G~C~C~U~G~G*~A~U~U~A~C~U~U~A~A~A~U~C 3' (#)
' C~C~U~A~U~C~C~U~G~GXA~U~U~A~C~U~U~G~A~A~U~C 3' (#)
' A~U~C~C~U~G~G~A~U~U~A~C~U~U~G 3' (#)
' A~U~C~C~U~G~G~A*~U~U~A~C~U~U~G 3' (#)
Set 7 Sense strands:
These sense strands have been designed to be complementary to the miR-26a antisense
strands that form hairpins. They will produce activity in both mouse and human cells
and in cells from any other species that has the same miR-26a antisense strand.
' C~U~C~A~A~A~U~A-A-U-G~G-A~U-U~A~C~U~U~G~A~A 3' (#)
' A~A~A~U~A-A-Y-G~G-A~U-U~A~C~U~U~G~A~A 3' (#)
5' C~U~C~A~A~A~U~A~A~Y~G~G-A~U~U~A~C~U~U~G~A~A 3' (#)
' C~U~C~A~A~A~U~A~A~Y~G~G-A~U~U~A~C~U~U~U~A~A 3' (#)
' C~U~C~A~A~A~U~A~A~U*~G~G-A~U~U~A~C~U~U~G~A~A 3' (#)
' C~U~C~A~A~A~U~A~A~U*~G~G-A~U~U~A~C~U~U*~G~A~A 3' (#)
' A~A~A~U~A~A~U~G~G-A~U~U~A~C~U~U 3' (#)
5' A~A+~A~U~A~A~U~G~G-A~U~U~A~C~U+~U 3' (#)
1) The nucleosides shown in bold have the 2’methyl modification, those that are
underlined are 2’-fluoro and those that are neither bold nor underlined are native ribose.
2) One or more contiguous dashes represent phosphodiester linkages and ~ represents
phosphorothioate linkages
3) Any asterisk after a letter indicates it is an ed nucleic acid r. These
nucleosides do not have other ribose modifications such as 2'-fluro or 2'methyl.
4) Any + after a letter indicates the nucleoside is an LNA
) Any Y indicates an abasic nucleoside
6) The C in any CpG may be methylated at the C5 position
7) The 5'end of the sense strand may have a 5'methyl group
Antisense strands for both miR-26a-1 and miR-26a-2 all sense strand sets:
miR-26a nse s (both miR-26a-1 and 2 for both mouse and human) based on:
' UUCAAGUAAUCCAGGAUAGGCU 3' (seed region is underlined)
Related strands modified for i use:
Group 1 (alternating 2'-fluoro modified nucleosides with native ribose):
' U~R~C-A-A-G-U-A-A-U~C~C~A~G~G~A~U~A~G~G~C~U 3' (#)
' U~R~C~A-A-G-U-A-A-U~C~C~A~G~G~A~U~A~G~G~C~U 3' (#)
' U~R~C-A-A-G-U-A-A~U~C~C~A~G~G~A~U~A~G~G~C~U 3' (#)
' U~R~C~A-A-G-U-A-A-U~C~C~A~G~G~A~U~A~G~G~C~U 3' (#)
5' U~R~C~A-A-G-U-A~A~U~C~C~A~G~G~A~U~A~G~G~C~U 3' (#)
' U~R~C~A~A-G-U-A~A~U~C~C~A~G~G~A~U~A~G~G~C~U 3' (#)
' A~A~G-U-A~A~U~C~C~A~G~G~A~U~A~G~G~C~U 3' (#)
' U~R~C~A~A~G~U-A~A~U~C~C~A~G~G~A~U~A~G~G~C~U 3' (#)
' U~R~C~A~A~G~U~A~A~U~C~C~A~G~G~A~U~A~G~G~C~U 3' (#)
Group 2 (alternating 2'-fluoro with 2'methyl modified nucleosides):
' U~R~C-A-A-G-U-A-A-U~C~C~A~G~G~A~U~A~G~G~C~U 3' (#)
' A-A-G-U-A-A-U~C~C~A~G~G~A~U~A~G~G~C~U 3' (#)
' U~R~C-A-A-G-U-A-A~U~C~C~A~G~G~A~U~A~G~G~C~U 3' (#)
' U~R~C~A-A-G-U-A-A~U~C~C~A~G~G~A~U~A~G~G~C~U 3' (#)
5' U~R~C~A-A-G-U-A~A~U~C~C~A~G~G~A~U~A~G~G~C~U 3' (#)
' U~R~C~A~A-G-U-A~A~U~C~C~A~G~G~A~U~A~G~G~C~U 3' (#)
' U~R~C~A~A~G-U-A~A~U~C~C~A~G~G~A~U~A~G~G~C~U 3' (#)
' U~R~C~A~A~G~U-A~A~U~C~C~A~G~G~A~U~A~G~G~C~U 3' (#)
' U~R~C~A~A~G~U~A~A~U~C~C~A~G~G~A~U~A~G~G~C~U 3' (#)
5' U-R-C-A-A-G-U-A-A-U~C~C~A~G~G~A~U~A~G~G~C~U 3' (#)
' U~R-C~A-A~G-U~A-A~U~C~C~A~G~G~A~U~A~G~G~C~U 3' (#)
' U~R~C-A-A-G-U-A-A-U~C~C~A~G~G~A~U~A~G~G~C~U 3' (#)
' U~R~C~A-A-G-U-A-A-U~C~C~A~G~G~A~U~A~G~G~C~U 3' (#)
' U~R~C-A-A-G-U-A-A~U~C~C~A~G~G~A~U~A~G~G~C~U 3' (#)
5' A-A-G-U-A-A~U~C~C~A~G~G~A~U~A~G~G~C~U 3' (#)
' U~R~C~A-A-G-U-A~A~U~C~C~A~G~G~A~U~A~G~G~C~U 3' (#)
' U~R~C~A~A-G-U-A~A~U~C~C~A~G~G~A~U~A~G~G~C~U 3' (#)
' U~R~C~A~A~G-U-A~A~U~C~C~A~G~G~A~U~A~G~G~C~U 3' (#)
' U~R~C~A~A~G~U-A~A~U~C~C~A~G~G~A~U~A~G~G~C~U 3' (#)
5' U~R~C~A~A~G~U~A~A~U~C~C~A~G~G~A~U~A~G~G~C~U 3' (#)
' U-R-C-A-A-G-U-A-A-U~C~C~A~G~G~A~U~A~G~G~C~U 3' (#)
' U~R-C~A-A~G-U~A-A~U~C~C~A~G~G~A~U~A~G~G~C~U 3' (#)
Group 3 (hair pin design):
' A-A-G-U-A-A-U-C~C~A~U~U~A~U~U~U~G~A~G 3' (#)
5' U-U-C-A-A-G-U-A-A-U-C~C~A~U~U~A~U~U~U~G~A~G 3' (#)
' U-U-C-A-A-G-U-A-A-U-C~C~A~U~U~A~U~U~U~G~A~G 3' (#)
' U-U-C-A-A-G-U-A-A-U-C~C~A~U~U~A~U~U~U~G~A~G 3' (#)
' U-U-C-A-A-G-U-A-A-U-C~C~A~U~U~A~U~U~U~G~A~G 3' (#)
' U~U-C-A-A-G-U-A-A-U-C~C~A~U~U~A~U~U~U~G~A~G 3' (#)
5' U~U~C-A-A-G-U-A-A-U-C~C~A~U~U~A~U~U~U~G~A~G 3' (#)
' A-A-G-U-A-A-U-C~C~A~U~U~A~U~U~U~G~A~G 3' (#)
' U~U~C~A-A-G-U-A-A-U-C~C~A~U~U~A~U~U~U~G~A~G 3' (#)
' U~U~C~A-A-G-U-A-A-U-C~C~A~U~U~A~U~U~U~G~A~G 3' (#)
' U~U~C-A-A-G-U-A-A-U-C~C~A~U~U~A~U~U~U~G~A~G 3' (#)
5' U~U~C~A-A-G-U-A-A-U-C~C~A~U~U~A~U~U~U~G~A~G 3' (#)
' U~U~C~A-A-G-U~A-A-U-C~C~A~U~U~A~U~U~U~G~A~G 3' (#)
' U~U~C~A-A-G-U~A-A-U-C~C~A~U~U~A~U~A~U~G~A~G 3' (#)
1) The nucleosides shown in bold have the 2’methyl modification, those that are
underlined are 2’-fluoro and those that are r bold nor underlined are native .
2) One or more contiguous dashes represent phosphodiester linkages and ~ represents
phosphorothioate linkages
3) Any asterisk after a letter indicates it is an unlocked nucleic acid monomer. These
nucleosides do not have other ribose modifications such as 2'-fluro or 2'methyl.
4) The C in any CpG may be methylated at the C5 position
) The 5'end of the antisense strand may have a 5'-phosphate group
6) R is U (ribose) or U (2'-fluoro)
83. seqRNAi miRNA Mimic Compounds Based on Human miR-26a for use in the
sequential administration method described .
miR-26a-1 hairpin (unmatched nucleosides are offset - U may pair with G):
g u c --g ca
gug ccucgu caaguaauc aggauaggcu ug g
||| |||||| ||||||||| |||||||||| || g
cgc ggggca guucauugg ucuuauccgg ac u
a c u gua cc
miR-26a-2 hairpin (unmatched nucleosides are offset - U may pair with G):
gg ug uu c guuucc
ggcugu c ga caaguaauc aggauaggcu a
|||||| | || ||||||||| ||||||||||
ucgacg g cu uag ucuuauccgg u
ga gu uu u aguguc
Endogenous sense strand top and antisense strand bottom with unmatched nucleosides
indicated by both italics and underline, with G:U matches underlined and overhangs in
bold:
miR-26a-1
5' CUUGGUUACUUGCACG 3' (#)
3' UCGGAUAGGACCUAAUGAACUU 5'
miR-26a-2
' CCUAUUCUUGAUUACUUGUUUC 3' (#)
3' UCGGAUAGGACCUAAUGAACUU 5'
Sense strand top and antisense strand bottom where sense strand has been adjusted to
have only matched nucleosides with the antisense strand and includes G:U matches
indicated by underline and overhang is indicated in bold:
miR-26a-1
' CCUAUUCUGGGUUACUUGAACG 3' (#)
3' UCGGAUAGGACCUAAUGAACUU 5'
miR-26a-2
' CCUAUUCUGGAUUACUUGAAUC 3' (#)
3' UCGGAUAGGACCUAAUGAACUU 5'
Sense strand top and antisense strand bottom where sense strand has been adjusted to
have only matched nucleosides where G:U ated by adjusting sense strand to have
standard match to the ponding antisense strand side the overhang is shown
in bold:
miR-26a-1
' CCUAUCCUGGAUUACUUGAACG 3' (#)
3' UCGGAUAGGACCUAAUGAACUU 5'
miR-26a-2
' CCUAUCCUGGAUUACUUGAAUC 3' (#)
3' UCGGAUAGGACCUAAUGAACUU 5'
Endogenous antisense strand with overhang shown in bold and shown n in both
directions:
' UUCAAGUAAUCCAGGAUAGGCU 3' (#)
3' UCGGAUAGGACCUAAUGAACUU 5'
s modified for seqRNAi miRNA use:
Set 1 Sense strands:
miR-26a-1 sense strands based on:
' CCUAUUCUUGGUUACUUGCACG 3'
Related strands modified for seqRNAi use:
Same as mouse miR-26a-1 Set 1
1) The nucleosides shown in bold have the 2’methyl modification, those that are
underlined are 2’-fluoro and those that are neither bold nor underlined are native ribose.
2) One or more contiguous dashes represent phosphodiester es and ~ represents
phosphorothioate linkages
3) Any sk after a letter indicates it is an unlocked c acid monomer. These
nucleosides do not have other ribose modifications such as 2'-fluro or 2'methyl.
4) Any X indicates the lack of a linkage
) Any Y indicates an abasic side
6) The C in any CpG may be methylated at the C5 position
7) The 5'end of the sense strand may have a 5'methyl group
Set 2 Sense strands:
miR-26a-1 sense strands based on:
' CCUAUUCUGGGUUACUUGAACG 3'
Related strands modified for seqRNAi use:
Same as mouse miR-26a-1 Set 2
1) The nucleosides shown in bold have the 2’methyl modification, those that are
underlined are 2’-fluoro and those that are neither bold nor underlined are native ribose.
2) One or more contiguous dashes represent phosphodiester linkages and ~ represents
phosphorothioate linkages
3) Any asterisk after a letter indicates it is an unlocked nucleic acid monomer. These
nucleosides do not have other ribose modifications such as 2'-fluro or 2'methyl.
4) Any X indicates the lack of a e
) Any Y indicates an abasic nucleoside
6) The C in any CpG may be methylated at the C5 position
7) The 5'end of the sense strand may have a 5'methyl group
Set 3 Sense strands:
miR-26a-1 sense strands based on:
' CUGGAUUACUUGAACG 3'
Related strands modified for seqRNAi use:
Same as mouse miR-26a-1 Set 3
1) The sides shown in bold have the ethyl modification, those that are
underlined are 2’-fluoro and those that are neither bold nor underlined are native ribose.
2) One or more contiguous dashes represent phosphodiester linkages and ~ ents
phosphorothioate linkages
3) Any asterisk after a letter indicates it is an ed nucleic acid monomer. These
nucleosides do not have other ribose modifications such as 2'-fluro or 2'methyl.
4) Any X indicates the lack of a linkage
) Any Y indicates an abasic nucleoside
6) The C in any CpG may be methylated at the C5 position
7) The 5'end of the sense strand may have a 5'methyl group
Set 4 Sense strands:
miR-26a-2 sense strands based on:
' CUUGAUUACUUGUUUC 3'
Related strands modified for seqRNAi use:
' C~C~U~A~U~U~C~U-U-G-A~U~U-A~C~U~U~G~U~U~U~C 3' (#)
' C~C~U~A~U~U~C~U-U-G-A-U~U~A~C~U~U~G~U~U~U~C 3' (#)
5' C~C~U~A~U~U~C~U-U-G-A~U~U-A~C~U~U~G~U~U~U~C 3' (#)
' C~C~U~A~U~U~C~U-U-G-A-U~U~A~C~U~U~G~U~U~U~C 3' (#)
' C~C~U~A~U~U~C~U-U-Y-A-U~U~A~C~U~U~G~U~U~U~C 3' (#)
' C~C~U~A~U~U~C~U~U~Y~A~U~U~A~C~U~U~G~U~U~U~C 3' (#)
' C~C~U~A~U*~U~C~U~U~Y~A~U~U~A~C~U~U~G*~U~U~U~C 3' (#)
5' C~C~U~A~U*~U~C~U~U~G*~A~U~U~A~C~U~U~G*~U~U~U~C 3' (#)
' A~U*~U~C~U-U-G*-A-U~U~A~C~U~U~G*~U~U~U~C 3' (#)
' C~C~U~A~U*~U~C~U~U-G*-A-U~U~A~C*~U~U~G*~U~U~U~C 3' (#)
' C~C~U~A*~U~U~C~U*~U-G-A-U~U*~A~C~U~U*~G~U~U~U~C 3' (#)
' C~C~U~A~G~U~C~U~U~G*~A~U~U~A~C~U~U~A~U~U~U~C 3' (#)
5' C~C~U~A~U~U~C~U~U~GXA~U~U~A~C~U~U~G~U~U~U~C 3' (#)
' A~U~U~C~U~U~G~A~U~U~A~C~U~U~G 3' (#)
' A~U~U~C~U~U~G~A*~U~U~A~C~U~U~G 3' (#)
1) The nucleosides shown in bold have the 2’methyl modification, those that are
ined are 2’-fluoro and those that are neither bold nor underlined are native ribose.
2) One or more contiguous dashes represent phosphodiester linkages and ~ represents
orothioate linkages
3) Any asterisk after a letter indicates it is an unlocked nucleic acid monomer. These
nucleosides do not have other ribose modifications such as 2'-fluro or 2'methyl.
4) Any X indicates the lack of a linkage
5) Any Y indicates an abasic nucleoside
6) The C in any CpG may be methylated at the C5 position
7) The 5'end of the sense strand may have a 5'methyl group
Set 5 Sense strands:
miR-26a-2 sense strands based on:
5' CCUAUUCUGGAUUACUUGAAUC 3'
d s modified for seqRNAi use:
' C~C~U~A~U~U~C~U-G-G-A~U~U-A~C~U~U~G~A~A~U~C 3' (#)
' C~C~U~A~U~U~C~U-G-G-A-U~U~A~C~U~U~G~A~A~U~C 3' (#)
' C~C~U~A~U~U~C~U-G-G-A~U~U-A~C~U~U~G~A~A~U~C 3' (#)
5' A~U~U~C~U-G-G-A-U~U~A~C~U~U~G~A~A~U~C 3' (#)
' C~C~U~A~U~U~C~U-G-Y-A-U~U~A~C~U~U~G~A~A~U~C 3' (#)
' C~C~U~A~U~U~C~U~G~Y~A~U~U~A~C~U~U~G~A~A~U~C 3' (#)
' C~C~U~A~U*~U~C~U~G~Y~A~U~U~A~C~U~U~G*~A~A~U~C 3' (#)
' C~C~U~A~U*~U~C~U~G~G*~A~U~U~A~C~U~U~G*~A~A~U~C 3' (#)
5' C~C~U~A~U*~U~C~U-G-G*-A-U~U~A~C~U~U~G*~A~A~U~C 3' (#)
' C~C~U~A~U*~U~C~U~G-G*-A-U~U~A~C*~U~U~G*~A~A~U~C 3' (#)
' C~C~U~A*~U~U~C~U*~G-G-A-U~U*~A~C~U~U*~G~A~A~U~C 3' (#)
' C~C~U~A~G~U~C~U~G~G*~A~U~U~A~C~U~U~A~A~A~U~C 3' (#)
' C~C~U~A~U~U~C~U~G~GXA~U~U~A~C~U~U~G~A~A~U~C 3' (#)
5' A~U~U~C~U~G~G~A~U~U~A~C~U~U~G 3' (#)
' A~U~U~C~U~G~G~A*~U~U~A~C~U~U~G 3' (#)
1) The nucleosides shown in bold have the 2’methyl modification, those that are
underlined are 2’-fluoro and those that are neither bold nor underlined are native ribose.
2) One or more contiguous dashes represent phosphodiester linkages and ~ represents
phosphorothioate linkages
3) Any asterisk after a letter indicates it is an unlocked nucleic acid monomer. These
sides do not have other ribose modifications such as 2'-fluro or 2'methyl.
4) Any X indicates the lack of a linkage
) Any Y indicates an abasic nucleoside
6) The C in any CpG may be methylated at the C5 position
7) The 5'end of the sense strand may have a ethyl group
Set 6 Sense strands:
miR-26a-2 sense strands based on:
5' CCUAUCCUGGAUUACUUGAAUC 3'
Related strands modified for seqRNAi use:
Same as Set 6 for mouse miR-26a-1
Set 7 Sense strands:
These sense strands have been designed to be complementary to the a antisense
s that form hairpins. They will produce activity in both mouse and human cells
and in cells from any other species that has the same miR-26a antisense .
Same as Set 7 for mouse miR-26a
1) The nucleosides shown in bold have the 2’methyl modification, those that are
underlined are 2’-fluoro and those that are neither bold nor underlined are native ribose.
2) One or more contiguous dashes represent phosphodiester linkages and ~ represents
phosphorothioate linkages
3) Any asterisk after a letter indicates it is an unlocked nucleic acid r. These
nucleosides do not have other ribose cations such as 2'-fluro or 2'methyl.
4) Any + after a letter indicates the nucleoside is an LNA
5) Any Y indicates an abasic nucleoside
6) The C in any CpG may be methylated at the C5 position
7) The 5'end of the sense strand may have a 5'methyl group
Antisense strands for both miR-26a-1 and a-2 all sense strand sets:
miR-26a antisense strands (both miR-26a-1 and 2 for both mouse and human) based on:
' UUCAAGUAAUCCAGGAUAGGCU 3' (seed region is underlined)
Related strands modified for seqRNAi use:
Group 1 (alternating 2'-fluoro modified nucleosides with native ribose):
Same as antisense strands for mouse miR-26a
Group 2 (alternating 2'-fluoro with 2'methyl modified nucleosides):
Same as nse strands for mouse miR-26a
Group 3 (hair pin design):
Same as antisense strands for mouse miR-26a
1) The nucleosides shown in bold have the 2’methyl modification, those that are
underlined are 2’-fluoro and those that are neither bold nor underlined are native ribose.
2) One or more contiguous dashes represent phosphodiester linkages and ~ represents
phosphorothioate linkages
3) Any asterisk after a letter indicates it is an unlocked nucleic acid r. These
nucleosides do not have other ribose modifications such as 2'-fluro or 2'methyl.
4) The C in any CpG may be methylated at the C5 position
) The 5'end of the antisense strand may have a 5'-phosphate group
6) R is U (ribose) or U (2'-fluoro)
84. seqRNAi miRNA Mimic Compounds Based on Mouse miR-29 for use in the
tial administration method described herein.
84A. Mouse a:
miR-29a n (unmatched nucleosides are offset - U may pair with G):
a uuagagg uuu c ucaa
cccc gauuuc ugguguu agag u
|||| |||||| ||||||| |||| a
gggg cuaaag accacga ucuu g
a uuaguaa ucu - uuaa
Endogenous sense strand top and nse strand bottom with unmatched nucleosides
indicated by both italics and underline, with G:U matches underlined and overhangs in
bold. X represents no corresponding nucleoside:
' ACUGAUUUCUUUUGGUGUUCAG 3' (#)
3' AUUGGCUAAAGUCUACCACGAXU 5'
Sense strand top and antisense strand bottom where sense strand has been adjusted to
have only matched nucleosides with the antisense strand and includes G:U matches
indicated by underline and overhang is indicated in bold:
' ACUGAUUUCAGAUGGUGUUA 3' (#)
3' UAAAGUCUACCACGAU 5'
Sense strand top and antisense strand bottom where sense strand has been adjusted to
have only d nucleosides where G:U eliminated by adjusting sense strand to have
standard match to the corresponding antisense strand nucleoside the overhang is shown
in bold:
' ACCGAUUUCAGAUGGUGCUA 3' (#)
3' AUUGGCUAAAGUCUACCACGAU 5'
Endogenous antisense strand with overhang shown in bold and shown written in both
directions:
' UAGCACCAUCUGAAAUCGGUUA 3' (#)
3' AUUGGCUAAAGUCUACCACGAU 5'
Strands modified for seqRNAi miRNA use (note these also apply to human miR-29a):
84B. Mouse miR-29b:
miR-29b-1 n (unmatched nucleosides are offset - U may pair with G):
a u gu uuaaa
agga gcugguuuca auggug uuagau u
|||| |||||||||| |||||| |||||| a
ucuu ugacuaaagu uaccac gaucug g
g u -- uuagu
miR-29b-2 hairpin (unmatched nucleosides are offset - U may pair with G):
- c g u uuuucc
gaa gcugguuuca auggug cu agau a
||||||||| |||||||||| |||||| || ||||
gaggauuuu ugacuaaagu uaccac ga ucua u
g u - - uguuuc
Endogenous sense strand top and antisense strand bottom with hed nucleosides
indicated by both italics and ine, with G:U matches underlined and overhangs in
bold. X Represents no corresponding nucleoside:
miR-29b-1
5' GCUGGUUUCAUAUGGUGGUUUA 3' (#)
3' UUGUGACUAAAGUUUACCACXXGAU 5'
miR-29b-2
' CUGGUUUCACAUGGUGGCUUAGAUU 3' (#)
3' UUGUGACUAAAGUUUACCACXGAU 5'
Sense strand top and antisense strand bottom where sense strand has been adjusted to
have only matched nucleosides with the antisense strand and includes G:U matches
indicated by underline and overhang is indicated in bold:
miR-29b-1
' GCUGGUUUCAAAUGGUGCUA 3' (#)
3' UUGUGACUAAAGUUUACCACGAU 5'
miR-29b-2
5' CUGGUUUCAAAUGGUGCUAGAUU 3' (#)
3' UUGUGACUAAAGUUUACCACGAU 5'
Sense strand top and antisense strand bottom where sense strand has been adjusted to
have only matched nucleosides where G:U eliminated by adjusting sense strand to have
standard match to the corresponding antisense strand nucleoside the overhang is shown
in bold:
miRb1
' ACUGAUUUCAAAUGGUGCUA 3' (#)
3' UUGUGACUAAAGUUUACCACGAU 5'
miRb2
5' CUGAUUUCAAAUGGUGCUAGAUU 3' (#)
3' UUGUGACUAAAGUUUACCACGAU 5'
Endogenous nse strand with overhang shown in bold and shown n in both
ions:
' UAGCACCAUUUGAAAUCAGUGUU 3' (#)
3' UUGUGACUAAAGUUUACCACGAU 5'
Strands modified for seqRNAi miRNA use:
miR-29b-1 (note these also apply to human miR-29b-1):
miR-29b-2 (note these also apply to human miR-29b-2):
84C. Mouse miR-29c:
miR-29c hairpin (unmatched nucleosides are offset - U may pair with G):
a - ggc ucc --- u
aca ca ugaccgauuuc ugguguu cagag c
||||||||| || ||||||||||| ||||||| ||||| u
gggggaugu gu auuggcuaaag accacga guuuu g
a a --- uuu ucu u
nous sense strand top and antisense strand bottom with unmatched nucleosides
ted by both italics and underline, with G:U matches underlined:
' UGACCGAUUUCUCCUGGUGUUC 3' (#)
3' AUUGGCUAAAGUUUACCACGAU 5'
Sense strand top and antisense strand bottom where sense strand has been adjusted to
have only matched nucleosides with the antisense strand and includes G:U matches
indicated by underline:
' UGACCGAUUUCAAAUGGUGUUA 3' (#)
3' AUUGGCUAAAGUUUACCACGAU 5'
Sense strand top and antisense strand bottom where sense strand has been adjusted to
have only matched nucleosides where G:U eliminated by adjusting sense strand to have
standard match to the ponding antisense strand nucleoside:
' UAACCGAUUUCAAAUGGUGCUA 3' (#)
3' AUUGGCUAAAGUUUACCACGAU 5'
Endogenous antisense strand with overhang shown in bold and shown n in both
directions:
' UAGCACCAUUUGAAAUCGGUUA 3' (#)
3' AUUGGCUAAAGUUUACCACGAU 5'
Strands modified for seqRNAi miRNA use (note these also apply to human miR-29c):
85. seqRNAi miRNA Mimic Compounds Based on Human miR-29 for use in the
sequential administration method described herein.
85A. Human miR-29a:
Pre-miRNA (unmatched nucleosides are offset - U may pair with G):
uuu c ucaa
augacugauuuc ugguguu agag u
|||||| | |||| a
uauuggcuaaag accacga ucuu u
ucu - uuaa
Endogenous sense strand top and antisense strand bottom with unmatched nucleosides
indicated by both italics and ine, with G:U matches ined and overhangs in
bold:
Same as for mouse miR-29a
Sense strand top and antisense strand bottom where sense strand has been adjusted to
have only matched nucleosides with the antisense strand and es G:U matches
indicated by underline and overhang is indicated in bold:
Same as for mouse miR-29a
Sense strand top and antisense strand bottom where sense strand has been adjusted to
have only matched nucleosides where G:U eliminated by adjusting sense strand to have
standard match to the corresponding antisense strand nucleoside the overhang is shown
in bold:
Same as for mouse miR-29a
nous antisense strand with overhang shown in bold and shown written in both
directions:
Same as for mouse a
Strands ed for seqRNAi miRNA use:
Same as for mouse miR-29a
85B. Human miR-29b:
miR-29b-1 hairpin (unmatched nucleosides are offset - U may pair with G):
- - u gu uuaaa
cuucaggaa gcugguuuca auggug uuagau u
||||||||| |||||||||| |||||| |||||| a
gggguucuu ugacuaaagu uaccac gaucug g
g g u -- uuagu
miR-29b-2 hairpin (unmatched nucleosides are offset - U may pair with G):
- c g u uuuucc
cuucuggaa gcugguuuca auggug cu agau a
||||||||| |||||||||| |||||| || ||||
gaggauuuu ugacuaaagu uaccac ga ucua u
g u - - uguuuc
Endogenous sense strand top and antisense strand bottom with unmatched nucleosides
indicated by both italics and underline, with G:U matches underlined and overhangs in
bold:
Same as for mouse miR-29b-1 (except human has a GA rhang in the sense )
Same as for mouse miR-29b-2 (except human lacks terminal AUU in 3'-overhang in the
sense strand)
Sense strand top and antisense strand bottom where sense strand has been adjusted to
have only matched nucleosides with the antisense strand and includes G:U matches
indicated by underline and overhang is ted in bold:
Same as for mouse miR-29b-1
Same as for mouse miR-29b-2
Sense strand top and antisense strand bottom where sense strand has been adjusted to
have only d sides where G:U eliminated by adjusting sense strand to have
standard match to the corresponding antisense strand nucleoside the overhang is shown
in bold:
Same as for mouse miR-29b-1
Same as for mouse miR-29b-2
nous antisense strand with overhang shown in bold and shown written in both
ions:
Same as for mouse miR-29b-1
Same as for mouse miR-29b-2
Strands modified for seqRNAi miRNA use:
Same as for mouse miR-29b-1
Same as for mouse miR-29b-2
85C. Human miR-29c:
miR-29c hairpin (unmatched nucleosides are offset - U may pair with G):
a - ggc ucc --- u
ucucuuaca ca ugaccgauuuc ugguguu cagag c
||||||||| || ||||||||||| ||||||| ||||| u
gggggaugu gu auuggcuaaag accacga guuuu g
a a --- uuu ucu u
Endogenous sense strand top and antisense strand bottom with unmatched nucleosides
indicated by both italics and underline, with G:U matches underlined and overhangs in
bold:
Same as for mouse miR-29c
Sense strand top and antisense strand bottom where sense strand has been adjusted to
have only matched nucleosides with the nse strand and includes G:U matches
indicated by ine and overhang is indicated in bold:
Same as for mouse miR-29c
Sense strand top and antisense strand bottom where sense strand has been adjusted to
have only matched nucleosides where G:U eliminated by ing sense strand to have
standard match to the corresponding antisense strand nucleoside the overhang is shown
in bold:
Same as for mouse miR-29c
Endogenous nse strand with overhang shown in bold and shown written in both
directions:
Same as for mouse miR-29c
Strands modified for seqRNAi miRNA use:
Same as for mouse c
86. seqRNAi miRNA Mimic Compounds Based on Mouse miR-122 for use in the
sequential administration method described herein.
miR-122 hairpin (unmatched nucleosides are offset - U may pair with G):
gg c - uc
agcugu aguguga aaugguguuug ug c
|||||| ||||||| ||||||||||| || a
ucgaua ucacacu uuaccgcaaac ac a
aa a u ca
Endogenous sense strand top and antisense strand bottom with unmatched nucleosides
indicated by both italics and underline, with G:U s underlined and overhangs in
bold:
' AAACGCCAUUAUCACACUAA 3' (#)
3' GUUUGUGGUAACAGUGUGAGGU 5'
Sense strand top and antisense strand bottom where sense strand has been adjusted to
have only matched nucleosides with the antisense strand and includes G:U matches
indicated by underline and overhang is indicated in bold:
' AAACGCCAUUGUCACACUCC 3' (#)
3' GUUUGUGGUAACAGUGUGAGGU 5'
Sense strand top and antisense strand bottom where sense strand has been adjusted to
have only d nucleosides where G:U eliminated by adjusting sense strand to have
standard match to the corresponding antisense strand nucleoside the overhang is shown
in bold:
' CAUUGUCACACUCC 3' (#)
3' GUUUGUGGUAACAGUGUGAGGU 5'
nous antisense strand with overhang shown in bold and shown written in both
directions:
' UGGAGUGUGACAAUGGUGUUUG 3' (#)
3' GUUUGUGGUAACAGUGUGAGGU 5'
Strands modified for seqRNAi miRNA use:
87. seqRNAi miRNA Mimic nds Based on Human miR-122 for use in the
sequential administration method described herein.
miR-122 hairpin (unmatched sides are offset - U may pair with G):
c - gg c --u c
cuuagcag agcugu a aaugguguuug gu u
|||||||| |||||| ||||||| ||||||||||| ||
ggaucguc ucgaua ucacacu uuaccgcaaac ca a
c a aa a uau a
Endogenous sense strand top and nse strand bottom with unmatched nucleosides
indicated by both italics and underline, with G:U matches underlined and overhangs in
bold:
5' AACGCCAUUAUCACACUAAAUA 3' (#)
3' GUUUGUGGUAACAGUGUGAGGU 5'
Sense strand top and antisense strand bottom where sense strand has been adjusted to
have only matched nucleosides with the antisense strand and includes G:U matches
indicated by ine and ng is indicated in bold:
' AACGCCAUUGUCACACUCCAUA 3' (#)
3' GUUUGUGGUAACAGUGUGAGGU 5'
Sense strand top and antisense strand bottom where sense strand has been adjusted to
have only matched nucleosides where G:U eliminated by adjusting sense strand to have
standard match to the corresponding antisense strand nucleoside the overhang is shown
in bold:
' AACACCAUUGUCACACUCCAUA 3' (#)
3' GUUUGUGGUAACAGUGUGAGGU 5'
Endogenous antisense strand with overhang shown in bold and shown written in both
directions:
' UGGAGUGUGACAAUGGUGUUUG 3' (#)
3' GUUUGUGGUAACAGUGUGAGGU 5'
Strands modified for i miRNA use:
88. seqRNAi miRNA Mimic Compounds Based on Mouse miR-146a for use in the
sequential administration method described herein.
miR-146a hairpin ched nucleosides are offset - U may pair with G):
cu c auauc
agcu gagaacugaauu cauggguu a
|||| |||||||||||| ||||||||
ucga uucuugacuuaa guguccag a
-c a acugu
Endogenous sense strand top and antisense strand bottom with hed nucleosides
indicated by both italics and underline, with G:U matches underlined and overhangs in
bold. X represents no ponding nucleoside:
' CCUGUGAAAUUCAGUUCUUCXAG 3' (#)
3' UUGGGUACCUUAAGUCAAGAGU 5'
Sense strand top and antisense strand bottom where sense strand has been adjusted to
have only matched nucleosides with the antisense strand and includes G:U matches
indicated by underline and ng is indicated in bold:
' CCUGUGGAAUUCAGUUCUUAAG 3' (#)
3' UUGGGUACCUUAAGUCAAGAGU 5'
Sense strand top and antisense strand bottom where sense strand has been adjusted to
have only matched nucleosides where G:U ated by adjusting sense strand to have
standard match to the corresponding antisense strand nucleoside the overhang is shown
in bold:
5' CCCAUGGAAUUCAGUUCUCAAG 3' (#)
3' UUGGGUACCUUAAGUCAAGAGU 5'
Endogenous antisense strand with overhang shown in bold and shown written in both
ions:
' UGAGAACUGAAUUCCAUGGGUU 3' (#)
3' UUGGGUACCUUAAGUCAAGAGU 5'
Strands modified for seqRNAi miRNA use:
89. seqRNAi miRNA Mimic nds Based on Human miR-146a for use in the
sequential administration method described herein.
miR-146a n (unmatched nucleosides are offset - U may pair with G):
c -----u u uu c u g uc
cgaug guaucc cagcu gagaacugaauu ca ggguu ug a
||||| |||||| ||||| |||||||||||| || ||||| || g
gcuac uauagg gucga uucuugacuuaa gu uccag ac u
u ugucuc - -c a c - ug
Endogenous sense strand top and antisense strand bottom with unmatched nucleosides
indicated by both italics and underline, with G:U matches underlined and overhangs in
bold:
' CCUCUGAAAUUCAGUUCUUCAG 3' (#)
3' UUGGGUACCUUAAGUCAAGAGU 5'
Sense strand top and antisense strand bottom where sense strand has been adjusted to
have only matched sides with the antisense strand and includes G:U matches
indicated by underline and overhang is indicated in bold:
' CCUAUGGAAUUCAGUUCUUAAG 3' (#)
3' UUGGGUACCUUAAGUCAAGAGU 5'
Sense strand top and antisense strand bottom where sense strand has been adjusted to
have only matched nucleosides where G:U eliminated by adjusting sense strand to have
rd match to the corresponding antisense strand nucleoside the overhang is shown
in bold:
5' CCCAUGGAAUUCAGUUCUCAAG 3' (#)
3' UUGGGUACCUUAAGUCAAGAGU 5'
Endogenous antisense strand with overhang shown in bold and shown n in both
directions:
' UGAGAACUGAAUUCCAUGGGUU 3' (#)
3' ACCUUAAGUCAAGAGU 5'
Strands modified for seqRNAi miRNA use:
90. seqRNAi miRNA Mimic Compounds Based on Mouse miR-203 for use in the
sequential administration method bed herein.
miR-203 hairpin (unmatched nucleosides are offset - U may pair with G):
u c u g a c
gcc gguc agugguucu gaca uuca caguu ugu
||| |||| ||||||||| |||| |||| ||||| || a
cgg ccag ucaccagga uugu aagu guuaa acg
c a u a - c
Endogenous sense strand top and antisense strand bottom with hed nucleosides
indicated by both italics and underline, with G:U matches underlined and overhangs in
bold. X represents no corresponding nucleoside:
' AGUGGUUCUUGACAGUUCAACA 3' (#)
3' CAGGAUUUGUAAAGUXG 5'
Sense strand top and antisense strand bottom where sense strand has been adjusted to
have only matched nucleosides with the antisense strand and includes G:U matches
indicated by underline and overhang is indicated in bold:
' AGUGGUUCUAGACAUUUCACA 3' (#)
3' GAUCACCAGGAUUUGUAAAGUG 5'
Sense strand top and antisense strand bottom where sense strand has been adjusted to
have only matched nucleosides where G:U eliminated by ing sense strand to have
standard match to the corresponding antisense strand nucleoside the overhang is shown
in bold:
' AGUGGUCCUAAACAUUUCACA 3' (#)
3' GAUCACCAGGAUUUGUAAAGUG 5'
Note: this strand pair is the same as for human miR-203
Endogenous antisense strand with ng shown in bold and shown n in both
directions:
' UGUUUAGGACCACUAG 3' (#)
3' GAUCACCAGGAUUUGUAAAGUG 5'
Strands modified for i miRNA use:
91. seqRNAi miRNA Mimic Compounds Based on Human miR-203 for use in the
sequential administration method described herein.
miR-203 hairpin (unmatched nucleosides are offset - U may pair with G):
g gg a u g c u g a - ug
uguug g c cgc cgcuggguc agugguucu aaca uuca caguu c u
||||| | | ||| ||||||||| ||||||||| |||| |||| ||||| |
gcgac c g gcg cag ucaccagga uugu aagu guuaa g a
a ag g c g a u a - c cg
Endogenous sense strand top and nse strand bottom with unmatched nucleosides
indicated by both italics and underline, with G:U matches underlined and overhangs in
bold. X represents no corresponding nucleoside:
' AGUGGUUCUUAACAGUUCAACA 3' (#)
3' GAUCACCAGGAUUUGUAAAGUXG 5'
Sense strand top and antisense strand bottom where sense strand has been adjusted to
have only matched nucleosides with the antisense strand and includes G:U matches
indicated by underline and overhang is indicated in bold:
' AGUGGUUCUAAACAUUUCACA 3' (#)
3' GAUCACCAGGAUUUGUAAAGUG 5'
Sense strand top and antisense strand bottom where sense strand has been adjusted to
have only matched nucleosides where G:U ated by adjusting sense strand to have
standard match to the corresponding antisense strand nucleoside the overhang is shown
in bold:
Same as for mouse miR-203
Endogenous antisense strand with overhang shown in bold and shown written in both
directions:
' GUGAAAUGUUUAGGACCACUAG 3' (#)
3' GAUCACCAGGAUUUGUAAAGUG 5'
Strands modified for seqRNAi miRNA use:
92. seqRNAi miRNA Mimic Compounds Based on Mouse miR-214 for use in the
sequential stration method described herein.
miR-214 hairpin (unmatched nucleosides are offset - U may pair with G):
ggccu acaga u aca aacau
ggcugg guugucaugug gucu cuugcugugcag c
|||||| ||||||||||| |||||||||| |||||||||||| c
ccgacc caacaguacac caga ggacgacauguc g
----u ----- u cac cacuc
nous sense strand top and antisense strand bottom with unmatched nucleosides
indicated by both italics and underline, with G:U matches underlined and overhangs in
bold:
' UGCCUGUCUACACUUGCUGUGC 3' (#)
3' UGACGGACAGACACGGACGACA 5'
Sense strand top and antisense strand bottom where sense strand has been adjusted to
have only d nucleosides with the antisense strand and includes G:U matches
indicated by underline and overhang is indicated in bold:
' UCUGUGCUUGCUGUGC 3' (#)
3' UGACGGACAGACACGGACGACA 5'
Sense strand top and antisense strand bottom where sense strand has been adjusted to
have only d nucleosides where G:U eliminated by adjusting sense strand to have
standard match to the corresponding antisense strand nucleoside the overhang is shown
in bold:
5' UGCCUGUCUGUGCCUGCUGUGC 3' (#)
3' UGACGGACAGACACGGACGACA 5'
Endogenous antisense strand with overhang shown in bold and shown written in both
directions:
' ACAGCAGGCACAGACAGGCAGU 3' (#)
3' UGACGGACAGACACGGACGACA 5'
Strands modified for seqRNAi miRNA use:
93. seqRNAi miRNA Mimic Compounds Based on Human miR-214 for use in the
sequential administration method described herein.
miR-214 hairpin (unmatched nucleosides are offset - U may pair with G):
ggccu acaga u aca aacau
ggcugg augug cugccugucu cuugcugugcag c
|||||| ||||||||||| |||| |||||||||||| c
ccgacc caacaguacac gacggacaga ggacgacauguc g
----u ----- u cac cacuc
Endogenous sense strand top and antisense strand bottom with unmatched nucleosides
indicated by both s and underline, with G:U matches underlined and overhangs in
bold:
' UGCCUGUCUACACUUGCUGUGC 3' (#)
3' UGACGGACAGACACGGACGACA 5'
Sense strand top and antisense strand bottom where sense strand has been adjusted to
have only matched nucleosides with the antisense strand and includes G:U matches
indicated by underline and overhang is indicated in bold:
' UGCCUGUCUGUGCUUGCUGUGC 3' (#)
3' UGACGGACAGACACGGACGACA 5'
Sense strand top and antisense strand bottom where sense strand has been adjusted to
have only matched nucleosides where G:U eliminated by adjusting sense strand to have
rd match to the corresponding antisense strand nucleoside the overhang is shown
in bold:
5' UGCCUGUCUGUGCCUGCUGUGC 3' (#)
3' UGACGGACAGACACGGACGACA 5'
Endogenous antisense strand with overhang shown in bold and shown written in both
directions:
' ACAGCAGGCACAGACAGGCAGU 3' (#)
3' ACAGACACGGACGACA 5'
s modified for seqRNAi miRNA use:
94. seqRNAi miRNA Mimic Compounds Based on Mouse miR-499 for use in the
tial administration method described herein.
miR-499 hairpin (unmatched nucleosides are offset - U may pair with G):
gggu u ua a --- uc
gggcagc gu gc gugauguuua gc c
||||||| || |||||||| |||||||||| ||
g cg ucugaacg aagu cg u
---- u ug a gua uc
Endogenous sense strand top and antisense strand bottom with unmatched nucleosides
indicated by both italics and underline, with G:U matches underlined and overhangs in
bold:
' GAACAUCACAGCAAGUCUGUGCU 3' (#)
3' UUUGUAGUGACGUUCAGAAUU 5'
Sense strand top and antisense strand bottom where sense strand has been adjusted to
have only matched nucleosides with the antisense strand and includes G:U s
indicated by underline and overhang is indicated in bold:
' GAACAUCACUGCAAGUCUUAGCU 3' (#)
3' UUUGUAGUGACGUUCAGAAUU 5'
Sense strand top and antisense strand bottom where sense strand has been adjusted to
have only matched sides where G:U eliminated by adjusting sense strand to have
standard match to the corresponding antisense strand nucleoside the overhang is shown
in bold:
' AAACAUCACUGCAAGUCUUAACU 3' (#)
3' UUUGUAGUGACGUUCAGAAUU 5'
Endogenous antisense strand with overhang shown in bold and shown written in both
directions:
' UUAAGACUUGCAGUGAUGUUU 3' (#)
3' GUGACGUUCAGAAUU 5'
Strands modified for i miRNA use:
95. seqRNAi miRNA Mimic Compounds Based on Human miR-499 for use in the
sequential administration method described herein.
miR-499 hairpin (unmatched nucleosides are offset - U may pair with G):
ccugu cuu - c u ua a acucc
gcccugucc gc ggg cggg ggc gu gc gugauguuua u
||||||||| || ||| |||| ||| || |||||||| |||||||||| c
ugggacggg cg ccc gccc ucg cg ucugaacg cacuacaagu u
uccgu cau u u u ug a gcacc
Endogenous sense strand top and antisense strand bottom with unmatched nucleosides
indicated by both italics and underline, with G:U matches underlined and overhangs in
bold:
miR5p
' AACAUCACAGCAAGUCUGUGCU 3' (#)
3' UUUGUAGUGACGUUCAGAAUU 5'
miR3p
' CUUGCAGUGAUGUUU 3' (#)
3' UCGUGUCUGAACGACACUACAA 5'
Sense strand top and antisense strand bottom where sense strand has been adjusted to
have only matched nucleosides with the antisense strand and includes G:U matches
indicated by underline and ng is indicated in bold:
miR5p
5' AACAUCACUGCAAGUCUUAGCU 3' (#)
3' UUUGUAGUGACGUUCAGAAUU 5'
miR3p
' UACAGACUUGCUGUGAUGUUU 3' (#)
3' UCGUGUCUGAACGACACUACAA 5'
Sense strand top and antisense strand bottom where sense strand has been adjusted to
have only matched nucleosides where G:U ated by adjusting sense strand to have
standard match to the corresponding nse strand nucleoside the overhang is shown
in bold:
9-5p
5' AACAUCACUGCAAGUCUUAACU 3' (#)
3' UUUGUAGUGACGUUCAGAAUU 5'
miR3p
' CACAGACUUGCUGUGAUGUUU 3' (#)
3' UCGUGUCUGAACGACACUACAA 5'
Endogenous antisense strand with overhang shown in bold and shown written in both
directions:
miR5p
' UUAAGACUUGCAGUGAUGUUU 3' (#)
3' UUUGUAGUGACGUUCAGAAUU 5'
miR3p
' AACAUCACAGCAAGUCUGUGCU 3' (#)
3' UCGUGUCUGAACGACACUACAA 5'
Strands ed for seqRNAi miRNA use:
While certain of the preferred embodiments of the present invention have been
described and specifically ified above, it is not intended that the invention be limited
to such embodiments. Various modifications may be made thereto without departing from the
scope and spirit of the present invention, as set forth in the following claims.
We Claim
1. An in vitro screening method for selecting an antisense strand binding site
on a ribonucleic acid target of interest, said method comprising;
(i) identifying a site on said target that is available for antisense strand g
using an antisense oligonucleotide;
(ii) obtaining a set of a first and a second oligonucleotide with sequences capable
of forming a duplex or a set of a first and a second oligonucleotide that are not
complementary to each other but which are capable of forming a duplex with a third
strand where in at least one strand is complementary to the site identified as available
for binding in (i);
(iii) modifying said oligonucleotide strands to increase their stability and activity;
(iv) contacting a cell expressing said target with said first oligonucleotide
strand or said two non-complementary strands and providing a suitable amount of
time for said (s) to enter said cell;
(v) contacting said cell with said second or said second and third
ucleotide strands not complementary to each other but complementary to a
strand in (iv) and;
(vi) determining the expression of the target ce as compared to the
expression of the target sequence without step (iii).
2. An in vitro method according to claim 1 wherein said first oligonucleotide
is ted with respect to the second oligonucleotide.
3. An in vitro method according to claim 1or 2 wherein one or both of said strands
comprise an overhang precursor at the 3’ end and/or where one strand comprises a 5’
end overhang precursor.
4. An in vitro method according to any one of claims 1 to 3 n two or
more first oligonucleotides are provided as a contiguous sequence.
. An in vitro method according to any one of claims 1 to 4 wherein said first
oligonucleotide is a sense strand and the second oligonucleotide is an antisense sense
strand.
6. An in vitro method according to any one of claims 1 to 5 wherein said
oligonucleotides are selected from the group provided in any one of indices 1 - 95.
7. An in vitro method according to any one of claims 1 to 6 wherein said first or
second strand is an antisense strand and said target ribonucleic acid sequence is a
mRNA that comprises a region of complementarity with said antisense strand within its
3’ UTR that is 6-7 contiguous nucleosides in , said region being complementary
to a sequence t at positions 2-7 or 2-8 counting from the 5’-end of said antisense
strand and n nucleoside positions 10 and/or 11 from the 5’end of said antisense
strand optionally comprise a modification selected from the group consisting of abasic,
UNA and FANA.
8. An in vitro method according to any one of claims 1 to 7 wherein said
complementary region in said mRNA is mentary to a sequence t at
positions 2-7 or 2-8 counting from the 5’- end of said antisense strand and is the same
as an endogenous miRNA seed sequence.
9. An in vitro method according to any one of claims 1 to 8 wherein said
complementary region in said mRNA is complementary to a sequence present at
positions 2-7 or 2-8 counting from the 5’- end of said antisense strand and comprises a
novel seed sequence complementary to a ce in the 3’-UTR of at least one
mRNA target sequence.
. An in vitro method according to any one of claims 1 to 9 wherein said sequence
present at positions 2-7 or 2-8 counting from the 5’-end of said antisense strand is
modified such that affinity for said target is altered.
11. An in vitro method ing to any one of claims 1 to 10, wherein said first or
second strand is an antisense strand and said target ribonucleic acid is a mRNA or
miRNA that comprises a region of complementarity that is at least 8 uous
nucleosides in length with a sequence present in said antisense strand at positions 7-14
counting from the 5’-end.
Figure 1
Figure 2
1:} Base
OH (33’
Claims (11)
1. An in vitro screening method for selecting an antisense strand binding site on a ribonucleic acid target of interest, said method comprising; (i) identifying a site on said target that is available for antisense strand g using an antisense oligonucleotide; (ii) obtaining a set of a first and a second oligonucleotide with sequences capable of forming a duplex or a set of a first and a second oligonucleotide that are not complementary to each other but which are capable of forming a duplex with a third strand where in at least one strand is complementary to the site identified as available for binding in (i); (iii) modifying said oligonucleotide strands to increase their stability and activity; (iv) contacting a cell expressing said target with said first oligonucleotide strand or said two non-complementary strands and providing a suitable amount of time for said (s) to enter said cell; (v) contacting said cell with said second or said second and third ucleotide strands not complementary to each other but complementary to a strand in (iv) and; (vi) determining the expression of the target ce as compared to the expression of the target sequence without step (iii).
2. An in vitro method according to claim 1 wherein said first oligonucleotide is ted with respect to the second oligonucleotide.
3. An in vitro method according to claim 1or 2 wherein one or both of said strands comprise an overhang precursor at the 3’ end and/or where one strand comprises a 5’ end overhang precursor.
4. An in vitro method according to any one of claims 1 to 3 n two or more first oligonucleotides are provided as a contiguous sequence.
5. An in vitro method according to any one of claims 1 to 4 wherein said first oligonucleotide is a sense strand and the second oligonucleotide is an antisense sense strand.
6. An in vitro method according to any one of claims 1 to 5 wherein said oligonucleotides are selected from the group provided in any one of indices 1 - 95.
7. An in vitro method according to any one of claims 1 to 6 wherein said first or second strand is an antisense strand and said target ribonucleic acid sequence is a mRNA that comprises a region of complementarity with said antisense strand within its 3’ UTR that is 6-7 contiguous nucleosides in , said region being complementary to a sequence t at positions 2-7 or 2-8 counting from the 5’-end of said antisense strand and n nucleoside positions 10 and/or 11 from the 5’end of said antisense strand optionally comprise a modification selected from the group consisting of abasic, UNA and FANA.
8. An in vitro method according to any one of claims 1 to 7 wherein said complementary region in said mRNA is mentary to a sequence t at positions 2-7 or 2-8 counting from the 5’- end of said antisense strand and is the same as an endogenous miRNA seed sequence.
9. An in vitro method according to any one of claims 1 to 8 wherein said complementary region in said mRNA is complementary to a sequence present at positions 2-7 or 2-8 counting from the 5’- end of said antisense strand and comprises a novel seed sequence complementary to a ce in the 3’-UTR of at least one mRNA target sequence.
10. An in vitro method according to any one of claims 1 to 9 wherein said sequence present at positions 2-7 or 2-8 counting from the 5’-end of said antisense strand is modified such that affinity for said target is altered.
11. An in vitro method ing to any one of claims 1 to 10, wherein said first or second strand is an antisense strand and said target ribonucleic acid is a mRNA or miRNA that comprises a region of complementarity that is at least 8 uous nucleosides in length with a sequence present in said antisense strand at positions 7-14 counting from the 5’-end.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161477283P | 2011-04-20 | 2011-04-20 | |
US201161477291P | 2011-04-20 | 2011-04-20 | |
US61/477283 | 2011-04-20 | ||
US61/477291 | 2011-04-20 | ||
US201161477875P | 2011-04-21 | 2011-04-21 | |
US61/477875 | 2011-04-21 | ||
PCT/US2012/034595 WO2012145729A2 (en) | 2011-04-20 | 2012-04-20 | Methods and compositions for modulating gene expression using components that self assemble in cells and produce rnai activity |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ617944A NZ617944A (en) | 2016-01-29 |
NZ617944B2 true NZ617944B2 (en) | 2016-05-03 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20160272972A1 (en) | Methods and compositions for modulating gene expression using components that self assemble in cells and produce rnai activity | |
US20150291957A1 (en) | METHODS AND COMPOSITIONS TO PRODUCE ss-RNAi ACTIVITY WITH ENHANCED POTENCY | |
US20230220393A1 (en) | METHODS AND MODIFICATIONS THAT PRODUCE ssRNAi COMPOUNDS WITH ENHANCED ACTIVITY, POTENCY AND DURATION OF EFFECT | |
JP5244087B2 (en) | Small internal segmented interfering RNA | |
JP6472087B2 (en) | Double-stranded agent for delivering therapeutic oligonucleotides | |
JP2010537640A (en) | Compositions of asymmetric RNA duplexes as microRNA mimetics or inhibitors | |
JP2014519806A5 (en) | ||
WO2011028550A1 (en) | Segmented micro rna mimetics | |
US20150225722A1 (en) | Methods for selective targeting of heterochromatin forming non-coding rna | |
AU2016371624A1 (en) | siRNA structures for high activity and reduced off target | |
Grünweller et al. | Chemical modification of nucleic acids as a key technology for the development of RNA-based therapeutics | |
Lennox et al. | Chemical modifications in RNA interference and CRISPR/Cas genome editing reagents | |
NZ617944B2 (en) | Methods and compositions for modulating gene expression using components that self assemble in cells and produce rnai activity | |
WO2019044974A1 (en) | Small guide antisense nucleic acid and use thereof | |
US20230257753A1 (en) | Products and compositions | |
JP5995849B2 (en) | Heptamer-type small guide nucleic acid induces apoptosis of human leukemia cells | |
WO2013022092A9 (en) | Heptamer-type small guide nucleic acid capable of inducing apoptosis of human hematologic cancer cells |